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Chapter 1 
Chemical Modifications Designed to Improve Peptide Stability 
1. Introduction 
Peptides are amino acid derived compounds containing at least one amide (peptide) bound. Conventionally, 
peptides up to 20 amino acids are named oligopeptides, while the term polypeptatide refers to peptides up to 
100 amino acids. From the structural point of view, peptides encompass diverse types such as linear, cyclic 
peptides, depsipeptides, and peptides modified with diverse nonpeptide moietes including phosphoryl groups 
or carbohydrate, polyketides or terpenoids, etc [1]. 
The evolution of enzymatic synthesis, recombinant DNA technology, and automated synthetic methodologies 
in particular SPPS, allow for the production of large libraries of diverse peptides characterized by a range of 
pharmacological effects. Peptide or peptidomimetic drugs are currently utilized for the treatment of prostate 
and breast cancer, as HIV protease inhibitors or as ACE inhibitors, against hypertension and heart failures, 
as antibiotics, hormone, neurotrasmetters, immunomodulators, and so on. Peptides have the potential to be 
potent pharmaceutical agents for the treatment of many diseases of the Central Nervous System (CNS) [2,3]. 
Unfortunately, the clinical use of these promising drugs is hampered by their rapid degradation and scarce 
permeation across biological barriers, such as the intestinal lumen, the intestinal mucosa, the blood-brain 
barriers (BBB), etc. these problems lead to short in vivo half-lives (generally <30 min) and low oral 
bioavailability (1-2%)[4,5]. 
The peptidomimetic strategy consists of altering the physico-chemical characteristics of a peptide without 
changing the biological activity [2]. Peptidomimetic compounds bear identifiable similarity to the parent 
peptides and imitate or inhibit their biochemical effects. Very often, they contain non peptidic structural 
elements [6], such as peptide bond-surrogates not cleaved by peptidases, a feature also found in natural 
peptidase inhibitors. 
The design of a peptidomimetic based on the structure of a native peptide begins with a extensive SAR 
investigation of the parent peptide, aimed to identify the minimal sequence and the pharmacocophoric 
groups responsible for the bioactivity. Next, the most active 3D display of these key residues is determined 
by means of conformationally rigid analogues [7,8]. Moving from the resulting 3D model, the pharmacophores 
can then be recombined by the use of non-peptidic scaffolds. Finally, the resulting compounds are tested to 
demonstrate the biological activity, stability, bioavailability and conformational stability, and ADMET profile. 
Many non-peptide mimetics of bioactive peptides have been reported in the literature. The αvβ3 -integrin 
inhibitor (1), SB223245, with a 1-4 benzodiazepine nucleus as central ɣ-turn mimetic scaffold [9], the TRH 
(pGlu-His-Pro-NH2 ) analogue (2), containing a cis-1,3,5-trisubstituted cyclohexane scaffold [10], the glucose-
derived non-peptidomimetic of somatostatin (3) [11], and the C2-symmetric cyclic urea as HIV protease 
inhibitor (4) [12], represent outstanding example of non-peptidomimetics with high biological activity and 
increased enzymatic stability, Fig (1). However, in several cases the non-peptidic compounds have failed to 
reproduce the biological activity of the natural peptide [13,14]. Therefore, peptidomimetics still preserve their 
attractiveness for replacing the original peptides.   
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The field of peptidomimetics has been very extensively reviewed. Some of the most relevant kinds of 
peptidomimetic therapeutic agents describe in the literature are the HIV protease inhibitors [15], anti 
thrombotic agents [16], ACE [17] and renin inhibitors [18], etc. 
It is worth notice that many of the tricks used by chemists to enhance activity and stability, by protecting 
peptides against both endo and exo-peptidases, can also be found in active peptides of microbial or marine 
origin: D-amino acids or inusual amino acids instead of the natural L-residues, cyclization, glycosilation, 
deamination, complete removal of the first residue, N-acylation or N-formylation at the N-terminus, amidation 
of the C-terminus, etc [1,2]. 
 
 
 
 
Fig.(1) Selected examples of non-peptidomimetics 
 
It is  also possible to introduce temporary modifications using a prodrug approach [19]. A peptide prodrug can 
be obtained by combining a biolagically active peptide with additional elements which give the whole 
molecule increased resistance against enzymatic hydrolysis and/or bioavaibility [19,20] . 
Proteolytic cleavage of the additional molecule, especially a short truncation at the N-terminus, in the 
proximity of the site of action, release the pharmacologically active drug. Prodrug or prodrug-enzyme 
inhibitor combinations may optimize the delivery of peptide or protein drugs to the CNS. For example, the N-
terminal 4-imidazolidinone prodrugs of Leu-enkephalin, being metabolically stable and bioreversible, have 
been proposed as a suitable prodrug candidates for delivery of Leu-enkephalin to the brain [21]. 
Peptide stability can be achieved by conjugation to a polymer [22]. Polymer conjugation improves 
pharmacokinetics by increasing the molecular mass of protein and peptides, preventing the approach of 
antibodies or antigen processing cells and shielding them from proteolytic  enzymes. The most promising 
polymer is PEG [23], which shows little toxicity and is eliminated from the body intact. Polymer conjugation 
allows an increase peptide stability, and reduce elimination. The conjugated PEG-DPDPE seems to act as a 
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pro-drug, enhancing peripheral stability, while undergoing hydrolysis in the brain and allowing nonconjugated 
DPDPE to act at the receptor [24]. 
Finally, proteolytic peptide degradation can be defeated using alternative routes of administration, including 
controlled-release parenteral route (subcutaneous, intramuscular or intravenous), mucosal route (nasal 
spray, pulmonary delivery, sublingual delivery), oral route (penetration enhancers, protease 
inhibitors,carriers) and transdermal route (patches) [25]. 
 
1.1. ENZYMATIC DEGRADATION OF PEPTIDES 
The therapeutic efficacy of a peptide drug candidate is linked to its activity at the specific receptor,as well as 
to its pharmacokinetic properties (adsorption, transport, ability to cross biological barriers, excretion) and 
toxicity. Besides to aqueous solubility, lipophilicity, molecular size and weight, and ability to form H-bonds 
(Lipinski's Rule of 5), chemical and metabolic stability plays a major role in determining peptide bioavailability. 
Peptide degradation by protelytic enzyme is followed by rapid excretion of the metabolites from the 
circulation by the liver and kidneys [4,5]. 
The enzymatic stability of a peptide is dependent upon several factors, in particular kind and sequence of the 
amino acids, overall size, flexibility, and conformations. Side chain metabolism, such as the oxidation and 
reduction of disulfide bonds, can also play a important role. Amino acid composition and peptide structure 
also determine lipophilicity, the degreeof protein binding, cellular sequestration, uptake into non-target tissue, 
clearance rate, and affinity for carrier mechanisms. 
Peptidase that are capable of cleaving the internal peptide bonds of a substrate are designated as 
endopeptidases ( e.g., serine proteinases, metalloproteinases). The peptidase which remove one or more 
residues from the termini of the peptide are classified as exopeptidases (e.g.,aminopeptidases, 
carboxipeptidases) [26,27.] Large peptides or peptides protected at the N-terminus, or at the C-terminus, 
require endopeptidases to initiate hydrolysis. 
After administration, peptides meet proteolytic enzymes at many compartments [28]. In case of intravenous 
injection, the peptide is immediately subjected to numerous proteolytic enzymes such as esterases and 
peptidases in the human plasma [29]. In case of oral delivery, a part from the strong acidic gastric enviroment, 
the peptide encounters two main biophysical and biochemical barriers, the lumen of the small intestine, and 
the brush border membrane. For peptides drugs targeting the CNS, the BBB also costitutes a formidable 
barrier [30]. 
The metabolic activity in the intestinal lumen reduces the absorption of peptide-based drugs. The 
gastrointestinal tract degrades proteins and peptides by using variety of enzymes into smaller sequences, 
which can be easily absorbed across the intestinal mucosa [31,32].In the duodenum, the degradation can be 
mediated by pancreatic proteases. The contribution of luminal hydrolysis in the overall degradation process 
depends on the size and composition of the peptide. Most of the degradation of peptides requires at least 
contact with the brush-border membrane and/or uptake into the intestinal mucosal cells. 
Among the most relevant peptidases which can be found in the intestine, it is possible to mention 
aminopeptidase P, aminopeptidase W, aminopeptidase N and dipeptidyl peptidase IV. The lumen of the 
small intestine contains a number of pancreatic peptidases, α-chymotrypsin, trypsin, pancreatic elastase, 
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carboxypeptidases A, B, D, N, U, etc., and cellular peptidases secreted by mucosal cells. The brush border 
membrane of the epithelial cells contains many different peptidases [33], dipeptidyl-peptidase IV, prolyl 
tripeptidylpeptidase, ACE, leucyl-aminopeptidase, aminopeptidase M, aminopeptidase A, neprilysin, etc. 
Many enzymes are also present in the liver [34], kidney and other organs, or in different tissues. For instance, 
lysosomal peptidases, leukocyte elastase, cathepsins B, D, etc., can be found in epithelial or endothelial 
cells; other enzymes are the interstitial collagenase (MMP-1), or carboxypeptidase C or Y. 
The BBB is a unique physical and enzymatic barrier that segregates the brain from the systemic circulation. 
BBB capillary endothelia are sealed by tight junctions, which inhibit any significant paracellular transport [30.] 
Specific transporters exist at the BBB that permit nutrients to enter the brain and toxicants/waste products to 
exit. These transporters are potential routes for mimetic designed drugs. The main peptidases which can be 
found in the brain microcapillaries of the BBB are gamma-glutamyl transpeptidase alkaline phosphatase, 
monoamine oxidase catechol-O-methyl transferase, butyrylcholinesterase and aromatic-L-amino-acid 
carboxylase (or Dopa-decarboxylase or aromatic-L-amino-acid decarboxylase), epoxidehydrolase (or 
epoxide hydrolase), UDP-glucuronosyl-transferase, benzyloxyresorufin-O-deethylase (cytochrome P-450 
CYP2B1), NADPH cytochrome P-450 reductase and glutathione-S-tranferase [22]. The protein-disulfide 
reductase, is also present in the brain and can alter peptide structures stable in plasma. 
In many cases, the active peptides are enzymatically converted to products which retain some bioactivity. 
These bioactive metabolites may mimic but also counteract the action of the parent peptide. 
The released fragment may serve as a modulator of the response of the original compound [35]. This 
phenomenon has been found to occur in several neuropeptide systems, including the opioid peptides, 
tachykinins, as well as peptides belonging to the renin-angiotensin system. Normally, the products interact 
with the same receptor as the native compound, but sometimes it appears that the released fragments 
interact with sites distinct from those of the original peptide. 
 
1.2. STRUCTURE MODIFICATIONS TO IMPROVE PEPTIDE STABILITY 
As mentioned in the introduction, peptidomimetics resemble native peptides or proteins but contain some 
synthetic element designed to reduce metabolism and to optimize the biological activity of the agent. Peptide 
bond hydrolysis in vivo can be limited by specifically protecting or replacing the targeted bond, by introducing 
atypical moieties, or by modifying the peptide conformation alltogether, in such a way that it is no longer 
recognized by the protease of concern. Even modest structural changes near the scissile peptide bond can 
result in significant conformational differences. Example are the introduction of a N-alkyl group, that 
increases the incidence of the cis configuration of the amide bond, the use of a D-amino acid, or of a residue 
containing an unnatural side chain. In many cases, the introduction of non-peptidic scaffolds to imitate the 
secondary structure that are thought to be especially involved in binding interactions, including the ɣ- and β-
turn, β-sheet and the α-helix, proved to be a very effective strategy. 
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1.2.1. Pseudopeptides 
The backbone of a peptide can be modified in various ways by changing at least one peptide bond with a 
isosteric or isoelectronic surrogate. Examples are shown in Fig. (2). The mostly utilized isosters are the 
reduced amides, azapeptides, retro-inverso peptides, and peptoids; these are discussed in detail in the next 
sections. Other isosters less frequently appeared in the literature, such as the urea peptide mimetics [36,37], 
sulphonamide peptides/peptoids [38], etc., are not reviewed here. 
The replacement of a labile peptide bond with a isoster was of great help for designing therapeutic agents 
targeting proteases, like those associated with the HIV virus, as well as targets like ACE, renin, endothelin, 
interleukin-converting enzyme and others [15-18]. Very often, the isoster imitates the transition state of peptide 
bond cleavage, including the hydroxyl group resulting from enzyme nucleophilic addition, Fig. (2), 
hydroxyethylamino, hydroxyethylene isosters, etc. 
 
 
 
 
Fig.(2) Isosteric surrogates of the peptide bond 
 
1.2.2. Reduced Peptide Bonds 
The incorporation of reduced peptide bonds (CH2-NH), Fig. (2), renders the native sequences of opioid 
peptides highly resistant towards enzymatic hydrolysis in the modified positions. Synthetic peptides 
containing reduced bonds have found applications as vaccines for their immunogenic properties, linear 
pseudooligolysines, containing multiple adjacent CH2-NH bonds have been designed as DNA carriers in 
gene delivery. Reduced amides have also seen use in the preparation of peptide nucleic acids and 
antibacterial peptides [2,6]. Representative examples in the field of opioid peptides are the TIPP-derived 
opioid antagonists with subnanomolar affinity and high δ-receptor selectivity, obtained by introduction of a 
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reduced peptide bond between Tic2 and Phe3 residues, to give H-Tyr-TicΨ[CH2NH]Phe-Phe-OH (TIPP[Ψ]) 
and H-Tyr-TicΨ[CH2NH] Cha-Phe-OH, Cha: cyclohexylalanine (TICP[Ψ]). The modification conferred the 
molecules a high stability against chemical and enzymatic degradation [39]. 
Introduction of the CH2-NH peptide bond isoster can be accomplished in solid phase. The free N-terminal 
amino group of the resin-bound peptide is reductively alkylated by the requisite protected α-aminoaldehyde 
in the presence of sodium cyanoborohydride (NaBH3CN) in DMF containing 1% AcOH. Microwave irradiation 
can be utilized to shorten the reaction times and improve the yields [40]. 
 
1.2.3. Azapeptides 
In azapeptide isosters the α-CH group of the backbone is substituted by a isoelectronic nitrogen atom, the 
side chains remaining unaltered, Fig. (2). Azapeptides have been developed by several groups for the 
design of hormone analogues, protease inhibitors, etc [41]. Examples of therapeutically useful peptides 
incorporating the azapeptide modification can be found in the field of serine and cysteine proteases inhibitors 
[42]. Atazanavir (5), Fig. (3), BMS-232632, is a highly active azapeptide inhibitor of the HIV protease, that has 
recently received approval as a human immunodeficiency virus (HIV) treatment [43,44]. It inhibits the protease 
enzyme, thereby preventing the cleavage of the viral polyproteins and resulting in an immature, non-
infectious virion. It is the first, and to date the only, protease inhibitor designed to be applied once daily, with 
comparable anti-HIV efficacy to nelfinavir, efavirenz and the combination of ritonavir and saquinavir [45]. 
The synthesis of azapeptides generally starts from substituted hydrazines or hydrazides [46].The preparation 
of Atazanavir (5) is shown in Fig. (3). The key building blocks are the hydrazino carbamate, obtained in turn 
by a Suzuki-Miyaura coupling, the amino acid-derived N-protected threo-3-amino-1,2 epoxybutane, and two 
equivalents of N-protected-tert-leucine [45]. 
 
 
 
Fig.(3) Synthesis of Atazanavir 
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1.2.4. Retro-Inverso Peptides 
In these peptide-mimetics the normal sequence from N- to C- terminus is reversed, and the natural L-amino 
acids are changed by D-amino acids, Fig. (2) [47].This reversal warrants that the side chain topologies of the 
natural peptide and the peptidomimetic are the same. Peptide-bond reversal represents an important 
structural alteration for peptides, and proved to be useful to reduce the degradation rate of the peptides by 
peptidases. In a retro-inverso sequence the N- and C-termini are reversed, therefore the positive charge 
located at the N-terminus of the natural sequence is replaced by a negative one in the peptidomimetic, and 
vice-versa, unless modified termini are introduced. This may be the cause of the low biological activity 
observed in several cases. The introduction of end-group modifications, Fig. (2), increases the 
complementarity with the native peptide (see also PMRI). 
Retro-inverso peptides have found applications as immunogens, immunomodulators, immunostimulators; 
and as anti-inflammatory, antimicrobial, and diagnostic reagents, as well as modified isomers of membrane-
penetrating peptides as delivery systems [48]. An evolution of the retro-inverso concept is the partially 
modified retro-inverso (PMRI) peptide, in which the retro-inverso structures is incorporated into a normal 
sequence; the retro inverso and the normal portions are connected by a diamine and/or a diacid. 
The PMRI Tuftsin analogue 6 [49], Fig. (4), is degraded less than 2 % in 50 min, while maintaining the 
biological activity of Tuftsine, H-Thr-Lys-Pro-Arg-OH, a immune system stimulator, which is completely 
degraded in vivo in about 8 min. Other nice examples can be found as mimetics of enkephalin, CCK, RGD, 
gastrin antagonists, etc. [47,48].  In general, the analogues displayed higher activity than the parent peptides in 
an in vitro test. Another example is the angiotensin analogue incorporating aza-α'- homoamino acids of 
natural and inverted configuration, [Asn1, aza- α'-homoTyr4, Val5]angiotensin II (7), Fig. (4). 
 
 
Fig.(4) PMRI analogues of Tuftsin (6) and Angiotensin II (7).  
 
The synthesis of a PMRI peptide requires standard conditions. The principal concern of PMRI peptide 
synthesis is the construction of the gem-diaminoalkyl (8), Fig. (5), and C-2-substituted malonyl residues (9), 
Fig. (6).  
The Curtius and Hofmann rearrangements remain the methods used most commonly for the syntheses of 
gem-diaminoalkyl derivatives (8); during these rearrangements the migrating groups retain the configuration, 
Fig. (5). Acyl azides undergo the Curtius rearrangement to yield the corresponding isocyanates, whose 
hydrolysis give the gem-diamines. Acyl azides can be prepared from the amino acids by treatment with 
diphenylphosphoryl azide (DPPA), or via the intermediate mixed anhydride [47]. 
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The isocyanates can be reacted with a carboxylic acid derivative to yield a PMRI peptidic unit directly [50], the 
so-called “Goldschmidt and Wick type reaction”. The Hofmann rearrangement is extensively employed for 
the synthesis of PMRI peptides, using exclusively the mild oxidant iodobenzene bis(trifluoroacetate) (IBTFA). 
Other procedures to synthesize monoprotected gemdiaminoalkyl (8), are based on the Mannich reaction [51], 
on the formation of intermediate oxazolones, or nitriles, etc. 
 
 
 
 
Fig.(5) Preparations of the gem-diaminoalkyl residues. 
 
 Concerning the preparation of C-2-substituted malonyl derivatives (9), the classical method is the alkylation 
and partial hydrolysis of malonic acid diesters, and of cyanoacetates. A very convenient method is based on 
the use of Meldrum’s acid, Fig. (6). The Knoevenagel reaction with aldehydes or some ketones and in situ 
reduction yields mono-C-5-substituted Meldrum’s acids. Subsequent alcoholysis gives C-2-substituted 
malonic acid monoesters. The acylation of the enolate of a tert-butyl carboxylate with a carbonate, a 
chloroformate, or a isocyanate, can be utilized to obtain C-2-substituted malonates. Special issues to take 
into consideration are the acidity of the C-2 hydrogen of malonates, and the configurational lability of the C-2 
malonyl position during synthesis. 
 
 
Fig.(6) Preparations of the C-2-substituted malonyls 
 
1.2.5. Peptoids 
In the early 1990’s Bartlett defined peptoids as pseudopeptides containing N-alkylated glycines linked by 
peptide bonds. Formally, the nitrogen atom of some residues is shifted to the α-CH position, and the NH-
groups have been substituted by CH2-groups, Fig. (2). 
Therefore, the side chains and the carbonyl groups remain at their positions, while the backbone CH- and 
NH-groups change their places. The sequence of peptoids are opposite to the ones of native peptides, and 
the stereogenic α-carbons of natural amino acids are lost; besides, they have higher conformational flexibility 
respect to natural peptides. Peptoid analogues of most natural amino acids are commercially available, or 
they can be easily prepared. Peptoids (10) can be routinely synthesized on Rink amide linker-derivatized 
solid supports using the submonomer synthesis method developed by Zuckermann et al., Fig. (7) [52,53]. 
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Metabolically stable, successful compounds based on the peptoid concept are the α-amylase inhibitors Ac-
Nhtrp-Nharg-Nhtyr- NH2, and Ac-Nhtyr-Nharg-Nhtrp-NH2 [14], active as or more active then their natural 
parent peptides (Nh indicates the peptoid homologue of the natural amino acid); other examples are the 
antimicrobial peptoids derived from pexiganan, protegrins, and melittin [54]. 
 
 
Fig.(7) Example of SPPS of peptoids. 
 
1.3. Incorporation of Non-Natural Amino Acids 
Peptide analogs containing non-natural residues have been obtained by diverse approaches [55], ranging 
from the simple replacement of the natural L-amino acids with their D-enantiomers, to the use of N-alkyl 
amino acids, α-substituted α-amino acids, β-substituted α-amino acids, proline analogues, ɣ- and β-amino 
acids, substituted α- or β-amino acids, and so on. For the huge number of non natural amino acids described 
in the literature [56,57], only these relevant families are discussed in the following paragraphs. 
In some cases, it has been observed that peptide coupling with unusual amino acids can be troublesome. 
For instance, with N-methyl or Cα,α-disubstituted amino acids, racemisation, diketopiperazine formation, etc., 
are common side-reactions. 
 
1.3.1. D-amino Acids 
The introduction of D-amino acids [58] in a sequence can give the peptide an increased stability, since only a 
few enzymes that effectively hydrolyse peptide bonds involving D-amino acids have been discovered and 
characterized in multicellular organisms [59]. 
Moreover, D-residues often enforce a different conformation of the peptide [60], and strongly influence 
receptor affinity and selectivity [61]. Some of the first successes of this approach [62] in the field of opioid 
peptides have been the δ-receptor selective enkephalin analogues DADLE, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH, 
and the μ-receptor selective DAMGO, H-Tyr-D-Ala-Gly-MePhe-Glyol, widely used as a radioligand for 
binding experiments in its [3H]-form [3,63]. 
 
1.3.2. N-Alkylated Amino Acids 
N-alkylation (generally N-methylation) is present in a number of biologically active, natural peptides from 
different sources, in particular of marine or microbial origins, including antibiotics, monamycins, echinomycin, 
or insecticides, antitumor agents, such as bouvardin, or antiinflammatory peptides [64,65]. For instance, the 
cyclic undecapeptide cyclosporine A [66], isolated from Trichoderma polysporum, contains seven N-
methylated amino acids. 
This immunosuppressant with low toxicity is utilized as an effective drug after organ transplantations. 
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Several N-alkyl amino acids are commercially available, allowing their direct use in solid phase peptide 
synthesis, while many others can be prepared [64,67-69]. N-methyl amino acids (11) can be synthesized from 
N-protected amino acids, by direct methylation of carbamate or diphenylphosphinamide (Dpp) protected 
amino acids, Fig (8)A, or by the Mitsunobu reaction, with arylsulfonyl protecting group, Fig (8)B. 
Oxazolidinones obtained from the N-carbamate amino acids and formaldehyde can be reduced to N-
methylamino acid with triethylsilane, Fig (8)C. Alternatively, oxazolidinones obtained with hexafluoroacetone 
can be treated with paraformaldehyde and thionyl chloride; reduction and deprotection affords the N-methyl 
amino acid. 
 
 
 
Fig. (8). Syntheses of N-methyl amino acids. 
 
The alkylation of amino acids has been obtained by two successive reductive aminations of aldehydes, Fig. 
(9)A [64]. N-methylation has been performed via sultam-directed “enolate” hydroxyamination of non-chiral 
acyl chains, Fig. (9)B. The sultam chiral auxiliary served also for the alkylation of chiral enolate derived from 
sarcosine (N-methylGly). 
Finally, the N-methylation of a peptide can be directly performed on solid support; for instance, the key step 
of Fig. (9)C is the selective deprotonation of the resin-bound free amine peptide protected as o-nitrobenzene 
sulfonamide with a non-ionic base, and alkylation with methyl p-nitrobenzenesulfonate. This strategy has 
been applied to the N-methyl scan of the thrombin receptor agonistpeptide H-SFLLRNNH2 [70]. 
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Fig. (9). Other syntheses of  N-methyl amino acids. 
 
Generally, peptides modified by the use of N-methyl amino acids resulted in analogues with improved 
pharmacological properties and stability. The role of the position to be N-methylated for peptide protection 
from proteolysis is essential. Substance P (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) had been 
shown to be degraded in the human brain at peptide bonds 5-6, 7-8 and 8-9. 
The heptapeptide analogue, Glu-Gln-Phe-NMePhe-NMeGly-Leu-Met-NH2, was almost completely resistant 
[71]. To mention another case, in comparison to endothelin (half-life circa 10-20 min), the N-methylated 
analogues revealed an increased stability by 500-800 fold [72]. In neurotensin(7-13) (Pro-Arg-Arg-Pro-Tyr-Ile-
Leu), the scissile bonds are the positions Arg8-Arg9, Pro10-Tyr11 and Tyr11- Ile12. N-methylation in position 8 
led to increased half-life in plasma [73]. Finally, the N-methyl modification has been applied also to enzyme 
inhibitors, enkephalin, LHRH, angiotensin, and CCK [64,65]. 
The presence of the N-alkyl group affects the conformational freedom of the backbone and of the side chain 
of the residues close to the N-alkyl group. In particular it eliminates the predominance of trans versus cis 
peptide bond configuration. Besides, the substitution of NH by N-alkyl groups eliminates some inter- and 
intramolecular hydrogen bonds. Finally, the adjacent carbonyl group increases basicity and decreases 
polarity [74]. 
Besides to their utility to protect biologically active peptides against enzymatic degradation without 
concomitant loss of biological activity, N-alkyl residues have been also widely utilized for SAR studies. By 
successively alkylating each backbone NH and evaluating the biological activity (N-alkyl-scan), the 
pharmacophoric residues can be identified. A prototypic example is represented by the N-methyl scan 
performed on the cyclo RGD analogues by Kessler et al., discussed in the paragraph dedicated to cyclization. 
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1.3.2. α-Substituted  α-Amino Acids 
α-Substituted α-amino acids, or α,α-disubstituted glycines, are present in many natural sequences, for 
instance in several peptide antibiotics [75], such as alamethicin, an antimicrobial membraneactive peptide [76]. 
Among the more represented α -alkyl α -amino acids it is possible to cite α -aminobutyric acid (Aib), 
diethylglycine (Deg), or isovaline (Iva), Cα-methyl-Cα-allylglycine (Mag), (αMe)- α,α-diphenylalanine (α
MeDip), and several kinds of cyclic or heterocyclic derivatives, Fig.(10). 
α-Substituted α-amino acids have been used for the synthesis of peptidomimetics as enzyme inhibitors, and 
to provide peptides with a higher resistance to biodegradation. For example, in contrast to angiotensin II, the 
[ α MeTyr4] analogue is resistant to chymotrypsin [77]. Aib-containing analogues of the insect kinin 
neuropeptide family also demonstrate resistance to an insect ACE [78]. Incorporation of Aib has been 
described also for enkephalin, bradykinin, angiotensin II [64]. 
 
 
 
 Fig. (10). Examples of alfa-alkyl alfa-amino acids. 
 
One of the more relevant features of α-substituted α-amino acids is the conformational constraint introduced 
into peptide backbones [79,80]. Aib, the most widely studied of the family, restricts ϕ and Ψ to angles present in 
α- or 310 helices. When Deg is utilized, the preferred conformation is extended with trans ϕ and Ψ angles. A 
noteworthy conformational restriction is obtained when residues having the two side chains in a ring are 
utilized, leading to a β-turn secondary structure or a helix 310. Interestingly, this introduction gives the 
peptides increased resistance against hydrolysis [81,82]. A nice example is represented by the family of the α-
aminocycloalkane carboxylic acids, Acn c. For instance, the introduction of Ac6 c into various positions of 
Leu-Enkephalin, resulted in peptide mimetics with greater in vivo activity. 
The synthesis of α-substituted α-amino acids (12) [64] can be performed by the stereoselective alkylation of 
imidazolidinones, Fig. (11A). Variants based on the use of other intermediate heterocycles are the alkylation 
of bis-lactim ether (13), obtained by treatment of the L-alanine diketopiperazine, or the alkylation of 
metallated imidazolidinones (14), obtained by cyclization of chiral α-isocyanoamides. α-Methylamino acids 
can be prepared by alkylation of Schiff bases derived from chiral amino acids and Oppolzer’s sultam, Fig. 
(11B). The asymmetric alkylation of alanine enolates with chiral phase transfer catalysts, for instance with 
copper complexes of Salen, proceeded with ee up to 90%, Fig. (11C). 
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Fig. (11). Syntheses of alfa-substituted alfa-amino acids. 
 
1.3.4. β-Substituted α-Amino Acids 
Analogues of natural amino acids alkylated at the β -carbon have been often utilized to induce a 
conformational preference in side chains. Some β-Me analogues of Phe, Trp, and Tyr, are shown in Fig. (12). 
These β-substituted α-amino acids have also an additional β-stereogenic center, therefore four preferred 
configurations (-gauche, +gauche, and two enantiomeric trans geometries) are accessible from varying the 
two stereocenters, Fig. (13). 2-(Carboxycyclopropyl)- glycine (CCG) is a different kind of β-substituted amino 
acid. 
 
 
 
Fig. (12). Examples of beta-substituted alfa-amino acids. 
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Fig. (13). Preferred conformations of beta-substituted alfa-amino acids. 
 
Replacement of the natural amino acids often resulted in a comparably higher activity and increased 
biological stability with respect to the modified peptides [83]. For instance, the activity of short peptides which 
are active at the δ-opioid receptor was successfully improved by exchanging phenylalanine by its β-Me 
analogue [84,85].  Also, the introduction of three methyl groups at the 2’-, 6’- and β-position of natural tyrosine 
hinders the free rotation around the χ an angle giving compounds with improved biological activity [86]. 
 
1.3.5. Proline Analogues 
The cyclic structure of proline forces the ϕ angle to -65°+/-15°, thus preventing the formation of a α-helix, and 
promoting the formation of a β-turn. Besides, while the barrier to secondary amide cis/trans isomerization is 
about 10 kcal/mol, Fig. (14), the presence of Pro reduces the barrier to just 2 kcal/mol, hence influencing the 
biological behaviour of peptides [87,88].Many Pro derivatives were found in proteins of microbial or marine 
origins, Fig. (14), in antibiotics and cytotoxic peptides. Many other Pro derivatives were synthesized by the 
introduction of alkyl chains, aromatic groups, heteroatoms, or halogens in different positions of the 
fivemembered ring [89]. 
Some analogues are characterized by smaller or larger rings, such as azyline-2-carboxylic acid (Azy), 
azetine-2-carboxylic acid (Aze), or pipecolic-2-carboxylic acid (Pip). The difference among Azy, Aze and Pro 
is largely the steric bulk of the side chain rather then ϕ and Ψ angles, while Pip prefers a chair conformation 
in which the COOH group is axial. Finally, the 5,5-dimethylthiazolidine- 4-carboxylic acid (Dtc) allows angles 
in the β-turn region. 
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Fig.(14) Proline analogues. 
 
It has been utilized in place of Pro in Angiotensin II, H-Asp-Arg- Val-Tyr-Ile-His-Pro-Phe-OH, a key 
octapeptide in blood pressure regulation, resulting in a peptidomimetic with about 40% greater activity 
respect to the native peptide [90]. 
 
1.3.6. β -Amino Acids 
β- (and ɣ-) amino acids have been utilized to construct the mimetics of naturally occurring peptide hormones, 
MHC-binding beta-peptides, opioid peptides, somatostatin, or amphipathic betapeptide inhibitors of 
membrane-bound proteins [91]. There are different kinds of β-amino acids, the β2- or β3- versions, Fig. (15), 
which can be further distinguished in homologated β-amino acids, possessing an extra C atom, or isomeric β
-amino acids, which maintain the same MW of the corresponding α-analogue. 
 
 
 
Fig.(15) Beta-amino acids 
 
The β3-amino acids are much more utilized than the β2 ones. All appropriately protected β3-derivatives with 
proteinogenic side chains, with a few exceptions, are commercially available. The enzymatic resolution of 
racemates with isolated immobilized enzymes or with cell cultures constitutes a cheap and easy method to 
obtain optically active β-amino acids [92]. Among the many enzymes which have been utilized, chymotrypsin, 
β-lactamases, nitrilases, hydantoinases, lipases, transferases and isomerases, one of the most general and 
substrate-tolerant is the penicillin acylase. 
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The β3-amino acids, with proteinogenic or non proteinogenic side chains, are readily obtained by direct 
Arndt–Eistert homologation of the Boc or Fmoc β-amino acids, Fig (16A). Other homologation procedures 
have been also proposed, but these are generally less efficient. 
Concerning the preparation of substituted β3-amino acids [93], the best options are the functionalization of 
intermediate di- or perhydropyrimidin- 4-ones, Fig (16B), and the conjugate addition to α,β-unsaturated 
esters or imides Fig (16C). The latter procedure was developed in particular with lithium amides of chiral 
amines as nucleophiles, or with chiral auxiliaries. 
 
 
 
 
Fig.(16) Synthesis of beta-amino acids 
 
The β2-amino acids have been prepared by a number of different synthetic strategies [94].The use of chiral 
auxiliaries and catalysts for C(2)–C(3) bond formation is well documented. To mention a specific approach, 
aminomethylating agents or synthetic equivalents (for instance CbzNHCH2Oi-Pr [95] ) are utilized with 
enolates carrying chiral auxiliaries (e.g. Evans oxazolidinones), Fig. (17A). 
β2-Amino acids can be obtained by formation of the C(2)–R bond,via classical β-alkylations of chiral enolates 
(with a chiral auxiliary) derived from N-protected β-aminopropanoic acid, Fig. (17B). 
Alternatively, diastereoselective protonation, hydrogenation, or hydrogen- atom transfer of enols or enolates 
derived from 3- aminopropanoic acid afford β2-amino acids by stereoselective formation of the C(2)-H bond, 
Fig. (17C). In some cases, the enolate was generated in situ, by addition of an N-nucleophile to an acrylate 
carrying the side chain R in the a-carbonyl position. 
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Fig.(17)  Other syntheses of beta-amino acids. 
 
Most of the reactions required the presence of a chiral auxiliary. Conversely, the use of acrylates or 
nitroolefins allowed the convenient synthesis of β-amino acids by enantioselective hydrogenation, with 
rhodium or ruthenium or enzymatic catalyst. Also the enantioselective formation of the C(1)–C(2) bond by 
conjugate additions of carbon nucleophiles to the C=C bond of α,β-unsaturated carboxylic acid derivatives 
can be conducted catalytically Fig. (18). 
 
 
 
Fig.(18) Synthesis of beta amino acids. 
 
Peptides formed by homologated β-amino acids have been studied for years to discover stable secondary 
structures [96-98]. In general, the substitution of α-amino acids by their β-isomers in biologically active peptides 
gave increased activity and enzymatic stability [99].Tests with proteolytic enzymes of all types (from mammals, 
microorganisms, yeasts) and in vivo examinations (mice, rats, insects, plants) showed β- and ɣ-peptides to 
be completely stable towards proteolysis and, as demonstrated for two β-peptides, extraordinarily stable 
towards metabolism. Even the introduction of a single β-amino acid in a strategic position of a native peptide 
can confer stability towards hydrolysis. A few examples of opioid peptidomimetics 
are discussed here. The introduction of β2-isomeric or β3-homologue amino acids in the native sequence of 
endomorphin-1, H-Tyr-Pro-Trp-PheNH2, gave μ-opioid receptor agonists whose affinity largely varied 
depending on the β-amino acid. In particular, the affinity of the modified endomorphins [β2-Pro3] [100], and [β3-
homo-Pro3]endomorphin-1 [101] were in the nanomolar range. It has been also determined that the 
modifications introduced allowed an enzymatic stability enhancement with respect to endomorphin-1 [101,102],  
and in vivo analgesic efficacy [103]. 
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1.4. Cyclization 
The first bioactive cyclopeptide, gramicidin S, was discovered in 1947. Subsequently, a growing number of 
cyclopeptides of marine or microbial origins attracted attention for their potential utility in medicinal chemistry. 
For instance, cyclodepsipeptides widely exist in marine sponges, tunicates, cyanobacteria, fungi, etc. and 
exhibit varieties of biological activities, such as anti-inflammatory, anti HIV, anti-tumor activities, etc [2]. Also 
worth of mention are the antimicrobial cyclopeptides defensins and their derivatives [104,105], and many other 
naturally occurring circular peptides, cyclotides, and proteins [106,107]. 
The interest in these compounds encouraged the development of cyclic mimetics of biologically active, 
naturally occurring linear peptides. In general, the cyclic analogues are much more stable with respect to the 
native peptides, conformationally more defined, and more selective towards the specific target. Some 
selected examples of pharmacologically relevant cyclic peptidomimetics are shown in Fig. (19). 
Different kinds of connections have been utilized to restraint peptide structure into a cyclic framework, 
including macrolactons, ether bridges, biaryl bridges, or by disulfide bridges or mimics, etc. 
Linkage of the N- with the C-terminus of the backbone is quite usual [108], but often the connection of two side 
chains that are not involved in the interaction with the targets (Lys, Ornitine), or eventually the connection of 
either the C- or the N-terminus with one of the side chains, is preferred [109]. A example is the selective and 
potent μ-opioid receptor agonist (15) (Tyr-c[-D-Orn-2-Nal-D-Pro-NMe-Ala]), analogue of the natural occurring 
β-casomorphin-5, a peptide derived from the milk protein β-casein, Fig. (19) [110,111]. 
The connection between Lys and Asp has been utilized in the 31 N-terminal residues of the human 
parathyroid hormone (hPTH) to give a therapeutic osteogenic agent. This analogue contains three lactam 
bridges, thus resulting in a peptide with a helical structure, much more active than the natural compound [112]. 
Disulfide bridges are key structural features of many peptides and proteins, playing a role in folding and 
stabilization of bioactive conformations. Several cyclic peptidomimetics active towards the opioid receptors 
have been prepared by linking Cys residues or penicillamine residues via the oxidation to give a disulfide 
bridge. 
This method was utilized in the cyclic enkephalin analogue DPDPE, Fig. (19), which is active at the δ-opiate 
receptor [3,63]. 
The disulfide group is sensitive to reduction, so many efforts have been made to mimic this kind of 
conformational constraint, (e.g. thioether-bridges, dicarba analogues, RCM). The use of sulphur- based 
bridges is commonly found in the field of opioid peptidomimetics. 
Selected examples are the μ-selective JOM-6, Fig. (19), and the δ-selective JOM-13 [3,113]. The 16-ammino 
acid peptide α-conotoxin MII, having two labile disulfide bonds between the Cys residues in positions 2-8, 3-
16, was further stabilized by cyclization with a range of short peptide linkers. The cyclic MII analogue 
containing a seven-residue linker joining the N and C termini was as active and selective as the native 
peptide, and its resistance to proteolysis against a specific protease and in human plasma was significantly 
improved [114]. Another member of the conotoxin family is ziconotide, a cyclic synthetic analog of the ω-
conotoxin containing three disulfide bonds, presently in the final stages of clinical development as non-opioid 
treatment for severe chronic pain [115]. 
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Other kinds of cyclization strategies can be appreciated in the methylamine-bridged enkephalin derivatives 
MABE [116,117], or in the antiangiogenic compound (16), a dual inhibitor of α5β1/αvβ3 integrin-mediated cell 
adhesion, showing a RGD sequence embedded in a PMRI structure, Fig. (19) [118]. 
Selected examples of cyclopeptidemimetics obtained by connection of phenolic side chains are shown in Fig. 
(19). The analogue of K-13 (17), a natural non-competitive inhibitor of ACE [119], is a competitive inhibitor for 
aminopeptidase B. The compounds family 18 exhibits immunopotentiating activity and were confirmed to 
have antitumor activity, but they lack classical toxicity [120]. Another example is the inhibitor of HIV-1 protease 
(19); the tripeptide sequence Phe-Ile-Val from the natural peptide Ac-Leu- Val-Phe-CHOHCH2-{Phe-Ile-Val}-
NH2 was replaced by a cyclic motif consisting of a tyrosine, a leucine and an alkyl amine [121,122]. 
 
 
 
 
Fig.(19) Selected examples of pharmacologically relevant cyclic peptidomimetics. 
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As for the synthetic methodologies and strategies [123], cyclization can be simply performed in solution 
starting from the linear precursor. Macrolactamization or cycloetherification are performed in the presence of 
carbodiimide activating agents, or phosphonium, uronium, or uronium/aminium-type coupling reagents, the 
latter being more efficient. The process is affected by many parameters, concentration, temperature, base, 
additives, ratio of substrates, time, and requires a careful retrosynthetic analysis to identify the peptide bond 
designed for cyclization, in order to reduce side reactions such as oligomerization and racemization. 
Examples of cyclopeptidomimetics prepared by simple cyclization with diphenylphosphoryl azide (DPPA) are 
the RGD integrin inhibitors developed by Kessler for treatment of human tumor metastasis and tumor 
induced angiogenesis, bone remodelling and osteoporosis [124,125]. N-methylation scan on these cyclic 
peptides c[Arg-Gly-Asp-D-Phe-Val] provided c[Arg-Gly-Asp-D-Phe-NMeVal], Cilengitide, with enhanced 
biological activity and affinity. 
These conformationally defined RGD mimetics have been utilized also for investigating the relationship 
between the 3D display of the pharmacophores and the different selectivity towards different kinds of RGD-
binding integrins [126]. 
Another approach is the cyclization in solid phase. This process required to take into account for parameters 
such as the resin, resin load, the orthogonal protecting groups, and protection/deprotection steps. However, 
the problem of oligomerization is completely suppressed. 
The most common way is through anchoring an amino acid on resin by its side chain or its main chain at the 
C-terminal, Fig. (20). The amino acids whose side chain can be attached onto the resin are Asp (protected 
as Fmoc-Asp-Oallyl, Fmoc-Asp-ODmab, etc.), Glu, Lys, Tyr, Ser. For instance, the antibacterial peptide (20) 
was prepared starting from Fmoc-Asp(resin)-ODmab [127]. 
 
 
 
 
Fig.(20) Peptide cyclization in solid phase. 
 
In the cleavage-by-cyclization approach, the linear precursor anchored on the resin is subjected to 
concurrent cleavage and cyclization,  by using special linkers such as Kaiser’s oxime, active esters, or 
safety-catch linkers. The linker should be stable during the SPPS, but should, at the same time, enable on-
resin acid induced deprotection followed by nucleophilic displacement by the Nterminus. 
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The examples reported show the synthesis of the human calcitonin fragment analogue (21) by using the 
oxime linker [128], and the synthesis of (22) by the use of a safety-catch linker [129]. 
These linkers are masked variants of active esters, and can be activated by a specific chemical modification 
(Boc deprotection with HF, in the selected example), Fig. (21). 
 
 
 
 
Fig.(21) Cleavage - by-cyclization 
 
The arylsilane-based traceless linker strategy can be regarded as a variant of the side-chain anchoring 
method, but the preparation of the aryl silyl amino acid requires several steps, and is limited to Phe and other 
amino acids carrying a hydrophobic side chain. At the end of the peptide synthesis, the C-Si bond is cleaved 
with TFA. The backbone amide linker strategy does not require the side chain functionality, since the 
nitrogen of the C-terminal amino acid is connected to a handle by reductive amination, as shown in the 
synthesis of the cytotoxic stylostatin 1 (23) [130], Fig. (22). 
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Fig.(22) Synthesis of the cytotoxic stylostatin 1. 
 
Bisaryl ether bonds, see for instance (17) and (18), Fig. (19), exist in different naturally occurring 
cyclopeptides including the well known glycopeptide antibiotic vancomycin [2], a effective clinical agent useful 
against bacterial infections caused by drugresistant pathogens. The ruthenium-catalyzed intramolecular 
nucleophilic aromatic substitution allowed to prepare (17) [119]. 
Other synthetic methodologies for the formation of such bond are based on intramolecular aromatic 
substitution, or the Ulmann reaction, the oxidative thallium trinitrate-mediated macrocyclization, or 
arylboronic acid-mediate ring closure [123]. 
A extremely powerful approach to peptide cyclization is the ring-closing methatesis (RCM)[131,132] of dienes. 
The reaction, which can be performed also in water, is catalyzed by the Grubbs catalysts, such as 
benzylidene-bis(tricyclohexylphosphine) dichlororuthenium, Fig. (23) [133,134]. Cross-links consisting of 
hydrocarbons are much more stable in vivo respect to disulphide or lactam bridges, as the latter also occur 
in natural sequences and are susceptible to degradation. To take advantage of the reaction, protected 
allylglycines, or in general amino acid residues bearing an alkene side chain, can be incorporated into one 
chain by solid phase peptide synthesis, and they can be cyclized by the use of Grubbs catalysts [38,135]. One 
example is the mimic of the domain BH3 of the pro-apoptotic sub-family of proteins, forced into a helical 
conformation through a metathesis reaction, resulting in a significantly enhanced stability and an altered in 
vitro and in vivo activity [136]. Other examples are shown in Fig. (23). 
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Fig.(23)  Ring-closing methatesis. 
 
1.5. β-Turn Mimetics 
β-Turns are the most frequently mimicked protein secondary structures. They are defined as tetrapeptide 
sequences where the distance between the Cα of the residues i and i+3 is less or equal to 7 Å, Fig. (24). The 
turn can be stabilized by a ten membered ring intramolecular H-bond, or by chelation of a cation, such as 
Ca++. An ideal β-turn mimic has a rigid scaffold that orients the side chain residues in the same direction as 
the natural protein, while conferring good solubility and resistance to enzymatic degradation [137]. 
Unfortunately, many of the peptidomimetics synthesized by the use of these building blocks were inactive. 
Selected examples of β-turn mimetics are reported in Fig. (24) [138,139]. A nice example of turn mimetic is the 
compound (25), which has been utilized to prepare different biologically active peptidomimetics. In particular, 
a wide library of analogues was prepared on solid support and screened in binding assays against the fMLF 
receptor [137]. 
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Fig.(24) Beta-turn mimetics. 
 
The preparation of the scaffolds can be very tricky, in particular for the eventual presence of stereogenic 
centres. For instance, the bicyclic scaffold (24) was obtained by RCM, Fig (23) [140]. A very effective strategy 
to favour a geometry compatible with the β-turn requisites is to cyclize the peptide using a covalent linkage, 
by the amide nitrogen, the α-carbon or a side chain [141], Fig. (25). The Freidinger lactam (26) was designed 
as a mimic of Gly-Leu, and embedded in the backbone of LHRH [142,143].The new analog showed greater 
potency than its parent hormone, which was attributed to a higher binding affinity for its receptor and 
increased metabolic stability. 
 
 
Fig.(25) Freidinger lactam. 
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A β-turn peptidomimetic based on a spiro-lactam scaffold was introduced within the structure of Substance P, 
H-Arg-Pro-Lys-Pro-Gln-Gln-PhePhe-Gly-Leu-MetNH2, a tachykinin neuropeptide with therapeutic potential 
towards gastrointestinal inflammation, arthritis, Parkinson’s and Alzheimer’s diseases, in place of the Phe8- 
Gly9 portion. Indeed, SAR studies indicated the presence of a β- turn centered on the sequence Phe8-Gly9-
Leu10, fundamental for receptor binding. The incorporation of the spiro-lactam peptidomimetic GR71251 (27) 
resulted in a potent antagonist of the NK1 Substance P receptor, Fig. (26) [144]. 
 
 
 
 
Fig.(26) Example of spiro-lactam scaffold. 
 
1.6. CONCLUSIONS 
In spite of their potential as therapeutic agents, natural peptides have found few practical applications, 
mainly due to their poor stability in physiological conditions. Therefore, many efforts have been profused to 
design peptide-derived compounds with improved stability and ability to mimic peptide functions. The 
peptidomimetic approach represents a well-established strategy for developing novel, effective non-toxic 
therapeutic agents. Apart from the many uses in pharmacology, recent evidence have stated that the 
peptidomimetic strategy is the front runner in biotechnology and nanotechnology, for creating new 
biomaterials and biodevices, biosensors, bioelectronics, to perform specific operations within a physiological 
environment. In this paper we have discussed the main classes of peptide modifications intended to increase 
peptide stability towards proteases. The pharmacokinetic profile of a bioactive natural peptide can be 
strongly improved by introducing peptide bond mimetics, unnatural amino acids, conformational constraints, 
or non-peptide scaffolds. Many of these modifications are currently considered routine, some others are still 
pioneering work. These classes have been illustrated by means of selected, representative examples, 
supported by a brief overview of the synthetic methodologies so far developed. 
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Chapter 2 
Cyclopeptide Analogs for Generating New Molecular and 3D Diversity 
 
Abstract  
Cyclic peptides have been often utilized as metabolically stable, conformationally restricted mimics of 
different kinds of biologically active peptides, including peptide antibiotics, endogenous opioid peptides, 
integrin inhibitors, peptide hormones, anticancer peptides, and so on. And in particular, cyclic compounds 
which can mimic important secondary structure elements such as β-turns are of outstanding importance. 
Since greater chemical and structural diversity are primary features to pursue for finding novel leads for 
pharmacological and biotechnological applications, we explored the potential utility of the retro-inverso 
modification. We introduced this modification into the sequence of 13-membered cyclotetrapeptides, which 
can be regarded as easily available, conformationally stable analogs of cyclotetrapeptides composed of all α-
residues. 
In this paper we describe the synthesis of a selected mini-library of partially modified retro-inverso cyclic 
peptides as conformationally homogeneous scaffolds for medicinal chemistry applications. The different 
compounds have been obtained by simple scramble of the same residues. Finally, we discuss the 
conformational features of such molecules as turn mimics. The comparison suggests that the retro-inverso 
modification allows a higher degree of three-dimensional diversity then normal peptides.  
 
2. Introduction    
Protein-protein and peptide-protein/receptor interactions play a key role in most biological processes and in 
mediating signals, thus representing important classes of targets for human therapeutics. In addition, other 
peptides or short proteins are the natural inhibitors or activators of such interactions. Although these 
biologically active molecules have a great potential for pharmaceutical and medical applications, they 
generally need to be modified to overcome their poor pharmacological properties, in particular their 
susceptibility to enzymatic degradation [1]. Peptides are degraded by proteases in the stomach and should be 
administered intravenously. In the blood, peptides are degraded and cleared from the circulation very rapidly. 
Peptides are often too water-soluble to be able to pass the biological barriers that separate them from their 
targets in the cells and in the brain. Apart from their to poor bioavailability, peptides are highly flexible, a 
quality that counteracts a good selectivity towards a specific receptor. 
All these disadvantages prevent peptides from becoming drugs and stimulate efforts to replace them with 
modified analogues capable of mimicking or antagonizing the biological action of the parent compounds. 
Many kinds of modifications have been utilized, such as N- or C-α-substitution, introduction of D-amino acids, 
cyclization, glycosylation. In addition, amino acids can be deleted, or added, or replaced with 
conformationally constrained or novel amino acids; backbone peptide bonds can be replaced with surrogates, 
or the backbone may be replaced altogether by a non-peptidic structure, etc [Errore. Il segnalibro non è definito.-3]. 
Such peptidomimetics are generally more stable than peptides and less easily cleared from the blood stream 
[4].It is worth mention that many of the above described modifications designed to enhance peptide activity 
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and stability can also be found in peptides of microbial origin, such as Bestatin, Vancomycin, Lantibiotics, 
Epoxomicin, Lactacystin, etc. or of marine origin, including the Conotoxins, Hemiasterlin, Dolastatins, and 
many others peptides endowed with biological and pharmacological activity as antibiotic or anticancer agents 
[Errore. Il segnalibro non è definito.]. 
Over past decades, with the development of combinatorial techniques huge arrays of new molecules, 
including peptides, peptidomimetics, or non-peptidomimetics, can be produced in relatively short periods of 
time. Besides, various experimental high throughput screening methods as well as computational methods 
for rational design of peptidomimetics have been developed [5]. 
Despite the number of successful examples reported in the literature, the development of effective methods 
for finding new bioactive peptidomimetics as drug leads remains a nontrivial problem. In addition, even the 
biggest libraries of compounds used in screening may not reflect the rich chemical diversity of the much 
smaller numbers of natural products [6]. 
The total descriptor space that encompasses all the molecules that could in principle be created is often 
referred as ‘chemical space’, a or ‘multi-dimensional descriptor space’ [7]. Among the many descriptors which 
can be utilized to characterize a set of biomolecules (sequence, molecular mass, dimension, lipophilicity, oral 
absorption, side effects, toxicity, etc.). Molecular Topology deals with the complicated problems of including 
information on three-dimensional (3D) molecular structure and shape [8].Topological information obtained 
from the analysis of naturally occurring peptides can be elaborated by means of mathematic models or 
virtual screening. The resulting topological model can be utilized for predicting the structural features 
required to give a peptidomimetic high biological activity. Many practical problems arise when the synthesis 
of such an “ideal” molecule leads to the generation of synthetically unfeasible or chemically unstable 
structures. 
In many cases, it has been observed that naturally occurring peptides or proteins exert their biologically 
activity by means of relatively small, ordered regions [9-10]. As a consequence, the ideal compound can be in 
principle substituted by a smaller, simple molecule which can structurally mimic the fundamental units of 
protein architecture. Many kinds of molecular peptidomimetic or non-peptidomimetic scaffolds capable of 
mimicking the structure of specific, biologically relevant regions of a peptide or a protein have been reported 
in the literature [11-16]. In particular, cyclic tetrapeptides or analogs [17-20] have been often used as scaffolds for 
the design of different kinds of turn-like structures. 
We estimated that, in comparison to the parent peptides, peptidomimetics should allow a higher number of 
structural combinations, giving rise to higher topological diversity. In this paper we describe the preparation 
of a selected library of cyclotetrapeptide mimetics as scaffold models, based on a partial retro-inverso (PMRI) 
structure, Fig.(1), obtained by introduction of a bilateral diamine and a diacid in different positions. Further, 
we discuss and compare the conformational features of some of these compounds (see Results, and 
Discussion sections). 
The convention for the construction of peptide sequence representation proceeds from the amino terminus, 
written on the left, to the carboxy terminus, written on the right, Fig.(1), “normal” peptide. Hence, it is possible 
to envisage the retro-isomer of a peptide (RI), that is an isomer in which the direction of the sequence and 
each amino acid stereochemistry are reversed.  
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Fig.(1). Comparison of the structures of a "normal" peptide, a retro-inverso peptide (RI), and a partially modified retroinverso peptide 
(PMRI). 
 
In a partially modified retro-inverso (PMRI) peptide, this modification involves some of the residues, while the 
rest of the structure is unaltered. A geminal diamine or diacid can be eventually introduced to connect the 
normal and the retro-inversion sections [21-26]. The retro peptide bond of a RI or a PMRI peptide can be 
regarded as a true peptide bond surrogate; the presence of this modified peptide bond is expected to 
increases the biological half-life of the compound.  
 
2.1. Results  
In this section we describe the preparation of the 13-membered cyclotetrapeptides 7-10, based on a partial 
retro-inverso (PMRI) structure, by introduction of a 1,2-diamine as a β 2-amino acid mimetic, a L-
phenylalanine, a L-alanine, and a malonyl residue in a diverse position of the peptidic sequence. 
The diamine (2-amino-1-benzyl-ethyl)-carbamic acid benzyl ester (1) has been easily obtained by reduction 
of Cbz-Phe-NH2 [30] with BH3, Fig. (2) [31]. Optically pure, differently functionalized diamines, can be prepared 
by a variety of methods from amino acids, amino alcohols, alkenes, unsaturated amines, dienes, aziridines, 
imines, diols, dihalides, nitroalkenes, amino ketones, etc [32]. The availability of all of these methods allows in 
principle to obtain a high chemical diversity. 
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Fig.(2). Synthesis of substitued 1,2-diamine. 
 
To test the feasibility of synthesizing a cyclotetrapeptide containing a N-substituted 1,2-diamine, we prepared 
also the diamine 2. [2-(4-Methyl-benzylamino)-ethyl]-carbamic acid tert-butyl ester (2) has been prepared by 
reduction with NaBH4 in methanol (MeOH) of the corresponding imine obtained in turn by condensation of (2-
aminoethyl)carbamic acid tert-butyl ester [33] with p-methylbenzaldehyde in the presence of MgSO4 in DCM. 
The diamines were coupled to the remaining residues under standard in-solution conditions. As an example, 
the synthesis of 7 is shown in Fig. (3). 
 
 
 
Fig.(3). In-solution synthesis of cyclopeptide. 
 
Coupling the Cbz-diamine (Cbz: carbobenzyloxy) with N-Fmoc protected Phe (Fmoc: 
fluorenylmethoxycarbonyl) gave the dipeptide 3 in good yield. Deprotection of the dipeptide by treatment with 
2M dimethylamine (DMA) in tetrahydrofurane (THF) followed by coupling with Fmoc-Ala gave the tripeptide 4. 
The geminal diacid has been introduced as phenylmethyl hydrogen propanedioate 5, easily synthesized from 
46 
 
Meldrum’s acid and benzyl alcohol [34], giving tetrapeptide 6. The compounds were characterized by HPLC-
MS analysis. Interestingly, we observed that the N-protected, linear intermediate peptides 3, 4, and 6 
showed a noteworthy solubility in chlorinated solvents, such as chloroform and DCM, while they were 
practically insoluble in solvents such as ether, ethylacetate, and very poorly soluble in dimethylformamide 
(DMF) and MeOH, probably due to the presence of the 1,2-diamine. On the other hand, the N-deprotected 
peptides were highly soluble in ethylacetate or ether. This observation prompted us to attempt purification of 
the intermediate protected peptides by simple precipitation and filtration, leading to an almost solid phase-
like stepwise synthesis (see Materials and Methods). As an example, the HPLC analysis of 6 after simple 
precipitation is shown in Fig. (4).  
 
 
 
Fig.(4). HPLC analysis (conditions: see Experimental Section) of the crude reaction mixtures for 6 (A), Rt=10.02 min, and 7 (B), Rt= 
4.72 min. 
 
Final deprotection of 6 by catalytic hydrogenation and cyclization of the fully deprotected tetrapeptidemimetic 
with diphenylphosphoryl azide (DPPA) gave the cyclic compound 7 in good yield. The HPLC analysis of the 
crude reaction mixture after work up is reported in Fig. (4). The compound was purified by semi-preparative 
RP-HPLC (see General Methods). Purity was determined to be 94% by RP-HPLC analysis. 
In a similar way, we synthesized the other cyclopeptide analogs, Fig. (5). The introduction of the diamine and 
the diacid in diverse positions of the sequence gave rise to different compounds having one, two or three 
retro-peptide bonds. According to the IUPAC nomenclature, the Ψ notation for amide bond surrogates 
indicates that the amide bond between the two residues is reversed. Therefore, the peptide 7 can be referred 
to as [ΨPhe-Ψ(NHCO)-Gly-Ala-Phe], 8 as [ΨPhe-Ψ(NHCO)-Ala-Ψ(NHCO)-Gly-Phe], 9 as [ΨPhe-Ψ(NHCO)-
Ala-Ψ(NHCO)-Phe-Ψ(NHCO)-Gly-], and 10 as [N-Bz-ΨAla-Ψ(NHCO)-Ala-Ψ(NHCO)-Gly-Phe], Fig. (6). A 
higher number of combinations is possible, but at the present stage we are mostly interested in addressing 
the atypical topological features of the cyclopeptidomimetics. 
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Fig.(5). Structures of the PMRI cyclotetrapeptides containing one (7), two (8,10), and three (9) retro-peptide bonds, and a N-substituted 
diamine (10). 
 
The conformational analyses of the cyclopeptides 7, 8 [35], and 9 were performed by spectroscopy and 
Molecular Dynamics (MD) simulations. The NMR analysis was conducted using standard techniques at 400 
MHz in DMSO-d6. We could not perform experiments in water, for the peptides were practically insoluble. 
This is a familiar situation when peptidomimetics are used instead of normal peptides; in these situations 
DMSO is generally accepted as the solvent of choice [36]. For each peptide, the 1H-NMR revealed a single 
set of resonances, suggesting conformational homogeneity or a fast equilibrium, Fig. (7) [37-38]. The 
unambiguous assignment of the resonances was performed by COSY analysis. 
 
 
Fig. (6). 1H-NMR of 7,8, and 9, performed at 400MHz in DMSO-d6, r.t. For the attribution of diamine protons NHa, NHb, Hc (see Fig.5). 
 
2.1.1. VT-1H-NMR (variable temperature) experiments were utilized to deduce the presence of H-bonds 
(Table 1). The analyses indicated that in cyclopeptide 7, PheNH very likely participates to a strong H-bond, 
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as revealed by the Δδ/δt value, -0.4 ppb/°K [37,39]. On the other hand, in 8 the two NHs of the diamine could 
be involved in H-bonds. Indeed, the Δδ/δt values for NHa, and NHb are (ppb/°K) +1.4 and -1.2, respectively. 
For 9, the VT-1H-NMR analysis suggests that the protons involved in H-bonds could be AlaNH, and NHa, 
being the respective Δδ/δt values (ppb/°K) -1.4 and -1.3. These evidences are suggestive of the existence of 
a population of ordered structures with definite secondary structural elements, albeit for 8 and 9 different 
structures in equilibrium could exist. 
 
2.1.2. 2D-ROESY data were utilized to investigate the spatial disposition of molecular backbones. The highly 
diagnostic region of amideNH – Hα and amideNH – Hβ cross peaks of 9 is reported in Fig. (7). 
 
 
 
Fig. (7). Inset of 2D-ROESY of 9, 400MHz, DMSO-d6, r.t. Relevant cross-peak between non-vicinal hydrogens are labelled. For the 
attribution of diamine protons NHa, NHb, Hc, see Fig.(5). 
 
For the absence of Hαi -Hαi+1 cross peaks, indicative of a cis peptide bond conformation, all of the ω bonds 
were set at 180°. Conformations consistent with the spectroscopic analysis were obtained by restrained MD, 
using the distances deduced from ROESY as constraints, and minimized with AMBER [23] force field, with ε = 
4 x r. Simulations were conducted in vacuo using a set of 100 random structures generated by means of a 
unrestrained high-temperature MD. The structures were subjected to restrained MD with a scaled force field, 
followed by a high-temperature simulation with full restraints, after which the system was gradually cooled. 
After minimization, the structures with the lowest internal energy and the least number of violations of the 
experimental data were selected and analyzed, Fig. (8). 
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Fig. (8). Representative low-energy structures of 7, 8, and 9 consistent with ROESY analysis. 
 
None of the structures confirms the presence of H-bonds as predicted by VT-1H-NMR analysis, probably for 
the occurrence of a fast equilibrium between slightly different geometries, whose average in the NMR time 
scale gives the NMR-derived structure. Nevertheless, ROESY-derived structures and VT-NMR analysis are 
consistent. The cyclopeptide 7 is roughly compatible with a structure having the diamine and Phe in the 
positions i+1, i+2 of a pseudo β-turn. However, an alternative conformation showing the residue Phe in the 
position i+1 of a inverse ɣ-turn cannot be ruled out. The structure of 8 is compatible with the presence of two 
alternative type I β-turns, one having Phe-diamine in the positions i+1, i+2, and the other Ala-diamine. Finally, 
the structure of 9 is compatible with a type II β-turn having in the positions i+1, i+2  the diamine and Ala, and 
a pseudo inverse ɣ-turn centered on the diamine. The comparatively higher number of ROESY-derived 
distance constraints determined for 7 (see Materials and Methods Section) suggests that this cyclopeptide 
likely adopts a more ordered conformation respect to 8 and 9. 
To estimate the behaviour of the cyclopeptides in water, the structures derived from NMR in DMSO were 
analyzed by unrestrained MD for 4.5 ns in a box of explicit, equilibrated water molecules. During the 
simulations, the structural features observed in the former solvent were confirmed. In addition, the 
examination of the trajectories revealed the occurrence of H-bonds in agreement with VT-NMR analysis. The 
cyclopeptide 7 shows an explicit H-bond between PheNH and malonylCO(1), Fig. (9), 7. Occasionally, a H-
bond between NHb and malonylCO(2) can also be observed (for the attribution of the two carbonyls 
malonylCO(1), malonylCO(2), see Fig. (5). For 8, the simulation shows two alternating H-bonds between NHb 
and malonyl CO(1), Fig. (9), 8a, and between NHa and malonylCO(2), Fig. (9), 8b. For 9, the simulation 
confirms the presence of a H-bond between AlaNH and malonylCO(2), Fig. (9), 9a. The simulation evidences 
also a structure compatible with a inverse β-turn centered on the diamine, Fig. (9), 9b, albeit an explicit H-
bond between NHa and malonylCO(2) cannot be observed.  
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Fig. (9). Representative structures of 7, 8, and 9 showing relevat secondary elements 
 
2.2. Discussion 
In recent years we have been interested in cyclic peptides as restricted mimics of biologically active, 
naturally occurring peptides [40-41]. And in particular, we pursued the design of small, conformationally defined 
cyclic peptides or analogues that mimic important secondary structures such as β- or ɣ-turns, Fig.(10). 
Among the different cyclic peptides, cyclotetrapeptides are considered the smallest system capable to 
reproduce all kinds of turns, Fig.(10) [17], but their potential utility is often diminished by difficult synthesis. On 
the other hand, it has been reported that cyclotetrapeptides containing a distinct β-amino acid within the 
sequence may be easier to synthesize and conformationally more stable with respect to the “normal” 
cyclotetrapeptides composed of all α-amino acids, and for these reasons it has been suggested that they can 
be effectively utilized as β-turn mimetics [42,43]. Two different β-amino acids can be utilized; β-amino acids 
having the side chain at the α-carbon are named β2-amino acids, while those having the side chain at the β-
carbon are named β3-amino acids, Fig.(10). 
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Fig.(10). Top: β- and ɣ-turnstructures; bottom: cyclotetrapeptides composed of all α-amino acids, and13-membered analogues including 
a β2- or β3-amino acids. 
 
In order to overcome the typical limitations associated with the peptidic structure as mentioned in the 
Introduction, we turned our attention to the partial retro-inverso peptide bond modification, Fig.(1). We 
estimated that the introduction of the retro-inverso modification should lead to distinct 3D structures, 
depending on the specific sequence. In normal tetrapeptides, the 3D structure is largely determined by the 
specific combination of residue chiralities, while the nature of the residue, and hence the sequence, is less 
important. Therefore, in normal cyclopeptides, changing the positions of two residues (for instance from: 
Xaa1-Xaa2-Xaa3-Xaa4, to Xaa1-Xaa3-Xaa2-Xaa4), in general has no or little consequences on the overall 3D 
structure of peptide backbone. On the contrary, the reversal of the sequence in a peptide containing a retro 
modification (such as for instance from: Xaa1-diamine2-Xaa3-diacid4, to Xaa1-Xaa3-diamine2-diacid4) has 
some consequences, since a diamine or a diacid is not comparable to an amino acid. Further, the 
substitution of a normal amino acid with the same residue in retro-fashion corresponds to positioning its side 
chain on the opposite side of the molecule. Finally, the 3D structures are less predictable, since unusual 
intramolecular H-bonds can occur. 
Therefore, we synthesized a small library of cyclic peptidomimetics by introducing a 1,2-diamine as a β2-
amino acid mimetic, a L-phenylalanine, a L-alanine, and a malonyl residue in a diverse position of the 
peptidic sequence. To confirm the value of the cyclopeptide mimetics in generating new spatial diversity, we 
investigated the in-solution structures of 7, 8 and 9. As expected, the cyclopeptides revealed distinct 
geometries and characteristic secondary structural elements, Fig. (8) and Fig. (9).  
In addition, the PMRI cyclotetrapeptides represent alternative 13-membered scaffolds respect to those 
composed of α-amino acids plus a β-residue, reported in Fig. (10) [42]. For instance, the peptidomimetic 7, [β
Phe-Ψ(NHCO)-Gly-Ala-Phe], can be considered a PMRI analogue of the recently reported β2-amino acid-
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containing CTP, c[(S)-β2hPhe-D-Pro-Lys-Phe] [42] 11, Fig. (11). Indeed, the two peptides 7 and 11 share a 
common stereochemistry pattern. The first residue in 7, the (S)-diamine, matches with the first residue (S)-β
2Phe in 10. Secondly, the malonyl mojety, Ψ(NHCO)-Gly, can act as a D-amino acid, mimicking D-Pro in 11. 
Finally, the L-Ala in 7 matches the stereochemistry of L-Lys in 11, and the last residue Phe is the same for 7 
and 11. 
 
 
Fig.(11). Comparison of the PMRI cyclic RGD mimetics 12 and 13 as αvβ3 
 
The comparison between the two structures proves that the two scaffolds show distinct features, Fig. (11), in 
particular for the presence of a cis β-Phe-D-Pro omega bond in 11, while 7 shows an all-trans ω bond 
conformation. Besides, the two structure also differ for the position of β-Phe side chain, that in 11 is placed 
below the plane, while in 7 it points towards the opposite side. 
Finally, we have recently performed a preliminary test of the potential utility of the PMRI-CTP scaffolds in 
medicinal chemistry, by synthesizing a couple of simple PMRI cyclotetrapeptides, c[βAla-Ψ(NHCO)-Asp-Ψ
(NHCO)-Gly-Arg] (12), and c[ β Ala- Ψ (NHCO)-Asp- Ψ (NHCO)-Gly-D-Arg] (13), as RGD (Arg-Gly-Asp) 
mimetics, Fig. (12) [35]. 
 
 
 
 
 
Fig.(12). Structures of the PMRI cyclic RGD mimetics 12 and 13 as αvβ3 integrin inhibitors. 
 
We tested their ability to inhibit the adhesion of an αvβ3 integrin-expressing cell line, SK-MEL-24, to the 
specific ligand fibronectin. The RGD mimetics 12 and 13 showed IC50 values of 5·10-4 and 3.7·10-7 M, 
respectively [35]. The two cyclopeptides differ for the inversion of configuration at Arg. This leads to a different 
display of the side chains of Asp and Arg, which lie on opposite sides in 11, while in 12 they lie on the same 
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side of the molecule. It is well known that a comparatively short distance between the β carbons (7-8 Å) of 
Asp and Arg favoured selective binding to αvβ3 integrins over other RGD-binding integrins [44,45]. The 
inhibitory activity displayed by 13 confirmed that the pharmacophores actually adopt spatial positions 
compatible with an efficient ligand-receptor interaction. 
 
2.3. Materials and Methods  
2.3.1. General Methods. Unless stated otherwise, standard chemicals were obtained from commercial 
sources and used without further purification. Analytical RP-HPLC was performed with an ODS column, 4.6 
m particle size, 100 Å pore diameter, 250 mm, DAD 210 nm, from 9:1 H2O/CH3CN to 2:8 H2O/CH3CN in 20 
min at a 1.0 mL/min flow, followed by 10 min at the same composition. Semi-preparative RP-HPLC was 
performed on a C18 column, 7 μm particle size, 21.2 x 150 mm, from 9:1 H2O/CH3CN to 3:7 H2O/CH3CN in 
15 min, at a 12 mL/min flow.  
1H NMR spectra were recorded using the five-millimeter tubes, using 0.01 M peptide at 400 MHz at room 
temperature. Chemical shifts are reported as δ values relative to the solvent peak. VT-1H-NMR experiments 
were performed over the range 298-348 °K. 2D spectra were acquired in the phase sensitive mode and 
processed using a 90° shifted, squared sine-bell apodization. 1H-NMR resonances were assigned from 
gCOSY and ROESY spectra. gCOSY experiments were recorded with a proton spectral width of 3103 Hz. 
ROESY experiments were recorded with a 300 ms mixing time with a proton spectral width of 3088 Hz. 
 
2.3.2.General procedure for peptide coupling. The iterative couplings and deprotection steps have been 
performed in the same 100 mL two-necked round bottom reactor, with a stopcock equipped with a fritted 
glass filter. The reactor was loaded with a solution of the amino partner (0.5 mmol) in 9/1 DCM/DMF (5 mL). 
In a separate flask, a mixture of HOBt (0.6 mmol) and N-protected amino acid (0.5 mmol) in 9/1 DCM/DMF 
(5 mL) was mechanically shaken at r.t. After 5 min the homogeneous mixture was transferred into the reactor 
while stirring, then EDCI-HCl salt (0.6 mmol), and TEA (1.5 mmol) were added while stirring at r.t. After 4 h 
the mixture was diluted with Et2O (30 mL) and 0.5 HCl (10 mL) while stirring; after 5 min the liquids were 
removed through the stopcock under moderate suction. The crude peptide which precipitated was collected 
over the filter. The precipitate w1as washed with Et2O (30 mL) and sat. Na2CO3 (10 mL). The liquids were 
eliminated again through the stopcock under suction, and the peptide was triturated with Et2O (30 mL). The 
crude peptides were dried at reduced pressure. The peptides (65-85% yield) were characterized by ES-MS 
analysis, see also Fig. (4), and were utilized without further purifications. Purities were determined 70-80% 
by RP-HPLC/ES-MS analysis (see General methods). 
 
2.3.3. Boc group deprotection was performed in the same reactor by treatment with 1:2 TFA/DCM at r.t. After 
20 the reactor was equipped with a condenser and solvent was removed at reduced pressure and moderate 
heating. The resulting oily residue was treated again for 20 min with 1:2 TFA/DCM. After final evaporated of 
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the mixture, the residue was triturated with Et2O, solvent was filtered under suction, and the collected 
deprotected amine-TFA salt which precipitated was used for the next coupling without further purification.  
 
2.3.4. Fmoc group deprotection was performed in the same reactor by treatment with 2M DMA in THF at r.t. 
After 20 min the reactor was equipped with a condenser, and solvent was removed at reduced pressure and 
moderate heating. The treatment with DMA in THF was repeated. After final evaporation of the solution, the 
residue was triturated with 1:3 Et2O/cyclohexane, solvent was filtered under suction, and the collected 
deprotected amine which precipitated was used for the next coupling without further purification.  
 
2.3.5. Cbz and benzyl group deprotection was performed in a 50 mL two-necked round bottom flask, by 
treatment of the protected tetrapeptide with H2 and cat. Pd/C in EtOH at r.t. After 5 h the mixture was filtered 
over celite under suction, and solvent was evaporated at reduced pressure. The residue was used without 
further purification.  
 
2.3.6. General procedure for peptide cyclization. A mixture of deprotected linear tetrapeptide (0.2 mmol), 
DPPA (0.5 mmol), NaHCO3 (3 mmol), in DMF (60 mL) was stirred in a 250 mL two-necked round bottom 
flask at r.t. for 48 h. After that, solvent was distilled at reduced pressure, the residue was diluted with water, 
and the mixture was extracted three times with DCM. The solvent was evaporated under reduced pressure, 
and the residue was precipitated from DCM/Et2O. For the RP-HPLC analysis of the crude cyclopeptide, see 
also Fig. (4). The cyclopeptides were purified (60-70% yield) by semi-preparative RP-HPLC (see General 
Methods). Purities were determined 93-97% by RP-HPLC analysis (see General methods). 
 
2.3.7. Conformational Analysis 
The Restrained MD simulations were conducted using AMBER [27] force field with a distance dependent ε= 
4.0xr. A 50 ps simulation at 1200 °K was used for generating 100 random structures that were subsequently 
subjected to a 20 ps restrained MD with a 50% scaled force field at the same temperature, followed by 20 ps 
with full restraints (distance force constant: 7 kcal/mol Å2), after which the system was cooled in 5 ps to 50 °K. 
For the absence of Hα(i, i+1) ROESY cross peaks, the ω bonds were set at 180° (force constant: 16 
kcal/molÅ2). Apart from the constraints on the ω bonds, only ROESY-derived distance constraints were 
included in the restrained molecular dynamics. For 7, 8 and 9, 27, 24 and 20 ROESY-derived constraints 
were used, respectively. ROESY intensities were classified according to a calibration against the intensity of 
geminal protons (Tables 2-4) Very strong, strong, medium, and weak signals were associated to distances of 
2.3 2.6, 3.0, and 4.0 Å, respectively. Geminal couplings and other obvious correlations were discarded. The 
resulting structures were minimized with 3000 cycles of steepest descent and 3000 cycles of conjugated 
gradient (convergence: 0.01kcal/Å mol). The structures that showed the lowest internal energy and the least 
number of violations of the experimental data were selected and analyzed. 
MD simulation in explicit water was performed for 4.5 ns at 298°K using the AMBER force field in a 
30x30x30 Å box of standard TIP3P models of equilibrated water [28], with a minimum solvent-solute distance 
of 2.3 Å, at constant temperature and pressure (Berendsen scheme [29], bath relaxation constant 0.2). 
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Table 1. Δδ/δt values (ppb/°K) of amide protons for 7, 8, and 9, determined by VT-1H-NMR analysis in DMSO-d6 at 400 MHz over the 
range 298-348 °K 
Compd PheNH AlaNH NHa NHb 
7 -0.4 -5.2 -5.0 -1.3 
8 -5.0a -5.5a +1.4 -1.2 
9 -1.9 -1.4 -1.3 -2.0 
a PheNH and AlaNH in 8 are superimposed. 
 
Table 2. Non obvious ROESY cross-peaks observed for 7 in DMSO-d6 at 400 MHz (r.t.). 
Cross peak a Intensity Cross peak a Intensity 
AlaNH-Me s AlaNH-COCH2CO vs 
AlaNH-AlaHα m AlaNH-PheNH vs 
AlaNH-NHa w NHa-diamHβ s 
NHa-COCH2CO vs NHa-diamHα m 
NHa-NHb s NHa-PheNH w 
NHa-Hc(2.6) m diamArH-Hc(3.7) m 
diamArH-diamHα s diamArH-NHb m 
PheArH-Me s PheArH-PheHα vs 
PheNH-Me s PheNH-AlaHα m 
PheNH-PheHα s PheNH-NHb s 
NHb-Hc(2.6) vs NHb-Hc(3.7) s 
NHb-diamHα m NHb-AlaHα w 
NHb-PheHα s PheHα-Me w 
PheHα-AlaHα- m   
aFor the attribution of diamine protons NHa, NHb, Hc.(Fig.5) 
 
Table 3. Non obvious ROESY cross-peaks observed for 8 in DMSO-d6 at 400 MHz (r.t.). 
Cross peak a Intensity Cross peak a Intensity 
AlaNH-NHa s AlaNH-COCH2CO(3.2) vs 
AlaNH-AlaHα m AlaNH-COCH2CO(3.3) w 
PheNH-COCH2CO(3.2) w AlaNH-CH3 s 
PheNH-COCH2CO(3.3) vs PheNH-NHb s 
NHb-PheHα m PheNH-PheHα m 
NHa-NHb m NHb-Hc m 
diamArH-diamHα m diamArH-NHa m 
diamArH-NHb m diamHβ(2.75)-diamArH s 
NHa-diamHβ(2.6) m NHa-AlaHα m 
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diamHα-Hc s NHa-diamHα m 
diamHα-diamHβ(2.6) m diamHα-diamHβ(2.75)  m 
PheHα-PheHβ(2.9) m PheHα-PheHβ(3.1) m 
aFor the attribution of diamine protons NHa, NHb, Hc.(Fig.5) 
 
Table 4. Non obvious ROESY cross-peaks observed for 9 in DMSO-d6 at 400 MHz (r.t.). 
Cross peak a Intensity Cross peak a Intensity 
PheNH-PheHα m PheNH-COCH2CO(3.2) vs 
NHb-NHa m NHb-diamHα m 
NHb-COCH2CO(2.9) vs AlaNH-NHa vs 
AlaNH-PheHα w AlaNH-AlaHα m 
AlaNH-PheHβ s AlaNH-Me m 
diamArH-diamHα s diamArH-Hc(3.5) m 
diamArH-Me m NHa-AlaHα m 
NHa-diamHα s NHa-Hc(3.5) m 
NHa-Me m diamHα-Hc(2.9) vs 
diamHα-Hc(3.5) m Hc(3.5)-diamHβ s 
a For the attribution of diamine protons NHa, NHb, Hc, see Fig. (5). 
 
2.4.  Conclusions 
In summary, we believe that the compounds described can be considered useful scaffolds for the design of 
stable, easy available, conformationally defined novel peptidomimetics, which allow for the exploration of a 
variety of chemical and spatial diversity.  
The introduction of the retro modification in a 13-membered cyclotetrapeptide sequence gave us access to 
structurally diverse molecular scaffolds. The comparison of the structures of 7, 8 and 9, which share the 
same composition, yet differ in the scrambling of the sequence, provided evidence that the scaffolds show 
distinct features. The results seem to indicate that the combination of the different residues in the modified 
cyclopeptides gives rise to a higher degree of three-dimensionally diverse compounds with respect to normal 
cyclopeptides. 
The availability of topologically diverse peptidomimetic scaffolds can be useful in a large range of 
biochemical, pharmacological, biotechnological and medical applications. Indeed, topologically definite 
scaffolds can be introduced in a number of peptide-derived compounds: integrin inhibitors, antibiotics, 
probes for non-invasive imaging, organocatalysis, self-assembling structures, nano-structures, peptide-
based bio-materials, and finally bio-electronic devices such as bio-microchips, biosensors, and peptide-metal 
wires [Errore. Il segnalibro non è definito.]. 
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Chapter 3 
Synthesis and Conformational Analysis of Cyclotetrapeptide Mimetic β-Turn 
Templates and Validation as 3D Scaffolds 
 
3. Introduction  
The initial event that is essential for modulating a biological response is molecular recognition between a 
ligand and a receptor. 
For peptide or protein ligands, recognition generally involves the interaction of restricted portions of the outer 
3D surface with a complementary surface on the receptor. Peptide backbones generally serve as scaffolds 
for the key side chains that participate in the interaction. Very often, the backbones adopt secondary 
structure motifs, g- or b-turns, or various kinds of helices. As a consequence, the bioactive compounds can, 
in principle, be substituted by smaller, simpler molecules that mimic the folded architectures [1]. 
In particular, cyclic peptides have been widely used as templates for the design of turn-like structures[1, 
2].However, small cyclic tetrapeptides[3] are difficult to synthesize, and they usually display mixtures of 
conformers due to cis/trans isomerization of peptide bonds. Conversely, larger cyclic penta- and 
hexapeptides are easier to prepare, but they retain significant backbone flexibility[4]. 
Concerning peptidomimetic and nonpeptidic scaffolds[1,2,5], several examples of cyclic, bicyclic, and 
spirocyclic compounds have been reported as turn-mimicking structures. Nevertheless, several cases have 
met with more limited success when the turn itself contains most of the pharmacophore elements[1a,6]. 
Therefore, cyclic peptides maintain their appeal as templates for applications in medicinal chemistry. In the 
last few years, it has been reported that cyclic tetrapeptide structures enlarged by the introduction of a b-
amino acid may render the structures easier to synthesize and conformationally more stable[7]. Very recently, 
we further customized a cyclotetrapeptide structure by implementation of a partially modified retro-inverso[8] 
(PMRI) sequence. A 1,2-diamine was used as b-amino acid analogue, and a malonic acid completed the 
sequence[9]. Conformational analysis revealed that the PMRI models containing an unsubstituted diamine 
exhibit notable flexibility. In contrast, the presence of a chiral, substituted 1,2-diamine (compound 1, Figure 1) 
rendered the backbone more rigid, inducing b-turn structures and showing alternative conformations with 
respect to those of previously reported cyclotetrapeptide mimetics[7]. 
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Fig. (1). Structure of the partially modified retro-inverso cyclic tetrapeptide models 1-4 
 
Herein we describe the syntheses and conformational analyses of all stereoisomers of PMRI 
cyclotetrapeptide models of the general sequence cyclo-[bPhe-yACHTUNGTRENUNG(NHCO)Ala-
yACHTUNGTRENUNG(NHCO)Gly-Phe], obtained by introducing a chiral (S)- or (R)-1,2-diamine[10] as a b2-
amino acid mimetic, (S)- or (R)-phenylalanine, (S)- or (R)- alanine, and a malonyl residue (Figure 1). 
Furthermore, we provide preliminary validation of these compounds as effective scaffolds for the design of 
molecules with predictable 3D displays of the pharmacophores, useful for targeting specific bioactive 
conformations. As a prototypic example, we used those models for testing some selected novel RGD 
peptidomimetic compounds capable of interfering with integrin receptors. 
We prepared models 1–4 as shown in Scheme 1, with the remaining being the enantiomers. The cyclic 
tetrapeptide analogues were prepared by solid-phase coupling of two dipeptide analogues 6 and 7. 
Fragment 6 was prepared by a standard solution-phase procedure by coupling Fmoc-Phe-OH and Boc-
protected diamine 5[10b,11], obtained, in turn, by reduction of Boc-PheNH2 with BH3[12].The dipeptide was 
deprotected with dimethylamine (DMA), and the resulting crude product 6 was used without purification. 
Wang resin pre-loaded with alanine was treated with Meldrum’s acid under microwave irradiation (MW) at 
300 W. The complete conversion of resin-supported alanine to the dipeptide acid 7 was monitored by 
Kaiser’s test. The solid-phase coupling of 7 with 6 afforded the tetrapeptide 8. Subsequent cleavage from the 
resin with trifluoroacetic acid (TFA) and scavengers gave 9, which was subjected to cyclization by treatment 
with diphenylphosphorylazide (DPPA). After 48 h, the cyclic tetrapeptide analogues were isolated in 55–70% yield 
(cyclization step) by semipreparative RPHPLC, and were 92–95% pure as determined by analytical RPHPLC. 
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Scheme 1. Synthesis of partially modified retro-inverso cyclic models 1–4. 
 
The presence of stereoisomers originating from epimerization was excluded on the basis of HPLC–ESMS 
and 1H NMR analyses. 
The 3D structures of models 1–4 were investigated by NMR spectroscopy and molecular dynamics (MD) 
simulations. The NMR analysis was conducted using standard techniques at 400 MHz in the biomimetic 
medium [D6]DMSO/H2O 8:2[13]; (the compounds were nearly insoluble in water). For 1 and 3, the analyses 
generally confirmed the results previously obtained in [D6]DMSO[9], with few differences. In any case, their 
conformational features are discussed herein for comparison. 
For each peptide, 1H NMR data revealed a single set of resonances, indicative of conformational 
homogeneity or a fast equilibrium[4]. COSY analysis allowed unambiguous assignment of the resonances. 
Variable temperature (VT)-1H NMR experiments were used to deduce the presence of H bonds involving 
amide protons (Table 1)[14]. For 1, 3, and 4, the comparatively low Δδ/ΔT values of diamine NHa and NHb 
(Figures 1, and 2) with respect to PheNH and AlaNH suggest the presence of secondary structures in 
equilibrium, alternatively stabilized by H bonds involving NHa or NHb, whereas for 2, only the NHb amide 
proton seems to be H bonded. 
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Molecular backbone conformations were investigated by 2D ROESY. The full list of ROESY crosspeaks is 
given in the Supporting Information (S.I.). 
The analyses indicated that the cyclic tetrapeptide analogues adopt all-trans conformations of the w bonds, 
deduced from the absence of Hαi-Hαi+1 cross-peaks, indicative of cis peptide bonds. Structures consistent 
with the spectroscopic analyses were obtained by restrained MD, using the distances obtained from ROESY 
as constraints, and minimized with the AMBER[15] force field, with ε=4xr. Simulations were conducted in 
vacuo by using a set of 50 random structures generated by an unrestrained high-temperature MD. The 
structures were subjected to restrained MD with a scaled force field, followed by a high-temperature 
simulation with full restraints. 
Finally, the system was gradually cooled, and the structures were minimized. The conformations with the 
lowest internal energy and the fewest number of violations of the experimental data were selected and 
analyzed (Figure 2 and S.I.). 
The vastmajority of the structures calculated for 1 and 2 by restrained MD did not show any violations of the 
restraints, and were well ordered. For 3 and 4, on the other hand, the computations essentially gave two 
families of structures, 3a/3b and 4a/4b ( Figure 2), with nearly the sane energy, differing exclusively, each 
showing some costraintviolations. 
 As expected, for 1 and 3, the analyses confirmed the results previously obtained in [D6]DMSO[9]. 
To estimate the dynamic behavior of the cyclopeptides in water, and in particular to determine secondary 
structures stabilized by H bonds, the structures derived from ROESY were analyzed by unrestrained MD for 
10 ns in a box of explicit, equilibrated water molecules. During the simulations, the structural features 
deduced by ROESY were maintained, and the examination of the trajectories revealed the occurrence of H 
bonds in agreement with VT-NMR analysis, not explicitly revealed by ROESY. 
The representative structure of 1 calculated by ROESY-restrained MD in Figure 2 is compatible with a type I 
β-turn centered on Phe-diamine, and a second one centered on Ala-diamine. 
This structure shows no H bonds. However, analysis of the trajectories of the unrestrained MD revealed the 
presence of the two β -turn conformations in equilibrium, with NHa and NHb either alternately or 
simultaneously engaged in explicit H bonds with COb and COa, respectively (S.I.). 
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Concerning compound 2, the ROESY-derived conformation shows a distinct H bond between NHb and COa, 
as anticipated on the basis of VT-NMR, and an overall type II β-turn conformation on Ala-diamine (Figure 2). 
This conformation was very stable during the unrestrained MD simulation. 
The occurrence of two slightly different structures for 3 and 4 reflects the observation of contradictory 
ROESY cross-peaks between H1/H2 protons and PheNH or AlaNH (Figure 2). In 3, both AlaNH and PheNH 
show strong cross-peaks with H1, and this situation is compatible with the structure 3a. On the other hand, 
PheNH also gives a cross-peak of medium intensity with H2. Moreover, while AlaNH gives a medium cross-
peak with AlaHa, PheNH gives a strong cross-peak with PheHa. These observations are compatible with the 
structure 3b, showing PheNH reversed relative to its position in 3a. Both 3a and 3b are compatible with a 
type I β-turn on the Ala-diamine fragment, and 3a manifests an explicit H bond between NHb and COa. 
Compound 3b is also compatible with a type I β-turn on Phe-diamine. The two structures 3a/3b reasonably 
represent conformers in equilibrium. However, 3b shows fewer distance violations and a structure more 
compatible with VT-NMR data, which are suggestive of two H bonds on both NHa and NHb. 
Unrestrained MD simulations performed on 3a confirmed the stability of the H bonded structure. The 
unrestrained MD performed on 3b show the H bonded structures involving NHa and/or NHb (S.I.). The 
simulations failed to reproduce the inversion of PheNH; evidently, this rotation is slow relative to the time 
selected for the simulation. 
In a similar manner as with 3, for compound 4 the strong cross-peaks between H2 and both AlaNH and 
PheNH account for the structure 4a, compatible with a type I β-turn centered on Phe-diamine. On the other 
hand, the cross-peak of medium intensity between AlaNH and H1, and the strong cross-peak between AlaNH 
and AlaHa account for the structure 4b, (Figure 2) characterized by a reversed orientation of AlaNH, 
compatible with a type I β-turn centered on Phe-diamine, and a second one on Ala-diamine. As for 3a/3b, the 
two structures 4a/4b likely represent conformers in equilibrium. During the unrestrained MD performed on 4a 
and 4b, analysis of the trajectories revealed the presence H bonded structures involving NHa and NHb (S.I.), 
as suggested by VT-NMR data. 
In summary, compounds 1 and 2 show stable preferred backbone conformations, although 1 presents 
modest residual flexibility. The diastereomers 3 and 4 exhibit two slightly different conformers a and b in 
equilibrium; nevertheless, the overall 3D displays of the side chains are almost coincident. Notably, the 
different stereoisomers tend to adopt a similar 3D structure, with a β-turn centered on Ala-diamine and a 
second β-turn on Phe-diamine (with the exception of 2), regardless of the stereochemistry assortment. This 
observation is not trivial; indeed, it is generally observed that the stereochemistry inversion of a distinct 
residue in a cyclic peptide leads to alternative secondary structures[4, 8b, 16].This difference can be ascribed to 
the peculiar structure of the mimetics. Apparently, the PMRI cyclotetrapeptides show a strong tendency to 
stabilize type I or type II β-turn conformations involving the diamine amide protons. 
It is accepted that the conformation of a cyclic peptide is scarcely controlled by the precise nature of the 
residues[4, 8b]. 
Therefore, the β-turn templates 1–4 and the respective enantiomers 5–8 can be used as topologically 
defined scaffolds for the design of biologically active compounds that having their pharmacophoric side 
chains in precise and well-defined diverse spatial arrangements. A schematic topographic depiction of the 
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eight stereoisomeric PMRI cyclotetrapeptide models, simplified according to the Dunitz–Waser concept[8b, 17], 
is shown in Figure 3. Relevant distances (in Å) between the Cβ atoms of the residues and H bonds are also 
shown. 
To endorse the effectiveness of the novel PMRI scaffolds in medicinal chemistry, we used a selection of the 
models described above for the design of some unprecedented RGD peptidomimetic compounds capable of 
interfering with integrin receptors[18]. Integrins are a large family of heterodimeric transmembrane receptors 
involved in cell–cell adhesion and in the adhesion of cells to proteins of the extracellular matrix, such as 
fibronectin and vitronectin, as well as in signal transduction. 
Integrins are also involved in many major diseases, including cancer, asthma, thrombosis, osteoporosis, and 
risthenosis. 
Among the various kinds of integrins, αvβ3-integrins are generally considered privileged targets for anticancer 
therapy. 
Many types of integrins, including αvβ3, bind their ligands by recognition of the same tripeptide motif: the Arg-
Gly-Asp (RGD) sequence. As a consequence, many RGD-like ligands have been reported as αvβ3-integrin 
inhibitors. Massive SAR investigations of ligands based on peptide, peptidomimetic, or nonpeptide scaffolds 
have given detailed structural information about ligand–receptor interactions[1d, 4a, 19]. More recently, the 
crystal structure of the extracellular section of the receptor, with a cyclic RGD peptide bound to the active site, 
has been disclosed[20], providing the opportunity to design novel antagonists based on the receptor-bound 
conformation of the RGD tripeptide[21]. 
In essence, the criteria for designing effective αvβ3-integrin inhibitors reside in specific reciprocal orientations 
and distances between the Asp and Arg side chains, and in the orienta-and analyzed (Figure 2 and S.I.). 
The vast majority of the structures calculated for 1 and 2 by restrained MD did not show any violations of the 
restraints, and were well ordered. For 3 and 4, on the other hand, the computations essentially gave two 
families of structures, 3a/3b and 4a/4b (Figure 2), with nearly the same energy, differing exclusively by the 
opposite orientation of PheNH, and AlaNH, respectively, each showing some constraint violations. 
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Fig. (2). Rapresentative lowest-energystructure of 1-4 calculated by ROESY-restained MD with the fewest violations of ROESY data 
 
Formation of a third aromatic pharmacophore flanking Asp. Also, the presence of secondary structures in 
RGD ligands has often been correlated with specificity[19, 22].For this purpose, based on models 1–3 and 7, 
we substituted Ala and Phe with Asp and Arg, respectively, to give the stereoisomeric cyclic PMRI RGD 
analogues 9–12 of general sequence cyclo-[bPhe-y- ACHTUNGTRENUNG(NHCO)Asp-
yACHTUNGTRENUNG(NHCO)Gly-Arg] (or cyclo-[bF-yACHTUNGTRENUNG(NHCO)D-y- 
ACHTUNGTRENUNG(NHCO)GR] in brief; Table 2). For this preliminary investigation, models 1 and 2 were 
selected on the basis of their comparatively higher conformational stability, while models 3 and 7 were 
tentatively chosen for comparison. 
We tested the activity of 9–12 as integrin antagonists by measuring the percent inhibition of fibronectin 
adhesion to the αvβ3-integrin-expressing cell line SK-MEL-24 (human malignant melanoma)[23]. Fibronectin 
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was immobilized on each well of a standard assay plate. Cells were pre-incubated with the cyclopeptides 
and dispensed on the wells. After removal of nonadherent cells, the number of adherent cells was quantified 
by fluorimetry. The activity of potential antagonists was determined by the number of adherent cells relative 
to the control. Table 2 shows the sequences of RGD mimetics 9–12, the corresponding parent models 1–3, 
and 7, and the inhibitory activity (%) of 9–12, at a concentration of 10-6M, toward αvβ3-integrinmediated cell 
adhesion. The activity of the well-known αvβ3-integrin antagonists Ac-DRGDS[23b] and GRGDNP[24], assayed 
under the same conditions, was also measured as a positive control. For the inhibitory activity at various 
ligand concentrations, see the S.I. 
 
 
 
Statistical analysis reveals that all the compounds display significant and concentration-dependent potency 
in blocking SK-MEL-24 cell adhesion (S.I.). The biological activities of the four peptides vary radically 
(10>11>12_9), although the constitution of the peptides is identical. This observation confirms the 
anticipation that compounds based on the PMRI cyclotetrapeptide models behave as topologically distinct 
structures. 
These results can be tentatively rationalized by comparing the topographic depiction of the parent models 1–
3 and 7 (Figure 3) with the structural requisites reported for αvβ3-integrin inhibitors (the conformations of 9–12 
have not been reexamined [25]). An illustrative model of the bioactive conformation of a prototypic αvβ3-
selective cyclopentapeptide ligand[19a, 26] is shown in Figure 4A[20, 21]. The simplified Dunitz–Waser sketch, 
Figure 4B and the relevant distances between the pharmacophoric groups and between the Cβ atoms are 
also presented. 
For the noteworthy conformational freedom of the side chains, the precise disposition of the pharmacophoric 
groups of a cyclopeptide in solution and in the bioactive conformation can be very different. For this reason, 
the 3D structure of a cyclopeptide is often characterized by the disposition of the Cβ atoms with respect to 
the cyclopeptide scaffold[4a, 8b, 16, 19a]. 
Therefore, the use of topographic models, such as those depicted in Figures 3 and 4B, can be very useful to 
compare the structures of different compounds. Compound 10 shows the best activity as an inhibitor of 
integrin- mediated adhesion; it is inferior, but still comparable to that of the reference compound Ac-DRGD 
(Table 2). It can be perceived that 10 (see model 2, Figure 3) shows a comparatively higher topological 
similarity with the prototypic pharmacophore (Figure 4B) in comparison with the other compounds (see 
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models), both in terms of the orientations and distances between the Cβ atoms. The lower activities 
displayed by 11 and 12 seem to be correlated with a short distance between the Cβ atoms of Asp and Arg, 
and the diamine (models 3 and 7, Figure 3). Interestingly, compound 9 shows the lowest inhibitory activity, 
despite having a similar disposition of Asp and Arg side chains with respect to 10 (based on the comparison 
of the parent models 1 and 2), highlighting the role of the aromatic pharmacophoric group of the diamine. 
In conclusion, we have presented cyclotetrapeptide mimetic β-turn templates based on the retro-inverso 
concept, and we have described their conformational and topological features. 
 
Fig. (3). Schematic topographic depiction of the PMRI cyclotetrapeptide models 1-4 and therespective enantiomers 5-8, with the 
distance (Å) between the Cβ atoms indicated. Large grey arrows show the pseudo-axial or pseudo-equatorial disposition of the side 
chains (Cα-Cβ vectors). Thin arrows indicate the H bonds. 
 
The 3D structures are largely dominated by the tendency of the diamine residue to stabilize β-turn structures. 
As a consequence, the various stereoisomers can be viewed as diverse scaffolds assembled on a common 
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β-turn template, which can find applications in medicinal chemistry. To confirm the assumptions, we 
prepared a selected set of RGD peptidomimetics based on the structures of the scaffold models.  
 
 
 
Fig.(4). Models of the bioactive conformation of the αvβ3-selective ligand cyclo-[RGDf(NMe)V], along with A) the distances (Å) between 
the pharmacophores,and B) between the Cβ atoms of Asp, D-Phe, and Arg. 
 
The biological assay gave evidence for a clear relationship between the supposed 3D structures of the RGD 
mimetics and the experimental activities as inhibitors of integrin-mediated cell adhesion. 
 
3.1.  Experimental Section 
 
3.1.1. General methods. Unless stated otherwise, standard chemicals were obtained from commercial 
sources and used without further purification. Analytical RP-HPLC was performed with an ODS column (4.6 
m particle size, 100 Å pore diameter, 250 mm, DAD 210 nm) using a linear gradient of H2O/CH3CN (9:12→
2:8) over 20 min at a flow rate of 1.0 mLmin-1, followed by 10 min isocratic H2O/CH3CN 2:8. Chiral HPLC 
analysis was performed on a Chiralcel ODH column [0.46 cm (∅) x 25 cm (l)], n-hexane/2-propanol 85:15, at 
0.8 mLmin-1. Semipreparative RP-HPLC was performed on a C18 column (7 m particle size, 21.2x150 mm) 
with a linear gradient of H2O/CH3CN (7:3→100% CH3CN) over 15 min, at a flow rate of 12 mLmin-1. 
Fluorimetry to evaluate the number of adherent cells was performed with a Victor2 multilabel counter. 1H 
NMR spectra were recorded at 400 MHz at room temperature with 5- mm tubes, using 0.01M peptide. 
Chemical shifts (d) are reported relative to the solvent peak. VT-1H NMR experiments were performed over 
the range T=298–348 K; 2D spectra were acquired in the phase-sensitive mode and processed using a 908 
shifted, squared sine-bell apodization. 1H NMR resonances were assigned from 2D gCOSY and 2D ROESY 
spectra; gCOSY experiments were recorded with a proton spectral width of 3103 Hz. ROESY experiments 
were recorded with a mixing time of 300 or 350 ms with a proton spectral width of 3088 Hz. Materials for 
bioassays were purchased from Invitrogen (Carlsbad, CA, USA) and Cambrex (Walkersville, MD, USA). SK-
MEL-24 (human malignant melanoma) cells were obtained from American Type Culture Collection (ATCC, 
Rockville, MD, USA). Plates (96-well) were obtained from Corning, New York, NY, USA. The Victor2 
multilabel counter was obtained from PerkinElmer (Waltham, MA, USA). 
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3.1.2. Synthesis of 6. HOBt (0.12 g, 0.9 mmol) was added to a stirred solution of Fmoc-Phe-OH (0.29 g, 0.75 
mmol) in 9/1 CH2Cl2/DMF (9:1, 10 mL) at room temperature. After 10 min, 5[10b,11] (0.19 g, 0.75 mmol, 94% 
pure by chiral HPLC analysis, see General methods), EDCI·HCl salt (0.19 g, 0.9 mmol) and TEA (0.15 mL, 
1.1 mmol) were added while stirring at room temperature. After 3 h, the mixture was diluted with CH2Cl2, and 
the solution was washed with 0.5m HCl, and saturated Na2CO3. The organic layer was dried over Na2SO4, 
and the solvent was removed at reduced pressure. The protected dipeptide was isolated by crystallization 
from CH2Cl2/ Et2O (0.39 g, 83 %, 85% pure by RP-HPLC). ESMS m/z: 620.3 [M+1]; calcd: 620.3. The crude 
protected dipeptide was treated while under magnetic stirring with 2M DMA in THF (5 mL) at room 
temperature. After 30 min, the solution was evaporated at reduced pressure, and the treatment was 
repeated. The residue was triturated in n-hexane. The dipeptide 6 (0.23 g, 96%, 82% pure by RPHPLC) was 
used without further purification. ESMS m/z: 398.3 [M+1], calcd: 398.2. 
 
3.1.3. Synthesis of 9. Wang resin pre-loaded with alanine (0.5 g, 0.6 (mmol Ala)g-1) was suspended in DMF 
(4 mL) and treated with Meldrum’s acid (0.36 g, 2.4 mmol). The suspension was heated by MW irradiation at 
300 W. After 90 min, the resin was filtered and washed with MeOH, DMF, and CH2Cl2 (5 mL each), and the 
procedure was repeated twice. The complete conversion of resin-supported Ala to the resin-bound dipeptide 
acid 7 was monitored by Kaiser’s test. The resin-bound dipeptide 7 was suspended in CH2Cl2 (5 mL) and 
treated with 6 (0.24 g, 0.6 mmol), DCC (0.13 g, 0.7 mmol), and HOBt (0.10 g, 0.8 mmol). The mixture was 
mechanically shaken for 6 h. The mixture was then filtered, and the resin was washed with MeOH, DMF, and 
CH2Cl2 (5 mL each). The washing procedure was repeated twice. 
 
3.1.4. Peptide cleavage. The resulting resin-bound 8 was suspended in a mixture of TFA (5 mL), H2O (0.15 
mL), TIPS (0.1 mL), and PhOH (0.15 g), and mechanically shaken at room temperature. After 2 h, the 
mixture was filtered, the resin was washed twice with 10% TFA in Et2O (5 mL), and twice with Et2O. The 
collected filtrates were evaporated, and the residue was precipitated from ice-cold Et2O. 
The resulting precipitate was centrifuged at 4000 rpm (ALC Centrifugette 4206), and the crude solid 
peptide·TFA salt 9 was crystallized from MeOH/Et2O (0.14 g, 80 %, 82% pure by RP-HPLC). ESMS m/z: 
455.3 [M+1]; calcd: 455.2. 
 
3.1.5. Cyclization to 1–4. The peptide·TFA salt 9 (0.14 g, 0.24 mmol) was dissolved in dry DMF (60 mL) and 
treated, while under magnetic stirring, with NaHCO3 (0.25 g, 3 mmol) and DPPA (0.17 g, 0.6 mmol) at room 
temperature. After 72 h, the mixture was filtered, and the solvent was distilled at reduced pressure. The 
residue was diluted with H2O (5 mL), and the mixture was extracted with EtOAc (4x20 mL). The collected 
organic layers were dried over Na2SO4, and the solvent was evaporated at reduced pressure. The oily 
residue was purified by semipreparative RP-HPLC to afford the cyclopeptides 1–4 (0.58–0.73 g, 55–70% 
yield, 92–95% pure by RP-HPLC). ES MS m/z: 437.3 [M+1]; calcd: 437.2. 
 
3.2. Conformational analysis. The restrained MD simulations were conducted using the AMBER[15] force field 
with a distance-dependent ε=4xr. A 100-ps simulation at 1200 K was used for generating 50 random 
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structures that were subsequently subjected to a 20-ps restrained MD with a 50% scaled force field at the 
same temperature, followed by 20 ps with full restraints (distance force constant: 7 kcalmol-1-2), after which 
the system was cooled over 10 ps to 50 K. Due to the absence of Hαi and Hαi+1 ROESY cross-peaks, the w 
bonds were set at 1808 (force constant: 16 kcalmol-1-2). Only ROESY-derived constraints were included in 
the restrained MD. 
H bond interactions as well as torsion angle restraints were excluded. ROESY intensities were classified as 
very strong, strong, medium, and weak, and were associated with distances of 2.3, 2.6, 3.0, and 4.0 Å, 
respectively. Geminal couplings and other clear correlations were discarded. The resulting structures were 
minimized with 3000 cycles of steepest descent and 3000 cycles of conjugated gradient (convergence: 0.01 
kcal-1mol-1). The structures that showed the lowest internal energy and the fewest violations of the 
experimental data were selected and analyzed. MD simulation in explicit water was performed for 10.0 ns at 
298 K using the AMBER force field in a 30x30x30 x3 box of standard TIP3P models of equilibrated water[27], 
with a minimum solvent–solute distance of 2.3Å, at constant temperature and pressure (Berendsen 
scheme[28], bath relaxation constant: 0.2). 
 
3.3. Cell adhesion assays. SK-MEL-24 cells were routinely grown in minimal essential medium (MEM) 
supplemented with 10% fetal bovine serum, nonessential amino acids, and sodium pyruvate. 
Cells were kept at 37°C in a 5% CO2 humidified atmosphere. 
Plates (96-well) were coated by passive adsorption with fibronectin (10 mgmL-1) overnight at 4°C. Cells were 
counted and exposed to the drug at three different concentrations (10-8, 10-6, and 10-4M) for 30 min at room 
temperature to allow ligand–receptor equilibrium. 
Stock solutions (10-2M) of the assayed compounds were prepared in 33% DMSO and 66% phosphate 
buffered saline (PBS) (v/ v), and were further diluted with PBS alone. Control cells were exposed to the 
same concentration of DMSO (vehicle). At the end of the incubation time, the cells were plated (50000 cells 
per well) and incubated at room temperature for 1 h. All the wells were then washed with PBS to remove the 
nonadherent cells, and the hexosaminidase substrate, 4-nitrophenyl-N-acetyl-b-d-glucosaminide (50 mL, 
dissolved at 7.5 mM in 0.09M citrate buffer solution, pH 5, and mixed with an equal volume of 0.5% Triton X-
100 in H2O), was added. This product is a chromogenic substrate for β-Nacetylglucosaminidase that is 
transformed in 4-nitrophenol, the absorbance of which is measured at ʎ=405 nm. As previously described[29], 
there is a linear correlation between absorbance and enzymatic activity. It is therefore possible to identify the 
number of adherent cells in treated wells, interpolating the absorbance values of the unknowns in a 
calibration curve. The reaction was blocked by adding 100 L stop solution (50 m glycine, 5 m EDTA, pH 
10.4), and the plate was read in a multilabel counter. Experiments were carried out in triplicate. All data are 
expressed as the mean ±SEM for the number of experiments indicated. Statistical comparisons were made 
by ANOVA and post hoc Dunnet’s or Turkey’s tests with differences of p<0.05 considered significant. Data 
were analyzed using Prism 5.0 software (GraphPad Software Inc., San Diego, CA, USA). 
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3.4  Supporting Information 
H  N
HN NH
NH
O
O
O
O
Ph
Ph
a b
c
H1
H2a b  Figure S1. Structures of 1-4 
Characterization of 1-4. Residue stereochemistry has been omitted; NHa, NHb, Hc, H1, H2, see Figure S1. 
 
c[Phe-(NHCO)-Ala-(NHCO)-Gly-Phe] (1). 94% pure by RP-HPLC. ES-MS m/z: 437.1 (M+1); calcd: 
437.2; 
1
H-NMR (8/2 DMSO-d6/H2O): 1.06 (d, J=7.1 Hz, 3H, CH3), 2.60 (dd, J=9.8, 13.8 Hz, 1H, diamHβ), 
2.73 (dd, J=5.6, 13.8 Hz, 1H, diamHβ), 2.90 (dd, J=8.5, 14.7 Hz, 1H, PheHβ), 2.90-3.10 (m, 2H, Hc), 3.11 
(dd, J=3.6, 14.7 Hz, 1H, PheHβ), 3.15 (d, J=10.2, 1H, H1), 3.20 (d, J=10.2, 1H, H2), 3.90 (dq, J=5.7, 7.5 Hz, 
1H, AlaH, 3.90-3.99 (m, 1H, diamH), 4.30-4.40 (m, 1H, PheH), 6.13 (d, J=8.3 Hz, 1H, NHa), 6.81 (br.t, 
1H, NHb); 7.06-7.17 (m, 10H, ArH), 8.99 (br.d, 1H, AlaNH), 9.02 (br.d, 1H, PheNH); []
20
D = -1.6 (c 1.2, 
MeOH). 
c[D-Phe-(NHCO)-Ala-(NHCO)-Gly-Phe] (2). 95% pure by RP-HPLC. ES-MS m/z: 437.2 (M+1); calcd: 
437.2; 
1
H-NMR (8/2 DMSO-d6/H2O): 1.09 (d, J=6.8 Hz, 3H, CH3), 2.68 (dd, J=6.4, 13.2 Hz, 1H, diamHβ), 
2.75-2.82 (m, 1H, diamHβ), 2.82-2,90 (m, 1H, PheHβ), 2.90-3.00 (m, 1H, Hc), 3.00 (d, J=11.0, 1H, H1), 3.05 
(d, J=11.0, 1H, H2), 3.00-3.10 (m, 1H, PheHβ), 3.40-3.50 (m, 1H, Hc), 3.61-3.72 (m, 1H, diamH), 4.12 
(quintet, J=7.2 Hz, 1H, AlaH), 4.21-4.30 (m, 1H, PheH), 7.06 (br.t, 1H, NHb), 7.22 (d, 1H, NHa), 7.12-7.24 
(m, 5H, PheArH), 7.25-7.36 (m, 5H, diamArH), 8.52 (d, J=8.4 Hz, 1H, PheNH), 8.62 (d, J=7.2 Hz, 1H, AlaNH); 
[]
20
D = -12.5 (c 2.0, MeOH). 
c[Phe-(NHCO)-Ala-(NHCO)-Gly-D-Phe] (3). 92% pure by RP-HPLC. ES-MS m/z: 437.2 (M+1); calcd: 
437.2; 
1
H-NMR (8/2 DMSO-d6/H2O): 1.15 (d, J=7.1 Hz, 3H, CH3), 2.70 (dd, J=8.3, 14.1 Hz, 1H, diamH), 
2.78 (dd, J=6.4, 14.1 Hz, 1H, diamH), 2.78-2.89 (m, 1H, Hc), 2.90 (d, J=10.4, 1H, H2), 3.00 (dd, J=9.6, 13.2 
Hz, 1H, PheHβ), 3.19 (d, J=10.4, 1H, H1), 3.28 (dd, J=4.9, 13.2 Hz, 1H, PheHβ), 3.44-3.53 (m, 1H, Hc), 3.78-
3.84 (m, 1H, diamH), 3.89 (quintet, J=7.2 Hz, 1H, AlaH), 4.10-4.21 (m, 1H, PheH), 6.60 (d, J=7.9 Hz, 1H, 
NHa), 6.90 (br.t, 1H, NHb); 7.00-7.26 (m, 10H, ArH), 8.60 (d, J=7.4 Hz, 1H, PheNH), 8.69 (d, J=5.6 Hz, 1H, 
AlaNH); []
20
D = +45.2 (c 0.8, MeOH). 
c[Phe-(NHCO)-D-Ala-(NHCO)-Gly-Phe] (4). 93% pure by RP-HPLC. ES-MS m/z: 437.2 (M+1); calcd: 
437.2; 
1
H-NMR (8/2 DMSO-d6/H2O): 1.08 (d, J=7.0 Hz, 3H, CH3), 2.65-2.70 (m, 2H, diamHβ), 2.70-2.79 (m, 
1H, PheHβ), 2.80 (d, J=11.6, 1H, H1), 2.90 (dd, J=6.8, 14.0 Hz, 1H, Hc), 3.11 (dd, J=4.2, 14.2 Hz, 1H, 
PheHβ), 3.22 (d, J=11.6, 1H, H2), 3.45-3.55 (m, 1H, Hc), 3.85-3.96 (m, 1H, diamH), 4.06 (quintet, J=7.2 Hz, 
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1H, AlaH), 4.38-4.46 (m, 1H, PheH), 6.99 (d, J=8.4 Hz, 1H, NHa), 7.09 (t, J=4.8 Hz, 1H, NHb); 7.15-7.22 
(m, 5H, diamArH), 7.22-7.35 (m, 5H, PheArH), 8.29 (d, J=8.0 Hz, 1H, PheNH), 8.31 (d, J=7.2 Hz, 1H, AlaNH); 
[]
20
D = -14.1 (c 0.6, MeOH). 
Tables S1-S4. Non obvious ROESY cross-peaks observed for 1-4 in 8/2 DMSO-d6/H2O at 400 MHz (r.t.). Residue stereochemistry has 
been omitted. Very strong, strong, medium, weak cross peaks, have been associated to distances of 2.3, 2.6, 3.0, and 4.0 Å, 
respectively. NHa, NHb, Hc, H1, H2, see Figure S1. 
 
Table S1, 1. 
Cross peak Intensity Cross peak Intensity 
AlaNH-NHa s AlaNH-H1 vs 
AlaNH-AlaH m AlaNH-H2 w 
PheNH-H1 w AlaNH-CH3 s 
PheNH-H2 vs PheNH-NHb s 
NHb-PheH m PheNH-PheH m 
NHa-NHb m NHb-NHbCH2 m 
diamArH-diamH m diamArH-NHa m 
diamArH-NHb m diamH(2.7)-diamArH s 
NHa-diamH(2.6) m NHa-AlaH m 
diamH-Hc s NHa-diamH m 
diamH-diamH m PheH-PheH(3.1) m 
PheH-PheH(2.9) m   
 
Table S2, 2. 
Cross peak Intensity Cross peak Intensity 
AlaNH-NHa w PheNH-NHb vs 
PHeNH-PheArH m AlaNH-Me s 
AlaNH-AlaH m AlaNH-H1 vs 
PheNH-PheH m/s PheNH-PheH(2.8) m 
NHb-Hc(2.9) s PheNH-H2 vs 
NHb-PheH s NHb-NHa vs 
NHa-AlaH vs NHb-diamH m 
diamArH-diamH vs NHa-diamH s 
NHa-Hc(2.9) m PheArH-PheH(3.0) w 
PheArH-PheH s PheArH-PheH(2.8) s 
NHb-Hc(3.4) m diamArH-diamH(2.7) m 
diamArH-diamH(2.75) m diamH(2.7)-NHa s 
PheH-PheH(2.8) m PheH-PheH(3.0) s 
diamH-diamH(2.65) s diamH-diamH(2.75) w 
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Table S3, 3. 
Cross peak Intensity Cross peak Intensity 
AlaNH-NHa s AlaNH-PheNH w 
AlaNH-AlaH m AlaNH-H1 vs 
PheNH-H1 s AlaNH-H2 w 
PheNH-H2 m AlaNH-CH3 w 
NHb-PheH s PheNH-NHb s 
NHa-NHb m PheNH-PheH s 
diamH-NHb m PheNH-NHa w 
NHb-Hc(3.5) m NHb-Hc(2.9) vs 
NHa-diamH s NHa-AlaMe m 
NHa-Hc(3.5) w NHa-AlaH m 
PheH-PheH(3.3) vs NHa-diamH s 
PheH-PheAr s PheH-PheH(3.0) m 
diamH-Hc(3.5) m diamH-diamH s 
diamH-diamH vs diamH-Hc(2.9) vs 
Hc(3.5)-diamH m Hc(3.5)-diamH s 
 
Table S4, 4. 
Cross peak Intensity Cross peak Intensity 
AlaNH-Me m AlaNH-H1 m 
AlaNH-AlaH s AlaNH-NHa m 
AlaNH-H2 s PheNH-H2 vs 
PheNH-PheH m PheNH-NHb s 
PheNH-Phe(2.8) m NHb-Hc(2.9) s 
NHb-diamH w NHb-diamH w 
NHb-PheH vs NHb-PheNH vs 
NHb-Hc(3.5) m NHa-diamH s 
NHa-Hc(2.9) m NHa-diamH s 
NHa-AlaH vs NHa-PheH w 
diamArH-Hc(2.9) m diamArH-diamH vs 
diamArH-diamH vs diamArH-AlaH w 
PheArH-PheH vs diamArH-Hc(3.5) m 
PheH-PheH(2.7) m PheH-PheH(3.1) s 
diamH-diamH vs diamH-Hc(2.9) m 
diamH-Hc(3.5) s   
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 Figure S2. Torsion angles of 1-4. 
Table S4. Torsion angles of the NMR-derived structures of 1-4 (see Figure S2); Ψ bonds are all trans. 
 -Phe    Ala  Mal  Phe   
Compd            
1 -139 -44 -83 +75 -68 -37 -94 -75 -93 +19 -63 
2 -108 -52 +133 +61 -84 +86 -76 -68 -127 +17 -55 
3a -111 -43 -94 -165 -77 -22 -132 +86 +122 -40 +58 
3b -124 +20 -147 -169 -109 -1 -76 -54 -64 -68 +57 
4a +174 -27 -127 -59 +142 -49 +83 -88 -141 +46 -65 
4b -151 -37 -101 -56 -52 -55 -73 -70 -131 +41 -63 
 
Figures S3-S8. Stereoviews of 1-4 from Figure 2.  
 
Figure S3. Stereo picture of 1.  
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Figure S4. Stereo picture of 2. 
Figure S5. Stereo picture of 3a.  
Figure S6. Stereo picture of 4a.  
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Figure S7. Stereo picture of 3b.  
Figure S8. Stereo picture of 4b.  
Figures S3-S6. Representative, minimized structures of 1, 3b, 4a, 4b, sampled during a 10 ns unrestrained 
MD simulation in explicit water, characterized by secondary structural elements stabilized by H-bonds. 
 
 
Figure S9. 1                                   
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Figure S10. 3b                            
 Figure S11. 4a                                           
 
Figure S12. 4b               
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Figure S13. Inhibition (%) of αVβ3 integrin-mediated SK-MEL-24 cell adhesion to fibronectin in the presence of 9-12 and of the reference 
compounds H-3528 (Ac-DRGDS) and H-3174 (GRGDNP) at three different concentrations (10-8; 10-6, and 10-4 M). Control cells were 
treated with the vehicle alone as described under the experimental section. Data represent the means of triplicate determinations (n=3) 
and the error bars indicate ± SEM. One-way ANOVA was performed, followed by a Dunnet's multiple comparison test. *** p < 0.0001 vs 
vehicle; ** p < 0.001 vs vehicle; §§§ p < 0.0001 vs H-3528 (10-4 M); §§ p < 0.001 vs H-3528 (10-4 M); § p < 0.05 vs H-3528 (10-4M); # p < 
0.05 vs 9, 11 and 12 (10-4 M); p < 0.0001 vs 9 (10-4 M). 
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Chapter 4 
Antiangiogenic Effect of Dual/Selective α5 β1/αvβ3 Integrin Antagonists 
Designed on Partially 
Modified Retro-Inverso Cyclotetrapeptide Mimetics 
 
Recent evidence highlighted the role of α5β1 integrin in angiogenesis and in regulating αvβ3 integrin function. 
As a consequence, selective α5β1 integrin inhibitors or dual α5β1/αvβ3 integrin inhibitors are considered 
promising candidates for the development of cancer therapeutic agents. In this paper, we describe the 
synthesis and pharmacological characterization of a minilibrary of cyclotetrapeptide mimetics containing a 
PMRI Arg-Gly-Asp sequence. In particular, c[(R)-βPheψ(NHCO)Aspψ- (NHCO)Gly-Arg] (3) displayed a good 
activity in inhibiting the αvβ3 integrin-mediated cell adhesion of fibronectin or vitronectin, as well as the 
adhesion of fibronectin to the α 5β1 integrin. Interestingly, the diastereomeric compound c[(S)-
βPheψ(NHCO)Aspψ(NHCO)Gly-Arg] (2) maintained a good efficacy in inhibiting α5β1 integrin while gaining a 
certain selectivity over αvβ3 integrin. These two integrin antagonists significantly inhibited bFGF-induced 
human endothelial cell tube formation at submicromolar concentrations. Conformational analysis and 
Molecular Docking calculations suggest that the different α5β1 versus αvβ3 selectivity of 2 and 3 can be 
rationalized on the basis of the alternative display of the aromatic side chain adjacent to Asp. 
 
4.Introduction 
Among the different members of the integrin receptor family, αvβ3 integrin is generally considered a privileged 
target for antiangiogenic therapy[1-6]. At the same time, α5β1 integrin has emerged as a new promising target 
for the development of cancer therapeutic agents. Besides an important function in the migration of activated 
lymphocytes during the immune response and the involvement in diabetes and inflammatory diseases like 
rheumatoid arthritis[7], the proangiogenic function of the α5β1 receptor has been clearly demonstrated[8]. 
Interestingly, the α5β1 integrin has been shown to affect αvβ3-mediated endothelial cell migration and 
angiogenesis via regulation of αvβ3 integrin function[9]. A study with αvβ3 and α5β1 specific antibodies 
demonstrated that integrin α5β1 regulates the function of integrin αvβ3 on endothelial cells during their 
migration in vitro or angiogenesis in vivo[10]. 
Likewise, it has been reported that the combined antagonism of both αvβ3 and α5β1, as opposed to αvβ3 alone, 
induces apoptosis of angiogenic endothelial cells cultured on type I collagen[11]. 
Another approach to developing integrin inhibitors is tomodify extracellular matrix proteins like angiostatin, 
tamustatin, arresten, and endostatin capable of antagonizing αvβ3 and α5β1[12]. A laminin-1-derived peptide 
that similarly blocks αvβ3 and α5β1 has been shown to inhibit growth ofmelanoma cells in vivo[13]. 
The endogenous extracellular matrix ligands vitronectin and fibronectinbind to the α vβ3 integrin, and 
fibronectin binds also to α5β1 integrin by recognition of the acidic and guanidino side chain groups of the 
same tripeptide motif, the Arg-Gly-Asp (RGD)a sequence[14]. Therefore, small RGD-mimetic molecules that 
are able to interfere with the α5β1 and/or αvβ3 integrins are currently considered of interest for the angiostatic 
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therapy of cancer[15-17]. The RGD sequence is the recognition site for various integrin receptors, and the 
conformation of the sequence in the individual adhesion protein or peptide is critical for the specificity of this 
recognition[18,19]. 
 
 
 
Fig.(1). General structure of the PMRI-cyclotetrapeptide models c[(S/R)-βPheΨ (NHCO)(S/R)-AlaΨ (NHCO)Gly-(S/R)-Phe] 1, and 
structures of stereoisomeric PMRI RGD-mimetics c[(S/R)-βPheψ(NHCO)(S/R)-Aspψ(NHCO)Gly-(S/R)-Arg] 2-9. 
 
With regard to the α vβ3 integrin receptor, a large number of peptidic, peptidomimetic[20,21], and non 
peptidomimetic[22] scaffolds have been successfully employed to provide the desired conformational 
constraint to maintain the acidic and basic side chains at the appropriate distance and in a conformation 
suitable for binding. The cyclopentapeptide c[Arg-Gly-Asp-(R)-Phe-Val] has represented the first highly 
active and selective αvβ3 integrin antagonist[23-25] and has served as a lead structure for the development by 
Kessler et al. of the cyclic pentapeptide cilengitide, c[Arg-Gly-Asp-(R)-Phe-NMeVal] (EMD121974)[26], 
currently in clinical trials for antiangiogenic cancer therapy[27,28]. Furthermore, the crystal structure of the 
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extracellular segment of the αvβ3 integrin with cilengitide bound to the active site has been disclosed 
previously[29], giving the opportunity to design novel integrin antagonists based on the receptor-bound 
conformation of the RGD tripeptide[30]. 
On the other hand, the experimental 3D structure of α5β1 integrin is not available, and few structural details 
about ligand-receptor interactions have been obtained until now[31,32]. 
As a consequence, only some potent and selective antagonists of α5β1 or dual α5β1/αvβ3 antagonists have 
been described[33-36]. 
Recently, a homology model of the receptor has been published [37], which has successfully been used to 
optimize ligand activity and selectivity[38]. 
In essence, the criteria for designing integrin antagonists showing selectivity for a certain RGD-binding 
integrin type over the others seem to reside for the most part in subtle differences in the reciprocal 
orientation and distance between the Asp and Arg side chains, and in the disposition of an aromatic side 
chain adjacent to Asp. In particular, the presence of definite secondary structure elements in RGD linear or 
cyclic peptides has often been correlated to the ligand’s specificity[20,30,31,38]. Therefore, the synthesis of novel, 
conformationally definite RGD-containing scaffolds to mimic important secondary structure elements such as 
γ- or β-turns is of great interest. 
Very recently[39,40], we designed a new kind of cyclotetrapeptide (CTP) scaffold based on a partially modified 
retroinverso (PMRI) variant of CTP containing a β-amino acid, forming 13-membered rings[41]. Retro-inverso 
and PMRI analogues have beenwidely utilized to improve the performance of a bioactive parent peptide[42-46]. 
We envisaged the opportunity to utilize these scaffolds for designing peptidomimetic molecules with a well-
defined 3D display of the RGD sequence and aimed to discover selective α5β1 integrin antagonists or dual α
vβ3/α5β1 integrin antagonists, whose activity could be synergistically effective in preventing angiogenesis. 
 
4.1. Results 
Design and Synthesis. Compared to CTPs composed of all α-amino acids, which can be considered the 
smallest turnmimetic structure, 13-membered analogues incorporating a β3- or β2-amino acid proved to be 
easier to synthesize and conformationallymore defined[41,47-49]. The eight stereoisomeric PMRI-CTPmodels (1) 
of the general sequence c[(S/R)-βPheψ-(NHCO)(S/R)-Alaψ(NHCO)Gly-(S/R)-Phe] (Figure 1) contain a 1,2-
diamine to replace the β-amino acid, and a diacid as a Gly mimetic. Conformational analysis revealed that 
these 13-membered scaffolds manifest specific 3D geometries in comparison to normal 13-membered 
CTPs[39] and have a strong tendency to adopt turn structures. This preference can be ascribed to the 
propensity of the PMRI-CTP structures to stabilize H-bonded conformations involving the diamine amide 
protons[50]. 
On the basis of the structures of the scaffolds 1, we designed a minilibrary of PMRI RGD-mimetic 
compounds[21], aiming to obtain integrin antagonists having the pharmacophoric side chains in well-defined, 
predictable spatial dispositions. For this purpose, we prepared the stereoisomeric compounds c[(S/R)-
βPheψ(NHCO)(S/R)-Aspψ(NHCO)Gly-(S/R)-Arg] 2-9 by introducing (S)- or (R)-Asp and (S)- or (R)-Arg in 
place of (S)- or (R)-Ala and (S)- or (R)-Phe, respectively (some preliminary results of the αvβ3 integrin-
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mediated cell adhesion inhibition in the presence of 2-4 and 8, at a single concentration, have been reported 
in a previous paper[50]). 
 
 
 
Scheme 1. Synthesis of 2. Reagents and conditions: (i) EDCI/HOBt/TEA, DCM/DMF; (ii) DMA/THF; (iii) CH3CN, 70°C; (iv) H2 Pd/C, 
EtOH; (v) DPPA/NaHCO3, DMF; (vi) TFA/PhOH/PhSH/H2O/Et2S 94/2/1/2/1. 
The cyclic PMRI RGD mimetics were easily obtained from the corresponding linear precursors. As a 
prototypic example, the synthesis of 2, the first member of the minilibrary, is shown in Scheme 1, the 
syntheses of the other stereoisomers (3-9) being the same. 
The retrosynthetic analysis of the protected linear precursor 13 was thought to proceed by in-solution 
coupling of fragments 11 and 12. Reduction of Cbz-Phe-NH2 [51] with BH3 [52] gave chiral Cbz-1,2-diamine 10 
in excellent yield. The coupling of 10 under standard conditions with Fmoc-Arg- (Mtr)-OH afforded dipeptide 
11, whose deprotection was performed by treatment with 2 M DMA in THF. 
The second fragment was straightforwardly prepared from Meldrum’s acid and H-Asp(Ot-Bu)-OBz, giving 
dipeptide acid 12, not needing further deprotection steps. The standard coupling of dipeptides 11 and 12 
gave fully protected linear tetrapeptide 13. The removal of the Cbz and benzyl ester protecting groups at the 
N- and C-termini, respectively, by hydrogenolysis, followed by cyclization with DPPA, gave cyclopeptide 14 
in good yield and purity after preparative RP-HPLC. The final deprotection of Asp and Arg side chains was 
performed with TFA in the presence of a mixture of scavengers. PMRI-CTP 2 was isolated by preparative 
RP-HPLC. 
Accordingly, we prepared the remaining PMRI RGD analogues 3-9; purities and mass characterizations are 
reported in Table 1. 
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4.1.2. Inhibition of Cell Adhesion. The ability of compounds 2-9 to inhibit the adhesion of K562 (human 
erythroleukemic cells, expressing α 5β1 integrin) or SK-MEL-24 (human malignant melanoma cells, 
expressing αvβ3 integrin) to immobilized fibronectin and the adhesion of HUVEC (human umbilical vein 
endothelial cells, expressing αvβ3 integrin) to immobilized vitronectin was evaluated. These cell models are 
widely used to investigate potential antagonists of αvβ3 integrin (HUVEC and SK-MEL-24)[53,54] or of α5β1 
integrin (K562)[55]. In these experiments, the cells were seeded onto plates coated with different substrata 
and allowed to adhere before quantitation of the number of adherent cells. Under these conditions, no 
significant cell adhesion was observed for BSA-coated plates (negative control) or nonspecific substrate-
coated plates (i.e., collagen I for SK-MEL-24 and HUVEC expressing αvβ3 integrin and vitronectin for K562 
expressing α5β1 integrin) (data not shown). Results are summarized in Table 1. The compound c[Arg-Gly-
Asp- (R)-Phe-Val] was included as reference cyclic peptide, being a potent inhibitor of cell adhesion[23,56,57] 
and the peptide c[Arg-Ala-Asp-(R)-Phe-Val] was used as a negative control[58]. 
Compound 3, c[(R)-βPheψ(NHCO)Aspψ(NHCO)Gly-Arg], containing (S)-Arg and (S)-Asp, exhibited the 
highest potency as an inhibitor of cell adhesion mediated by αvβ3 and α5β1 integrins. The IC50 value versus α
5β1 integrin-mediated cell adhesion was 10 times lower than that versus αvβ3 integrin (Table 1). The 
diastereoisomer 2, c[(S)-βPheψ-(NHCO)Aspψ(NHCO)Gly-Arg], which differs from 3 exclusively for the 
stereochemistry of the diamine moiety, maintained a notable efficacy as α5β1 integrin inhibitor and gained 
selectivity versus αvβ3 integrin. Indeed, although 2 exhibited an IC50 of 0.52 μM as an α5β1 integrin antagonist, 
the activity toward αvβ3 integrin dropped to an IC50 value of 11 μM against fibronectin and of 25.2 μM against 
vitronectin. PMRI RGD mimetic 4 containing (S)-Asp and (R)-Arg, and mimetic 8 containing (R)-Asp and (S)-
Arg, gave comparatively inferior results with respect to 2 and 3. Both compounds exhibited modest IC50 
values, in the micromolar range (Table 1). The rest of the compounds poorly affected adhesion of cells to 
immobilized fibronectin or vitronectin, with an IC50 of >100 μM. 
Compounds 2-4 and 8 possess IC50 values comparable to those of αvβ3 integrin inhibitors in the two cell 
models expressing this integrin toward the two ligands fibronectin (employed in SK-MEL-24) and vitronectin 
(employed in HUVEC)[59,60]. 
In agreement with previous studies[23,56,57,61], c[Arg-Gly-Asp-(R)-Phe-Val] displayed a micromolar inhibitory 
activity on the cell adhesive capacity driven by αvβ3 and α5β1 integrin, whereas the cyclic peptide c[Arg-Ala-
Asp-(R)-Phe-Val] had IC50 values of >100 μM. Interestingly, compound 3 was more potent than reference 
compound c[Arg-Gly-Asp-(R)-Phe-Val] as it inhibited cell adhesion mediated by αvβ3 and α5β1 integrin 
possessing IC50 values 40- and 1445-fold less, respectively. 
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Table 1. Analytical characterization of 2-9 and inhibition of αvβ3- and α5β1 integrin mediated cell adhesion to fibronectin (FN) and 
vitronectin (VN) in the presence of 2-9, or the reference cyclic peptide c[Arg-Gly-Asp-(R)-Phe-Val] and the negative control peptide 
c[Arg-Ala-Asp-(R)-Phe-Val], c[RGDfV] and c[RADfV], respectively, in brief. 
 
compd Purity (%) MS 
[M+1]a 
αvβ3 vs FN  
(SK-MEL-24 cells)   
IC50 (M)b 
αvβ3 vs VN 
(HUVEC cells) IC50 
(M)b 
α5β1 vs FN  
(K562 cells)  
IC50 (M)b 
2 97 490.2 11 ± 6 25.2 ± 5.2 0.52 ± 0.04 
3  96 490.3 0.18 ± 0.05 0.24 ± 0.08 0.024 ± 0.003 
4 95 490.3 2.3 ± 0.3 1.5 ± 0.4 4.7±0.4 
5 95 490.4 > 100 > 100 > 100 
6 95 490.2 > 100 > 100 > 100 
7 95 490.1 > 100 > 100 > 100 
8 96 490.2 2.1 ± 0.3 0.92 ± 0.09 1.3 ± 0.1 
9 96 490.3 > 100 > 100 > 100 
c[RGDfV]c - - 7.1 ± 2.7 9.6 ± 2.9 34.7 ± 8.4 
c[RADfV]c - - > 100 > 100 > 100 
a Calculated [M+1]: 490.2. b Values are means ± standard error of three experiments carried out in quadruplicate. c Purchased from 
Bachem. 
 
4.1.3. Effect of Integrin Antagonists on in Vitro Angiogenesis Elicited by Basic Fibroblast Growth Factor 
(bFGF). The formation of capillary-like tube structures by HUVEC in the extracellular matrix (ECM) is the 
pivotal step in angiogenesis and is also involved in cell migration and invasion[62-64]. To evaluate any potential 
antiangiogenic activity of these novel αvβ3/α5β1 integrin antagonists, in vitro angiogenesis assays were 
conducted by evaluating bFGF-induced angiogenesis of HUVECcultured in a 3D gel consisting of Matrigel. 
As shown in Figure 2, when HUVEC were plated on wells coated with Matrigel without the addition of the 
growth factor, they showed only a few spontaneous tube formations (taken as an index of neo-angiogenesis), 
and most of them were still in a highly proliferating state with a cobblestone shape. On the other hand, when 
HUVEC were plated on Matrigel with addition of bFGF (30 g/mL), cells formed a capillary-like network 
within 16 h (Figure 2). In the presence of compounds 2 and 3 (1 μM), the extent of tube formation induced by 
bFGF was significantly reduced (Figure 2) in comparison to that in cells treated with the vehicle alone 
(containing up to 1% DMSO dissolved in cell culture medium). Interestingly, 3 exhibited the greatest 
inhibitory effect in blocking bFGFinduced angiogenesis. The number of tube branches per square millimeter 
was reduced from 10 ±3 (bFGF-treated HUVEC) to 5.1 ± 0.7 (3-treated HUVEC), and 6.8 ±0.9 (2-treated 
HUVEC). The minimal concentration of these compounds yielding a complete inhibition of endothelial 
morphogenesis on Matrigel was 1 μM; lower concentrations (100 and 500nM) were less effective or (10 nM) 
ineffective (data not shown), whereas compound 8 (10 μM) did not cause any significant reduction in the 
level of angiogenesis (Figure 2). Similarly, compounds 4-7 and 9, added to the cells to a final concentration 
of up to 10 μM, were not effective as angiogenesis inhibitors (see the Supporting Information). 
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Fig. (2). αvβ3/α5β1 integrins antagonists inhibit bFGF-induced HUVEC tube formation on Matrigel. Representative pictures of capillary-
like structures (black bar in the pictures corresponds to 100 μm). CTRL) HUVEC cells plated on Matrigel in the absence of bFGF. bFGF) 
HUVEC cells plated on Matrigel in the presence of bFGF (30 ng/mL) for 16 h. Vehicle) HUVEC cells treated with vehicle alone 
(containing up to 1% of DMSO dissolved in cell culture medium). Compd2) HUVEC cells treated with compound 2 (1 μM); Compd3) 
HUVEC cells treated with compound 3 (1 μM); Compd8) HUVEC cells treated with compound 8 (10 μM). The ability to form capillary-like 
sproutings on Matrigel was significantly diminished when HUVEC cells were treated with compounds 2 and 3. Data are presented as 
mean ± S.E.M. of the number of tubes/mm2 These experiments were carried out in quadruplicate and repeated three times. *P<0.01; 
**P<0.05 vs control (Newman-Keuls test after ANOVA). 
4.1.4.  α5β1/αvβ3 Integrin Antagonists Do Not Affect Endothelial Cell Viability. 
 To determine whether α5β1 and αvβ3 integrin antagonists could alter endothelial cell viability, morphology 
and flow cytometric analysis were evaluated inHUVEC after treatment for 16 h with 1 and 10 μM RGD 
cyclopeptides. 
These data indicate that neither significant changes in the morphology (data not shown) nor significant 
increases in the level of apoptosis or necrosis (Supporting Information) were observed in endothelial cells, 
suggesting that these compounds do not display any relevant cytotoxicity in HUVEC. 
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4.2. Conformational Analysis of 2 and 3 in Solution.  
Then biological activities of some of the compounds vary radically (Table 1), although the sequence of the 
peptides is identical. 
This observation confirms the anticipation that RGDmimetic compounds based on the PMRI CTPs behave 
as topologically distinct structures. It is accepted that the conformation of a cyclic peptide is controlled by the 
stereochemistry array of the residues, while the precise nature of the residues has a minor impact[21,65,66]. In 
this section, we discuss the in-solution structural features of 2 and 3, aiming to deduce useful clues about the 
biologically active structures of this class of pseudopeptides, while the conformations of the less active or 
inactive compounds 4 and 5 are discussed in the Supporting Information. The conformations of 6-9, the 
mirror images of 2-5, respectively, were not re-examined. 
The conformational analyses were performed by NMR spectroscopy and molecular dynamics (MD) 
simulations. 
The NMR analyses of cyclopeptides 2 and 3 were conducted using standard techniques in the 8:2 DMSO 
d6/H2O biomimetic medium[67] We could not perform experiments in water, since the peptides were very 
poorly soluble. The 1H NMR analyses of 2 and 3 revealed a single set of resonances, suggesting 
conformational homogeneity or a fast equilibrium[21,65]. VT 1H NMR experiments were utilized to deduce the 
presence of H-bonds (Table 2). The analyses indicated that in the two cyclopeptides, AspNH and ArgNH do 
not seem to be involved in intramolecular H-bonds. On the other hand, for both compounds, diamineNHb 
[NHa, NHb, and Hc (see Figures 1 and 3-6)] very likely participates in a strong H-bond (|Δδ/Δt| e 1 
ppb/K).65,68 With regard to diamineNHa, while in 2 the low Δδ/Δt value is suggestive of the involvement in 
H-bonds (Δδ/Δt = 1.4 ppb/K), the comparatively higher |Δδ/Δt| value observed in 3 accounts for solvent-
exposed protons (Δδ/Δt=-4.0 ppb/K). 
 
Table 2.  Δδ/Δt values (ppb/°K) of amide protons for 2 and 3, determined by VT-1H-NMR analysis in 8/2 DMSO-d6/H2O at 400 MHz over 
the range 298-348 °K (NHa, NHb, see Figure 1 and Figures 5-8). 
Compd AspNH ArgNH NHa NHb 
2 -6.1 -5.8 +1.4 -0.6 
3 -6.3 -5.0 -4.0 -1.0 
 
2D ROESY data were utilized to investigate the spatial disposition of molecular backbones (Tables 3 and 4). 
For the absence of Hαi-Hαi+1 cross-peaks, indicative of a cis peptide bond conformation, all of the ω bonds 
were set to 180°. 
Conformations consistent with the spectroscopic analysis were obtained by restrained MD in a box of explicit, 
equilibrated water molecules[69], using the distances deduced from ROESY as constraints and minimized 
with the AMBER 70 force field. A set of 50 random structures generated by means of a unrestrained high-
temperature MD simulation was subjected to restrained MD with a scaled force field, followed by a high-
temperature simulation with full restraints, after which the system was gradually cooled. 
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These structures were clustered by the rmsd analysis of the backbone atoms. For both peptides, one major 
cluster comprising more than 90% of the structures was obtained; the lowest-energy structures of the major 
clusters are shown in Figures 3 and 5. 
 
 
Fig. (3). Representative structure of 2 consistent with ROESY analysis. 
 
The ROESY-derived structure of 2 (Figure 3) does not show explicit H-bonds, which were predicted on the 
basis of the VT NMR analysis. Apparently, the conformations determined by ROESY analyses represent the 
average on the NMR time scale of different geometries in equilibrium[21,65]. 
To estimate the residual flexibility of the cyclopeptide, the dynamic behavior of the structure derived from 
ROESY was analyzed by unrestrained MD for 10 ns in a box of explicit water. During the simulation, the 
main structural features described on the basis of ROESY were maintained. In addition, the examination of 
the trajectories revealed the occurrence of explicit H-bonds in agreement with VT NMR analysis. 
Indeed, the trajectories of 2 clearly revealed the occurrence of two slightly different backbone structures. 
One is characterized by a type I β-turn centered on Arg-diamine and stabilized by a H-bond between 
malonylCO and diamine-NHa (Figure 4, left). The second one is characterized by a type I β-turn centered on 
Asp-diamine, with a H-bond between the other malonylCO and diamineNHb (Figure 4, right). 
 
                              
 
Fig. (4). Representative, minimized structures 2a (left) and 2b (right) calculated by unrestrained MD in a 30x30x30 Å box of standard 
TIP3P water molecules, characterized by explicit H-bonds and secondary structural elements. 
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As for compound 3, the ROESY-derived conformation shows a distinct H-bond between NHb and 
malonylCO, as anticipated on the basis of VT NMR, and an overall type II β-turn conformation on Asp 
diamine (Figure 5). Unrestrained MD simulation was performed as reported for 2. 
 
 
 
Fig.(5). Representative structure 3a consistent with ROESY analysis. 
 
In addition to the conformation of 3a shown in Figure 5, the analysis of the trajectories of 3 gave a second 
conformer, 3b, whose structure is in agreement with a pseudoinverse γ-turn centered on Asp, and an inverse 
γ-turn on Arg[71]. This alternative secondary structure (Figure 6) is still compatible with the involvement of the 
NHb proton in a H-bond as predicted by VT NMR analysis. Despite the different secondary structures, the 
two conformers, 3a and 3b, still maintain a very similar display of the pharmacophores. 
However, the two situations slightly differ for the distance between the Cβ atoms of Asp and Arg: ∼8.3 Å in 
3a and ∼8.8 Å in 3b. 
 
 
 
Fig. (6). Representative, minimized structure 3b calculated by unrestrained MD in a 30x30x30 Å box of standard TIP3P water molecules, 
characterized by secondary structural elements. 
 
The structures of 2 and 3 share a certain similarity in the RGD-mimetic region. The main difference among 
the two structures resides in the different orientations of the diamine aromatic side chain and of NHa. In 2, 
the aromatic side chain and NHa point above the molecular plane; in 3, the situation is reversed. In particular, 
in 2, the diamine phenyl side chain adopts a pseudoaxial disposition; in 3, it adopts a pseudoequatorial 
disposition. 
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4.3. Molecular Docking.  
To interpret on a molecular basis the different affinities of compounds 2 and 3 for the αVβ3 receptor, docking 
studies were performed using Glide (version 4.5)[72] by starting from the representative macrocycle 
conformations sampled during the unrestrained MD simulations. Molecular docking of compounds 4-9 is 
discussed in the Supporting Information. The protein binding site was derived from the X-ray crystal structure 
of the extracellular segment of integrin αVβ3 in complex with the cyclic pentapeptide ligand cilengitide [Protein 
Data Bank (PDB) entry 1L5G][29] In this X-ray structure, the potent αVβ3 antagonist cilengitide, bound to the 
headgroup of the integrin, features an extended conformation of the RGD sequence with a distance of ∼9 Å 
between the Cβ atoms of Asp and Arg. The crystal complex interaction pattern involves the formation of an 
electrostatic clamp between the guanidinium group of the ligand and the negatively charged side chains of 
Asp218 and Asp150 in the α unit and between the carboxylic group of cilengitide and the metal cation in the 
metal ion-dependent adhesion site (MIDAS) region of the β unit. Moreover, further stabilization occurs 
through hydrogen bonds between the NH group of the ligand Asp residue and the carbonyl oxygen atom of 
Arg216 in the β subunit as well as between the ligand carboxylate oxygen not coordinated to MIDAS and the 
backbone amides of Asn215 and Tyr122 in the β unit (Figure 7). 
 
 
 
Fig.(7). Top-ranked docking poses of (a) ligand 3 (atom colour tube representation, macrocycle geometry “inverse ɣ/inverse ɣ” 3b) and 
(b) ligand 2 (atom colour tube representation, macrocycle geometry “β-turn” 2b) into the crystal structure of the extracellular domain of α
Vβ3 integrin (α unit cyan and β unit orange wire representation) overlaid on the bound conformation of cilengitide (green tube 
representation). Only selected integrin residues involved in the interactions with cilengitide are shown. The Mn2+ ion at MIDAS is shown 
as a green CPK sphere. Nonpolar hydrogen atoms were removed for clarity. 
 
The experimentally observed binding mode of cilengitide with αVβ3 integrin was taken as a reference model 
for the interpretation of the docking results in terms of the ligandbound conformation and ligand-protein 
interactions. 
The models built for the interaction of compounds 2 and 3 with αVβ3 integrin through docking studies showed 
that suitable macrocycle conformations of these ligands enable them to fit properly in the shallow cleft of the 
receptor, sharing the binding features of the crystal structure of the cilengitide-αVβ3 complex, especially those 
governing the recognition process. Among the conformations selected from the MD simulations of 2 and 3, 
only the macrocycle geometries “inverse γ/inverse γ” 3b and “β-turn” 2b generate top-ranked docking poses 
b) a) 
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conserving the relevant ligandprotein interactions observed in the crystal structure of the cilengitide-αVβ3 
complex. However, the inverse γ/inverse γ geometry of 3b reproduces the RGD backbone of the X-ray ligand 
better than the β-turn geometry of 2b (Figure 7). 
Moreover, the pseudoequatorial benzyl group in 3b points to the same direction of the Phe side chain of the 
reference ligand, that is, toward the outside of the integrin binding site, allowing the aromatic ring to fit 
unhindered and to form a T-shaped interaction with the Tyr122 side chain of the β subunit (Figures 7 and 8). 
 
 
 
Fig.(8). Top-ranked docking poses of mimics 3b (green tube representation) and 2b (purple tube representation) into the crystal 
structure of the extracellular domain of αvβ3 integrin represented as a molecular surface (α unit cyan, β unit orange). Mn2+ ions are 
represented as yellow CPK spheres. 
 
The β-turn structure of 2b properly drives the pharmacophoric groups within the binding site to form the key 
electrostatic interactions with the receptor. Nevertheless, the pseudoaxial benzyl group forces the entire 
molecule to enter the receptor lopsided. The benzyl group fails in forming the T-shaped interaction with the 
aromatic ring of the Tyr122 side chain. Accordingly, the Glide score values suggest a slightly better binding for 
epimer 3. 
 
4.4. Discussion 
In this study, a selected minilibrary of stereoisomeric, modified retro-inverso cyclotetrapeptides 2-9 having 
the general structure c[(S/R)-βPheψ(NHCO)(S/R)-Aspψ(NHCO)Gly-(S/R)-Arg] inhibited adhesion of cells to 
vitronectin- or fibronectin- coated surfaces and inhibited angiogenesis. The different compounds displayed 
variable activities as αvβ3 or α5β1 integrin receptor antagonists, as determined by testing the inhibition of 
adhesion of fibronectin and vitronectin to αvβ3 or α5β1 integrin receptor-expressing cell lines. Interestingly, 
c[(S)-βPheψ(NHCO)Aspψ(NHCO)Gly-Arg] (2) displayed a submicromolar activity for α5β1 integrin, and a 
certain selectivity over αvβ3 integrin, while c[(R)-βPheψ-(NHCO)Aspψ(NHCO)Gly-Arg] (3) was demonstrated 
to be a potent dual antagonist, with 10-8 and 10-7 activities for α5β1 and αvβ3 integrins, respectively. On the 
other hand, c[(S)-βPheψ(NHCO)(S)-Aspψ(NHCO)Gly-(R)-Arg] (4) and c[(R)-βPheψ(NHCO)(R)-
Aspψ(NHCO)Gly-(S)-Arg] (8) revealed moderate micromolar inhibitory activities, while the remaining 
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compounds, 5-7 and 9, were ineffective. These results demonstrate that compound 2 is more specific as an 
α5β1 integrin antagonist whereas compounds 3, 4, and 8 nonselectively antagonized αvβ3 and α5β1 integrins, 
albeit with different efficacies, 3 being the most potent. 
Moreover, we showed that α5β1 and αvβ3 integrin antagonists inhibited bFGF-induced human endothelial cell 
tube formation at submicromolar concentrations as examined using theMatrigel assay. Among them, 
compound 3 showed themost potent antiadhesion and antiangiogenic effects; it can directly interact with αvβ3 
integrin expressed on melanoma and endothelial cells and can prevent adhesion of endothelial cells to 
vitronectin displaying higher binding selectivity for αvβ3 integrin in cell culture. 
Blockade of αvβ3 integrin-mediated functions by antibodies or RGD peptides disrupts blood vessel formation 
in various animal models; αvβ3 antagonistsmay perturb the growth and/ or maturation of blood vessels 
without detectable alteration on the preexisting blood vessels[73]. 
Angiogenesis is also directly regulated by binding of fibronectin to its receptor, the α5β1 integrin. Specific 
antibodies, peptides, and novel nonpeptide antagonists of α5β1 integrin can block angiogenesis induced by 
several growth factors in both chick embryo and murine models. In fact, these α5β1 antagonists inhibited 
tumor angiogenesis, thereby causing regression of human tumors in animal models[74]. Antagonists of αvβ3 
and α5β1 integrins substantially prevent angiogenesis induced by bFGF, suggesting that these integrins 
regulate similar pathways of angiogenesis. 
The results of this study suggest that the partially retroinverso RGD motif in the cyclotetrapeptide retains the 
αvβ3 and α5β1 integrin antagonist activity. Therefore, we propose that the potent antiangiogenic effect of 3 in 
cell adhesion and tube formation assays is probably due to the interference of the αvβ3 and α5β1 integrin-
mediated interactions between endothelial cells and ECM protein. Indeed, 3 significantly decreased the level 
of bFGF-induced angiogenesis in an in vitro model. Therefore, the mechanism of action of these compounds 
in suppressing bFGF-elicited angiogenesis could be mediated by the specific blockade of αvβ3 ligation. 
Finally, these integrin antagonists did not cause any cytotoxic effect as evidenced by flow cytometric analysis. 
The sequence of peptides 2-9 is identical, the only difference being the stereochemistry array. The 
comparatively higher inhibitory efficacy toward α5β1 integrin observed for compounds 2 and 3, the most 
potent of the minilibrary, can  be correlated to the specific (S,S) stereochemistry of the retro-inverso RGD 
sequence, ψ(NHCO)(S)-Asp-ψ(NHCO)- Gly-(S)-Arg. Indeed, the remaining compounds possess (S,R), (R,R), 
or (R,S) (Arg,Asp) configurations. 
It is worth mentioning that, due to the partial retro-inverso nature of the RGD sequence, the (S,S) 
stereochemistry of Arg and Asp in 2 and 3 leads to overall conformations showing the Arg and Asp 
pharmacophoric side chains on the opposite sides of the molecular scaffold, an unusual biologically active 
conformation in comparison to other well-known RGD cyclopentapeptide integrin antagonists, such as c[Arg- 
Gly-Asp-(R)-Phe-Val] or c[Arg-Gly-Asp-(R)-Phe-NMeVal] (cilengitide), having the pharmacophoric side 
chains placed on the same side. Apparently, in the smaller cyclotetrapeptide structures, an opposite 
orientation allows for a correct distance between the pharmacophores. For both 2 and 3, during the 
unrestrained MD simulations, the average distance between Asp and Arg Cβ was ∼8.5 Å, and that between 
the carboxylate and guanidino functions was ∼13Å, very similar to that of the α5β1 or αvβ3 selective 
cyclopentapeptides[29,30,38]. 
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As revealed by conformational analysis (Results), the two compounds show a very similar display of the 
retro-inverso RGD sequence. On the other hand, the different α5β1 versus αvβ3 selectivity displayed by 2 and 
3, sharing the same (S,S) stereochemistry of the RGD-mimetic sequence, can be attributed to the presence 
of an (S)-diamine in 2 and an (R)- diamine in 3.Themost relevant 3D difference can be identified in the 
disposition of the diamine portion. Apart from the different location of diamineNHa andNHb, in 2 the diamine 
phenyl side chain adopts an axial position while in 3 it is equatorial (Figure 9). 
 
 
Fig. (9). Overlap of the backbone structures of 2 (2b, white) and 3 (3b, black) determined by ROESY and MD analysis. Side chains have 
been positioned in trans extended conformation. 
 
The experimental 3D structure of α5β1 integrin is not yet available. As a consequence, the comparison of the 
structures of 2 and 3 with the structures of a few ligands, and with a in silico model, previously reported in 
the literature, could furnish some useful information about the biologically active conformation at this receptor. 
Goodman et al. described the receptor-bound conformation of the RGD sequence in the partially 15N-
labeled α 5β1 integrin weak antagonist c[Mpa15N-Arg-15N-Gly-15N-Asp-15N-Asp-15N-Val-Cys]-NH2 
(IC50=1.2 μM), determined by 15N-edited 2D transferred nuclear Overhauser effects[31]. Data were indicative 
of a tilted conformation, leading to a very short average distance between Arg and Asp Cβ of ∼5.6 Å. More 
recently, Sewald et al. reported for the α5β1 integrin cyclohexapeptide ligand c[Arg-Gly-Asp-D-Phe-Val-βAla] 
(IC50=2 ( 1 μM in K562 adhesion assays) a preferred extended RGD conformation showing a quite longer 
average distance between Arg Cβ and Asp Cβ of ∼9.3 Å [32]. Apparently, the average Cβ-Cβ distance of 8.5Å  
observed for 2 and 3 is somewhat between the two values reported above. 
More recently, a homology model of the α5β1 integrin has been reported by Kessler, Novellino, and co 
workers[37].The model, obtained by comparative protein modeling and validated with experimental data of 
nonpeptide ligands, allowed identification of a distance between the carboxylate function and the basic 
moiety of ∼13Å. This value is very close to the distance of∼13.8Å between the carboxylate and basic groups 
determined for αvβ3 integrin-bound ligands[20,29,30].As a consequence, the distance between the basic and 
acid moieties does not constitute a discriminant for αvβ3 versus α5β1 selectivity. Therefore, the different 
pharmacological profile of 2 and 3 toward αvβ3 and α5β1 integrins cannot be explained on the basis of the Cβ-
Cβ distance alone. 
However, the comparison of α5β1 and αvβ3 binding pockets revealed the occurrence of mutated residues in 
the β subunit. 
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Indeed, (β3)-Arg214 is replaced with (β1)-Gly217, and (β3)-Arg216 ismutated to (β1)-Leu219. The substitution of 
both the bulky Arg residues expands the site of the α5β1 binding pocket in comparison to the αvβ3 integrin. 
The authors concluded that ligands carrying bulky aromatic substituents in the proximity of the Asp (or Asp 
mimetic) residue can still fit the larger α5β1 binding pocket, but not the cramped αvβ3 binding pocket, 
therefore showing a certain selectivity for α5β1 over αvβ3 integrins. 
The model highlights the fundamental role of the aromatic residue flanking Asp in determining selectivity. 
This rationalization is corroborated by the molecular docking computations performed by us on compounds 2 
and 3 positioned within the αvβ3 integrin receptor binding site (see Results). 
The results lead to conjecture that the different disposition of diamine side chain is responsible of the 
different activity of 2 and 3 toward αvβ3 integrin. 
Molecular modeling studies showed that the pseudoequatorial benzyl group of 3 points toward the outside of 
the integrin binding site, allowing the aromatic ring to fit unhindered and reproducing the orientation of 
cilengitide (Results), matching side by side the Tyr122 side chain. Conversely, the axial disposition of the 
benzyl group of 2 gives rise to less favorable interactions, forcing the entire molecule to go into the receptor 
lopsided. 
With regard to the α5β1 integrin, on the basis of the homology model discussed above, the α5β1 integrin 
seems to be more tolerant in hosting the aromatic side chain of both 2 and 3. In particular, its larger binding 
site would more easily accommodate the phenyl ring of 2 with respect to the αvβ3 integrin, leading to a 
pronounced α5β1 selectivity, while the disposition of 3 would be adequate for both integrins, leading to a 
generally good affinity (Figure 10). 
 
 
 
Fig.(10). Schematic representation of the proposed disposition of 3 (left, black) and 2 (right, white) within α5β1 (black line) and αvβ3 (grey 
lines) integrin binding site sketches. Unfavourable interactions are also shown (transparent grey flashes). 
 
Despite the moderate or absent activity as adhesion inhibitors, compounds 4-9 can be utilized to confirm the 
validity of the model proposed above for the more active compounds, 2 and 3. Indeed, the structures of 4-9 
obtained by conformational analysis (see the Supporting Information) in general correlate well with the 
activity profile of the compounds toward α5β1 and αvβ3 integrins. Finally, the different affinities of 4-9 for the α
Vβ3 receptor can be explained on the basis of docking analyses performed by Glide (see the Supporting 
Information). 
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4.5. Conclusions 
In summary, we have reported the synthesis of a selected small library of RGD mimetics as αvβ3 and/or α5β1 
integrin antagonists. The compounds have been designed starting from 13-membered CTP scaffolds based 
on a partially retroinverso structure, containing (S)- or (R)-Asp, (S)- or (R)-Arg, and an (S)- or (R)-diamine as 
a β-Phe surrogate. 
The different compounds exhibited variable activities as αvβ3 or α5β1 integrin receptor antagonists, as 
determined by testing the inhibition of adhesion of fibronectin or vitronectin to αvβ3 or α5β1 integrin receptor-
expressing cell lines. c[(S)-βPheψ(NHCO)Aspψ(NHCO)Gly-(R)-Arg] (4) and c[(R)- βPheψ(NHCO)(R)-
Aspψ(NHCO)Gly-Arg] (8) revealed moderate micromolar inhibitory activities; c[(S)-βPheψ-
(NHCO)Aspψ(NHCO)Gly-Arg] (2) displayed a submicromolar activity for α 5β1 integrins, and a certain 
selectivity over αvβ3 integrins, while c[(R)-βPheψ(NHCO)Aspψ(NHCO)-Gly-Arg] (3)was demonstrated to be a 
potent dual antagonist, with activities of 10-8 and 10-7 M for α5β1 and αvβ3 integrins, respectively, and 
significantly inhibited bFGF-induced angiogenesis of HUVEC cultured in vitro. The different α5β1 versus αvβ3 
selectivity of 2 and 3 has been explained on the basis of their alternative secondary structures, discussed on 
the basis of NMR, ROESY, MD, and molecular docking analyses. In particular, the 3D display of the phenyl 
substituent of the diamine, pseudoaxial in 2 and pseudoequatorial in 3, seems to be a major contributor to 
receptor selectivity. 
These αvβ3 and α5β1 antagonists may be potentially effective and safe for therapeutic purposes. Small RGD-
containing peptidomimetics may be used as lead compounds for developing the potential therapeutic agents 
for angiogenesisrelated diseases, including cancer. 
 
4.6. Experimental Section 
4.6.1. General Methods. Unless stated otherwise, standard chemicals were obtained from commercial 
sources and used without further purification. Flash chromatography was performed on silica gel (230-400 
mesh), using mixtures of distilled EtOAc and MeOH. Semipreparative RP-HPLC was performed on a C18 
column (7 μm particle size, 21.2mm x150 mm, from a 7:3H2O/ CH3CN mixture to 100% CH3CN in 15 min) at 
a flow rate of 12 mL/min. The purity (>95%) of tested compounds was assessed by analytical RP-HPLC, on 
an ODS column (4.6 μm particle size, 100Å pore diameter, 250 mm, DAD 210 nm, from a 9:1 H2O/CH3CN 
mixture to a 2:8 H2O/CH3CN mixture in 20 min) at a flow rate of 1.0 mL/min, followed by 10 min at the same 
composition. 1H NMR spectra were recorded using 5 mm tubes, using 0.01 M peptide at 400 MHz at room 
temperature. 
Solvent suppression was performed by the solvent presaturation procedure implemented in varian (presat). 
Chemical shifts are reported as δ values relative to the solvent peak. The unambiguous assignment of 1H 
NMR resonances was performed by gCOSY, HMBC, and HSQC. gCOSY experiments were conducted with 
a proton spectral width of 3103 Hz. VT 1H NMR experiments were performed over the range of 298-348 K. 
Peaks were calibrated on DMSO. Conformational rearrangement was excluded since signal broadening was 
absent. 2D spectra were recorded in the phase sensitive mode and processed using a 90°-shifted, squared 
sine-bell apodization. ROESY experiments were recorded with a 300 or 350 ms mixing time with a proton 
spectral width of 3088 Hz. 
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4.6.2. Representative Synthetic Procedures and Analytical Characterization of PMRI RGD Mimetics 2 and 3. 
11. HOBt (0.16 g, 1.2 mmol) was added to a stirred solution of Fmoc-Asp(Mtr)- OH (0.61 g, 1.0 mmol) in a 
9:1 DCM/DMF mixture (15 mL) at rt. After 10 min, 10 (0.28 g, 1.0 mmol), EDCI-HCl salt (0.24 g, 1.2 mmol), 
and TEA (0.40 mL, 3.0 mmol) were added while the mixture was stirred at rt. After 4 h, the mixture was 
diluted with DCM, and the solution was washed with 0.5 M HCl and saturated Na2CO3. The organic layer 
was dried over Na2SO4, and the solvent was removed under reduced pressure. The Fmoc dipeptide 11 was 
isolated by crystallization from a DCM/Et2O mixture [0.74 g, 85%, 88% pure by RP-HPLC (see General 
Methods); Rf=11.7 min]: ES-MSm/z 875.3(M+1), calcd 875.4; 1H NMR (200 MHz, CDCl3) δ 1.40-1.60 (m, 
2H), 1.60-1.80 (m, 2H), 2.10 (s, 3H), 2.60 (s, 3H), 2.68 (s, 3H), 2.70-2.78 (m, 3H), 3.00-3.15 (m, 2H), 3.15-
3.22 (m, 2H), 3.78 (s, 3H), 4.05 (m, 1H), 4.20 (m, 1H), 4.30-4.50 (m, 2H), 4.99 (s, 2H), 5.45 (br d, 1H), 5.50 
(br d, 1H), 5.70 (br s, 1H), 6.10 (br s, 2H), 6.50 (s, 1H), 7.05-7.42 (m, 15H), 7.55 (br d, 2H), 7.75 (br d, 2H). 
Fmoc group deprotection was performed by treatment with 2 M DMA in THF (6 mL) at rt. After 30 min, the 
solution was evaporated at reduced pressure, and the treatment was repeated. 
After final evaporation of the solution, the residue was triturated twice in n-pentane. The deprotected 
dipeptide [0.50 g, 90%, 86% pure by RP-HPLC (see General Methods); Rf=8.8 min] was used without further 
purification: ES-MS m/z 653.3 (M + 1), calcd 653.3. 12.  
A solution of Meldrum’s acid (0.85 g, 6 mmol) and H-Asp(Ot-Bu)-OBz (1.4 g, 5 mmol) in CH3CN (15 mL) was 
warmed to 70 °C under an inert atmosphere. After 3 h, a 4:1 cyclohexane/Et2O mixture (40 mL) was added, 
and the oily residue that precipitated was separated. This residue was washed twice with a 4:1 hexane/Et2O 
mixture (20 mL), and the resulting dense oil was dissolved in EtOAc (40 mL) and washed with 0.1 M HCl (5 
mL). The organic layer was dried over Na2SO4, and solvent was evaporated at reduced pressure (<40°C), 
giving 12 as a waxy solid, which was used for the following step without further purification (1.2 g, 68%, 84% 
pure by NMR analysis): 1H NMR (300 MHz, CDCl3) δ 1.31 (s, 9H), 2.72 (dd, J=5.1, 17.2 Hz, 1H), 2.86 (dd, 
J=4.8, 17.2 Hz, 1H), 3.28 (br s, 2H), 4.82 (m, 1H), 5.05 (d, J=12.1 Hz, 1H), 5.14 (d, J = 12.1 Hz, 1H), 7.25-
7.40 (m, 5H), 7.86 (br d, 1H), 9.70-10.4 (br s, 1H). 
 
13. Dipeptides 11 (0.33 g, 0.5 mmol) and 12 (0.18 g, 0.5 mmol) were coupled under the same conditions 
used for the synthesis of 11 with HOBt (0.082 g, 0.6 mmol), EDCI-HCl salt (0.12 g, 0.6 mmol), and TEA (0.20 
mL, 1.5 mmol) in a 9:1 DCM/DMF mixture (10 mL) at rt. After 5 h, the usual workup afforded the fully 
protected tetrapeptide 13, isolated by crystallization from a DCM/Et2O mixture [0.32 g, 65%, 86% pure by 
RP-HPLC (see General Methods); Rf=11.2 min]: ES-MS m/z 1001.3 (M +1), calcd 1001.4; 1H NMR (200 
MHz, CDCl3) δ 1.48 (s, 9H) 1.54-1.70 (m, 2H), 1.77 (m, 1H), 1.92 (m, 1H), 2.10 (s, 3H), 2.50 (br s, 1H), 2.70 
(s, 3H), 2.76 (s, 3H), 2.74-2.85 (m, 3H), 3.18-3.38 (m, 3H), 3.39-3.50 (m, 3H), 3.90 (s, 3H), 4.10 (m, 1H), 
4.60 (m, 1H), 4.93 (m, 1H), 5.03-5.25 (m, 4H), 6.01 (d, J= 8.0 Hz, 1H), 6.20-6.40 (br s, 1H), 6.42 (br s, 2H), 
6.60 (s, 1H), 7.18-7.42 (m, 15H), 7.78 (br t, 1H), 7.97 (br d, 1H), 8.10 (br d, 1H); 13C NMR (300 MHz, 9:1 
CDCl3/DMSO-d6) δ 14.5, 17.1, 23.6, 27.3, 29.0, 29.2, 35.5, 37.9, 38.5, 39.8, 48.7, 49.2, 53.3, 55.0, 56.1, 
69.6, 73.7, 111.0, 121.3, 125.8, 127.3, 127.3, 127.5, 128.3, 128.3, 128.4, 128.4, 128.6, 128.6, 128.7, 128.7, 
130.1, 130.1, 130.6, 132.3, 132.9, 133.8, 136.5, 138.8, 150.2, 157.2, 162.6, 163, 165.7, 167.6, 170.9, 170.9, 
172.0, 174.7. 
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4.6.3.14 {c[βPheψ(NHCO)Asp(Ot-Bu)ψ(NHCO)Gly-Arg(Mtr)]}. Removal of the protecting group from 13 (0.32 
g, 0.32 mmol) was performed by treatment with H2 and catalytic Pd/C in EtOH (15 mL) at rt. After 6 h, the 
mixture was filtered over Celite, and the solvent was evaporated at reduced pressure, giving the linear 
tetrapeptide H-βPheψ(NHCO)Asp(Ot-Bu)ψ-(NHCO)Gly-Arg(Mtr)-OH [0.24 g, 96%, 84% pure by RP-HPLC 
(see General Methods); Rf= 5.9 min], used without further purification: ES-MS m/z 776.3 (M + 1), calcd 776.4. 
A mixture of the deprotected tetrapeptide (0.24 g, 0.31 mmol), DPPA (0.15 mL, 0.62 mmol), and NaHCO3 
(0.42 g, 5.0 mmol) in DMF (70 mL) was stirred at rt. After 72 h, the solvent was distilled under reduced 
pressure, the residue was diluted with water, and the mixture was extracted three times with DCM. 
The solution was evaporated under reduced pressure, and the residue was precipitated from a DCM/Et2O 
mixture. Semipreparative RP-HPLC (General Methods) gave 14 [0.16 g, 69%, 96% pure by RP-HPLC (see 
General Methods); Rf=8.3 min]: ES-MS m/z 758.5 (M + 1), calcd 758.4; 1H NMR (400 MHz, DMSO-d6) δ 
1.39 (s, 9H, t-Bu), 1.40-1.60 (m, 3H, ArgHγ + ArgHβ), 1.70 (m, 1H, ArgHβ), 2.07 (s, 3H, CH3), 2.29 (dd, J= 
10.0, 16.5 Hz, 1H, AspHβ), 2.49 (dd, J=4.1, 16.5 Hz, 1H, AspHβ), 2.52 (s, 3H,CH3), 2.62 (s, 3H,CH3), 2.62-
2.85 (m, 2H, diamHβ), 2.95-3.18 (m, 4H, Hc+ArgHδ), 3.18 (d, J=11.0 Hz, 1H, COCH2CO), 3.26 (d, J=11.0 
Hz, 1H, COCH2CO), 3.81 (s, 3H, OCH3), 3.85 (m, 1H, diamHα), 4.05 (m, 1H, ArgHα), 4.25 (m, 1H, AspHα), 
6.30-6.50 (m, 2H, ArgNHη), 6.46 (d, J=8.4 Hz, 1H, NHa), 6.70 (s, 1H, 50-ArH), 6.82 (t, J=5.4 Hz, 1H, NHb), 
6.92 (m, 1H, ArgNHε), 7.15-7.35 (m, 5H, ArH), 8.88 (d, J=6.6 Hz, 1H, ArgNH), 9.04 (d, J=6.6 Hz, 1H, 
AspNH); 13C NMR (400 MHz, DMSO-d6) δ 18.5, 19.1, 24.0, 25.9, 29.1, 29.3, 36.0, 37.5, 39.1, 39.8, 48.8, 
50.4, 51.8, 55.0, 56.3, 73.2, 112.2, 121.3, 125.8, 128.3, 128.3, 128.6, 128.6, 132.6, 132.9, 136.3, 139.2, 
162.9, 165.8, 170.9, 170.9, 172.2, 174.7, 175.0. 
 
4.6.4. 2 {c[βPheψ(NHCO)Aspψ(NHCO)Gly-Arg]}. The protected cyclotetrapeptide 14 (0.16 g, 0.21 mmol) 
was treated with a 94:2:1:2:1 mixture of TFA and scavengers [TFA/PhOH/PhSH/ H2O/Et2S (5 mL)] at rt for 
30 min. The mixture was distilled under reduced pressure, and the treatment was repeated. The residue was 
suspended in Et2O, and the precipitate was centrifuged. 
The resulting crude residue was purified by semipreparative RP-HPLC (General Methods), giving 2 [0.077 g, 
76%, 97% pure by analytical RP-HPLC (see General Methods); Rf=1.8 min]: ES-MS m/z 490.2 (M + 1), 
calcd 490.2; 1H NMR (400 MHz, 8:2 DMSO-d6/H2O) δ 1.45-1.60 (m, 3H, ArgHγ +ArgHβ), 1.74 (m, 1H, 
ArgHβ), 2.30 (dd, J=9.5, 16.0 Hz, 1H, AspHβ), 2.47 (dd, J=4.0, 16.0 Hz, 1H, AspHβ), 2.60-2.86 (m, 2H, 
diamHβ), 2.92-3.20 (m, 4H, Hc+ArgHδ), 3.19 (d, J=10.8 Hz, 1H,COCH2CO), 3.24 (d, J=10.8 Hz, 
1H,COCH2CO), 3.68 (m, 1H, diamHα), 3.96 (m, 1H, ArgHα), 4.20 (m, 1H, AspHα), 6.70 (d, J=8.4 Hz, 1H, 
NHa), 6.90 (br t, 1H, NHb), 7.10-7.35 (m, 5H, ArH), 7.90 (br s, 1H, ArgNHε), 9.10 (br d, 1H, ArgNH), 9.28 (br 
d, 1H, AspNH); 13C NMR (400 MHz, 8:2 DMSO-d6/ H2O) δ 26.0, 29.2, 36.5, 37.5, 39.0, 39.8, 40.0, 48.8, 50.2, 
51.8, 55.0, 126.0, 128.1, 128.3, 128.8, 128.7, 138.8, 163.9, 171.0, 171.2, 174.7, 175.1, 177.7. 
 
4.6.5. 3 {c[(R)-βPheψ(NHCO)Aspψ(NHCO)Gly-Arg]}: 1HNMR (400 MHz, 8:2 DMSO-d6/H2O) δ 1.42-1.50 (m, 
2H, ArgHγ), 1.56 (m, 1H, ArgHβ), 1.74 (m, 1H, ArgHβ), 2.40 (dd, J=6.0, 16.8 Hz, 1H, AspHβ), 2.58 (dd, 
J=7.2, 16.8 Hz, 1H, AspHβ), 2.75 (dd, J=6.6, 16.0 Hz, 1H, diamHβ), 2.83 (dd, J=8.0, 16.0 Hz, 1H, diamHβ), 
2.95-3.15 (m, 3H, Hc + ArgHδ), 3.20 (d, J=10.2 Hz, 1H,COCH2CO), 3.21 (d, J=10.2 Hz, 1H,COCH2CO), 3.28 
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(m, 1H, Hc), 3.67 (m, 1H, diamHα), 3.95 (m, 1H, ArgHα), 4.26 (m, 1H, AspHα), 7.02 (br t, 1H, NHb), 7.10-
7.35 (m, 5H, ArH), 7.62 (d, J=6.9 Hz, 1H, NHa), 7.90 (br s, 1H, ArgNHε), 8.85 (br d, 1H, ArgNH), 9.22 (br d, 
1H, AspNH); 13CNMR (400 MHz, 8:2 DMSO-d6/H2O) δ 26.0, 29.0, 34.5, 36.6, 39.3, 39.8, 39.9, 48.8, 50.4, 
52.8, 56.6, 124.5, 127.9, 127.9, 129.0, 129.1, 138.8, 163.8, 171.3, 175.0, 175.1, 176.1. 
 
4.7. Pharmacological Assays 
4.7.1. Materials for Bioassays. Trypsin/ EDTA, nonessential amino acids, minimum essential medium (MEM), 
RPMI-1640 with L-glutamine, antibiotic and antimycotic solution, and glycine were purchased from Invitrogen 
(Carlsbad, CA). Fetal bovine serum (FBS) and phosphatebuffered saline (PBS) were from Cambrex 
(Walkersville, MD). 
Citrate buffer solution, EDTA, DMSO, Triton X-100, 4-nitrophenylN- acetyl-β-D-glucosaminide, phorbol 12 
myristate 13-acetate (PMA), pyruvic acid, fibronectin, and vitronectin, both from human plasma, were 
obtained from Sigma-Aldrich SRL (Milan, Italy). SK-MEL-24 (human malignant melanoma) and K-562 
(human erythroleukemia) were obtained from American Tissue Culture Collection (ATCC, Rockville, MD). 
HUVEC (human umbilical vein endothelial cells) were obtained from Clonetics (Cambrex). Matrigel-
precoated 96-well plates and human recombinant bFGF were from BD Biosciences (Bedford, MA). 
 
4.7.2. Cell Culture. SK-MEL-24 were routinely grown in MEM supplemented with 10% FBS, nonessential 
amino acids, and sodium pyruvate. K-562 were maintained as a stationary suspension culture in RPMI-1640 
and L-glutamine with 10% FBS. HUVEC were cultured in endothelial growth medium (EGM, Clonetics), 
containing fetal bovine serum, bovine brain extract, human epidermal growth factor, hydrocortisone, 
gentamicin, and amphotericin B; cells from passages 2-7 were used in this study. Cells were kept at 37 °C in 
a 5% CO2 humidified atmosphere. 
Forty hours before the experiment, K-562 were treated with 25 ng/mL PMA to induce differentiation with an 
increased level of expression of cell surface antigens[75]. 
 
4.7.3. Cell Adhesion Assays[76] Plates (96 wells) (Corning, New York, NY) were coated by passive adsorption 
with fibronectin (10 μg/mL) or vitronectin (10 μg/mL) overnight at 4°C. Cells were counted and exposed to 
different concentrations of each compound for 30 min at room temperature to allow the ligand-receptor 
equilibrium to be reached. Stock solutions (10-2 M) of the assayed compounds were prepared in 33% DMSO 
in phosphate-buffered saline (v/v); further dilutions were done in PBS alone. The highest concentration of 
DMSO in the assays was 1% of the stock solution. Control cells were exposed to the same concentration of 
DMSO. At the end of the incubation time, the cells were plated (50000 cells/well) and incubated at room 
temperature for 1 h. Then, all the wells were washed with PBS to remove nonadherent cells, and 50 μL of 
hexosaminidase [4-nitrophenylN-acetyl-β-D-glucosaminide dissolved at a concentration of 7.5 mM in 0.09 M 
citrate buffer solution (pH 5) and mixed with an equal volume of 0.5% Triton X-100 in water] was added. This 
product is a chromogenic substrate for β-N-acetylglucosaminidase that is transformed in 4-nitrophenol 
whose absorbance is measured at 405 nm. As previously described[77], there is a linear correlation between 
absorbance and enzymatic activity. Therefore, it is possible to identify the number of adherent cells in treated 
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wells, interpolating the absorbance values of the unknowns in a calibration curve. The reaction was blocked 
by addition of 100 μL of a stopping solution [50 μM glycine and 5 μM EDTA (pH 10.4)], and the plates were 
read in a Victor2 Multilabel Counter (Perkin-Elmer, Waltham, MA). Experiments were conducted in 
quadruplicate and were repeated at least three times. Data analysis and IC50 values were calculated using 
Graph-Pad Prism 3.0 (GraphPad Software, San Diego, CA). 
 
4.7.4. Flow Cytometry Assay. To assess the amount of intact, apoptotic or necrotic cells, an Annexin V-Fluos 
(Roche)/propidium iodide (PI) (Sigma-Aldrich) assay was performed. Double staining against annexin V 
together with PI separates cells, not necrotic, currently undergoing apoptosis from cells that have died of 
necrosis. HUVEC were treated with different concentrations of the assayed compounds for 30 min at 37°C; 
the cells were detached and fixed with 1% paraformaldheyde for 15 min and then washed with PBS. 
Thereafter, HUVEC were resuspended in Annexin-V-Fluos incubation buffer [10 mM Hepes/ NaOH (pH 7.4), 
140 mM NaCl, and 5 mM CaCl2] with prediluted Annexin-V-Fluos and PI, according to the manufacturers’ 
instructions. After incubation for 15 min at room temperature in the dark, the cells were analyzed with EPICS 
XLMCL (Beckman Coulter). 
 
4.7.6. In Vitro Tubular Formation of HUVEC. The endothelial tube formation assay was performed as 
described[78]. Matrigel precoated 96-well plates were used, and HUVEC (5000 cells/ well) were seeded in the 
presence of different concentrations of test compounds, in the absence (negative control) or presence of 
bFGF (30 ng/mL). Cells were incubated for 16 h at 37°C. After incubation, these cells underwent 
differentiation into capillarylike tube structures; tube formation was examined by a NIKON microscope 
equipped with a camera. The experiments were repeated three times. 
 
4.8. Conformational Analysis.  
ROESY intensities were classified very strong, strong, medium, and weak and were associated with 
distances of 2.3, 2.6, 3.0, and 4.0 Å , respectively. Geminal couplings and other obvious correlations were 
discarded. For the absence of HR-COCH2CO or HR-NHCH (i, i + 1) ROESY cross-peaks, the ω bonds were 
set at 180° (force constant of 16 kcal mol-1 Å -2). Only ROESY-derived constraints were included in the 
restrained MD. The restrained MD simulations were conducted using the AMBER70 force field in a 30 Å x 30 
Å x 30 Å box of standard TIP3P models of equilibrated water. All water molecules with atoms that come 
closer to a solute atom than 2.3 Å were eliminated. A 50 ps simulation at 1200 K was used for generating 50 
random structures that were subsequently subjected to a 20 ps restrained MD with a 50% scaled force field 
at the same temperature, followed by 20 ps with full restraints (distance force constant of 7 kcal mol-1 Å -2), 
after which the system was cooled in 5 ps to 50 K. H-Bond interactions were not included, nor were torsion 
angle restraints. The resulting structures were minimized with 3000 cycles of steepest descent and 3000 
cycles of conjugated gradient (convergence of 0.01 kcal Å-1 mol-1). The backbones of the structures were 
clustered by the rmsd analysis module of HyperChem. Unrestrained MD simulation in explicit water was 
performed for 10 ns at 298 K, at constant temperature and pressure (Berendsen scheme,79 bath relaxation 
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constant of 0.2)[80]. For 1-4 scale factors, van der Waals and electrostatic interactions are scaled in AMBER 
to half their nominal value.The integration time step was set to 0.1 fs. Box equilibration was set to 10 ps. 
 
4.8.1. Molecular Docking. All calculations were run using the Schrödinger suite of programs  
(http://www.schrodinger.com) through the Maestro graphical interface. 
 
4.8.2. Protein Setup. The recently determined crystal structure of the extracellular domain of the integrin αVβ3 
receptor in complex with cilengitide and in the presence of the proadhesive ion Mn2+ (PDB entry 1L5G) was 
used for docking studies. Docking was performed only on the globular head of the integrin because the 
headgroup of integrin has been identified in the X-ray structure as the ligand-binding region. The protein 
structure was set up for docking as follows; the protein was truncated to residues 41-342 for chain α and 
residues 114-347 for chain β. 
Due to a lack of parameters, the Mn2+ ions in the experimental protein structure were modeled via 
replacement with Ca2+ ions. 
The resulting structure was prepared using the Protein Preparation Wizard of the graphical user interface 
Maestro and the OPLSAA force field. 
 
4.8.3. Docking. The automated docking calculations were performed using Glide[72] (Grid-based Ligand 
Docking with Energetics) within the framework of Impact version 4.5 in a standard precision mode (SP). The 
grid generation step started from the extracellular fragment of the X-ray structure of the αVβ3 complex with 
cilengitide, prepared as described in Protein Setup. The center of the grid-enclosing box was defined by the 
center of the bound ligand. The enclosing box dimensions, which are automatically deduced from the ligand 
size, fit the entire active site. For the docking step, the size of the bounding box for placing the ligand center 
was set to 12Å. No further modifications were applied to the default settings. The Glide-Score function was 
used to select 20 poses for each ligand. Glide was initially tested for its ability to reproduce the crystallized 
binding geometry of cilengitide. The program was successful in reproducing the experimentally found binding 
mode of this compound, as it corresponds to the best-scored pose. 
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4.9. Supporting Information 
 
 
 
Figure S1. Tube formation of HUVEC cells on Matrigel. Representative pictures of capillary-like structures (black bar in the pictures 
corresponds to 100 μm). HUVEC cells were treated with or without integrin antagonists (10 μM) and then plated on Matrigel in the 
absence or presence of bFGF (30 ng/mL) for 16h. Compounds 4, 5, 6, 7 and 9 were not effective as angiogenesis inhibitors. 
 
 
 
Figure S2. αvβ3/α5β1 integrin antagonists did not induce apoptosis or necrosis in endothelial cells. No significant increase in apoptotic or 
necrotic cells was observed among endothelial cells treated with 10 μM integrin antagonists. HUVEC cells were treated with integrin 
antagonists for 16 h; then the cells were detached and stained with Annexin-V and PI to distinguish healthy cells (Annexin-V- and PI-), 
early apoptotic cells (Annexin-V+ and PI-), and late apoptotic/necrotic cells (Annexin-V+ and PI+). A representative experiment of three 
done with superimposable results is shown. 
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Analytical characterization of PMRI RGD-mimetics 4, 5.  
Compounds 6-9 are the enantiomers of 2-5, respectively. The syntheses of 3-9 were performed as reported 
for 2.  
 
 
HNNH OO
NHHN
OO
NH
HN
NH2
OH
O
Ph
2-9
a b
c
Figure S3 
 
(4), c[βPheψ(NHCO)Aspψ(NHCO)Gly-(R)-Arg]. 1H-NMR (400 MHz, 8/2 DMSO-d6/H2O): δ = 1.40-1.55 (m, 
3H, ArgHɣ+ArgHβ), 1.67 (m, 1H, ArgHβ), 2.36 (dd, J= 9.0, 15.0 Hz, 1H, AspHβ), 2.50 (dd, J= 4.0, 15.0 Hz, 
1H, AspHβ), 2.58-2.87 (m, 3H, Hc+diamHβ), 2.91 (d, J= 10.4 Hz, 1H, COCH2CO), 2.92-3.20 (m, 2H, ArgHδ), 
3.20 (d, J= 10.4 Hz, 1H, COCH2CO), 3.55 (m, 1H, Hc), 3.80 (m, 1H, diamHα), 3.90 (m, 1H, ArgHα), 4.18 (m, 
1H, AspHα), 6.65 (d, J= 8.4 Hz, 1H, NHa), 6.95 (br.t, 1H, NHb), 7.10-7.35 (m, 5H, ArH), 8.00 (br.s, 1H, 
ArgNHε), 8.61 (br.d, 1H, ArgNH), 8.75 (br.d, 1H, AspNH). 13C-NMR (400 MHz, 8/2 DMSO-d6/H2O): δ = 27.0, 
30.2, 36.0, 37.4, 38.5, 40.0, 40.6, 48.2, 49.9, 51.4, 55.3, 125.1, 128.0, 128.3, 129.0, 129.2, 138.2, 163.6, 
171.8, 173.2, 173.5, 175.0, 176.5.  
 
(5), c[βPheψ(NHCO)-(R)-Aspψ(NHCO)Gly-Arg]. 1H-NMR (400 MHz, 8/2 DMSO-d6/H2O): δ = 1.38-1.57 (m, 
3H, ArgHɣ+ArgHβ), 1.61 (m, 1H, ArgHβ), 2.41 (dd, J= 9.0, 15.0 Hz, 1H, AspHβ), 2.54 (dd, J= 4.0, 15.0 Hz, 
1H, AspHβ), 2.70-2.80 (m, 2H, diamHβ), 2.81 (d, J= 10.6 Hz, 1H, COCH2CO), 2.90 (m, 1H, Hc), 2.91-3.19 
(m, 2H, ArgHδ), 3.22 (d, J= 10.4 Hz, 1H, COCH2CO), 3.50 (m, 1H, Hc), 3.90 (m, 1H, diamHα), 4.05 (m, 1H, 
ArgHα), 4.25 (m, 1H, AspHα), 6.99 (d, J= 8.4 Hz, 1H, NHa), 7.08 (br.t, 1H, NHb), 7.10-7.38 (m, 5H, ArH), 
8.30 (br.s, 1H, ArgNHε), 8.40 (br.d, 1H, ArgNH), 8.75 (br.d, 1H, AspNH). 13C-NMR (400 MHz, 8/2 DMSO-
d6/H2O): δ = 26.7, 30.6, 36.9, 37.3, 38.4, 39.8, 40.4, 48.8, 49.7, 52.3, 55.3, 125.7, 128.2, 128.8, 129.4, 129.6, 
135.2, 164.6, 169.8, 173.7, 174.0, 175.6, 176.4.  
 
Table S1. Non-obvious ROESY cross-peaks observed for 4. Stereochemistry has been omitted. For Ha, Hb, Hc, see Figure S3; u = 
upfield, d = downfield; vs = very strong, s = strong, m = medium, w = weak 
Cross peak Intensity Cross peak Intensity 
AspNH-NHa s AspNH-ArgNH w 
AspNH-AspHα m AspNH-COCH2COu vs 
ArgNH-COCH2COu s AspNH-COCH2COd w 
ArgNH-COCH2COd m AspNH-AspHβd w 
NHb-ArgHα s ArgNH-NHb s 
NHa-NHb m ArgNH-ArgHα s 
diamHα-NHb m ArgNH-NHa w 
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NHb-Hcu m NHb-Hcd vs 
NHa-diamHβ s NHa-AspHβd m 
NHa-Hcu w NHa-AspHα m 
AspHα-AspHβd m AspHα-AspHβu w 
ArgHα-ArgHβu vs NHa-diamHα s 
ArgHα-ArgHβd m diamHα-diamHβ s 
ArgHα-ArgHɣ w ArgHα-ArgHδ m 
diamHα-Hcu m diamHα-Hcd vs 
diamHα-diamHβ vs Hcu-diamHβ s 
Hcu-diamHβ m ArgHδ-ArgHɣ s 
ArgHβ-ArgHɣ vs   
 
 
Table S2. Non-obvious ROESY cross-peaks observed for 5. Stereochemistry has been omitted. For Ha, Hb, Hc, see Figure S3; u = 
upfield, d = downfield; vs = very strong, s = strong, m = medium, w = weak 
Cross peak Intensity Cross peak Intensity 
AspNH-AspHβd m AspNH-COCH2COd m 
AspNH-AspHα s AspNH-NHa s 
AspNH-COCH2COu s ArgNH-COCH2COu vs 
ArgNH-ArgHα m ArgNH-NHb s 
ArgNH-ArgHβd m NHb-Hcd s 
NHb-diamHβ w NHb-diamHα w 
NHb-ArgHα vs NHb-ArgNH vs 
NHb-Hcu m NHa-diamHβ s 
NHa-Hcd m NHa-diamHα s 
AspHα-AspHβd m AspHα-AspHβu w 
NHa-AspHα vs NHa-ArgHα w 
diamArH-Hcd m diamArH-diamHβ vs 
diamArH-diamHα vs diamArH-AspHα w 
ArgHα-ArgHβd m diamArH-Hcu m 
ArgHα-ArgHɣ w ArgHα-ArgHδ m 
diamHα-diamHβ vs ArgHα-ArgHβu s 
diamHα-Hcu s diamHα-Hcd m 
ArgHβ-ArgHɣ s ArgHδ-ArgHɣ s 
 
Conformational analysis of 4 and 5 in solution. 
The conformational analyses of 4 and 5 were performed by NMR spectroscopy and Molecular Dynamics 
(MD) simulations as reported for 2, 3. The 1H-NMR of 4 and 5 revealed a single set of resonances. Variable 
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temperature 1H-NMR experiments were utilized to deduce the presence of H-bonds involving amide protons 
(Table S3).  
 
Table S3. Δδ/Δt values (ppb/°K) of amide protons for 4 and 5, determined by VT-1H-NMR analysis in 8/2 DMSO-d6/H2O at 400 MHz 
over the range 298-348 °K. (NHa, NHb, see Figure S3) 
Compd AspNH ArgNH NHa NHb 
4 -4.0 -3.0 -1.3 -0.2 
5 -2.8 -3.0 -0.7 -1.5 
 
As for 2, in 4 and 5 the comparatively low Δδ/Δt values of diamine NHa and NHb with respect to AspNH and 
ArgNH suggest the existence of secondary structures in equilibrium, alternatively stabilized by H-bonds 
involving NHa or NHb. 
Molecular backbone conformations were investigated by 2D ROESY and restrained molecular dynamics 
performed in a box of explicit water. For the absence of Hαi-Hαi+1 cross peaks, all of the ω bonds were set at 
180°. After cluster analysis, for both 4 and 5 the computations essentially gave two kinds of structures, 4a/4b 
(Figure S4) and 5a/5b (Figure S5), differing exclusively by the opposite orientation of ArgNH, and AspNH, 
respectively, each showing some constraint violations (Table S4).  
 
 
Figure S4. Representative, low-energy structure 4a (left) and 4b (right) consistent with ROESY analysis. 
 
          
Figure S5. Representative, low-energy structure 5a (left) and 5b (right) consistent with ROESY analysis. 
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The couples 4a/4b and 5a/5b reasonably represent conformers in equilibrium. The structure 4a is compatible 
with the strong cross-peaks observed between COCH2COu and both AspNH and ArgNH; the structure 4b is 
compatible with the medium cross peak between COCH2COd and ArgNH, and with the strong cross-peak 
between ArgNH and ArgHα. For compound 5, the strong cross peaks between COCH2COu and both AspNH 
and ArgNH account for the structure 5a; the cross peak of medium intensity between AspNH and 
COCH2COd, and the strong cross-peak between AspNH and AspHα account for the structure 5b. 
The structures 4b and 5b show a smaller number of distance violations (Table S4) with respect to 4a and 5a, 
respectively, and conformations more compatible with VT-NMR data, which are suggestive of H-bonds on 
both NHa and NHb. 
 
Table S4. Distance violations, calculated vs constraint (Å)a for ROESY-derived structures. Residue stereochemistry has been omitted. 
4a 4b 5a 5b 
ArgNH-ArgHα 
2.9 vs 2.6 
 
ArgNH-ArgHα  
2.3 vs 2.6 
AspNH-AspHα 
2.9 vs 2.6 
AspNH-AspHα  
2.3 vs 2.6 
ArgNH-NHb  
2.9 vs 2.6 
 
 AspNH-NHa 
2.9 vs 2.6 
 
ArgNH-COCH2COu 
2.3 vs 2.6 
 
ArgNH-COCH2COu 
3.5 vs 2.6 
AspNH-COCH2COu 
2.3 vs 2.6 
AspNH-COCH2COu 
3.5 vs 2.6 
ArgNH-COCH2COd 
3.5 vs 2.9 
 AspNH-COCH2COd 
3.5 vs 2.9 
 
a The authors are aware that being concerned about distance differences that are a few tenths of an Angstrom different could be 
misleading in this context.  
 
During the unrestrained MD in explicit solvent performed on 4a, 4b, 5a, and 5b, the analysis of the 
trajectories revealed the presence of H-bonded structures involving NHa and/or NHb (not shown), as 
suggested by VT-NMR data. The simulations failed to reproduce the inversion of ArgNH for 4, and the 
inversion of AspNH for 5; evidently, these rotations are slow compared to the time selected for the simulation.  
The compounds 6-9 were not investigated; their structures were generated as the mirror mages of the 
respective enantiomers 2-5. 
The comparison of the in-solution structures of 2 and 3 with the structures of 4-9, and the correlation with 
their experimental affinity for α5β1 and αvβ3 integrins give several clues to discuss the interaction with the 
receptors.  
Compounds 4, 5, 8, and 9, show a cis disposition of Asp and Arg (Figure S4 and S5 and respective mirror 
images). The analysis of the trajectories of unrestrained molecular dynamics confirms that the average 
distance between the pharmacophores is shorter with respect to the distance considered optimal for binding 
α5β1 and αvβ3 integrins.  
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In 4, the guanidino group of (R)-Arg is placed on the opposite side of the cyclic scaffold with respect to 2, 3 
(see the main text). Apparently, the long and flexible side chain of Arg still allows a certain interaction with 
the receptors. In the preferred conformation 4b, the benzyl side chain of the diamine points below the 
molecular plane, as for 2, but the pseudo-equatorial position seems scarcely effective in discriminating the 
different sizes/shapes of the lipophilic pockets of the αvβ3 (small pocket) or α5β1 (large pocket) receptors. 
This situation is consistent with a moderate affinity towards both the receptors, in the micromole range, with 
no selectivity. 
While in 4 the carboxylic group of Asp points towards the receptor’s cation in a straight line, as in 2 and 3, in 
5 the carboxylic group of (R)-Asp is placed on the opposite side of the cyclic scaffold. This difference 
accounts for the lack of activity of 5.  
Compound 6 and 7 are the enantiomers of 2 and 3, respectively, and the same distance between the 
pharmacophores can be observed (the conformational analysis was not repeated). This distance matches 
the one required for a good interaction with the receptors. However, as for 5, the D-Asp residue places the 
carboxylic group on the opposite side of the scaffold respect to the compounds 2-4. As a consequence, 6 
and 7 seem to be scarcely adapt to interact the receptors.  
In contrast, compound 8 shows a moderate experimental affinity for both α5β1 and αvβ3 integrins despite of 
the presence of (R)-Asp. Besides, the complete lack of activity of 9 towards both the αvβ3 and α5β1 receptors 
remains for the moment elusive. Further insight can be obtained for the αVβ3 integrin by molecular docking. 
 
Molecular docking of 4-9. 
In order to rationalize, on a molecular basis, the affinity of the compounds for the αvβ3 receptor, docking 
studies were performed following the same virtual screening protocol used for compounds 2 and 3. Ligands 
4 and 8 produced top-ranked poses conserving all the important interactions of the X-ray complex (Figure S6) 
with the benzyl side chain of the diamine pointing toward the outside of the integrin binding site, allowing the 
aromatic ring to fit unhindered. In the calculated docking poses, compound 4 fits the receptor by reproducing 
the RGD backbone of the X-ray ligand better than the conformations of ligand 8 (Figure S6). Altogether 
these computational findings agree with the comparable micromolar activity observed for 2, 3, 4 and 8 for the 
integrin αvβ3. 
On the contrary, most poses generated by the automated docking calculations for the inactive compounds 5, 
6, 7 and 9 failed in forming all the key ligand-protein interactions, as revealed by the less favourable Glide 
score values. The stereochemistry array of the residues in compounds 5, 6, 7 and 9 produce three-
dimensional pharmacophoric arrangements forcing the entire molecule to enter the receptor lopsided. In 
particular, the electrostatic interactions drive the fit of these ligands into the receptor binding site, but cause 
the loss of the complex network of hydrogen bonds. Especially, the presence of a (R)-Asp residue seems to 
hamper the proper fit of the ligands in the receptor cleft (see 5, 6, 7).  
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Figure S6. Top-ranked docking poses of ligands 4 (left side) and 8 (right side) (atom colour tube representation) into the crystal structure 
of the extracellular domain of αVβ3 integrin (α unit cyan and β unit orange wire representation) overlaid on the bound conformation of 
cilengitide (green tube representation). Only selected integrin residues involved in the interactions with cilengitide are shown. The Mn2+ 
ion at MIDAS is shown as a green CPK sphere. Nonpolar hydrogen atoms were removed for clarity. 
 
In conclusion, the conformational analyses and molecular docking computations of 2-9 confirm that the 
distance between the pharmacophores is the primary requisite for a correct interaction with the receptors, as 
expected, but this feature has no effect on selectivity. Data explain the experimental observation that the 
presence of (S)-Asp and (S)-Arg is a pre-requisite to obtain the highest affinity. The presence of (R)-Arg can 
be tolerated, due to the flexibility of its side chain, while the presence of (R)-Asp is generally deleterious for 
activity. The only exception is 8, which likely adopts an alternative receptor-bound conformation (calculated 
only for αVβ3 integrin).  
In the proposed model, the disposition of the benzyl group of the diamine plays a fundamental role in 
selectivity. It is possible to perceive that a pseudo-equatorial orientation of the benzyl group is well tolerated 
by both α5β1 and αVβ3 integrins. Interestingly, compound 2, the only compound with a well precise axial 
disposition of the benzyl, is also the only compound selective for α5β1 over αVβ3 integrin. 
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Chapter 5 
Molecular Docking of Opioid Peptides and Analogues, a Powerful Tool for the 
Design of Selective Agonists and antagonists, and for the Investigation of 
Atypical Ligand-Receptor Interactions.  
 
Abstract. In the last years, molecular docking emerged as a powerful tool to investigate the interactions 
between opioid ligands and their receptors, thus driving the design and development of new selective 
agonists or antagonists of therapeutic interest. This review especially covers the most representative and 
recent comparative molecular docking analysis of structurally related compounds, as well as of agonists and 
antagonists within the active and inactive states of the receptors. The comparative analyses gave important 
information on the structural determinants responsible for the affinity and selectivity of the ligands, and 
defined the features responsible for the activation of the receptors. A special section is dedicated to the 
analyses of recently discovered, unusual agonists lacking of the tyramine pharmacophore, such as 
Salvinorin A, and the cyclopeptides including the D-Trp-Phe pharmacophoric motif. For the atypical structure 
of these compounds, the docking proved to be essential to disclose how they interact with and activate the 
receptors. 
 
5. Introduction 
In medicinal chemistry, the rational drug design (structure based drug design or de novo drug design), is the 
process of finding new bioactive molecules based on the knowledge of the biological target. The final goal is 
to design molecules that are complementary in shape and charge to their receptor to which they interact and 
bind to. When the drug design is centered on computer modeling, it is often referred to as Computer-Aided 
Drug Design (CADD). In particular, the molecular docking is a method which estimates the preferred, 
energetically favorable orientations of a candidate drug inside its receptor. Molecular docking emerged as a 
powerful tool in drug discovery to find and optimize lead compounds. Structural information derived from the 
theoretically modeled complex may clarify the mechanism of molecular recognition, and can be also used to 
discover novel ligands by predicting binding affinities with the receptor before they are synthesized. Indeed, 
docking can be utilized to prescreen in silico “real” or “virtual” compounds, avoiding expensive in vitro or in 
vivo assays. This opportunity is of particular interest in regard to the screening of large compound libraries 
generated by Combinatorial Chemistry (in silico highthroughput screening). The distinction between docking 
and de novo design methods can be subtle and, in many cases, significant overlap in methodology occurs 
between the strategies. 
In the last years, continuous efforts have been dedicated to the quest for new potent analgesics devoid of 
the typical undesired side effects of the opiates. In this respect, docking may represent a useful technique; 
an accurate insight of the ligand-receptor complex and the comprehension of the mode of interaction might 
help in clarifying the origins of the adverse effects exerted by the opiates, in particular addiction and 
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tolerance, and might drive to the development of new opioid drugs and therapies with more desirable 
properties. 
A number of somewhat differing models have been proposed to explain the binding and selectivity of opioid 
agonists and antagonists. Albeit the structural differences might be minimal, the biochemical effects of 
agonists and antagonists are well distinct: agonists stabilize the receptor conformation in the active form 
whereas antagonists stabilize the receptor conformation in the inactive form and interfere with the binding of 
agonists. The classic pharmacophoric models of opiates have been exhaustively reviewed by Eguchi [1], 
Mosberg et al. [2], and by Ferguson et al. [3].For this reason, this review intends to discuss in details two 
issues: the most relevant and recent comparative docking analyses of opioid peptides and peptidomimetics 
bound to the active and inactive states of the μ-, δ-, k-opioid receptors (MOR, DOR, and KOR), and the 
docking analyses of some atypical agonists deprived of the tyramine pharmacophore. The latter is of 
particular interest; the docking procedure proved to be fundamental for the determination of the mechanism 
by which these unusual ligands interact with and activate the receptors. 
 
5.1 Structure and Functions of the Opioid Receptors, and Representative Opioid Ligands  
The opioid receptors belong to the class a G protein coupled receptor (GPCR) [4], and are expressed in 
different areas of the CNS: pons, medulla, spinal cord, telencephalon, diencephalon, mesencephalon, and 
myelencephalon. Three opioid receptors DOR, MOR, and KOR were cloned in the early 1990s [5].The MOR 
and KOR subtypes are widely distributed in the gastrointestinal tract, in particular in the stomach and 
proximal colon, while the DOR is expressed on neurons within myenteric and submucous ganglia [6]. 
The receptors are composed of seven transmembrane helices (TMH) that are packed together in an anti 
clockwise disposition, and have long extracellular N-terminus and intracellular C-terminus sequences. The 
helices are connected by three intra- and three extracellular loops (EL) that vary in size and composition. 
The opioid receptors share extensive sequence homology; in particular, the intracellular loops and the TMHs 
show high identity, while EL2, EL3, and the C-terminus share little to no homology. 
Based on the selectivity profiles of some agonists or antagonists, there are at least two variants for each 
receptor type, namely MOR1/2, DOR1/2, and KOR1/2. However, the cloning studies did not confirm the 
existence of distinct genes, therefore these subdivisions may result from splice variants, or different post 
translational modifications, distinct cellular localizations, dimerization, or interaction with some proteins. 
In the intracellular domain, the receptors are linked to a heterotrimeric G protein, composed of the Gα, Gβ, 
and Gɣ subunits. Upon binding with an agonist, the receptors undergo a conformational change, which 
promotes the exchange of GDP for GTP at the Gα subunit. This induces the dissociation from the Gβ,ɣ dimer; 
the subunits activate several effectors, until the GTP is hydrolyzed to GDP (intrinsic GTPase activity), leading 
to the reassembly of the subunits [7]. The inhibition of adenylyl cyclase activity is induced by the GTP bound 
Gαi subunit, so reducing the activity of cAMP-dependent PKA, while the Gβ,ɣ subunits mediate the activation 
of potassium conductance and inhibition of voltagegated calcium channels, decreasing excitability. 
There is evidence of homo- and heteromerization of the opioid receptors; these heteromers possess unique 
biochemical properties including allosteric modulation between units, changes in ligand recognition, G 
protein-coupling and trafficking [8, 9]. 
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The alkaloids found in the opium poppy plant have been used as remedies for pain relief for centuries [1]. The 
most abundant is morphine (1), which was isolated in 1803, and is still the drug of choice for treating severe 
pain caused by cancer or surgical operation; codeine (2), isolated in 1832, is the second-most predominant 
alkaloid in opium. Many semisynthetic derivatives of morphine revealed an agonist or antagonist behaviour. 
The progressive reduction of morphine structure resulted in several new classes of therapeutically useful 
opioid ligands such as morphinans, e.g. levorphanol (3), benzomorphans, e.g. pentazocine (4), 4- 
phenylpiperidines, e.g. meperidine (5), N-phenylpiperazines, e.g. fentanyl (6), and methadone-type 
compounds (7), Fig. (1). For instance, oripavine derivatives, e.g. buprenorphine (8), display a circa one 
thousand fold potency with respect to morphine. Other selected examples of opioid ligands described 
throughout the text are also given in Fig. (1), naltrindole (9), naltrexone (10), loperamide (11). 
 
 
 
Fig. (1). Structures of representative opioid ligands.  
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The endogenous opioid agonists Met-enkephalin, H-Tyr-Gly-Gly-Phe-Met-OH, and Leu-enkephalin, H-Tyr 
Gly-Gly-Phe-Leu-OH, were discovered in the mammalian brain in 1975; these peptides showed high affinity 
for DOR and MOR. A few years later, other endogenous peptides were described, namely β-endorphin, a 31 
amino acid peptide that revealed affinity to both MOR and DOR, and dynorphins (e.g. Dyn A: H-Tyr-Gly-Gly-
Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-OH), selective ligands of the KOR [10]. The 
tetrapeptides endomorphin-1 (EM1) and endomorphin-2 (EM2), H-Tyr-Pro-Trp-PheNH2 and HTyr-Pro-Phe-
PheNH2, showing high affinity and selectivity for MOR, were discovered in mammalian brain only in 1997 [11, 
12]. 
Most endogenous peptides originate from their propeptide precursors through hydrolysis by specific 
proteases. 
Proopiomelanocortin (POMC) is the precursor of β-endorphin, proenkephalin is the precursor of Met- and 
Leu-enkephalin, prodynorphin produces several dynorphin peptides, including Dyn A and B, while for the 
EMs, no propeptide precursors have been discovered yet, and very likely they are synthesized de-novo. 
The clinical use of these endogenous peptides is hampered by their rapid degradation and scarce 
permeation across biological barriers, especially the blood-brain barrier. One way to overcome these 
inherent limitations is the introduction of structural modification, including the insertion of non-peptidic 
structural elements, giving rise to the family of the peptidomimetics [13]. The peptidomimetics bear identifiable 
similarity to the parent peptides and imitate or inhibit their biochemical effects. The pseudopeptides have 
sequences in which at least one peptide bond is replaced with a isosteric or isoelectronic surrogate, such as 
a reduced peptide bond, or the azapeptides, the retro-inverso peptides, or the peptoids. 
Other strategies are the incorporation of non-natural amino acids, D-configured residues, N-alkylated amino 
acid, α- or β-substituted α-amino acids, β- or ɣ-amino acids, or the cyclization of the peptide sequence, etc [14, 
15].Examples of opioid peptidomimetics are DAMGO, H-Tyr-D-Ala-Gly-MePhe-Glyol, DADLE, H-Tyr-D-Ala-
Gly-Phe-D-Leu-OH, and the cyclopeptides DPDPE, Tyr-c[-D-Pen-Gly-Phe-D-Pen-]-OH (12), JOM-6, Tyr-c(S-
Et-S)[D-Cys-Phe-DPen]NH2 (13) and JOM-13, Tyr-c[D-Cys-Phe-D-Pen]OH (14), the palindromic biphalin, 
(H-Tyr-D-Ala-Gly-Phe-NH-)2, etc. In several cases these modifications resulted in high stability and 
bioavailability and consequently in a increased analgesic efficacy in vivo [16]. Besides, the constrained 
peptidomimetics, such as the cyclopeptides or the turn mimetics, have been utilized for the investigation of 
the bioactive conformation of the parent peptides. 
These extensive investigations led to the general definition of the proper spatial orientation of a cationic 
amine, a phenol group, and an additional hydrophobic group, that are necessary to manifest the biological 
activity through interaction with opioid receptors [17]. 
The mimetics of the opioid peptides in which the peptide character is no longer preponderant are referred to 
as non-peptidomimetics. 
Examples are the N-benzylpiperazine derivative SNC 80 (15), selective DOR agonists, and the KOR agonist 
U50,488 (16) [1], Fig. (1). 
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5.2. Insights Into the Interaction between Ligands and Receptors 
Ideally, the best approach for determining the 3D structure of a receptor and the interactions with its agonists 
and antagonists would be the X-ray analysis of the ligand-receptor complex [18]. Many of the required 
information can be found easily by consulting a variety of on-line services and databases. The Protein Data 
Bank (PDB) [19], Brookhaven National Library, is a database of experimentallydetermined 3D structures of 
almost 78500 proteins, nucleic acids, macromolecular complexes, etc. The Cambridge Structural Database 
(CSD) stores the crystallographic structures of small organic or metallo-organic molecules [20]. The Zinc 
Database [21] is a free database of more than 1.3x107 commercially-available and ready-to-dock compounds 
for virtual screening. Pubchem [22] is a database of chemical molecules and their activities against biological 
assays that contains descriptions of small molecules with less than 1000 atoms. The system is maintained 
by the National Center for Biotechnology Information (NCBI) and can be accessed for free through a web 
user interface. ChEMBL (or ChEMBLdb) [23] is a chemical database of bioactive molecules with drug-like 
properties, maintained by the European Bioinformatics Institute (EBI). ChEMBLdb can be accessed via a 
web interface or downloaded by File Transfer Protocol and is also integrated into other large-scale chemistry 
resources, including PubChem and the ChemSpider system of the Royal Society of Chemistry. The 
DrugBank [24] is a bioinformatics and chemoinformatics resource that combines detailed drug data together 
with comprehensive drug target information. The database is available at the University of 
Alberta and contains nearly 6707 drug entries including 1436 FDAapproved small molecule drugs, 134 FDA-
approved biotech (protein/peptide) drugs, 83 nutraceuticals, and 5086 experimental drugs. 
As a matter of fact, the opioid receptors belong to the wide class of the GPCRs, and the X-ray diffraction of 
membrane-bound GPCRs met with considerable experimental obstacles. Structural and biophysical 
information of ligand-receptor binding can be obtained by several modern techniques, such as the in-solution 
and solid-state NMR, fluorescence spectroscopy and single molecule fluorescence methods, flow cytometry, 
surface plasmon resonance, isothermal titration calorimetry, and atomic force microscopy [25, 26]. 
Alternatively, the putative ligand binding site of the receptor and the pharmacophores of the ligands involved 
in the interaction can be simulated by manual or automated docking computations [1- 3, 27]. This method 
predicts the preferred orientation of one molecule into a receptor to form a stable complex. Virtual models of 
the opioid receptors have been generated by homology modeling using templates constructed on the basis 
of the electron crystallographic study or the X-ray crystal structure of rhodopsin. 
For many years, rhodopsin has been the only GPCR with available crystallographic structural information. 
Solved 10 years ago [28], the crystal structure of inactive state rhodopsin covalently linked to cis-retinal 
provided the first near-atomic view of the GPCR architecture. In 2007, a new high-resolution crystal structure 
of GPCR, the β2 adrenergic receptor (β2-AR), was reported [29, 30]. 
Subsequently, the structures of other members of the GPCR class have been elucidated: avian β1-
adrenoceptor [31], squid rhodopsin [32], the human adenosine A2A receptor [33],and the human D3 receptor in 
complex with a D2/D3 selective antagonist [34]. As for the opioid receptors, there is a high degree of 
sequence similarity at the TMH and intracellular domains, which leads to the assumption that the 
homologous TMH regions of all opioid receptors have the same secondary structures. In some cases, multi-
template models produced better structures than single-template models. 
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The combination of experimental studies and modeling allowed the development of more realistic models, 
accounting for problematic issues such as helix distortions or divergent extracellular loops included in the 
binding pocket. Therefore, in some cases the rhodopsin X-ray template was supplemented by experimental 
structural constraints appropriate for the active or inactive receptor conformations, together with receptor-
specific and ligand-specific interactions. 
Experimental information has been derived from the investigation of the receptors features, site-directed 
mutagenesis and/or chimeric studies, or conversely from the investigation of the ligands structures by 
structure-activity relationship (SAR) studies. 
Other approaches are cross-linking studies, the substituted cysteine accessibility method, affinity labeling, 
correlative replacements of ligand and receptor groups, incorporation of metal binding sites between 
residues of receptors or receptors and ligands, etc [2, 35]. 
The conformational switch between the active form and inactive form of the receptor is currently the matter of 
much interest. For instance, plasmon resonance spectroscopy revealed the structural difference between 
agonist binding and antagonist binding conformations of the human DOR [36]. 
The site-directed mutagenesis grounds on the exchange of individual amino acids in the receptor protein 
with a Ala residue, to verify their role in ligand-receptor interaction [37]. The chimeric receptors approach 
consists in interchanging sequences of the MOR, DOR, and KOR. These chimeras allowed to identify 
receptor regions necessary for ligand recognition, as well as regions responsible for selectivity [38]. 
These methods revealed that several residues in the binding pocket are conserved across all of the opioid 
receptors, in particular Asp(3.32), Tyr(3.33), Lys(5.39), Phe(5.47), Trp(6.48), Ile(6.51), His(6.52), Ile(6.53), 
Ile(7.39), Tyr(7.43). On the other hand, these studies highlighted the fundamental role of non-conserved 
residues in the composition of specificity pockets, responsible for the binding with the selective ligands. 
The SAR approach consists in the comparison of the biological activities of large sets of structurally 
correlated opioid compounds (opiate, peptide, peptidomimetic, non-peptidomimetic agonists or antagonists), 
to evaluate the role of the different pharmacophores in ligand-receptor binding [39]. The SAR studies analyze 
the pharmacophores of the ligands, so that some information on the receptor can be obtained as a negative 
contour. Very often, the introduction of conformational and topographical constraints in endogenous opioid 
peptides proved to be beneficial in developing peptide ligands with high activity and selectivity, giving more 
definitive information. In essence, SAR studies revealed that opioid ligands contain different recognition 
elements that are responsible for their activities. The portion in common, generally a tyrosine or a 
tyramine, represents the “message,” responsible for receptor interaction, while the variable portion 
represents the “address,” responsible for the selectivity towards one subtype respect to the others. 
 
5.3. Principles of  Molecular Docking 
Initially, docking simulations were done quite manually, with both the receptor and the ligand represented by 
explicit atoms and the resulting complexes approximated as rigid bodies, fixing all internal degrees of 
freedom except for the translational and rotational ones; eventually, it was possible to make use of 
pregenerated conformational libraries of ligands. The development of molecular surface calculations and 
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their successive use in docking applications (DOCK [40]) significantly reduced the number of possible 
complexes and the time required for the simulation. 
Today there are many docking programs available, differing mainly in the sampling or search algorithms, 
scoring functions [41] and treatment of conformational freedom (flexibility) of ligand and receptor. Examples of 
recent programs developed to automatically dock ligands into receptor models are DOCK, AutoDock [42], 
AutoDock Vina [43], GOLD [44], FlexX [45], FDS, [46] Glide [47], LigandFit [48], ICM [49], and others. Many of these 
programs perform semiflexible docking, with a the flexible ligand and a rigid protein. Since a conformational 
search to identify the most favorable geometry is generally necessary, docking algorithms can be classified 
as systematic, stochastic, and deterministic [50]. 
Systematic search algorithms are based on the “anchor-andgrow” approach that consists of splitting a ligand 
into separate fragments, docking the fragments to the receptor, followed by linking again the fragments to 
obtain the whole ligand. An example of systematic search is represented by the fragment-based methods, as 
implemented in software like eHiTS [51]. 
Monte Carlo is an example of stochastic method, implemented in QXP [52] and LigandFit and useful for large 
systems. Since only some solutions are evaluated, the method might afford different and unrepeatable 
results. The ligand is considered as a whole and random changes are made to modify the torsion angles, as 
well as to translate and rotate the ligand. This is followed by energy minimization. 
To increase the chance of stochastic methods to achieve the global energy minimum, the simulation may 
consist of several cycles. The first cycle is performed at high temperature and later cycles are done at 
decreasing temperatures (simulated annealing). 
AutoDock was the first docking program to implement simulated annealing by using evolutionary (or genetic) 
algorithms. The best structures are carried on to the next generation and random or biased mutations can be 
made to increase genetic diversity and prevent premature convergence. GOLD, AutoDock, AutoDock Vina 
and FlexyDock, use a genetic search strategy. 
A different mathematical optimization method belonging to the class of trajectory-based techniques is Tabu 
search [53]. Tabu search enhances the performance of a local search method by using memory structures 
that describe the visited solutions: once a potential solution has been determined, it is marked as "taboo" so 
that the algorithm does not visit that possibility repeatedly. 
Finally, the ESCHER procedure (Evaluation of Surface Complementarity, Hydrogen bonding, and 
Electrostatic interaction in molecular Recognition) transforms a 3D structure in a set of polygons, with three 
modules that work in series: the first evaluates the geometric complementarity and produces a set of rough 
solutions, the second identifies molecular collisions within those solutions, and the third one evaluates their 
electrostatic complementarity [54]. 
Regardless of the strategy used, at the end of each docking run the reliability of the pose is numerically 
rendered with a score that permits, a priori, to appreciate interesting orientations [55]. Scoring functions 
estimate the binding free energy of a molecule or a molecular fragment in the active site of receptor and 
consists of both enthalpic and entropic contributions. The ranking of ligand docking poses according to 
certain scoring systems that identify the best fit, is the central step in virtual database screening for drug 
discovery. 
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The need for a fast, yet accurate, scoring function for docking studies has led to a number of different 
functions like the scaling approach, consensus scoring approaches and the addition of selected accuracy [56]. 
For example the scoring function of the docking program DOCK includes force field, contact score and 
chemical complementary score, while Gold, Glide, AutoDock, use empirical scoring functions. 
Anyway, ligand-receptor complexes are formed between partners that are complementary in structure as 
well as in physicalchemical properties. They are stabilized by intermolecular Van der Waals, electrostatic, 
dipole-dipole, and π-π interactions, and by H-bonds and hydrophobic effects [57]. Before binding, both 
molecules interact with the solvent. Desolvating polar and charged parts of the molecule upon complex 
formation come at a penalty, while desolvating nonpolar parts of the surface releases water molecules, thus 
increasing entropy. This entropy gain is favorable to complex formation so that the hydrophobic effect is a 
major stabilizing term for biomolecular complexes, while the Coulomb interactions and H-bonds provide 
specificity to protein-ligand interactions. 
To reach the binding site, ligands have to move from the transport fluid to the receptor through different 
phases characterized by increasingly ordered water, decreasing dielectric constant and reduced H-bonding 
activity. The trajectory of the ligands from the aqueous environment to the receptors is generally ignored. 
Very recently, the possible pathway for entry of the nonselective antagonist naloxone from the water 
environment into the binding pocket of DOR was explored using metadynamics simulations [58]. 
If the location of the binding site is unknown, it is possible to proceed using a method known as "blind 
docking". In this case the docking is conducted to search the entire surface of the macromolecule of interest 
[59, 60]. The first docking program to implement the use of automated grids was AutoDock. 
It has been also pointed out that the membrane promotes ligandreceptor docking. Since the docking event of 
a receptor and a ligand must take place near the membrane, ligand-membrane interactions should be 
important. Hence, understanding membrane-bound structures of ligands is indispensable for further insight 
into their diverse biological behaviors [61]. 
The rigid body and the flexible ligand approximations have clear limitations, in particular they do not account 
for the “inducedfit”. 
In the “induced fit” model hypothesis, the receptor and the ligand adapt their structures to bind to each other 
[62]; to reduce complexity, only selected receptor side chains are allowed to move. 
In MOBILE [63], an ensemble of homology models was generated and the ligands were docked into an 
averaged binding site representation using Autodock. The same result can be obtained using Molecular 
Dynamics (MD) experiments. Molecular dynamics is a deterministic simulation of physical movements of 
atoms and molecules. The trajectories of molecules and atoms are determined by numerically solving the 
Newton's equations of motion for a system of interacting particles, where forces between the particles and 
potential energy are defined by molecular mechanics force fields such as AMBER [64], CHARMM [65] and 
OPLS [66]. To account for the screening effect of the solvent on electrostatic interactions, a distance-
dependent dielectric constant is used. More accurate simulations require the introduction of the complex 
within a box of explicit, equilibrated solvent molecules with periodic boundary conditions. In this way MD 
simulations may account for dynamic phenomena not observed in X-ray structures. 
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Recently, with the development of very fast computing systems, hybrid quantum mechanics/molecular 
mechanics (QM⁄MM) methods have become a standard tool for the characterization of complex molecular 
systems [67]. Initially used to study enzyme complexes, these methods treat the part of the system that 
undergoes the most important electronic changes upon binding a substrate quantum mechanically, and the 
rest of the system by traditional molecular mechanics. In this way, a QM/MM optimization of the ligand-
receptor complexes give a more accurate description of the electronic and steric properties effects of the 
“induced fit”, and a complete description of reaction mechanisms and electronic properties. 
 
5.4. Exploring the Determinants of Ligand Affinity and Selectivity: Comparative Docking Studies 
By crossing the results of SAR analyses, mutagenesis, studies with chimeric receptors, homology modeling, 
etc., it appears that there are differences in binding cavity geometry among MOR, DOR, and KOR, related to 
the divergence in size, polarity, and charge of residues, especially from the top of TMHs 5 to 6, EL2, and 
EL3. The greatest difference is observed for KOR, whose 3- residue longer EL2 occupies more space 
between TMH3 and TMH7 and between TMH3 and TMH5, so that the binding pocket in KOR is 
consequently smaller. To allow a better comparison of the three opioid receptors, the residue numbers have 
been given also using the Ballesteros-Weinstein nomenclature. 
In general, great care should be taken in interpreting docking analyses for different classes of compounds, 
and even small differences in related structures might lead to alternative binding modes. The summation of 
all experimental data suggests that the different classes of ligands, morphine and the opiates, the fentanyls, 
peptides, cyclopeptides, and the atypical ligands, such as the benzodiazepine derivatives [68], the salvinorins 
(see next paragraph), etc., have distinct modes of receptor interaction and, for the agonists, different 
activation mechanisms. In these respects, comparative docking analyses proved to be very effective in the 
visualization of the structural features responsible for the selectivity of a given ligand towards the three 
receptor types, and in the identification of the specificities responsible for the different binding modes of the 
different ligands with a given receptor. 
Morphine, the prototypical MOR agonist, has been studied extensively with all of the techniques mentioned 
in the previous paragraphs. Nevertheless, these studies did not furnish a definitive and convincing ligand-
receptor 3D model. In general, the main interaction was that of the protonable tertiary amine with 
Asp147(3.32), but the rest of the structure was oriented in different ways [1, 69, 70], mainly due to its compact 
structure, which can be easily accommodated within the receptor binding site. One study [69] proposed a 
hydrophobic interaction between the phenol group of morphine and the phenol group of Tyr299(6.54) in TM VI 
and the hydrogen bonding interaction between the phenolic-OH of morphine and both the amino group of 
Lys303(6.58) and the phenolic-OH of Tyr148(3.33). In an more recent model [70], the aromatic ring of morphine 
interacts with side chain of Ile234(5.40), Trp293(6.48), Ile296(6.51) , and Val300(6.55) , Fig. (2a). The phenolic 
hydroxy group forms a hydrogen bond with the imidazole group of His297(6.52). The piperidine ring has a 
hydrophobic interaction with the side chains of Tyr148(3.33) and Ile322(7.39). 
The cyclohexene ring is placed in the hydrophobic pocket formed by the side chains of the Ile234(5.40) and 
Tyr148(3.33), and Asn230(5.36) and Trp318(7.35). 
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Also the molecular recognition of the MOR-selective agonist fentanyl (6) is poorly defined; besides, it has 
been pointed out that morphine and the fentanyls interact with the MOR in different ways [71]. The 
pharmacophores of fentanyl are the protonable tertiary amine, which interacts with Asp147(3.32), the N-
phenyl-N-piperidinyl propionamide, and the phenethyl group (but the phenyl can be substituted with a 
thiophene or methyl ester, in sufentanyl and remifentanyl, respectively). For the fentanyls, flexibility is the 
most relevant practical complication to docking analysis. 
Automated docking resulted in several docking orientations and conformations for each ligand, differing in 
particular for the position of the phenethyl group [1, 72-74]. 
For instance, in a recent study of fentanyl [73] the most probable model shows the piperidine ring positioned 
vertically in the region between the helices TM3 and TM7, with the protonated nitrogen at a distance of 3.38 
Å from the oxygen of Asp147(3.32), Fig. (2). The aromatic ring of N-phenethyl group is oriented towards 
His297(6.52), and the N-phenylpropanamide group is near to Trp318(7.35) and His319(7.36). The Tyr148(3.33) 
approaches the hydrocarbon part of the piperidine ring, and the Tyr326(7.43) is close to the linear bridge of 
the N-phenethyl group. Finally, Asn230(5.36) is close to the alkyl group of the N-phenylpropanamide group of 
the ligand. The computations gave other plausible binding poses with comparable scores, but these 
alternatives were excluded on the basis of experimental results reported in the literature, indicating the 
important amino acids constituting the ligand binding site within the receptor. 
 
 
     
 
Fig. (2). Schematic sketches of the interactions between the JOMs and the opioid receptors. Left, JOM-6 and MOR; right, JOM-13 and 
DOR. The TMHs 3, 5, 6, and 7, delimitating the binding-site, are rendered as ribbons, while the TMHs 1 and 2 are rendered as cylinders. 
TMH4, in front of the observer, has been removed for clarity; pale gray TMHs (6 and 7) are positioned far from the observer. Dottet lines 
indicate relevant interactions (ionic, H-bonds), dotted circles indicate other contacts (hydrophobic, stacking interactions). 
 
For the opiates, the tyramine moiety is generally regarded to as the classic message, while large 
substituents on the C ring represent the address. For example, naltrindole (9) contains a indole moiety, and 
is a DOR-selective ligand, while 5-guanidinylnaltrindole, containing a guanidinyl moiety, displays selectivity 
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for the KOR, and naltrexone (10) does not contain an address and thus is not selective [75-78]. In some cases, 
even minor differences showed a strong impact on activity and selectivity: 5’-guanidinonaltrindole (GNTI) is 
an antagonist, and 6’-GNTI is an agonist, as discussed in a recent docking analysis which compared these 
two very similar structures [79]. 
The universal opioid antagonist naltrexone (10) has been utilized as a probe molecule to identify the 
antagonist binding site in all three opioid receptors. Naltrexone was docked and the critical amino acid 
residues for binding were identified [80], revealing an alternative aromatic “address” binding domain in the 
extracellular loops of the MOR. On the basis of this model, a pyridinyl side chain was introduced in C-6 of the 
structure to target the aromatic binding locus at the extracellular loops of the MOR, resulting in a compound 
with high MOR selectivity [81]. 
Loperamide (11) is a piperidine analogue, acting as agonist on peripheral opioid receptors, and exhibiting 
affinity and selectivity for the cloned human MOR compared with the human DOR. The automatic docking 
studies of loperamide on human MOR and DOR was described; whilst no meaningful difference was 
detected concerning the docking of the arylpiperidine moiety, MOR/DOR selectivity was explained as a 
different accommodation of the two phenyl groups in the lipophilic pockets of receptors [82]. 
Very recently, an attempt to encompass the different kinds of ligands was discussed. A ligand-based 
pharmacophore modeling study on a medium-size training set of ligands including specific MOR, DOR and 
KOR agonists, was used to extract common and specific chemical features for three receptor subtypes. 
Other ligands were used as test set. Then, homology models of human MOR, DOR, and  KOR were built 
based on the crystal structure of β2-AR, and interactions between each receptor and their specific agonists 
were explored by subsequent molecular docking [83]. The docking complexes were compared to understand 
the detailed interactive mode of every subtype-agonist interaction, suggesting that MOR agonists could form 
two strong H bonds, whereas DOR and KOR ones form many hydrophobic interactions; KOR agonists could 
specifically form a strong H-bond with Tyr312, whereas that interaction was not found in DOR and MOR; MOR 
and DOR could form one H-bond with the Tyr150 or Tyr 129, respectively (TMH3). 
Because of their extreme flexibility, linear peptides are difficult subjects for the docking protocols. On the 
other hand, the endomorphins EM1, H-Tyr-Pro-Trp-Phe-NH2, EM1, and EM2, HTyr-Pro-Phe-Phe-NH2, 
discovered by Zadina et al. in 1997 [11], are very short molecules, so that their investigation should be 
comparatively easier. Nevertheless, the docking analyses appeared so far in the literature could not shed 
light into the bioactive structure, even in regard to the relevance of the cis or trans conformation of the Tyr-
Pro peptide bond. These tetrapeptides exhibited the highest affinity and selectivity for MOR receptor, and a 
strong antinociceptive effect on acute and neuropathic pain. 
According to the ‘message-address’ concept, it is possible to consider that H-Tyr-Pro-Trp/Phe and Phe-NH2 
correspond to the message and address domains, respectively. Representative conformers of EM2 were 
utilized for a docking study of a MOR receptor model [84]. Some key residues defining the binding pocket 
were already known by site-directed mutagenesis studies, such as Asp147(3.32), Tyr148(3.33), Glu229(5.35), 
His297(6.52), Trp318(7.35), Tyr326(7.43), therefore the possible docking site was devised in such a way that 
EM2 interacts with these residues of the receptor model as much as possible; the Tyr1 residue was placed at 
the bottom of the cavity, and Glu229(5.35) was considered as a possible residue for interacting with the C-
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terminal amide. The procedure gave a S-type open docked structure with a trans Tyr-Pro peptide bond, 
showing some interactions, among which the most relevant were those between Tyr1NH and Asp147(3.32), 
Tyr1OH and His297(6.52), Tyr1Ar and Trp293(6.48), CONH2 and Glu229(5.35), while the aromatic rings of Phe3 
and Phe4 were parallel and formed a pliers-like structure gripping the indole of Trp318(7.35). 
Some years later, an automated docking approach that allows ligand flexibility was performed starting from 
the NMR conformations of the EMs and some analogues, and the complexes were refined by molecular 
dynamics simulations in a membrane environment [85]. For all analogs the protocol gave similar structures, 
with refined contact interactions and scoring. Peculiarly, the authors omitted to discuss the resulting cis 
conformation of the Tyr-Pro peptide bond. 
One opportunity to investigate the bioactive conformation of the linear peptides is the integration of the 
results furnished by 3D-QSAR and docking analyses. Aiming at developing a quantitative model on the basis 
of molecular flexibility, Martinek et al. established a statistical thermodynamically supported 3D flexibility 
descriptor type which accounts for the conformational free energy changes upon receptor binding [86]. The 
resulting 3+3D-QSAR models were validated with a training set of a series of flexible tetrapeptide EM 
analogues (and a second set of prostaglandins, which are not discussed here). The methodology gave the 
predicted conformations for the different derivatives. The authors superimposed their rigid structure for EM2 
(without minimization) to the 3D structure of JOM-6 (13) (see next paragraph) inside the receptor cavity, and 
observed a good agreement between the two conformations. However, the resulting structure strongly 
differed from the previously described ones [84, 85] in the disposition of the aromatic ring Phe3, that in this case 
is perpendicular with respect to that of Phe4. 
Conformational and topographical constraint of the linear natural opioid peptides has played a major role in 
developing peptide ligands with high selectivity, since it allowed to understand the conformational, 
topographical, and stereoelectronic requirements for the interactions of the opioid peptides with opioid 
receptors [87]. The constraints can be introduced by means of nonnatural amino acids, non-peptide portions, 
turn-mimetics, or by cyclization (N to C terminus, side-chain to side-chain, side-chain to C terminus) [13]. 
Conformationally constrained cyclopeptide analogues of linear opioid peptides gave the opportunity to 
investigate ligand affinity and selectivity in much detail. Prototypic examples are the two structurally related 
cyclotetrapeptides JOM-6 (13), Tyr-c(S-Et-S)[D-Cys-Phe-D-Pen]NH2, and JOM-13 (14) [88], Tyr-c[D-Cys-Phe-
D-Pen]OH. Molecular docking [89] gave interesting clues about the specific interactions responsible for the 
MOR selectivity of JOM-6 and the DOR selectivity of JOM-13, confirming that the preference shown by a 
peptide for a specific receptor subtype over the other depends on the presence of structurally distinct 
pockets [2], Fig. (3). The bioactive conformation of both the peptides showed the expected interaction of the 
protonated amine of Tyr1 with the carboxylate side chain of the conserved Asp(3.32) from TMH3 (Asp147 and 
Asp128 in MOR and DOR, respectively); moreover, the phenolic-OH group is H-bonded with His(6.52) from 
TMH6 (His297 and His278), Fig. (3). This second pharmacophore is much less relevant than the former; the 
transposition of the Tyr1 with Phe3 in JOM-6, gave a MOR agonist JH-54 with only fourfold reduced affinity [90]. 
The remaining portion of the ligands occupy the address-binding region of the receptors and are responsible 
for the specificity. 
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In particular, in the position (7.35) MOR has Trp318, while DOR has Leu300. As a consequence, the interaction 
of the transoriented Phe3 side chain of JOM-6 with Trp318(7.35) consents high-affinity binding to MOR, 
whereas the same side chain would have a bad contact with the Leu300(7.35), resulting in a very poor 
DOR affinity. On the other hand, the gauche orientation of Phe3 side chain of JOM-13 nicely fits the address-
binding region of the DOR, but not that of MOR, Fig. (3). 
 
 
 
Fig. (3). Schematic sketch of the interactions between JOM derivative Tyr-c[D-Cys-Phe-D-Cys]NH2, S-S bridge, and KOR, to be 
compared to Fig. (3). The TMHs 3, 5, 6, and 7, delimitating the binding-site, are rendered as ribbons, while the TMHs 1 and 2 are 
rendered as cylinders. TMH4, in front of the observer, has been removed for clarity; pale gray TMHs (6 and 7) are positioned far from 
the observer. Dottet lines indicate relevant interactions (ionic, H-bonds), dotted circles indicate other contacts (hydrophobic, stacking 
interactions). 
 
A more detailed structural analysis allowed studying the different inner shapes of the binding pockets of the 
active and inactive states. These are slightly different, which implies distinct interaction modes of agonists 
and antagonists [91]. The improved models were obtained by site-directed mutagenesis studies and design of 
Zn2+-binding centers. The interaction of Tyr with the Trp293(6.48) of the receptor in the active state is of 
particular interest, since it appear to induce a circa 20° rotation of the TMH6, a event that triggers the 
dissociation of the G protein. 
On the basis of the above discussed modeling of the active and inactive conformations of the receptors, the 
same authors designed new cyclopeptide ligands, aiming at tuning MOR/DOR/KOR selectivity, as well as the 
agonist and antagonist behavior. Modeling of the KOR in the active state indicated that the address-binding 
pocket is smaller than that in the other receptors. This assumption led to the design of a series of new 
compounds, among which Tyrc[D-Cys-Phe-D-Cys]-NH2 demonstrated high binding affinity toward all opioid 
receptors [92]. This tetrapeptide was docked in the homology model of KOR. In the area of the Tyr1-binding 
site, the compound showed the same interactions created by JOM-6 in the MOR. However, in the KOR the 
cleft between TMH7 and EL2 is narrowed because of two residues of EL2, Asp204, and Val205, Fig. (4). As a 
consequence, the space available for interaction with the ligand’s fourth residue and disulfide/dithioether 
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bridge is reduced. For this reason, Tyr-c[D-Cys-Phe-D-Cys]-NH2, having a smaller-size cycle, can fit not only 
MOR and DOR, but also KOR. 
 
 
 
Fig. (4). Structures of opioid agonists lacking in the “classic” amino group. 
 
Another set of experiments was attempted aiming at obtaining dual ligands with similar MOR/DOR affinities, 
but displaying agonism at MOR and antagonism at DOR. Evidence implicating a role of DOR in modulating 
MOR-induced tolerance suggested that such compounds might find clinical applications for the treatment of 
chronic pain. Initially, the peptide Tyr-c(S-CH2-S)[D-Cys-Phe- Phe-Cys]NH2 [93] displayed a promising mixed-
efficacy profile, exhibiting full agonism at MOR and KOR but only partial agonism at DOR. The peptide was 
virtually docked in models of active and inactive conformations of MOR and DOR in a similar manner as 
JOM-6 and JOM-13. The results showed favorable aromatic interactions between its Phe3 side chain and the 
Trp318(7.35), accounting for the binding to MOR, as compared to DOR, which has Leu300(7.35) at the 
corresponding position. The same peptide, when fitted into the active conformation of DOR, demonstrated a 
clash between Phe4 and Trp284(6.58), which was not observed in the inactive DOR. 
Starting from this model, it was supposed that the incorporation of a bulkier naphthylalanine side chain in 
either the third or fourth position of the pentapeptide would differentially affect binding and efficacy properties 
at MOR and DOR, resulting in potent MOR agonist/DOR antagonist ligands. This hypothesis was partially 
achieved with the cyclopeptide Tyr-c(S-CH2-S)[D-Cys-Phe-2-Nal-Cys]NH2) [94], that showed similar affinity for 
MOR and DOR but decreased DOR efficacy without compromising MOR agonism. 
This behavior was rationalized by docking the peptide in the modeled active and inactive conformations of 
MOR and DOR. As premised, the 2-naphthylAla4 side chain showed minimal hindrance with receptor residue 
Lys303(6.58) in the MOR active conformation but an increased steric overlap with Trp284(6.58) side chain in 
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the DOR active conformation. These hindrances were absent in the inactive conformations of both MOR and 
DOR. This reduced compatibility for the active state of DOR supported the decreased agonism at DOR. 
Examples of constrained non natural amino acids are the phenylalanine analogue 1,2,3,4-
tetrahydroisoquinoline-3-carboxylic acid (Tic), 4-amino-1,2,4,5-tetrahydro-indolo[2,3-c]azepin-3-one (Aia), 
and 4-amino-1,2,4,5-tetrahydro-2-benzazepin-3-one (Aba) scaffolds. It was determined that Dmt-Tic-Gly-NH-
Bn (Dmt =dimethylTyr) and similar dipeptides, display a DOR over MOR selectivity, whereas MOR binding is 
preferred for the Aba containing analogues [95]. To rationalize the observed SAR data, the automated docking 
simulations of the Tic and Aba compounds in MOR and DOR were compared to that of the prototypic JOM-6 
and JOM-13 (see previous paragraph), respectively. The Tic and Aba compounds maintained the same 
interactions between the receptors and Dmt as shown for Tyr1 of the JOMs. The Tic group of DOR specific 
compounds occupies the same binding pocket as the Phe3 group of JOM-13, and also the benzyl group 
plays a role in DOR-specific binding. The Aba group of the MOR-specific compounds, on the other hand, 
stacks with Trp318(7.35), and occupies the same binding pocket as the Phe3 ring of JOM6. The benzyl group 
forms a cation–π interaction with the positively charged nitrogen atom of Lys233(5.39) of MOR. In essence, 
the different profiles seemed to be mostly due to the different geometries adopted by the six and seven 
membered rings within the receptors. 
Stereoisomeric 4- or 5-methyl-substituted Aba scaffolds have been introduced within the sequence of the 
tetrapeptide H-Dmt-DAla-Phe-Gly-NH2 in place of Phe3. Interesting effects of the Aba configuration on ligand 
binding affinity were observed: the erythro-(4S,5S) and threo-(4R,5S) 5-methyl variants exhibited 
subnanomolar affinity for OPRM, while in the 4-methyl substituted analogues, the (4R)-Me isomer was 
significantly more potent than the (4S) one. These results were rationalized by automated molecular docking; 
the simulations revealed that the (4R)-Me isomer binds in a different mode compared with the other 
analogues [96]. 
Replacement of the Tyr1 residue in the peptide TIPP, H-Tyr-Tic-Phe-Phe-OH, with the phenylalanine 
analogues 4’-[N-((4’-phenyl)phenethyl) carboxamido]phenylalanine (Bcp) and 2’,6’-dimethyl-4’-[N-((4’-phenyl) 
phenethyl)carboxamido]phenylalanine (Dbcp) resulted in tetra-, tri-, and dipeptides with subnanomolar DOR 
binding affinity and high selectivity [97]. Interestingly, [Bcp1]TIPP was an agonist, whereas [Dbcp1]TIPP an 
antagonist. 
The flexible docking studies indicated that in both cases, the Nterminal amino group of the ligand formed a 
salt bridge with Asp128(3.32) of the receptor. The large biphenylethyl group contained in the Bcp residue of 
the agonist interacts with an accessory binding site of the activated receptor distinct from the binding site of 
the biphenylethyl group of the Dbcp residue of the antagonist bound to the receptor in the inactive state. In 
particular, the biphenyl moiety differentially interacts with Glu201(EL2), Ser204(EL2), Asp210(5.35), and 
Thr211(5.36) in the case of the agonist and with Ile183(4.60), Thr213(5.38), and Val217(5.42) in the case of the 
antagonist. 
 
5.5. The Docking of Ligands of the Cationic Amino  
The ionic bond between a protonated amino group of the agonist and the conserved Asp(3.32) of the 
receptor is generally regarded to as the driving force of ligand-receptor interaction for all kinds of ligands, 
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including morphine, fentanyls, and the endogenous peptides [17, 73, 87, 98, 99]. In most cases, the removal or 
derivatization of this group resulted in inactive derivatives or antagonists; some outstanding examples of 
antagonists are given: the cyclic β-casomorphin-derived opioid peptide CHO-Dmt-c[D-Orn-2-Nal-Pro-Gly] 
showed MOR and DOR antagonist activity [100]; the cyclic opioid peptides containing 3-(2,6-dimethyl-4-
hydroxyphenyl)propanoic acid (Dhp), (2S)-2-methyl-3-(2,6-dimethyl-4-hydroxyphenyl)-propanoic acid [(2S)-
Mdp], or (3S)-3-methyl-3-(2,6-dimethyl-4-hydroxyphenyl) propanoic acid [(3S)-Mdp] instead of the classic 
Tyr1 residue, resulted in opioid antagonists [101-103]; the MOR and KOR antagonist N-formylnormorphine [104]; 
the dynorphin A analogue cyclo (N,5)[Trp3,Trp4,Glu5] dynorphin A-(1-11)NH2, an N-terminal to-side chain 
cyclic peptide showed good KOR antagonism [105]. 
However, in the last few years some compounds having no classic, protonable amino group proved to be full 
or partial nagonists. These very few examples are shown in Fig. (5) (for the references, see the next 
sections): the diterpene Salvinorin A (16) and its many analogues and derivatives; the bicyclic enkephalin 
mimetic by Eguchi (17); the cyclopentapeptide analogue of EM1, c[Tyr-D-Pro-D-Trp-Phe-Gly] (18); a cyclic 
enkephalin analogue containing Dhp in the place of Tyr (19); a “carba”- analogue of fentanyl, in which the 
classic piperidine nitrogen of the fentanyls was replaced by a carbon, but equipped with a ionisable 
guanidino group (20); the cyclotetrapeptide CJ-15,208 (21), discovered earlier, whose agonist character in 
vivo was proved only very recently, and some analogues. 
 
 
 
Fig. (5). Schematic sketch of the interactions between salvinorin A and KOR. The TMHs 3, 5, 6, and 7, delimitating the binding-site, are 
rendered as ribbons, while the TMHs 1 and 2 are rendered as cylinders. TMH4, in front of the observer, has been removed for clarity; 
pale gray TMHs (6 and 7) are positioned far from the observer.  
 
For their atypical structure, it is likely that these compounds elicit their opioid activity through alternative or 
more complex mechanisms than typical opioid receptor ligands. For this reason, some of them have been 
the object of extensive SAR analysis and/or molecular docking studies, aiming at obtaining information on 
the interactions with the receptors responsible for the activation. 
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5.5.1. Salvinorins 
Salvinorin A (16), isolated from the plant Salvia divinorum [106], is a highly potent and selective KOR receptor 
agonist and the most potent naturally occurring hallucinogen known, used for centuries by the Mazatec 
Indians of Mexico for divination. Salvinorin A is unique among opioids in that its chemical structure lacks a 
basic amine group, quite it has no N at all. For this reason, it can be anticipated that salvinorin A and its 
derivatives interact with the KOR via residues that are not utilized by conventional agonists. 
Salvinorin A consists of a rigid hydrophobic core that contains eight H-bond accepting oxygen atoms. During 
the years, Salvinorin A was the subject of many docking analyses, which often gave incoherent results even 
by the same authors. Extensive modifications were brought especially at the C-2 position, but also at C-4 
and at the furan ring, and these analogues were utilized for SAR studies and for refining the results of the 
docking computations. In the first model [107] four H-bonding interactions were identified: between amide-
NH of Gln115(2.60) and furanoic oxygen, phenolic-OH of Tyr139(3.33) and lacton-CO, phenolic-OH of 
Tyr312(7.35) and methoxycarbonyl group, and phenolic-OH of Tyr313(7.36) and acetyl group. The screening of 
several derivatives confirmed the importance of the methyl ester and furan ring but reduced the role of the 
lactone and ketone functionalities [108]. More recent data using an improved model of the KOR revolutionized 
this initial hypothesis [109], revealing interactions with Tyr313(7.36) and Tyr320(7.43) and Tyr119(2.64), plus a 
hydrophobic interaction of Tyr313(7.36) with 2-acetoxy group of Salvinorin A. A few years later also this 
second model was revisited. A combination of studies performed on wild-type, chimeric, and single-point 
mutant opioid receptors [110-112], lead to the proposal of a model showing the interaction of the furane with 
Tyr320(7.43), while the acetyl group interacts with Tyr312(7.35) and Tyr313(7.36), the methyl ester with 
Tyr119(2.64), and Gln115(2.60) serves as a H-bond donor for lacton carbonyl. Other recognition elements of 
the receptor initially regarded to as relevant for the interaction were not confirmed. 
Further experiments and docking analyses consistent with sitedirected mutagenesis studies, chimeric 
receptor studies [113], and affinity labeling experiments [114] again revolutionized the binding model [115-117], Fig. 
(6). The oxygen of the furan ring may form a H-bond with both Gln115(2.60) and Tyr320(7.43). An additional H-
bond may possibly exist between Tyr312(7.35) and the methoxy oxygen of the C-4 position methyl ester. In 
addition, there is a likely hydrophobic interaction between Tyr313(7.36) and the acetoxy moiety of Salvinorin. 
Besides to the already mentioned Gln115(2.60), Tyr119(2.64), Tyr313(7.36), and Tyr320(7.43), it appears that 
Salvinorin A interacts also with Ile316(7.39), as revealed by the complete lack of binding to the Ile316Ala 
mutant [118]. 
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Fig. (6). Interactions between the MOR and the carba-guanidinic fentanyl (20). The TMHs 3, 5, 6, and 7, delimitating the binding-site, 
are rendered as ribbons, while the TMHs 1 and 2 are rendered as cylinders. TMH4, in front of the observer, has been removed for 
clarity; pale gray TMHs (6 and 7) are positioned far from the observer. Dottet lines indicate relevant interactions (ionic, H-bonds), dotted 
circles indicate other contacts (hydrophobic, stacking interactions). 
 
5.5.2. 6,6-Bicyclic Enkephalin Mimetics 
The highly constrained 6,6-bicyclic system 17 belongs to a series of constrained peptidomimetics designed 
to mimic enkephalin or EM β-turn models. It showed an initial level of analgesic activity similar to that of 
morphine, but in vivo half-life was shorter [119]. On the basis of 2D NMR analysis and molecular mechanics 
computations, the authors noticed a good super-imposition of the structure of 17 with a trans EM1 type III β- 
turn backbone structure. Based on this similarity and on the MOR-selectivity profile, the authors implicitly 
suggested that the interaction with the receptor could mimic that of EM or enkephalins, but docking 
simulation to visualize a plausible 3D structure were not performed. 
 
5.5.3. Dhp-Peptide 
Cyclic enkephalin analogues were obtained by ring closing metathesis using a second generation Grubbs 
catalyst from precursors containing D-allylGly and (2S)-2-amino-5-hexenoic acid (Aha) in position 2 and 5, 
respectively. Compounds of this series containing 3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acid (Dhp) in 
place of Tyr such as trans Dhp-c[D-Allylgly-Phe-Phe-Aha]NH2 (19) or the cis isomer, or the saturated 
analogue, all lacking a positively charged nitrogen, were mixed DOR agonist MOR antagonists by the GPI 
and MVD bioassays. This peptide 19 was presented as the first example of a neutral compound with DOR 
agonist activity [120], but no docking analysis was reported to explain the unexpected agonism. 
 
5.5.4. Fentanyl “Carba”-Analogues 
In the MOR agonist fentanyl, the positively charged nitrogen is contained in the piperidine ring. The 
substitution of the piperidine nitrogen with a carbon atom and introduction of a 3- (guanidinomethyl)-benzyl 
group in place of the phenyl moiety attached to the ethylamido group gave “carba”-analogues of fentanyl (20) 
(cis and trans isomers). 
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These compounds showed reduced binding affinities, but retained full agonist activity [121]. Flexible docking 
studies indicated that the phenylethyl group is accommodated in a binding pocket formed by TMHs 3, 5, and 
6; in the trans isomer this group is in an extended conformation, while it assumes a bent conformation in the 
cis isomer. For both, the guanidino group forms a salt bridge with the side chain of Asp216(EL2), and its 
aromatic ring interacts with Phe313(7.30), Trp318(7.35), Thr218(EL2), Fig. (7). 
 
 
            
 
Fig. (7). Left, interactions between the MOR and CycloEM/1 (18); right, interactions between MOR and CycleEM/3. The TMHs 3, 5, 6, 
and 7, delimitating the binding-site, are rendered as ribbons, while the TMHs 1 and 2 are rendered as cylinders. TMH4, in front of the 
observer, has been removed for clarity; pale gray TMHs (6 and 7) are positioned far from the observer. Dottet lines indicate relevant 
interactions (ionic, H-bonds), dotted circles indicate other contacts (hydrophobic, stacking interactions). 
 
The calculated reduction in receptor binding energy is due to the inability of these “carba”-analogues to 
engage in an electrostatic interaction with Asp147(3.32), but this deficiency is partially compensated by the 
interaction between the guanidine group with Asp216(EL2), which contributes to binding the active 
conformation of the receptor and, thereby, maintaining the agonist activity. 
 
5.6. The D-Trp-Phe Pharmacophoric Motif 
The cyclopentapeptide c[Tyr-D-Pro-D-Trp-Phe-Gly], CycloEM-1 (18), is an analogue of EM1 lacking in the 
free amino group of Tyr1 but which can still bind and activate MOR. It is the most active member of a mini-
library of cyclic EM1 analogues having the same amino acids in L or D configuration [122], connected by a Gly. 
The diverse stereochemistry arrays of the diastereoisomers conferred them alternative 3D displays and 
different pharmacological features, since only the LDDL configured CycloEM-1 revealed a 10-8 M receptor 
affinity. 
CycloEM-1 produced a concentration dependent inhibition of forskolin-stimulated production of cAMP, thus 
acting as an agonist. 
In the visceral pain test, used for detecting both central and peripheral analgesia, CycloEM-1 significantly 
reduced the number of writhes; MOR antagonist, but not KOR and DOR antagonists, blocked antinociception 
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[123]. CycloEM-1 was even more effective in preempitive antinociception, with a similar profile, and maintained 
the effect when delivered by subcutaneous injection, which correlates to its lipophilicity and stability. In the 
tail flick test, the cyclopeptide i.p. administered gave a moderate response, suggestive of a partial 
penetration of the BBB. 
The significant receptor affinity and the agonist profile suggested that this atypical compound activates the 
MOR, but it must necessarily interact in a different way with respect to the large majority of the cases. The in-
solution conformations were docked into a model of the MOR [124], and computations were refined by hybrid 
QM/MM, giving a unprecedented orientation, showing the peptide deeply inserted between the TMH3, 5, and 
7, and featuring the indole NH of D-Trp3 H-bonded to Asp147(3.32), Fig. (8a). The absence of the ionic 
interaction is partially compensated by this Hbond; ligand polarization also represents a strong contribution 
to the overall binding energy, as determined by QM/MM. Tyr1-OH is Hbonded to Glu310, Phe4 interacts with 
the residues Phe221(EL2) and Trp318(7.35). Tyr also contributes to the overall binding with some stabilizing 
hydrophobic contacts. The interaction between D-Trp of the ligand and Trp293(6.48) is relevant, since the 
induced fit on this region of the receptor would be responsible for MOR activation, as proposed by Mosberg 
[91]. The overall bioactive conformation is compatible with a inverse type II β-turn centered on D-Trp-Phe. To 
corroborate this unprecedented model, a second generation of more rigid or, conversely, more flexible 
cyclopeptides modified in the position 5 was prepared and tested (CycloEMs-2). 
All the derivatives adopted the same binding poses of CycloEM-1, with different calculated docking scores 
and energies. The correlation between the calculated docking energies and the experimental free energies 
derived from the affinity parameters showed a nice linear regression with excellent statistics, supporting the 
liability of the model. 
The cyclopeptides adopt in the receptor a quite different conformation with respect to the preferred ones 
shown in solution, so that for optimal fit the backbone of the ligands if forced to assume a higher energy 
conformation. In principle, it should be possible to improve the efficacy of such compounds, taking into 
consideration that “the more the structures of the free ligands in solution resemble the structures at the 
receptor, the stronger the binding and affinity” [125]. Despite of some limitations, this assumption can be 
utilized as a indicative guide for structure optimization. Starting from the proposed model, new cyclopeptides 
were designed, fostering the beta-turn motif on D-Trp-Phe. The docking model indicated that neither D-Pro2 
nor Gly5 in CycloEMs really interacted with the receptor, being their role fundamental in stabilizing backbone 
geometries. In particular, D-Pro plays a major role in preventing CycloEM from assuming the bioactive 
conformation. 
A third generation of cyclopentapeptides was designed on the basis of these assumptions; backbone 
conformations were predetermined on the basis of the well-known structures of cyclo- Ala5 models or other 
cyclopentapeptides containing one or two Dresidues already reported in the literature, widely used as β/ɣ-
turn mimetics. Among the new cyclopeptides, c[Tyr-Gly-D-Trp-Phe-Gly], CycloEM-3, proved to be a selective 
ligand of MOR with nanomolar affinity, almost as good as the reference DAMGO, and about 10-fold better 
compared to the parent CycloEM/1 (18), a very good result for a compound lacking of the cationic amino 
group [126]. Another compound c[Tyr-Ala-D-Trp-Ala-Gly] was a selective, modest ligand of the DOR, and 
c[Tyr-Gly-D-Trp-Ala-Gly] had a significant affinity and selectivity for the KOR. 
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As expected, CycloEM-3 had a greater conformational freedom. The docking analysis revealed at least a 
couple of plausible poses; the binding pose with the best score is compatible with the required inverse β-turn 
on D-Trp-Phe. However, the intrinsic flexibility both in solution and in the receptor-bound state, diminished 
the reliability of the proposed model of bioactive conformation. For this reason, cyclopeptide candidates were 
modelled, characterized by lower conformational freedom and a predisposition to reproduce 
the inverse type II β-turn, whose conformational homogeneity allowed more definitive conclusions. The 
cyclotetrapeptide c[DAsp- 1-amide-β-Ala-D-Trp-Phe] (22), CycloEM-4, deprived of the Tyr, and including two 
β-amino acids, clearly adopted the expected backbone conformation, and showed a nanomolar MOR affinity, 
high selectivity, and an agonist behaviour. Docking analysis confirmed that CycloEM-4 retained the same 
geometry also into the receptor, Fig. (8b). The indole of D-Trp occupies the same hydrophobic cavity 
occupied by the corresponding residue of CycloEM-1. The most relevant contacts were the H-bond of 
indoleNH with Asp147(3.32), the two H-bonds of D-AspCONH2, one with Leu219(EL2), the other with 
Glu229(5.35), and the two H-bonds of β-Ala, one with Glu229(5.35), the other with Thr218(EL2). The phenyl of 
Phe has strong hydrophobic interaction with Phe221(EL2) and Trp318(7.35). 
 
 
 
 
Fig. (8). Schematic sketches of the interactions of CycloEM/1 (18) (left, a), and of CycloEM/3 (22) (right, b) with the MOR. The TMHs 3, 
5, 6, and 7, delimitating the binding-site, are rendered as ribbons, while the TMHs 1 and 2 are rendered as cylinders. TMH4, in front of 
the observer, has been removed for clarity; pale gray TMHs (6 and 7) are positioned far from the observer. Dotted lines indicate relevant 
interactions (ionic, H-bonds), dotted circles indicate other contacts (hydrophobic, stacking interactions). 
 
To improve the ability to cross the BBB, the structure of CycloEM-4 was reduced to the minimal bioactive 
sequence. 
According to the docking model, the most relevant pharmacophores were the indole and the phenyl aromatic 
rings, and the CONH2 group, while the remaining portion of D-Asp-β-Ala had scarce or no interactions at all 
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with the receptor. Accordingly, the linear peptide Ac-D-Trp-Phe-GlyNH2 (CycloEM-5) maintained the MOR 
agonism, and a nanomolar affinity [127]. Conformational analysis Nrevealed that, despite of intrinsic flexibility, 
in solution this linear peptide had a significant tendency to fold in a inverse β-turn stabilized by a H-bond 
between Ac(CO) and GlyNH, due to the presence of a D-configured amino acid in the position i+1. 
The cyclopeptides CycloEM-1 represents the first examples of MOR-agonists described in the literature 
(2004) whose bioactivity resides in the D-Trp-Phe sequence. Very recently, this pharmacophoric motif was 
proposed again in regard to c[D-Pro-Phe-D-Trp-Phe] and correlated compounds [128], derived from the 
naturally occurring cyclotetrapeptide c[D-Pro-Phe-Trp-Phe], CJ-15,208 (21) [129], isolated as a metabolite of a 
fungus. CJ-15,208 was reported to preferentially bind to KOR (IC50 47 nM, using a guinea pig brain 
membrane), and antagonize the activity of a KOR agonist in the rabbit vas deferens smooth muscle 
preparation. The D-configured Trp residue rendered the derivatives more potent than the natural product. 
c[D-Pro-Phe-D-Trp-Phe] was a KOR antagonists devoid of agonist activity, with a modest MOR affinity. 
The analogue c[D-Pro-Phe-D-Trp-Ala] practically maintained the same activity and selectivity as KOR 
antagonist. This suggests that the pharmacophoric sequence likely is Phe-D-Trp, rather than D-Trp-Phe. 
Therefore, the different pharmacologic profile of the MOR agonists CycloEM/1-5 with respect to the KOR-
antagonists derived from CJ-15,208 very likely origins in the inverted positions of D-Trp and Phe within the 
sequence, and in the 3D display of their side chains, correlated to the different sizes of the cyclopeptide 
structures. These differences strongly impact not only the affinity for a specific opioid receptor type, but also 
the ability to trigger the activation of G-proteins and activate signal transduction. 
Although CJ-15,208 (21) did not exhibit any agonist activity at either KOR or MOR in vitro, very recently 
Aldrich et al. observed a unexpected agonist activity in vivo in the 55°C warm-water tail withdrawal 
antinociceptive assay in addition to KOR-selective antagonist activity [130]. 
The same authors prepared and tested analogues of CJ-15,208 having one Ala instead of each of the 
natural residues [131]. The substitution of one Phe to give c[D-Pro-Phe-Trp-Ala] increased both KOR and 
MOR affinities by 4.4- and 19-fold, respectively. In contrast, substitution of the other three residues with Ala 
decreased KOR affinity from 3- to 44-fold, with the largest decrease occurring if the Trp residue is replaced. 
None of the peptides exhibited appreciable agonism in vitro (stimulation of [35S]GTPɣS binding) via either 
KOR or MOR, consistent with the lack of agonist activity of the parent peptide in this assay. Like the parent 
peptide, each of the analogues exhibited agonist activity in an antinociceptive assay in vivo. As observed for 
the CycloEMs, the agonist activity of the analogues was mediated predominantly by MOR; indeed, their 
antinociceptive activity was almost completely blocked by pretreatment with the MOR-selective irreversible 
antagonist β -funaltrexamine. These results strongly support the hypothesis above discussed for the 
CycloEMs, that Trp and Phe represent a unusual kind of agonist pharmacophoric motif in cyclopeptides. The 
stereochemistry of Trp, the disposition of Trp and Phe, and the secondary conformation of the dipeptide 
strongly influences affinity and selectivity and, likely, agonism vs antagonism. 
 
5.7. CONCLUSIONS 
In the last decades, continuous efforts have been dedicated to the design and synthesis of new opioid 
agonists or antagonists; in particular, the former raise much interest as potential analgesics devoid of the 
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unwanted side effects of the opiates. In this contest, the molecular docking approach emerged as a powerful 
tool in drug discovery to find and optimize lead compounds. Molecular docking is a method which estimates 
the preferred orientations of a candidate drug inside its receptor. The results of this computational analysis 
are much more realistic when the simulations take into account for the data furnished by experimental 
methods, especially SAR, mutagenesis, chimeric receptors, etc. The survey of the examples discussed in 
this review clearly shows that the different classes of ligands, such as morphine and the opiates, the 
fentanyls, the peptides, the peptidomimetics, etc., have distinct modes of receptor interaction and, for the 
agonists, activation. As a consequence, a number of specific models have been proposed to explain the 
binding and selectivity of each class. In addition, the analyses of ligands lacking of a well defined message 
or address, or of highly flexible ligands, often gave alternative models. For instance, morphine, the prototypic 
agonist of the MOR, is deprived of a relevant address portion, and therefore docking analyses gave different 
orientations within the receptor cavity. Nevertheless, some ligand classes, such as the conformationally 
constrained cyclic peptidomimetic JOMs, proved to be very effective in disclosing the structural requirements 
for receptor affinity and selectivity, as well as of agonism versus antagonism. Besides, docking has 
represented a useful technique for the analysis of the opioid agonists lacking in the cationizable amino group, 
generally regarded to as the fundamental pharmacophore interacting with the conserved Asp of TMH3, such 
as the salvinorins, and the cyclopeptides including the inverse β-turn on D-Trp-Phe. In particular, the results 
deduced for the latter might be of help to disclose the unexpected agonist activity of the structurally related 
cyclopeptide CJ-15,208 and its derivatives. 
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Chapter 6 
The Inverse Type II β-Turn on D-Trp-Phe, a Pharmacophoric Motif for MOR 
Agonist. 
 
6. Introduction 
Herein we propose the D-Trp-Phe sequence within an inverse type II β -turn as a new kind of 
pharmacophoric motif for -opioid receptor (MOR) cyclopeptide agonists. Initially, we observed that c[Tyr-D-
Pro-D-Trp-Phe-Gly] (4), an analogue of endomorphin-1 (H-Tyr-Pro-Trp-Phe-NH2) lacking the crucial 
protonatable amino group of Tyr1, is a MOR agonist with 10-8M affinity. 
Molecular docking analysis suggested that the relevant interactions with the receptor involve D-Trp-Phe. The 
bioactive conformation of this region was investigated by selected derivatives of 4 designed to adopt an 
inverse type II β-turn. These efforts led to c[Tyr-Gly-D-Trp-Phe-Gly] (14) and to the cyclotetrapeptide c[D-
Asp-1-amide-β-Ala-D-Trp-Phe] (15), showing improved nanomolar affinity. Both 14 and 15 selectively bind 
MOR, as they have negligible affinity for the k- and δ-opioid receptors. The compouds 14 and 15 behave as 
partial MOR agonists in functional assays. Conformational and docking analyses confirm the role of the 
inverse β-turn in binding. These results indicate that the D-Trp-Phe inverse β-turn structure can be used for 
designing non-endomorphin-like peptidomimetic opioid agonists in general, characterized by an atypical 
mechanism of interaction between ligand and receptor introduction 
The tetrapeptides Endomorphin-1 (EM1, H-Tyr-Pro-Trp-Phe-NH2 and Endomorphin-2 (H-Tyr-Pro-Phe-Phe-
NH2)[1], have been isolated from mammalian brain and were found to activate -opioid receptors (MOR) with 
high affinity and selectivity. Morphine and EMs act as agonists at the same receptor, but the latter are 
thought to inhibit pain without some of the undesired side effects of plant opiates[2]. This observation 
prompted extensive studies of EM mimetics[3], with the aim of obtaining analgesic compounds[4] with higher 
resistance against enzymatic degradation and better penetration of the blood–brain barrier (BBB). 
A survey of the many reported peptidomimetics reveals that the amino group of Tyr1 is generally maintained 
unaltered. 
Indeed, the ionic bond between the protonated amine and a conserved Asp of the receptor is considered the 
driving force of the ligand–receptor interaction for all kinds of endogenous opioid peptides[3, 5] as well as for 
exogenous agonists[6],  such as morphine (1) and fentanyls[7]. In most cases, the removal or derivatization of 
this group resulted in inactive derivatives or antagonists[8]. 
The very few compounds made without this pharmacophore[9] which retain agonist behavior are shown, 
consecutively numbered by the year of publication: the MOR-selective bicyclic enkephalin mimetic 2[10], the 
k-opioid receptor (KOR)-selective neoclerodane diterpene salvinorin A (3)[11], the MOR-active cyclic 
analogue of EM1 c[Tyr-D-Pro-D-Trp-Phe-Gly] (4)[12], and the “carba” analogues (both cis and the trans 
isomers) of a fentanyl equipped with a guanidino group (compound 5), in which the piperidine ring nitrogen 
atom is replaced by carbon[13]. Compound 5 likely retains the same binding mode as the “normal” fentanyls; 
however, it was observed that the ionic bridge between the guanidine moiety of the ligands and an Asp in the 
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second extracellular loop (EL) is significant for receptor binding. In contrast, compounds 3 and 4, which are 
deprived of any ionic interactions, have receptor binding modes different from that of the classical agonists[14]. 
The cyclopentapeptide 4 was the most active member of a mini-library of stereomeric, 3D distinct analogues 
of EM1 of general sequence c[L/D-Tyr-L/D-Pro-L/D-Trp-L/D-Phe-Gly], designed as lipophilic compounds with 
improved ability to cross the BBB and higher in vivo stability. Among them, 4 proved to be an agonist with an 
affinity of 10-8M for MOR. Further studies revealed in vivo analgesic efficacy upon peripheral administration 
which correlated to its lipophilicity and metabolic stability[15], whereas the parent opioid peptide EM1 was 
completely inactive[2, 16]. 
As 4 represents a lipophilic, atypical opioid agonist deprived of the primary pharmacophore, we performed 
investigations to understand how the compound might interact and activate the MOR[14c]. As revealed by 
NMR spectroscopy and molecular dynamics (MD), 4 in solution adopts two different conformations in 
equilibrium, one characterized by a type IIβ-turn on Tyr-D-Pro and an inverse ɣ-turn on Phe (Figure 1 a), the 
second by an inverse type I β-turn on D-Pro2-D-Trp3 and a ɣ-turn on Gly (Figure 1 b). 
 
 
Fig. (1). Structures of the MOR agonists 1, 3-5, and of the KOR agonist 2. 
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Fig. (2). Preferred conformations of 4 in solution (left), and schematic sketch of the receptor-bound conformation (right) with some 
relevant contacts (stick rendering).Errore. Il segnalibro non è definito.c  
However, a molecular docking investigation suggested that the ligand might have quite a different geometry 
within the receptor pocket. This analysis revealed a fundamental hydrogen bond between the indolic NH of 
D-Trp and the carboxylate of Asp147 (TMH-III), which partially compensates for the absence of the ionic 
interaction, and an overall conformation roughly compatible with an inverse β-turn centered on D-Trp- Phe 
(Figure 1c). 
Herein we show that an inverse type II β-turn centered on D-Trp-Phe is fundamental for activity, and 
represents a novel pharmacophoric motif for this atypical class of cyclopeptide MOR agonists. To this 
purpose, we used the putative bioactive conformation of 4 shown in Figure 1 as a model for designing new 
cyclopeptides with higher propensity to adopt the inverse β-turn on D-Trp-Phe, and with increased MOR 
affinity, therefore demonstrating the utility of the model. To further corroborate the model, we designed a 
cyclopeptide not based on the sequence of EM1, whose activity as a selective MOR agonist is clearly 
correlated to the D-Trp-Phe inverse β-turn bioactive conformation. 
6.1. Results 
6.1.1. Cyclopeptide design 
Despite the inadequate 3D structure in solution, ligand 4 can still attain a significant interaction with the 
receptor by taking advantage of its flexibility. In addition, the receptor itself can adapt its shape to host the 
ligand (induced fit)[17]. In principle, it is possible to improve the efficacy of such a flexible molecule by 
modifying its geometry[5a], taking into consideration that “the more the structure of a free ligand in solution 
resembles the structure in the complex, the stronger the binding”[18]. Despite the many limitations, this 
assumption sometimes works very well as an indicative guide for structure optimization. 
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Consequently, we supposed that analogues of 4 having the inverse type II β-turn on D-Trp-Phe might show 
improved receptor affinity, therefore confirming that this secondary structure represents the bioactive 
conformation. 
The docking procedure indicated that neither D-Pro nor Gly in 4 really interact with the receptor, but their role 
is fundamental in stabilizing the geometries observed in solution. In particular, it is well documented that D-
Pro induces alternative backbone conformations with respect to the other amino acids[5a, 18, 19]. 
The desired conformation can be predetermined on the basis of the well-known structures of cyclo-Ala5 
models, or other cyclopentapeptides already reported in the literature containing one D-residue, widely used 
as β/ɣ-turn mimetics. In particular, it is well known that an L,L,D,L,L chirality induces an inverse type II β-turn 
with the D-amino acid in the position i+1, with a few exceptions (see Conformational analysis and Discussion 
below)[18–20]. 
Based on these premises, we retained the amino acids of the pharmacophores, D-Trp, Phe, and Tyr, and we 
completed the sequences with L-Ala and/or Gly, giving cyclopeptides 11–14 of general sequence c[Tyr-Yaa-
D-Trp-Phe-Xaa], where Yaa, Xaa=Ala or Gly (Gly can act either as an L- or D-configured residue). We also 
designed and synthesized the non-EM1-like 14-membered cyclotetrapeptide c[D-Asp-1-amide-β-Ala-D-Trp-
Phe] (15), deprived of the Tyr, and characterized by a rigid backbone. 
It should be mentioned that replacement of D-Pro with its enantiomer to give c[Tyr-Pro-D-Trp-Phe-Gly] (16)[12] 
does not induce the desired conformation. In fact, 16 had ~1000-fold lower affinity than 4. L-Pro likely 
precludes the inverse β-turn on D-Trp-Phe, in particular, cyclopeptides containing an L-Xaa-L-Pro sequence 
strongly increase the probability of the peptide bond preceding Pro having a cis conformation[19,21]. 
 
6.1.2. Cyclopeptide synthesis 
The new cyclic pentapeptides 11–14 were obtained by cyclization of the linear precursors H-Xaa-Tyr-Yaad- 
Trp-Phe-OH, Yaa, Xaa=Ala or Gly (6–9), whereas 15 was prepared from the linear precursor H-D-Asp-1-
amide-β-Ala-D-Trp- Phe-OH (10) (Scheme 1). The peptides 6–10 were obtained in turn by SPPS by coupling 
Fmoc-protected amino acids on a Wang resin under standard conditions[22] using an automated peptide 
synthesizer. Fmoc deprotection was performed with piperidine in DMF, and coupling of the amino acids was 
done with HBTU/DIPEA as coupling agents. The cleavage from the resin was performed with trifluoroacetic 
acid (TFA) in the presence of scavengers. The sequence of 10 contains two β-amino acids, β-Ala, and D-
aspartic acid-1-amide (Scheme 1), the latter introduced in its Boc-protected form; Boc was removed during 
the cleavage of the peptide from resin. 
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Scheme 1. Synthesis of cyclopeptides 11-15 from the linear precursors 6-10. 
 
The crude peptides 6–10 were subjected to in-solution cyclization (high dilution) with diphenylphosphoryl 
azide (DPPA) and NaHCO3 without prior purification (Scheme 1). The cyclic peptides 11–15 were obtained 
pure (95–97%) after semipreparative RP-HPLC. Cyclization yields, purities, and ESI-MS characterizations 
are reported in Table 1. 
 
 
 
6.1.3. Binding affinity to the cloned human opioid receptors  
The affinities of compounds 11–15 toward the human MOR were determined by displacement binding 
assays; the Ki and IC50 values are reported in Table 1. The potent MOR-selective agonist DAMGO (H-Tyr-D-
Ala-Gly-N-MePhe-Glyol) and compound 4 were chosen as reference compounds. Compounds were added 
to HEK-293 cells stably expressing human MOR, using [3H]DAMGO as a -specific radioligand and were 
assayed in a wide range of concentrations, from 10-12 to 10-4M. The potency of DAMGO was in the 
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nanomolar range as previously reported[12, 23]. Compounds 11, 12, and 13 displaced [3H]DAMGO very poorly 
within the range of concentrations used, so preventing the calculation of Ki and IC50, whereas 14 and 15 
displayed an easily measurable concentration-dependent displacement of [3H]DAMGO, with affinity values in 
the region of 10-9M. DAMGO and 14 had Hill coefficients (nH) not significantly different from unity (Table 1). 
In contrast, 4 and 15 showed nH values significantly lower than unity. This phenomenon suggests that they 
displaced [3H]DAMGO binding with multiple affinities and can be interpreted by a negative cooperativity, that 
is, their binding at one side may lower the affinity at another site. 
Table 2 reports the affinities (Ki and IC50) of compounds 4, 11–15, and of the reference compounds DPDPE 
and U50,488, toward the cloned human δ-opioid receptor (DOR) or KOR expressed on HEK-293 cells. 
These values were determined by displacement binding assays using [3H]diprenorphine and [3H]U69,593 as 
DOR and KOR specific radioligands, respectively. 
As expected, the affinity of DPDPE[24] and U50,488[25] were in the nanomolar range. 
Compound 11 displayed a concentration-dependent displacement of [3H]diprenorphine from cloned human 
DOR, with a moderate 10-7M affinity, whereas the other compounds were ineffective; their Ki and IC50 values 
were higher than 10-4M (Table 2). On the other hand, all the compounds were ineffective in displacing 
[3H]U69,593 from cloned human KOR, apart from compound 13 that had an affinity of 10-8M. 
In summary, the cyclopeptide 14, c[Tyr-Gly-D-Trp-Phe-Gly], showed the highest MOR affinity, having Ki and 
EC50 values in the nanomolar range, approximately tenfold improved over the parent compound 4 [12], c[Tyr-
D-Pro-D-Trp-Phe-Gly], and almost as good as the reference compound DAMGO. Cyclopeptide 15, c[D-Asp-
1-amide-β-Ala-D-Trp-Phe], was slightly less effective, whereas 11–13 were practically inactive. 
The ligands 4, c[Tyr-D-Pro-D-Trp-Phe-Gly], 14, c[Tyr-Gly-D-Trp-Phe-Gly], and 15, c[D-Asp-1-amide-β-Ala-D-
Trp-Phe], selectively bind to the MOR, as they have negligible affinity for the KOR and DOR. Interestingly, 11, 
c[Tyr-Ala-D-Trp-Phe-Ala], showed a modest affinity for DOR, but not for MOR and KOR, whereas compound 
13, c[Tyr-Gly-D-Trp-Phe-Ala], which was ineffective as a MOR and DOR ligand, displayed a significant 
affinity for KOR (Table 2). 
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6.1.4. Effects on forskolin-stimulated cAMP production 
To assess if 14 and 15 behave as MOR agonists or antagonists, we evaluated their effects on forskolin-
stimulated cAMP formation in whole HEK-293 cells stably expressing MOR. The IC50 and maximal effect 
(Emax) values are reported in Table 3. The MOR agonist DAMGO[26] produced a concentration-dependent 
reduction of cAMP. Compounds 14 and 15 display a similar potency to DAMGO as they have similar IC50 
values, although they show a reduced Emax in comparison with DAMGO, consistent with an activity as 
partial agonists (Table 3). The IC50 values of 14 and 15 as inhibitors of forskolin-stimulated cAMP production 
were similar to those elicited by 4[12]. In control HEK-293 cells DAMGO, EM1, 14, and 15 did not inhibit cAMP 
production induced by forskolin (data not shown). 
The partial agonist activity of the cyclopeptides 14, an analogue of EM1, and 15, relative to the full agonism 
of DAMGO is not surprising. Also the efficacy of EMs in many bioassays is lower than that of DAMGO (but 
higher than that of morphine), albeit that their antinociceptive efficacy is higher[1–3]. In general, EM1 and EM2 
behave as partial agonists of the MORs[27], but in a few cases full agonist activities have been reported[1, 28]. 
 
6.1.5. Conformational analysis 
The in-solution conformations of 11, 13, 14, and 15 were investigated by NMR spectroscopy and MD 
simulations. The analysis of 12 was omitted because of its inactivity as an opioid ligand. As the compounds 
were poorly soluble in water, the NMR analyses were conducted using standard techniques at 400 MHz in 
the biomimetic medium 8:2 [D6]DMSO/H2O [29]. 
Apart from the solubility issue, a very recent comparative structural analysis of MOR ligands with similar 
affinity and selectivity confirmed that DMSO may be a better approximation for the mechanical and 
electrostatic environment of binding to the MOR than H2O is[30]. 
The 1H NMR analysis of the compounds 13, 14, and 15 revealed a single set of sharp resonances, indicating 
conformational homogeneity or a fast equilibrium between conformers. 
The 1H NMR of 11 appeared as a single set of resonances, but with a noteworthy broadening of the signals 
of TyrOH, TyrNH, XAlaNH (XAla: Xaa=Ala), and a less pronounced broadening of YAlaNH (YAla: Yaa=Ala), 
indicative of a slow switch between different NH orientations in the XAla-Tyr region. COSY and HMBC 
experiments allowed unambiguous assignment of all the resonances. 
Variable temperature (VT)-1H NMR experiments were used to deduce the presence of hydrogen bonds 
(Table 4). For 11 and 13, the comparatively lower Δδ/ΔT values of the amide protons of Yaa and Xaa with 
respect to D-Trp, Phe, and Tyr, are suggestive of structures in which one or both of the AlaNH in 11, c[Tyr-
Ala-D-Trp-Phe-Ala], and GlyNH and/or AlaNH in 13, c[Tyr-Gly-D-Trp-Phe-Ala], are involved in hydrogen 
bonds (Δδ/ΔT < or close to 2 ppbK-1)[31]. For 14, c[Tyr-Gly-D-Trp-Phe-Gly], the low Δδ/ΔT values suggest 
that D-TrpNH and GlyNH very likely contribute to hydrogen bonds. Finally, for compound 15, c[D-Asp-1-
amide-β-Ala-D-Trp-Phe], the d-AspNH (=Xaa in Table 4) is certainly involved in a very strong hydrogen bond 
(Δδ/ΔT=-0.5 ppbK-1). 
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6.1.6. Molecular backbone conformations were investigated by 2D 
ROESY analysis, and the intensities of the resulting cross-peak were ranked to infer plausible inter-proton 
distances (see Supporting Information tables S1–S4). Structures consistent with the spectroscopic analyses 
were obtained by restrained MD simulations[32], using the distances derived from ROESY as constraints, and 
minimized with AMBER[33] force field. The w bonds were set at 1808, as the absence of Hαi-Hαi+1 cross-
peaks excluded cis peptide bonds. Simulations were conducted in a box of explicit, equilibrated TIP3P water 
molecules[34] using a set of 50 random structures generated by means of unrestrained high-temperature MD. 
The structures were subjected to high-temperature restrained MD with a scaled force field, followed by a 
simulation with full restraints. Finally, the system was gradually cooled, and the structures were minimized. 
The results were clustered by the RMSD analysis of the backbone atoms. 
For 11, c[Tyr-Ala-D-Trp-Phe-Ala], computations essentially gave two clusters altogether comprising more 
than 95% of the structures. For each cluster, the representative geometries 11a and 11b with the lowest 
internal energy were selected and analyzed, Figure 2 (see figures S2 andS3, Supporting Information). 
The two conformers are characterized by nearly the same energy, and differ almost exclusively in the 
opposite orientation of the peptide bond of XAla-Tyr. The occurrence of these two different structures for 11 
reflects the lack of clear ROESY cross-peaks for TyrNH, XAlaNH, and YAlaNH, whose resonances appear 
as broad signals. These two conformations closely match that of other cyclopentapeptides sharing the same 
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L,L,D,L,L stereochemistry array[18–20], such as c[Asp-Trp-D-Met-Asp-Phe] and related peptides[20b]. Both 11a 
and 11b show an inverse type II β-turn centered on D-Trp-Phe, with an explicit hydrogen bond between 
YAlaCO and XAlaNH. In addition, 11 a also shows a ɣ-turn on Tyr, with a hydrogen bond between XAlaCO 
and YAlaNH. 
The structures 11a and 11b were analyzed by unrestrained MD for 10 ns in a box of explicit, equilibrated 
water molecules. 
The analysis of the trajectories did not show the conversion of one conformation into the other. Probably, the 
flip of the peptide bond of XGly-Tyr is slow with respect to the time scale of the simulation. 
The analysis of 13, c[Tyr-Gly-D-Trp-Phe-Ala], was conducted as for 11. ROESY-restrained MD and cluster 
analysis gave the two structures 13a and 13b (>95% of the structures), the latter being slightly more stable, 
whose representative low energy conformations are shown in Figure 3a and 3b, respectively. 
The two structures differ in the opposite orientations of the Ala-Tyr peptide bond, and show some violations 
of the distance constraints in this region. In particular, the strong crosspeaks of TyrNH-AlaHa, and TyrNH-
TyrHa, and the medium cross-peak of TyrNH-AlaNH, account for the conformation of 13b (Figure 3 b). Both 
these structures do not show any of the hydrogen bonds predicted by VT-NMR analysis, probably because 
of a fast equilibrium between different geometries whose average in the NMR time scale gave the ROESY-
derived structures. Nevertheless, the VT-NMR analysis of 13 is indicative of some preference for 
conformations stabilized by hydrogen bonds involving GlyNH and/or AlaNH. 
 
 
 
Fig. (3). Representative low-energy structures of 11a (left) and 11b (right) consistent with ROESY analysis, calculated by restrained MD 
in a 30x30x30 Å box of standard TIP3P water molecules 
 
To investigate the dynamic behavior, the structures 13a and 13b were analyzed by unrestrained MD for 10 
ns in a box of explicit, equilibrated water molecules. During the simulation, the conversion of 13a into 13b 
was not observed. Besides the different random conformations, the analysis of the trajectories of 13a 
revealed the occurrence of well-defined secondary structures (see figures S4 and S5, Supporting 
Information). The representative conformation 13c (Figure 4) is characterized by an inverse type II β-turn 
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having D-Trp-Phe in the positions i+1, i+2, stabilized by a hydrogen bond between GlyCO and AlaNH, as 
predicted by the VT-NMR temperature coefficient (Table 4). In a similar way, structures congruent to the 
same kind of β-turn were also observed during the unrestrained MD simulation of 13b. Cyclopentapeptides 
usually show fast rotations of the peptide bonds preceding Gly[18, 19]. As expected, the rotation of the peptide 
bond between Tyr-Gly in 13b led to the formation of a ɣ-turn centered on Tyr, with a hydrogen bond between 
AlaCO and GlyNH in agreement with VT-NMR, as represented by the structure 13d (Figure 4), the backbone 
of which is practically coincident with that of 11 a. 
For 14, c[Tyr-Gly-D-Trp-Phe-Gly], containing two glycines, a greater conformational freedom was expected. 
ROESY-restrained MD and cluster analysis performed as described above gave a preferred geometry 
(>90% of the structures), whose representative low-energy conformation is shown in Figure 4a. The VT-NMR 
analysis of 14 accounts for conformations stabilized by hydrogen bonds involving XGlyNH and/or D-TrpNH. 
However, the structure determined by ROESY-restrained analysis does not show any hydrogen bond, 
confirming that the compound can adopt different geometries in equilibrium. 
The structure 14 was analyzed by unrestrained MD for 10 ns in a box of H2O molecules. Among the different 
random conformations, the analysis of the trajectories revealed the occurrence of alternative secondary 
structures with hydrogen bonds predicted by the VT-NMR (see figures S6 and S7, Supporting Information). 
The conformation of 14a (Figure 4b) is characterized by a type II β-turn centered on Tyr-YGly (YGly: 
Yaa=Gly), stabilized by a hydrogen bond involving XGlyCO and D-TrpNH, and by an inverted ɣ-turn centered 
on Phe. During the simulation, the rotation of the peptide bonds between Phe-XGly and Tyr-YGly was 
observed, the latter leading to an alternative type I β-turn on Tyr-YGly. The conformation of 14b (Figure 4 c) 
is compatible with an inverse type II β-turn having D-Trp-Phe in the positions i+1, i+2, stabilized by a 
hydrogen bond between YGlyCO and XGlyNH. 
 
                  
 
 
Fig. (4). Representative low-energy structures of 13a (top, left), 13b (top, right) consistent with ROESY analysis, calculated by 
restrained MD, and of 13c (bottom, left),  13d (bottom, right), obtained by unrestrained MD, all in a 30x30x30 Å box of standard TIP3P 
water molecules. 
 
For the most part, the overall conformation of a cyclopentapeptide depends on the stereochemistry array. 
Therefore, the secondary structures of 13 and 14 can be rationalized by comparison with the structures of 
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cyclo-Ala5 models, or other cyclopentapeptides sharing the same chirality described in the literature[18–20]. Gly 
can act as either an L- or a D-residue, therefore different chirality arrays can be attributed to the compounds 
13, c[Tyr-Gly-D-Trp-Phe-Ala], and 14, c[Tyr-YGly-D-Trp-Phe-XGly]. 
Apparently, the structures 13c, 13d, and 14b adopt the same secondary structure as L,L,D,L,L 
cyclopentapeptides, namely an inverse type II β-turn centered on D-aa 3 L-aa 4 (see the discussion 
concerning 11 in the previous paragraph). In contrast, the structure 14a behaves as an L,D,D,L,D-
cyclopentapeptide, as its backbone reproduces the mirror image of that of D,L,L,D,L-cyclo-Ala5, as well as 
the mirror image of the backbone of the αvβ3-integrin inhibitor c[D-Phe-Val-Arg-Gly-Asp] (generally reported 
as c[RGDfV][20a]), having D,L,L,D,L chirality, the opposite of L,D,D,L,D both featuring an inverse type II β-turn 
on D-aa1L-aa2, and a ɣ-turn on L-aa 4. On the other hand, L,D,D,L,L-cyclo-Ala5 still maintains the type II β-
turn on L-aa 1-D-aa[19, 20]. Finally, the conformational analysis of 15, c[D-Asp-1-amide-β-Ala-D-Trp-Phe], 
performed as before, gave one major cluster comprising more than 95% of the structures, whose 
representative lowest-energy structure is shown in Figure 5 (see figure S8, Supporting Information). 
 
 
           
 
Fig. (5). Representative low-energy structures of 14 consistent with ROESY analysis calculated by restrained MD (top), and 
representative low-energy structures of 14a, (left) and 14b (right) obtained by unrestrained MD; all these structures were calculated in a 
30x30x30 Å box of standard TIP3P water molecules. 
 
The structure shows the inverse type II β-turn centered on D-Trp-Phe, stabilized by an explicit hydrogen 
bond between β-AlaCO and D-AspNH, fully compatible with the VT-NMR analysis (Table 4, Xaa=D-AspNH, 
Yaa=β -Ala). This conformation has no violations of the distance constraints, nevertheless, a 10 ns 
unrestrained MD simulation in explicit water revealed that the amide bond of D-Asp-β-Ala can rotate, pointing 
toward the opposite sides of the molecular plane. Apart from this residual flexibility, 15 shows higher 
conformational homogeneity with respect to the cyclopentapeptides, probably due to the smaller size of the 
cyclopeptide ring and strong hydrogen bond. For stereo views of the structures described in this section, see 
the Supporting Information, figures S2–S8. 
 
6.1.7. Molecular docking 
To explore the structural determinants responsible for the different MOR affinities of compounds 11 and 13–
15, molecular modeling studies were carried out in our previously obtained MOR model[14c] (see Supporting 
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Information, figure S1 and table S5) using AutoDock (ver. 4)[35], a docking suite that uses an automated 
approach that allows ligand flexibility, and it is able to locate poses in a consistent way with respect to the X-
ray crystal structures[36]. 
The docking computations were performed by starting from the representative conformations 11a, 11b, 13c, 
13d, 14a, 14b, and 15 observed in solution. 
For most docking analyses reported in the literature, the construction of ligand–MOR complex models 
postulated an electrostatic interaction of the protonated amine with Asp147 in TMH III[3, 6, 7, 9, 37]. Conversely, 
the compounds 11 and 13–15 do not include any ionic functionalities, so the main binding force toward the 
receptor should comprise hydrophobic and hydrogen bonding interactions. 
After docking, MD, energy minimization, clustering, and QM/MM induced fit calculations, the models obtained 
for compounds 14 and 15 showed suitable macrocycle conformations that enable them to fit the shallow cleft 
of the MOR. On the contrary, no satisfying poses were obtained for 11 and 13, presumably due to bad 
contacts of the Ala methyl side chain(s). 
The docking of 14 led to a few alternative docking orientation (DO), characterized by different binding 
energies, whereas only one orientation was obtained for 15. This can be correlated to the higher 
conformational flexibility of 14 with respect to 15 (see the previous section). The top-ranking 14-DO1 and 14-
DO2 are shown in Figure 6 a and 6b, respectively, whereas 15-DO is shown in Figure 7; for supplementary 
views of these DOs, see figures S9 and S10 in the Supporting Information. 
 
 
 
Fig. ( 6). Representative low-energy structure of 15 consistent with ROESY analysis, calculated by restrained MD in a 30x30x30 Å box 
of standard TIP3P water molecules. 
 
The binding site of 14-DO1, 14-DO2, and 15-DO is located in the central core of MOR, delimited by TMH III, 
VI, and VII, and EL III, IV. The list of the MOR residues in contact with the ligands is reported in table S6 
(Supporting Information). The D-Trp of 14 and 15 points toward the bottom of the binding site, with the indole 
NH in contact with the carboxyl group of Asp147 (TMH III); the rest of the ligand resides in a cavity delimited 
on top by EL III. 
Four hydrogen bonds are formed between 14-DO1 and the receptor. Two strong hydrogen bonds are 
located between the heterocyclic NH of D-Trp and Od1 Asp147 (2.48 Å), and between the phenolic OH of the 
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Tyr and Oe2 Glu310 (2.57 Å), whereas the other two are formed between the oxygen of YGly and the Og1H 
group of Thr 218 (2.57 Å), and between the amide group of XGly and NzH of Lys233 (2.81 Å). 
The aromatic moieties of 14-DO1 are stabilized by many stacking interactions (see table S2, Supporting 
Information). 
The indole of D-Trp points toward a hydrophobic pocket composed mainly of the aromatic residues Phe152 
(TMH III), Phe237 (TMH V), and Trp293 (TMH VI). The aromatic group of Tyr is involved in one cation–π 
interaction with the side chain of Lys303 (TMH VI) and two π–π stacking interactions with the aromatic centers 
of Phe221 and His 233 (EL III). The phenyl group of Phe interacts the residues Phe221 (EL III) and Trp318 (TMH 
VI). This interaction pattern leads to a calculated binding free energy (DGb) value of -9.88 kcalmol-1. The 
structure 14-DO2, Figure 6 (see figure S9, Supporting Information), is rotated by ~1808 with respect to 14-
DO1, and is involved in interactions with nearly the same residues of TMH III, V–VII, and EL III, IV, but also 
with Ile198 and Val 202 from TMH IV (see table S2, Supporting Information). 
Four hydrogen bonds are formed between 14-DO2 and the receptor. The hydrogen bond between D-TrpNH 
and Od1 Asp147 is retained, but with an appreciable elongation of the distance (2.59 Å versus 2.48 Å). The 
other hydrogen bonds involve the phenolic OH of Tyr and Oe2 Glu 229 (2.54Å), the backbone oxygen of XGly 
and the Ne2H of His 223 (2.60 Å), and one between the backbone oxygen of D-Trp and the Og1H of Thr 218 
(2.76 Å). 
The phenyl of Phe is now involved in stacking interactions with the side chain of Tyr148 (TMH III) whereas the 
indole of D-Trp occupies nearly the same hydrophobic cavity of 14-DO1 (Phe152 of TMH III and Trp293 of TMH 
VI). In this orientation the aromatic side chain of Tyr is rotated toward Glu229 and does not establish 
significant stacking interactions with residues of the hydrophobic cavity delimited mainly by Val 300 and Ala 304 
(TMH IV) and Thr307 (EL IV), giving a lower contribution to the complex stability that, in concert with the 
inferior interaction of D-Trp with Asp147, results in an overall calculated binding free energy value of -6.03 
kcalmol-1. 
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Figure 7. Side views of the top ranking docking orientations of 14-DO1 (left) and 14-DO2 (right) and the MOR binding site. The protein 
residues are represented in wireframe and sticks for the key-residues, with the C-atoms colored in blue for the residues in the first 
interaction shell, <3.5Å from the ligand, green for those at a distance <5Å; the ligand is depicted by balls and cylinders (CPK). The figure 
highlights essential H-bond interactions (green dotted lines). 
 
Interestingly, the structure 14-DO1 maintains a reasonable similarity to the structure 14b observed in solution 
(Figure 4). 
This, along with the more favorable binding energy, implies that 14-DO1 might be the bioactive conformation 
of the ligand. 
Concerning 15, the docking protocol revealed only one topranked pose, 15-DO (Figure 7, see figure S10, 
Supporting Information), likely due to its greater conformational rigidity. This structure maintains the inverse 
type II β-turn and the other features observed in solution (Figure 5), the only difference being the orientation 
of the peptide bond between D-Asp and β-Ala. 
The rotation of this peptide bond was also observed in solution during the unrestrained MD simulation. 15-
DO has five hydrogen bonds. The most relevant is between the indole NH and Od1 Asp 147 (2.57 Å). The 
CONH2 of D-Asp, situated within the upper part of the MOR, near EL III and surrounded by Thr 220, Phe221, 
His 223, and Glu 229, is involved in two hydrogen bonds, one with the backbone amide of Leu219 (3.06 Å) and 
the other with Oe2 Glu 229 (2.59 Å). 
Two hydrogen bonds involve the β-Ala residue, one between the NH and Oe2Glu 229 (2.82 Å), and the other 
between the backbone oxygen and the Og1H of Thr218 (2.73 Å). 
The phenyl of Phe has strong hydrophobic interaction with residues of EL III, in particular the π–π and 
cation–π interactions with His 216. The indole of D-Trp occupies the same hydrophobic cavity of 14 (Tyr148 
and Phe152 of TMH III, and Trp293 of TMH VI). The macrocyclic portion of the ligand interacts with the 
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hydrophobic rim of the tubular pocket (Figure 7), establishing hydrophobic interactions with Thr 218, Leu219, 
and Thr220 (EL III), Ile 296, Val 300, and Ala 304 (TMH VI), Thr307 (EL IV), and Ile322 (TMH VII). 
The calculated binding energy value of 15-DO is 9.53 kcalmol-1, very close to that of 14-DO1. This is 
consistent with the similar poses, hydrogen bond interactions, and hydrophobic contacts shown by the D-
Trp-Phe portion of the two ligands with the same regions of the receptor, confirming that this can be 
regarded to as the dominant pharmacophoric motif of this class of cyclopeptides. 
 
6.2. Discussion 
Data presented in the previous sections support evidence that a D-Trp-Phe sequence situated in positions 
i+1, i+2 of an inverse type II β-turn, might confer MOR agonist behavior to cyclopeptides. 
Initially, conformational and docking analyses led us to suppose that the atypical MOR agonist 4, c[Tyr-D-
Pro-D-Trp-Phe-Gly], adopted a bioactive conformation compatible with an inverse β-turn centered on D-Trp-
Phe. To confirm this hypothesis, we designed cyclopeptide derivatives c[Tyr-Yaa-D-Trp-Phe-Xaa] clearly 
adopting such a conformation. We supposed that these analogues should display higher receptor affinity 
with respect to the parent compound 4, therefore substantiating the proposed bioactive structure. Backbone 
conformations of the new generation of ligands were predetermined on the basis of the well-known 
structures of cyclo-Ala5 models or other cyclopentapeptides containing one or two D-residues already 
reported in the literature widely used as β/ɣ-turn mimetics (see previous sections). 
Gratifyingly, we observed that compound 14, c[Tyr-Gly-D-Trp-Phe-Gly], proved to be a selective MOR ligand 
with an approximate tenfold improved nanomolar affinity, while still maintaining the agonism. In solution, this 
compound adopts a couple of alternative secondary structures in equilibrium, amongst which is 14b, 
characterized by the desired inverse type II β-turn on D-Trp-Phe. The docking analysis furnished two 
alternative orientations of 14 within the receptor, the best of which (14-DO1) was compatible with the in-
solution structure 14b. On the other hand, the cyclopeptides 11–13, including one or two Ala as Yaa Xaa 
residues in c[Tyr-Yaa-D-Trp-Phe-Xaa], gave very poor MOR affinities, although 11 revealed a modest affinity 
for DOR and 13 a moderate KOR affinity. 
The complete lack of efficacy of 11 and 13 as MOR ligands was discussed on the basis of conformational 
and docking analysis. Conformational analysis confirmed that in solution, 11 stably adopts the inverse β-turn 
conformation on D-Trp-Phe, whereas 13 is more flexible, but is still cable to adopt the same geometry. 
However, docking analyses gave no suitable orientations of 11–13 inside the receptor cavity. 
These data highlight the functional role of the D-Trp-Phe for this class of cyclopeptides. This atypical opioid 
pharmacophoric motif can be used for designing non-endomorphin-like opioid cyclopeptide agonists. The 
intrinsic flexibility of 14, both in solution and in the receptor-bound state, might diminish the reliability of the 
proposed model of bioactive conformation. 
For this reason, we designed and tested the derivative 15, whose great conformational homogeneity allowed 
more definitive conclusions. 
The compound 15, c[D-Asp-1-amide-β-Ala-D-Trp-Phe], is deprived of the Tyr residue, and includes two β-
amino acids, D-Asp-1-amide and β -Ala. Compound 15 was designed on the basis of a preliminary 
conformational analysis conducted by MD in a box of explicit water molecules (not shown), which led us to 
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conjecture decreased conformational freedom and a predisposition to reproduce the inverse type II β-turn for 
this 14-membered cyclotetrapeptide. The CONH2 side chain of D-Asp-1-amide was engineered on the basis 
of the analogue group present in the potent MOR-selective agonist JOM-6[38]. 
Interestingly, 15 had a nanomolar affinity, high selectivity for the MOR, and an agonist behavior. 
Conformational analysis confirmed the stability of the inverse β -turn on D-Trp-Phe. Docking analysis 
indicated that 15 retains practically the same structure also in the receptor (see figure S10, Supporting 
Information, showing the comparison between the rear views of the receptor-bound 15-DO and of the in-
solution structure). 
Figure 8 shows the nice overlap of the D-Trp-Phe β-turn regions of 11a, 13d, 14b, and 15 observed in 
solution. It can be observed that an Ala methyl substituent of 11 and 13 occupy the same region of CONH2 of 
15, but the former precludes a proper receptor fitting, as revealed by the very poor binding affinities of 11 
and 13, and consistent with the docking analyses. 
Apparently, the amino acids flanking D-Trp-Phe in the positions i and i+3 of the β-turn seem to be limited in 
respect of the dimensions and kinds of side chains tolerated by the receptor. 
The comparison between the docking structures 14-DO1 and 15-DO revealed a few differences. 15-DO 
shows a strong hydrogen bond between CONH2 and Glu 229. On the other hand, the phenolic OH of Tyr in 
14-DO1 makes a strong hydrogen bond with Glu 310. Tyr also contributes to the overall binding with some 
stabilizing hydrophobic contacts. This subtle distinction could justify the slightly better experimental affinity of 
14 with respect to 15. 
15-DO and 14-DO1 share many features and show similar binding energy values, in agreement to the 
nanomolar experimental affinities. For both compounds, Phe strongly interacts the residues Phe221 (EL III) 
and Trp318 (TMH VI). The main interaction of D-Trp is the ionic bond between indolyl NH and Asp147 of TMH 
III, accompanied hydrophobic interactions with the aromatic residues Tyr 148, Phe152 (TMH III), and Trp293 
(TMH VI). 
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Figure 8. Side view of the top-ranked docking pose of 15 and the MOR binding site. Only selected MOR residues involved in the 
interactions are shown. The protein is represented in wireframe and sticks (for the key-residues), with the C-atoms colored in blue for 
the residues in the first interaction shell, <3.5Å from the ligand, green for those at a distance <5Å; the ligand is depicted by balls and 
cylinders (CPK). The figure highlights the essential H-bond interactions (green dotted lines). 
 
The stabilizing contact between D-Trp and Trp293 of TMH VI is of particular interest. Exhaustive 
investigations performed on the potent agonist JOM-6 indicated that the interaction with Trp293 might be 
responsible for receptor activation[38]. The rearrangement of Trp293 induced by the ligand would be 
accompanied by a rotation of the entire TMH VI, so determining the activation of the G protein. 
 
 
Fig.(9). Overlap of the D-Trp-Phe β-turn structures of 11a, 13d, 14b (rendered in sticks) and 15 (balls and cylinders rendering) observed 
in solution 
 
Cyclopeptide 4 represents the first example of a MOR-selective agonist reported (in 2004)[12] the bioactivity of 
which resides in the D-Trp-Phe sequence. Very recently, the same pharmacophoric motif has been proposed 
162 
 
again with regard to c[D-Pro-Phe-D-Trp-Phe] and correlated compounds[39] derived from the naturally 
occurring cyclotetrapeptide c[D-Pro-Phe-Trp-Phe], CJ-15,208[40], isolated as a metabolite of a fungus. CJ-
15,208 was a modestly selective KOR antagonist ligand (IC50=47 nm, using guinea pig brain membrane). 
The D-configured Trp residue rendered the derivatives more potent than the natural product. c[D-Pro-Phe-D-
Trp-Phe] was a KOR antagonist devoid of agonist activity, with a modest MOR affinity. 
The analogue c[D-Pro-Phe-D-Trp-Ala] maintained practically the same activity and selectivity as a KOR 
antagonist. This means that the pharmacophoric sequence very likely is Phe-D-Trp, rather than D-Trp-Phe. 
Therefore, the different pharmacologic profile of the agonists 4, 14, and 15 with respect to the antagonist 
derivatives of CJ-15,208 very likely resides in the inverted positions of D-Trp and Phe within the sequence, 
and in the 3D display of their side chains, which correlated to the different sizes of the cyclopeptide 
structures. These differences strongly impact not only the affinity for a specific opioid receptor type, but also 
the ability to trigger the activation of G-proteins and signal transduction. 
 
6.3. Conclusions 
Herein we discuss our investigations in support of an unprecedented pharmacophore for the MOR, the 
inverse type II β-turn on D-Trp-Phe. This bioactive structure was formerly supposed on the basis of 
conformational and docking analyses performed on the agonist c[Tyr-D-Pro-D-Trp-Phe-Gly] (4), a cyclic 
analogue of EM1 showing a 10-8M affinity for the MOR. To validate this initial hypothesis, we designed a new 
generation of analogues with improved receptor affinity, by fostering the inverse β-turn on D-Trp-Phe. 
Among the new compounds 11–14 of general sequence c[Tyr-Yaa-D-Trp-Phe-Xaa] (Yaa, Xaa=Ala, Gly), the 
cyclopeptide c[Tyr-Gly-D-Trp-Phe-Gly] (14) was a selective MOR agonist with 10-9M affinity. This result is of 
particular interest, taking into consideration that 14 is deprived of any ionic interactions which are generally 
considered fundamental in binding and activating the opioid receptor. Despite of the backbone flexibility 
generated by the two Gly residues, the conformational analysis revealed that in solution 14 can adopt an 
inverse type II β-turn (the conformation 14b). 
To further validate and to expand the scope of the D-Trp-Phe pharmacophore, we designed the 
cyclotetrapeptide c[D-Asp-1-amide- β -Ala-D-Trp-Phe] (15), not based on the sequence of EM1, and 
characterized in solution by a stable D-Trpi+1-Phei+2 inverse type II β-turn. This compound showed a 
selective, nanomolar MOR affinity, and a partial agonist behavior. 
Docking analyses further confirmed that the inverse type II β-turn on D-Trp-Phe allow the cyclopeptides 14 
and 15 to assume the correct poses within the binding site, while the structures of the other analogues 11–13 
were unsuitable for receptor fitting, possibly because of the presence of methyl substituents on the residues i, 
i+3 of the β-turn. These results indicate that cyclopeptides comprising a D-Trp-Phe motif in the proper 
secondary conformation may represent leads for the discovery of novel lipophilic opioid agonists, 
characterized by an atypical mechanism of receptor activation. 
The functional selectivity observed for the novel MOR ligands described in this study can be explored in 
further investigations to ascertain if they can direct the receptor toward a conformational selectivity, evoking 
a specific response. Recent pharmacological data and modeling studies strongly support the hypothesis that 
GPCRs, including opioid receptors, exist as dynamic entities that can occupy multiple conformations and 
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signaling states, depending on the ligand and accessory proteins within the signaling complex[41]. 
 
6.4. Experimental Section 
 
6.4.1. Chemistry 
General methods: Unless stated otherwise, standard chemicals were obtained from commercial sources and 
used without further purification. Flash chromatography was performed on silica gel (230–400 mesh), using 
mixtures of EtOAc and MeOH; solvents were simply distilled. Semipreparative RP-HPLC was performed on a 
C18 column (7 mm particle size, 21.2 mm x150 mm, from 7:3 H2O/CH3CN to 100% CH3CN in 15 min), flow 
rate of 12 mLmin-1. 
The purity (>95%) of tested compounds was assessed by analytical RP-HPLC on an ODS column (4.6 mm 
particle size, 100 pore diameter, 250 mm, DAD 210 nm, from 9:1 H2O/CH3CN to 2:8 H2O/ CH3CN in 20 
min), flow rate of 1.0 mLmin-1, followed by 10 min at the same composition. 1H NMR spectra were recorded 
at 400 MHz in 5 mm tubes, using 0.01M peptide in 8:2 [D6]DMSO/H2O, at RT. 
Solvent suppression was performed by the solvent presaturation procedure implemented in Varian (presat). 
Chemical shifts are reported as δ values. The unambiguous assignment of 1H NMR resonances was 
performed by 2D gCOSY, HMBC, and HSQC. gCOSY experiments were conducted with a proton spectral 
width of 3103 Hz. VT-1H NMR experiments were performed over the range of 298–348 K. Peaks were 
calibrated on DMSO. 2D spectra were recorded in the phase sensitive mode and processed using a 908- 
shifted, squared sine-bell apodization. 2D ROESY experiments were recorded with a 250 ms mixing time 
with a proton spectral width of 3088 Hz. 
 
6.4.2. Peptide synthesis: The linear precursors 6–10 were obtained by standard SPPS using an automated 
synthesizer apparatus on a Wang resin preloaded with Fmoc-Phe (0.5 g, 0.4–0.8 mmolg-1). 
Fmoc removal was performed with 4:1 DMF/piperidine (5 mL) under mechanical shaking. After 15 min, the 
mixture was filtered, the resin was washed with DMF (5 mL), and treated under mechanical shaking with a 
second portion of 4:1 DMF/piperidine. After 40 min, the mixture was filtered, and the resin was washed tree 
times in sequence with DMF (5 mL) and CH3OH (5 mL). The resin was suspended in CH2Cl2 (5 mL), and a 
solution of the next Fmoc protected amino acid (0.6 mmol) and HOBt (0.6 mmol) in DMF (3 mL) was added, 
followed by HBTU (0.6 mmol) and DIPEA (1.2 mmol). The mixture was mechanically shaken, and after 3 h 
the resin was filtered and washed three times with DMF (5 mL) and CH3OH (5 mL) in sequence. Coupling 
efficacy was determined by means of the Kaiser tests. 
 
6.4.3. Peptide cleavage: The N-deprotected resin-bound peptide was suspended in a mixture of TFA (4.7 
mL), H2O (0.15 mL), and PhOH (0.15 mL), and mechanically shaken at RT. After 2 h, the mixture was filtered, 
the resin was washed twice with 10% TFA in Et2O (5 mL), and twice with Et2O. Filtrate and washes were 
collected and the solvent and volatiles were removed under N2 flow at RT. 
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The resulting residue was suspended in Et2O, and the crude solid which precipitated was triturated and 
collected by centrifuge. Peptides were characterized by analytical RP-HPLC and ESI-MS (see General 
methods). 
 
6.4.4. Peptide cyclization: The peptides (0.15 mmol) were dissolved in dry DMF (40 mL) and treated while 
being magnetically stirred with NaHCO3 (2.0 mmol) and DPPA (0.5 mmol) at RT. After two days, the mixture 
was filtered, the solvent was distilled at reduced pressure, and the residue was transferred in a separating 
funnel. The residue was diluted with water (5 mL), and the mixture was extracted with EtOAc (4x20 mL). The 
collected organic layers were dried over Na2SO4, and the solvent was evaporated at reduced pressure. The 
oily residue was rapidly purified by flash chromatography over silica gel (eluent: 97:3 EtOAc/MeOH), followed 
by semipreparative RP-HPLC (see General methods), affording the cyclopeptides in 55–70% yield, 95–97% 
pure (Table 1) by analytical RP-HPLC analysis (see General methods). Cyclopeptides were characterized by 
analytical ESI-MS (Table 1 and General methods) and 1H NMR. 
 
Peptide 11: 1H NMR (400 MHz, 8:2 [D6]DMSO:H2O): δ=1.09 (d, J=6.4 Hz, 3H, YAlaMe), 1.90 (d, J=6.8 Hz, 
3H, XAlaMe), 2.65–2.85 (m, 2H, TyrHβ+D-TrpHβ), 2.85–2.94 (m, 3H, TyrHβ+D-TrpHβ+PheHβ), 2.98 (dd, 
J=4.0, 13.6 Hz, 1H, PheHβ), 4.04 (q, J=7.2 Hz, 1H, TyrHα), 4.15 (quint, J=7.4 Hz, 1H, XAlaHα), 4.27 (quint, 
J=7.0 Hz, 1H, YAlaHα), 4.33 (m, 1H, PheHα), 4.42 (q, J=7.2 Hz, 1H, D-TrpHα), 6.64 (d, J=7.6 Hz, 2H, 
TyrArH), 6.96 (s, 1H, IndH2), 6.97 (br t, 1H, IndH5), 6.98 (d, J=7.6 Hz, 2H, TyrArH), 7.06 (t, J=7.2 Hz, 1H, 
IndH6), 7.11–7.25 (m, 5H, PheArH), 7.32 (d, J=8.0 Hz, 1H, IndH7), 7.49 (d, J=7.6 Hz, 1H, IndH4), 8.06 (br d, 
1H, YAlaNH), 8.18 (br d, 1H, XAlaNH), 8.38 (br d, 1H, TyrNH), 8.47 (d, J=8.0 Hz, 1H, PheNH), 8.58 (d, J=7.2 
Hz, 1H, d-TrpNH), 9.25 (br s, 1H, TyrOH), 10.70 ppm (s, 1H, IndH1). 
 
Peptide 13: 1H NMR (400 MHz, 8:2 [D6]DMSO:H2O): d=1.20 (d, J=8.8 Hz, 3H, AlaMe), 2.76 (dd, J=10.8, 
13.2 Hz, 1H, PheHb), 2.80–2.90 (m, 3H, TyrHb+D-TrpHb), 2.90–3.00 (m, 2H, D-TrpHb+PheHb), 3.58 (dd, 
J=4.8, 15.6 Hz, 1H, GlyHα), 3.72 (dd, J=8.0, 15.6 Hz, 1H, GlyHα), 4.03 (q, J=7.6 Hz, 1H, TyrHα), 4.12 (quint, 
J=7.4 Hz, 1H, AlaHα), 4.19 4.33 (dt, J=5.6, 8.0 Hz, 1H, PheHα), 4.33 (q, J=6.8 Hz, 1H, D-TrpHα), 6.61 (d, 
J=8.0 Hz, 2H, TyrArH), 6.93 (d, J=8.0 Hz, 2H, TyrArH), 6.96 (m, 2H, IndH2+IndH5), 7.05–7.15 (m, 3H, 
PheArH+IndH6), 7.15–7.25 (m, 3H, PheArH), 7.27 (d, J=7.6 Hz, 1H, IndH7), 7.50 (d, J=7.2 Hz, 1H, IndH4), 
7.81 (d, J=7.8 Hz, 1H, AlaNH), 7.84 (t, J=6.6 Hz, 1H, GlyNH), 8.11 (d, J=6.8 Hz, 1H, d- TrpNH), 8.20 (d, 
J=7.2 Hz, 1H, TyrNH), 8.41 (d, J=7.2 Hz, 1H, PheNH), 9.21 (s, 1H, TyrOH), 10.70 ppm (s, 1H, IndH1). 
 
Peptide 14: 1H NMR (400 MHz, 8:2 [D6]DMSO:H2O): d=2.60–2.70 (m, 2H, TyrHβ+D-TrpHβ), 2.80–2.90 (m, 
2H, TyrHβ+D-TrpHβ), 2.95–3.05 (m, 2H, PheHβ), 3.25–3.35 (m, 1H, XGlyHα), 3.35–3.45 (m, 1H, YGlyHα), 
3.55–3.65 (m, 1H, YGlyHα), 3.95–4.15 (m, 1H, XGlyHα), 4.10–4.25 (m, 1H, TyrHα), 4.40–4.51 (m, 2H, PheH
α+d-TrpHα), 6.64 (d, J=8.4 Hz, 2H, TyrArH), 6.85 (s, 1H, IndH2), 6.96 (br t, 1H, IndH5), 7.01 (d, J=8.4 Hz, 
2H, TyrArH), 7.11 (t, J=7.2 Hz,1H, IndH6), 7.11–7.25 (m, 5H, PheArH), 7.31 (br t, 1H, IndH7), 7.54 (d, J=8 
Hz, 1H, IndH4), 7.78 (br t, 1H, XGlyNH), 7.86 (d, J=6.4 Hz, 1H, d-TrpNH), 8.25 (br t, 1H, YGlyNH), 8.71 (d, 
J=6.4 Hz, 1H, TyrNH), 8.76 (d, J=8.0 Hz, 1H, PheNH), 9.25 (br s, 1H, TyrOH), 10.66 ppm (s, 1H, IndH1). 
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Peptide 15: 1H NMR (400 MHz, 8:2 [D6]DMSO:H2O): d=2.08 (m, 1H, β-AlaHα), 2.30 (dd, J=4.6, 15.4 Hz, 1H, 
D-AspHβ), 2.40 (m, 1H, β-AlaHα), 2.67 (dd, J=6.8, 15.4 Hz, 1H, D-AspHβ), 2.75 (dd, J=6.8, 14.0 Hz, 1H, D-
TrpHβ), 2.80–2.90 (m, 2H, PheHβ+D-TrpHβ), 2.98 (dd, J=4.2, 14.2 Hz, 1H, PheHβ), 3.18 (m, 1H, β-AlaHβ), 
3.42 (m, 1H, β-AlaHβ), 4.27 (m, 2H, PheHα+D-AspHα), 4.57 (q, J=8.0 Hz, 1H, D-TrpHα), 6.90 (s, 1H, IndH2), 
6.96 (t, J=7.2 Hz, 1H, IndH5), 7.05–7.15 (m, 4H, PheArH2,6+IndH6+CONH2), 7.15–7.25 (m, 4H, PheArH3–
5+CONH2), 7.33 (d, J=7.6 Hz, 2H, IndH7+d-AspNH), 7.45 (d, J=7.6 Hz, 1H, IndH4), 7.64 (t, J=5.6 Hz, 1H, β-
AlaNH), 8.19 (d, J=8.4 Hz, 1H, D-TrpNH), 8.43 (d, J=8.4 Hz, 1H, PheNH), 10.7 ppm (s, 1H, IndH1). 
 
6.5. Biology 
Receptor binding to cloned human MOR on intact cells: HEK-293 cells stably expressing human MOR were 
employed to perform displacement binding assays on intact cells to evaluate the binding affinity of 
compounds 11–15 toward MOR. HEK-293 cells were transfected with the human MOR encoding plasmid 
pcDNA3.1+ OPRM1 (UMR cDNA Resource Center, Rolla, MO, USA) by using EXGEN 500 (Fermentas, 
Hanover, MD, USA) according to the manufacturer’s recommendations. Stable transfectants were selected 
by exposure to G418 (500 mgmL-1) for four weeks and then seeded in normal minimum essential medium 
(MEM; Sigma, Steinheim, Germany) to perform binding assays. Cell surface human MOR receptors were 
measured on intact cells using [3H]DAMGO (0.1–5 nm) as radioligand and naloxone (30 mm) to determine 
nonspecific binding. 
[3H]DAMGO binding to HEK-293 cells expressing human MOR was saturable, with a Kd (apparent 
dissociation constant of the radioligand) of 1.45x0.14 nm and a Bmax (maximal number of binding sites) of 
3189x18 dpm (5x105 cells)x1 (n=4). For displacement binding assays, HEK-293 cells expressing human 
MOR were incubated at RT for 2 h with [3H]DAMGO (5 nm), in the presence or absence of compounds at 
various concentrations (10-12–10-4M); nonspecific binding was determined in the presence of naloxone (30 
mm). Compounds were prepared as stock solutions (10-2 M) in ethanol and protected from light; compound 
dilutions were made in assay buffer. After incubation with the listed ligands, cells were washed in PBS (pH 
7.4) and lysed with 0.1N NaOH. Lysed samples were buffered with an equal amount of 0.1N  HCl and left in 
scintillation fluid for 8 h before counting. Data from at least three independent experiments were fitted by 
nonlinear regression analysis using GraphPad Prism. Ki values were calculated from the IC50 values using 
the Cheng–Prusoff equation[42]. IC50 values represent mean values from no less than four experiments. IC50 
values, relative potency estimates, and their associated standard errors were determined by fitting the data 
to the Hill equation by a computerized nonlinear least-squares method. 
 
6.5.1. Receptor binding assays to cloned human DOR and KOR: HEK-293 cells stably expressing human 
DOR (2700x100 fmolmg-1 protein; n=6) or KOR (2600x400 fmolmg-1 protein; n=6) were generated by 
EXGEN500 (Fermentas) by transfection with cDNAs cloned into the pcDNA3.1(+) vector (Invitrogen). The 
cDNAs were obtained from UMR cDNA Resource Center (Rolla, MO, USA). HEK-293 cells expressing DOR 
or KOR were grown as a monolayer culture in tissue culture flasks that were incubated at 37°C in a 
humidified atmosphere (5% CO2) in MEM (Lonza) containing 2 mm l-glutamine, 1_ nonessential amino acids 
(Invitrogen) and supplemented with 10% fetal calf serum (Lonza), and maintained in the presence of 400 
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mgmL-1 geneticin (Invitrogen). Cells were washed with icecold PBS, pH 7.4; scraped into an ice-cold buffer 
containing 10 mm HEPES/NaOH, pH 7.4 and 1 mm EDTA; and lysed with a Dounce tissue grinder. The cell 
lysate was centrifuged at 1000 g for 2 min at 4 °C. The supernatant was collected and centrifuged at 32 000 
g for 20 min at 4 °C. The pellet was resuspended in homogenization buffer at a protein concentration 
(determined by BCA assay) of 1.0 to 1.5 mgmL-1 and stored in aliquots at -80°C. Receptor binding assays 
were carried out by using [3H]diprenorphine to label DOR and [3H]U69,593 to label KOR and by incubating 
the membrane preparations at 25 °C for 90 min in buffer containing 100 mm Tris- HCl and 0.3% BSA. For 
saturation binding assays, the concentrations of [3H]diprenorphine and [3H]U69,593 ranged from 40 pm to 3 
nm and from 20 pm to 5 nm, respectively ([3H]diprenorphine Kd=0.22-0.03 nm; n=3) ([3H]U69,593 Kd=1.1-
0.1 nm; n=3). For competition binding assays, the concentration of [3H]diprenorphine or [3H]U69,593 was 1 
nm and 2 nm, respectively. 
Nonspecific binding was determined in the presence of either 10 mm DPDPE (DOR) or 10 mm U50,488 
(KOR) and corresponded to 8 –12% and 12–15% of total [3H]diprenorphine and [3H]U 69,593 binding, 
respectively. Triplicate determinations were made for each experiment. Reactions were terminated by 
filtration through Whatman GF/C filters presoaked with 0.3% polyethylenimine, which were washed three 
times with 5 mL of ice-cold buffer containing 50 mm Tris-HCl, pH 7.4. The radioactivity trapped was 
determined by liquid scintillation spectrometry. Data from at least three independent experiments were fitted 
by nonlinear regression analysis using GraphPad Prism. Ki values were calculated from IC50 values by the 
Cheng–Prusoff equation. IC50 values represent mean values from no fewer than four experiments. IC50 
values, relative potency estimates, and their associated standard errors were determined by fitting the data 
to the Hill equation by a computerized nonlinear least-squares method. 
 
6.5.2. Determination of inhibition of cyclic AMP accumulation: The agonist activity was determined by 
measuring the inhibition of forskolinstimulated cyclic AMP accumulation in whole HEK-293 cells stably 
expressing MOR. Cells were grown at 37°C and 5% CO2 in MEM, 2 mm l-glutamine, 1_ nonessential amino 
acids supplemented with 10% FBS. A 75 cm flask at 95–100% confluence was split into 24 wells and 
incubated overnight. When the confluence arrived at 85–95%, the medium was removed and the cells were 
washed three times with PBS; thereafter, cells were incubated in serumfree medium containing 0.5 mm 3-
isobutyl-1-methylxanthine (Sigma–Aldrich) and exposed for 15 min to 10 mm forskolin without and with each 
compound (0.01 nm–100 mm) at 37°C. Cells were then lysed in 0.1N HCl, scraped off and centrifuged (2000 
g, 5 min). 
Supernatants were assayed for cAMP concentration by using a Cyclic AMP EIA kit (Cayman Chemical 
Company, Ann Arbor, MI, USA) according to the manufacturer’s instructions. Each well was determined 
individually, the triplicates were averaged, and IC50 values were determined. In these experimental 
conditions, forskolin-stimulated cAMP production in control cells was 35-1 pmolmg-1 protein (n=4) and basal 
production of cAMP in untreated cells was 1.7-0.3 pmolmg-1 protein (n=4). Activity of DAMGO, EM1, and 
compounds 4, 14, and 15 has been expressed as percent inhibition of forskolin-induced cAMP production. 
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6.6. Conformational analysis 
ROESY intensities were classified as very strong, strong, medium, and weak, and were associated with 
distances of 2.2, 2.6, 3.0, and 4.2 Å, respectively. Geminal couplings and other obvious correlations were 
discarded. For the absence of Hα(i, i+1) ROESY crosspeaks, the w bonds were set at 1808 (force constant: 
16 kcalmol -1-2). Only ROESY-derived constraints were included in the restrained MD. The restrained MD 
simulations were conducted using the AMBER force field in a 30x30x30Å  box of standard TIP3P models of 
equilibrated water. All water molecules with atoms that come closer than 2.3 Å to a solute atom were 
eliminated. A 50 ps simulation at 1200 K was used for generating 50 random structures that were 
subsequently subjected to a 20 ps restrained MD with a 50% scaled force field at the same temperature, 
followed by 20 ps with full restraints (distance force constant of 7 kcalmol-1-2), after which the system was 
cooled in 5 ps to 50 K. Hydrogen bond interactions were not included, nor were torsion angle restraints. 
The resulting structures were minimized with 3000 cycles of the steepest descent and 3000 cycles of the 
conjugated gradient (convergence of 0.01 kcal-1mol-1). The backbones of the structures were clustered by 
the RMSD analysis module of HyperChem. Unrestrained MD simulation in explicit water was performed for 
10 ns at 298 K, at constant temperature and pressure (Berendsen scheme[43], bath relaxation constant of 
0.2). For 1–4 scale factors, van der Waals and electrostatic interactions are scaled in AMBER to half their 
nominal value. The integration time step was set to 0.1 fs. Box equilibration was set to 10 ps. 
 
6.6.1. Computational methods 
Molecular modeling studies and graphic manipulations were performed using the optimized Mac OSX 
versions of NAMD[44], Auto-Dock (ver. 4), MGL tools, and UCSF chimera software packages[45] on an Apple 
MacPro quad-Xeon workstation running Mac OSX Tiger (ver. 10.4.9). The analysis of the outputs from the 
docking runs as well as images were performed with PyMOL[46] and Accelrys DS Visualizer 
(http://www.accelrys.com) and rendered with POVRay[47]. The UCSF chimera was used to calculate the 
hydrogen bond distances measured between the hydrogen and its assumed binding partner. 
Preparation of the MOR-substrate systems: As the experimentally determined 3D structure of a MOR is not 
yet available, the MOR 3D model used in this study was that obtained in our previous work concerning 
comparative modeling. The MOR model was checked through MGL tools and the UCSF chimera to 
guarantee system conformity with the molecular modeling programs (in particular, the names of the side 
chains that must be congruent with the AMBER force field used). The amino acid chain of the MOR model 
was terminated with COO- and NH3+ groups in their zwitterionic forms, and the polar hydrogen atoms were 
added in their calculated positions. The protonation state was set to the normal ionization state at pH 7.0 for 
all the ionizable residues (in particular, Asp147, Asp216, Glu 229, and Glu 310) and His residues (His 223, His 297, 
and His 319), and both the topology and connectivity of the molecule had been created. Model building was 
followed by energy minimization up to an energy gradient lower than 10-4 kcalmol-1-1, choosing AMBER as 
the force field as implemented in the NAMD package. 
The ligands experimental conformation were used as starting structures and the first model building and 
geometry optimization of the studied compounds were accomplished with the Ghemical package,[48] 
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whereas the refinement was obtained using a systematic conformer search followed by geometry 
optimization of the lowest energy structure with MOPAC2009 (PM3 Method, RMS gradient 0.0100)[49].The 
atomic charges were assigned using the Gasteiger–Marsili formation, which uses the type of atomic charges 
used in calibrating the AutoDock empirical free energy function. 
 
6.6.2. Molecular docking: The docking of the cyclopeptides into the MOR model was performed with 
AutoDock. Default parameters (including a distance-dependent dielectric ’constant’) were used as described 
in the AutoDock manual, and both the receptor model and the ligands were prepared for docking by following 
the default protocols (except for those changes mentioned below). Auto-Dock uses an empirical scoring 
function that is able to approximate the binding free energies, because it includes a solvation free energy 
term. As a result of the absence of information on the binding region of compounds 11, 13, 14, and 15, the 
docking process was performed in two steps. The docking procedure was applied to the binding region of the 
protein target, represented by a box of 20x20x20 Å, centered on the best scored conformation obtained in 
our previous work (corresponding to x, y, and z values of -13.71, 9.56 and 0.47 Å, respectively), with a grid 
spacing of 0.300 Å. Movement of the ligands was limited to inside this search space during docking. Atomic 
solvation parameters were assigned to the protein, and the default parameters for the Lamarckian genetic 
algorithm were used as the search protocol, except for the maximum number of energy evaluations, which 
was changed to 10 million (the population size was raised to 500). For the GA algorithm, the default 
parameters were kept for mutation, crossover, and elitism. 
Ligand-induced fit phenomenon occurring at the ligand binding domain of the MOR was investigated by MD 
calculations. The ligand orientations resulting from the docking run were clustered into families, considering 
a RMSD clustering tolerance of 2.0 Å, and the lowest docking energy conformations were equilibrated for 4.0 
ns by MD, using the AMBER force field as implemented in the NAMD package. To study the induced fit 
phenomenon, the docked MOR–ligand complexes were prepared to use a smaller reacting subsystem 
consisting of the cyclopeptides and side chains of the amino acids within 10 _ from the ligands, whereas the 
rest of the protein was restrained by using the harmonic restraints feature of NAMD. The protocol for each 
instance involved an energy minimization of the initial structure (2000 steps), heating to 298 K (10 ps), 
equilibration at 298 K and 1 atm (50 ps), and the production run (to 5 ns). A round of optimization included 
100 steps of steepest descent and 400 steps of the conjugated gradient method. Both minimization and 
equilibration were conducted gradually by releasing initial harmonic constraints on the reacting subsystem 
(25 kcalmol-1). The schedules for removing the restraints involved decrements of 10 kcalmol-1 (5 kcalmol-1 in 
the end) every 500 steps or every 10 ps. The first 10 ps of equilibration were conducted at constant (E,V), 
after which the system was coupled to a (T,p) reservoir at a temperature of 298 K with a coupling time of 0.1 
ps, and the pressure was held at 1 bar, with a coupling time of 0.2 ps, using a Berendsen thermostat to 
maintain the constant temperature and pressure. Global rotations and translations were removed every 100 
steps, and the corresponding energy was accounted for by scaling the atomic velocities. The list of 
nonbonded atom pairs was updated at ten step intervals during MD, and every step during minimization. The 
time step used in the simulation was 1.0 fs and Particle-Mesh Ewald summation with a 10 Å short-range 
cutoff was used to treat long-range electrostatics. SHAKE[50] was used to constrain bond lengths between 
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heavy and hydrogen atoms. Hydrogen bonds and contacts were automatically identified using the ’contact’ 
module of CCP4[51] and the UCSF chimera, and the other interactions were identified visually. 
 
6.6.3. Hybrid QM/MM calculations: In the current study, we used the pseudo-bond ab initio QM/MM 
approach as implemented in Gaussian 03.[52] For the QM/MM calculations, the MOR–ligand system resulting 
from the docking study was first partitioned into a QM subsystem and an MM subsystem. The reaction 
system used a smaller QM subsystem consisting of the cyclopeptide and side chains of the amino acids 
within 3.5 Å, whereas the rest of the protein (the MM subsystem) was treated using the AMBER force field, 
together with a low memory convergence algorithm. The boundary problem between the QM and MM 
subsystems was treated using the pseudobond approach. With this MOR–substrate QM/MM system, an 
iterative optimization procedure was applied to the QM/MM system, using B3LYP/3-21G* QM/MM 
calculations, leading to an optimized structure for the reactants. The convergence criterion used was set to 
obtain an energy gradient of <10-4, using the twinrange cutoff method for nonbonded interactions, with a 
longrange cutoff of 14 Å and a short-range cutoff of 8 Å. 
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6.7. Supporting Information 
 
Table S1. Non-obvious ROESY cross-peaks observed for 11. 
Cross peak
 a
 Intensity
b 
Cross peak
 a
 Intensity
b
 
TrpNH-PheNH w TrpH4-TrpH s 
TrpNH-TrpH4 w PheArH-PheH2.9 vs 
TrpNH-TrpH2 m PheArH-PheH3.1 vs 
TrpNH-TrpH m PheArH-PheH s 
TrpNH-YAlaH vs TyrArH-TyrH vs 
TrpNH-TrpH2.9 m TyrArH-TyrH s 
TrpNH-TrpH3.0 m TrpH2-TrpH2.9 m 
TrpNH-YAlaMe m TrpH2-TrpH3.0 vs 
PheNH-PheArH m TrpH2-TrpH s 
PheNH-TrpH vs  TrpH-YAlaMe w 
PheNH-PheH m TrpH-TrpH2.9 m 
PheNH-PheH2.9 s TrpH-TrpH3.0 s 
PheNH-PheH3.1 w PheH-PheH2.9 s 
TrpH4-TrpH2.9 s PheH-PheH3.1 vs 
TrpH4-TrpH3.0 s TyrH-TyrH vs 
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak 
 
Table S2. Non-obvious ROESY cross-peaks observed for 13.  
Cross peak
 a
 Intensity
b
 Cross peak
 a
 Intensity
b
 
PheNH-PheH2.8 vs PheNH-PheH3.0 m 
PheNH-PheH m PheNH-TrpH vs 
PheNH-AlaNH s PheNH-PheArH s 
TyrNH-AlaMe vs TyrNH-TyrH s 
TyrNH-GlyNH s TyrNH-AlaH s 
TyrNH-AlaNH m TyrNH-TyrArH m 
TrpNH-TrpH3.0 w TrpNH-TrpH2.9 s 
TrpNH-GlyH m TrpNH-GlyH vs 
TrpNH-GlyNH m TrpNH-TrpH m 
TrpNH-TrpH4 w GlyNH-GlyH s 
GlyNH-TyrH s GlyNH-GlyH s 
AlaNH-AlaH s GlyNH-TyrH m 
AlaNH-PheH m AlaNH-AlaMe s 
AlaNH-PheH m AlaNH-PheH s 
AlaNH-TyrH w AlaNH-TrpH m 
TrpH4-Trp3.0 m TrpH4-Trp2.9 s 
PheArH-PheH s TrpH4-Trp s 
PheArH-PheH vs PheArH-PheH vs 
TrpH2-TrpH3.0 s TrpH2-TrpH2.9 s 
TyrArH-AlaMe m TrpH2-TrpH m 
TyrArH-TyrH vs TyrArH-TyrH s 
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PheH-PheH2.8 s PheH-PheH3.0 s 
TrpH-TrpH2.9 s PheH-TrpH3.0 m 
TyrH-TyrH m   
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak 
 
Table S3. Non-obvious ROESY cross-peaks observed for 14.  
Cross peak
 a
 Intensity
b
 Cross peak
 a
 Intensity
b
 
PheNH-TyrNH w TrpNH-TrpH2.6 m 
PheNH-YGlyNH w  TrpNH-TrpH2.8 m 
PheNH-TrpNH m  XGlyNH-PheH s  
PheNH-XGlyNH m  XGlyNH-XGlyH3.3 m 
PheNH-PheArH m  XGlyNH-XGlyH4.0 m 
PheNH-PheH m  TrpH4-TrpH w  
PheNH-TrpH vs  TrpH4-TrpH2.6 m 
PheNH-PheH m TrpH4-TrpH2.8 m 
TyrNH-YGlyNH m  PheArH-PheH m 
TyrNH-XGlyNH m  PheArH-PheH m  
TyrNH-TyrArH m TyrArH2,6-TyrH vs  
TyrNH-TyrH m  TyrArH2,6-TyrH2.6 s 
TyrNH-XGlyH4.2 s TyrArH2,6-TyrH2.8 s 
TyrNH-TyrH2.7 m TrpH2-TrpH s 
TyrNH-TyrH2.9 m TrpH2-TrpH2.6 m 
YGlyNH-TrpNH vs  TrpH2-TrpHb2.8 m 
YGlyNH-XGlyNH w  PheH-PheH s 
YGlyNH-TyrH vs  TrpH-TrpH2.6 m 
YGlyNH-YGlyH3.6 m TrpHa-TrpH2.8 m 
YGlyNH-YGlyH3.4 m TyrH-TyrH2.6 m 
TrpNH-XGlyNH m TyrH-TyrH2.8 m 
TrpNH-TrpH m   
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak 
 
Table S4. Non-obvious ROESY cross-peaks observed for 15.  
Cross peak
 a
 Intensity
b
 Cross peak
 a
 Intensity
b
 
PheNH-AspNH s AspNH-AspH m 
PheNH-PheArH w AspNH-PheH m 
PheNH-TrpH vs AspNH-PheH3.0 w 
PheNH-PheH m AspNH-PheH2.9 w 
PheNH-PheH3.0 w AspNH-AspH2.7 m 
PheNH-PheH2.9 s PheArH-PheH3.0 s 
TrpNH-TrpH2 w PheArH-PheH2.9 s 
TrpNH-TrpH m PheArH-PheH vs 
TrpNH--AlaH3.2 w TrpH2-TrpH m 
TrpNH-TrpH2.9 m TrpH2-PheH w 
TrpNH-TrpH2.8 s TrpH2-TrpH2.9 m 
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TrpNH--AlaH3.2 vs TrpH2-TrpH2.8 w 
-AlaNH--AlaH3.4 m TrpH-TrpH2.9 s 
-AlaNH--AlaH3.2 s TrpH-TrpH2.8 s 
-AlaNH-AspH2.7 vs PheH-PheH3.0 vs 
-AlaNH--AlaH2.4 m PheH-PheH2.9 s 
-AlaNH-AspH2.3 s AspH-AspH2.7 s 
-AlaNH--AlaH2.1 m AspH-AspH2.3 s 
TrpH4-TrpH m -AlaH3.4--AlaH2.4 m 
TrpH4-TrpH2.9 m -AlaH3.4--AlaH2.1 s 
TrpH4-TrpH2.8 s -AlaH3.2--AlaH2.4 s 
AspNH-TrpH w -AlaH3.2--AlaH2.1 m 
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak 
 
Figure S1. Top view of the MOR model, with the trans-membrane domains (ribbon) evidenced in different colors, numbered from I to VII, 
and the key-residues involved in the interaction with the ligands (stick). 
 
Table S5. Residue contents and position of the MOR structural elements.  
Domain Type Position Range Length Domain Type Position Range Length 
Loop  EL I 1 – 66 66 Loop EL III 212 – 236 25 
Transmembrane TMH I 67 – 96 30 Transmembrane TMH V 237 – 259 23 
Loop CL I 97 – 105 9 Loop CL III 260 – 282 23 
Transmembrane TMH II 106 – 123 18 Transmembrane TMH VI 283 – 305 23 
Loop EL II 124 – 145 22 Loop EL IV 306 – 313 8 
Transmembrane TMH III 146 – 165 20 Transmembrane TMH VII 314 – 330 17 
Loop CL II 166 – 195 30 Loop CL IV 331 – 400 70 
Transmembrane TMH IV 196 – 211 16     
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Figure S2. Stereoview of the in-solution structure 11a. 
 
Figure S3. Stereoview of the in-solution structure 11b. 
 
Figure S4. Stereoview of the in-solution structure 13c. 
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Figure S5. Stereoview of the in-solution structure 13d. 
 
Figure S6. Stereoview of the in-solution structure 14a. 
 
Figure S7. Stereoview of the in-solution structure 14b. 
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Figure S8. Stereoview of the in-solution structure 15. 
 
Figure S9. Rear view of the two top ranking docking orientations of 14 orientation 1 (a) and 2 (b) and the MOR binding site. The protein 
residues are represented in wireframe and sticks for the key-residues, with the C-atoms colored in blue for the residues in the first 
interaction shell, <3.5Å from the ligand, green for those at a distance <5Å; the ligand is depicted by balls and cylinders (CPK). The figure 
highlights essential H-bond interactions (green dotted lines). 
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Figure S10. Rear view of the top-ranked docking pose of 15 (a) and the MOR binding site. Only selected MOR residues involved in the 
interactions are shown. The protein is represented in wireframe and sticks (for the key-residues), with the C-atoms colored in blue for 
the residues in the first interaction shell, <3.5Å from the ligand, green for those at a distance <5Å; the ligand is depicted by balls and 
cylinders (CPK). The figure highlights the essential interactions between the MOR and the CONH2 (upper part) and indole (lower part) 
fragments of 15. Rear view of the in-solution conformation of 15 (b) in balls and cylinders. 
 
 
Table S6. List of MOR residues involved in the interaction with compound 14 orientation (or) 1 & 2 and 15, classified according to their 
structural elements. In the table, the Xs represents the contacts in the ligand-MOR complex at a distance <5Å. 
region residue 15 14-or 1 14-or 2 region residue 15 14-or 1 14-or 2 
TMH III Asp147 x x x TMH V Phe237 x x x 
 Tyr148 x x x TMH VI Trp293 x x x 
 Met151 x x x  Pro295   x 
 Phe152 x x x  Ile296 x x x 
 Ile155   x  His297 x x  
TMH IV Ile198   x  Tyr299 x x x 
 Val202   x  Val300 x x x 
EL III Gln212 x    Ile301  x  
 Gly213 x    Lys303 x x x 
 Ser214 x    Ala304 x x x 
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 Ash216 x x  EL IV Ile306  x  
 Cys217 x    Thr307 x x x 
 Thr218 x x x  Glu310 x x x 
 Leu219 x x x  Thr311  x  
 Thr220 x x x  Phe313  x  
 Phe221 x x x TMH VII Thr315 x   
 His223 x x x  Trp318 x x x 
 Glu229 x x x  His319 x x  
 Asn230   x  Cys321   x 
 Leu232   x  Ile322 x x x 
 Lys233 x x x  Tyr326   x 
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Chapter 7 
A Simple Route Towards Peptide Analogues Containing Substituted 
(S)- or (R)-Tryptophans 
 
7. Introductyion 
Peptides based on natural amino acids are widely used as therapeutic agents[1]. However, their efficacy is 
hampered by several problems, in particular high conformational flexibility, low in vivo stability against 
proteolysis and scarce ability to cross biological barriers, resulting in poor receptor selectivity, short duration 
of action and poor bioavailability. The preparation of unusual amino acids and their introduction in peptide 
sequences have attracted considerable interest to overcome the pharmacological limitations of bioactive 
peptides[1,2]. Modification of individual amino acids has been shown to be responsible for changes in peptide 
conformation and for increased enzymatic stability[3]. Besides, the introduction of modified amino acids has 
been utilized for the elucidation of an individual residue’s biological function[3,4]. In connection with on going 
projects[5] on the synthesis, conformational analysis and pharmacological behaviour of endomorphin-1[6] (H 
Tyr-Pro-Trp-Phe-NH2) analogues as potential drugs for pain management[7], we have been interested in the 
preparation of new peptide derivatives containing modified tryptophans. Several examples of tryptophans 
bearing substituent on the indole ring can be found in complex structures. For instance, halotryptophans are 
present in peptides of microbial[8] or marine origins[9]. A few preparations of (S)- or (R)-Trp analogues have 
been reported in the literature[10]. Halotryptophans can be obtained by palladium- mediated heteroannulation 
of a chiral auxiliary[11]; by electrochemical oxidation of proline followed by Fischer indole synthesis[12]; from 
serine, by means of the lysate of a commercially available microorganism containing tryptophan synthase[13]. 
(S)- and (R)-Br-tryptophans have been obtained with L-aminoacylase or D-aminoacylase[14]. More often, 
reactions lead to the preparation of racemates. Very recently, the regioselective electrophilic substitution of 
indoles with N-acetyl dehydroalanine (Dha), promoted by different transition metal salts, provided an efficient 
protocol towards racemic-functionalized tryptophans[15]. In this context, we envisaged the opportunity to 
develop a simple procedure to synthesize modified (S)- or (R)-tryptophans within a peptide sequence. Herein, 
we report our results on the Friedel–Crafts alkylation of indoles[15,16] with dipeptides containing 
dehydroalanine (Xaa-Dha) in the presence of different Lewis acids. Further, to endorse the methodology, we 
describe the preliminary synthesis in a few steps of two novel endomorphin-1[6] analogues, [(S)-2-MeTrp]-
endomorphin-1 and [(R)-2-MeTrp]-endomorphin-1. Among the different endogenous opioid peptides[1], 
endomophin-1 is unique for high receptor affinity and selectivity, being considered the endogenous agonist 
of the -opioid receptor (MOR). Since none of the other naturally occurring opioid peptides contain a Trp in 
the sequence, the preparation and pharmacological assay of endomorphin- 1 analogues containing modified 
Trp in position 3 could be of help to investigate the role of this pharmacophore in ligand-receptor 
recognition[17]. Besides, the presence of substituted Trp can also enhance lipophilicity and blood–brain 
barrier (BBB) permeability of peptide active towards the CNS[18].  
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7.1. Results and discussion 
As anticipated in the introduction, indoles undergo Friedel- Crafts (F-C) alkylation with N-Ac-Dha methyl 
ester in the presence of Lewis acids, giving racemic 3-indolyl-a-amino acids[15]. Since we were interested in 
optically pure amino acids, we thought to carry out a diastereoselective version of this reaction with 
dipeptides of type Xaa-Dha, taking advantage of the asymmetric induction exerted by Xaa. The protected 
dipeptides Xaa-Dha 2 were easily obtained from dipeptides Xaa-serine 1, prepared in turn by standard in-
solution peptide synthesis, using 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC-HCl) 
and 1-hydroxybenzotriazole hydrate (HOBt) as activating agents (Supplementary data). The dehydration of 1 
with N,N-disuccinimidyl carbonate (DSC) and N,N-diisopropylethylamine (DIPEA) gave 2 in very good 
yield[19], isolated by flash chromatography over silica gel (Scheme 1). Initially, the reaction was tested with 
indole. The treatment of Pro-Dha 2a with a Lewis acid and indole, in the presence of 3 Å molecular sieves, 
afforded the protected dipeptide Pro-Trp 3a as a mixture of diastereoisomers (Scheme 1). Yields and 
diastereomeric ratios strongly varied depending on the Lewis acid selected (Table 1). In the absence of 
molecular sieves, the reaction gave variable quantities of by-products arising from peptide bond and/or ester 
hydrolysis, as revealed by reversed phase (RP)-HPLC and electron- spray (ES)-MS analyses. On the other 
hand, molecular sieves lead to better yields, while the unreacted starting material was recovered unaltered. 
The diastereomeric ratios of the reaction mixtures (Table 1) were measured by normal phase-HPLC, with an 
analytical Kromasil Diol column. The separation of the diastereoisomers by analytical RP-HPLC under 
different conditions was unfeasible. Racemization was excluded on the basis of chiral HPLC by using a 
CHIRALPAK IC column. The configuration of the newly created stereocentre on Trp was determined by 
comparison with that of the authentic samples of (S,S)-3a and (S,R)-3a, prepared by standard peptide 
synthesis in solution from the commercially available amino acids. Yields (Table 1) were determined after 
isolation by flash chromatography over silica gel. The use of 1 equiv of ZnOTf2, FeCl3, InF3, CeCl3, RuCl3 and 
Yb(OTf)3 gave no reaction or traces of the dipeptide 3a. Other Lewis acids, MgBr2, BBu2OTf, TiCl4, Cu(OTf)2, 
Sc(OTf)3, ZrCl4, AlEtCl2 and AlEt2Cl (1 equiv), gave the product 3a in low yields (<5%, data not shown). All 
reactions were carried out at 0°C for 24 h in dichloromethane (DCM). Increasing time and temperature gave 
negligible improvements. The only exception was Yb(OTf)3; indeed, performing the reaction with 1 equiv of 
Yb(OTf)3 at 80 °C in dichloroethane (DCE) for 24 h, 3a was obtained in 20% yield (entry 1) and when the 
reaction was conducted under microwave (MW) irradiation (400 W) for 3.5 h, yield increased up to 55%, with 
a satisfactory 22/78 diastereomeric ratio in favour of (S,R)-3a (entry 2). 
 
183 
 
 
 
Scheme 1. Synthesis of the protected dipeptides Xaa-Dha 2a-d and Lewis acid-induced F.-C. alkylation of indole. 
 
Making use of a catalitic amount of Yb(OTf3) led to a drop of the yield, while the use of a excess seemed 
inexpedient, for the high molecular weight of such Lewis acid. Reactions with MgBr2, BBu2OTf, TiCl4, 
Cu(OTf)2, Sc(OTf)3 and ZrCl4 were slightly improved by increasing the amount of Lewis acid (yields 5–25%, 
Table 1, entries 3–8).  
 
Table 1. Synthesis of dipeptides Xaa-Trp 3a-d by F.-C. reaction of indole with dipeptides Xaa-Dha 2a-d promoted by different Lewis 
acids, at 0°C for 24h in DCM (with the exception of Entries 1, 2). 
 
Entry Lewis acid Equiv. 3 Yield (%)[c] S,S/S,R 
1 Yb(OTf)3[a] 1 a 20 - 
2 Yb(OTf)3[b] 1 a 55 22/78 
3 MgBr2 4 a 5 -  
4 BBu2OTf 2 a 5 - 
5 TiCl4 4 a 15 - 
6 CuOTf2 2 a 10 - 
7 ScOTf3 2 a 10 - 
8 ZrCl4 2 a 25 - 
9 AlEtCl2 3.5 a 70 50/50 
10 AlEt2Cl 3.5 a 60 24/76 
11 AlEtCl2 3.5 b 65 45/55 
12 AlEt2Cl 3.5 b 55 35/65 
13 AlEtCl2 3.5 c 65 55/45 
14 AlEt2Cl 3.5 c 55 62/38 
15 AlEtCl2 3.5 d 55 50/50 
16 AlEt2Cl 3.5 d 35 30/70 
[a] DCE, reflux. [b] DCE, MW, 400 W. [c] After isolation by flash chromatography over silica-gel. 
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Finally, in the presence of an excess of AlEtCl2 (3.5 equiv)15 the reaction gave the desired dipeptide 3a in 
reasonable yield, after isolation by flash chromatography over silica gel, albeit with a disappointing 50/50 
diastereomeric ratio (entry 9). On the other hand, in the presence of AlEt2Cl (3.5 equiv) the reaction gave 
lesser amount of 3a, but with a reasonable 24/76 diastereomeric ratio, in favour of the (S,R)-3a stereoisomer 
(entry 10). The eventual effect of the residue Xaa preceding Dha and the protecting groups R, R1 on yield 
and stereoselectivity was examined. The reaction of indole with the dipeptide Phe-Dha 2b occurred with 
comparable yield, but with lower stereoselectivity (entries 11 and 12). Changing the methyl ester with a 
benzyl ester (2c) lead to a moderate stereoselectivity, in favour of the isomer (S,S)-3c (entries 13 and 14). 
The presence of a Boc-protecting group (2d) instead of Fmoc gave lower yield and selectivity (entries 15 and 
16). The configuration of Trp in the dipeptides 3b–d was determined by comparison with authentic samples, 
prepared by standard peptide synthesis in solution. Interestingly, apart from the slightly different yields, 
changing the ester allowed preparing preferentially the dipeptides containing either (S)-Trp or (R)-Trp. 
Besides, the analysis of the crude reaction mixtures revealed no trace of concurrent a-amidoalkylation 
reaction[15,20]. The reaction of 2a with substituted indoles in the presence of 3.5 equiv of AlEt2Cl or AlEtCl2 
(Scheme 2) was performed at 0°C for 24 h in DCM and in the presence of 3 Å molecular sieves 
(Supplementary data). The reaction afforded the dipeptides 3e–o (Table 2). For the moment, we were mainly 
interested in verifying the applicability of the procedure to diverse kinds of indoles, therefore the 
diastereoselectivity issue was not faced in detail. The absolute configurations of the diastereoisomers were 
determined by comparison of the chiral-HPLC analyses with that of 3a. 
 
 
 
Scheme 2. Synthesis of the dipeptides 3e-o by Lewis acid-induced F.-C. alkylation of substituted indoles. 
 
The reaction of 2a with 50-fluoroindole promoted by AlEtCl2 (entry 1) or AlEt2Cl (entry 2) gave 3e in sufficient 
yield, albeit only AlEt2Cl ensured acceptable stereoselectivity. The reaction of 2a and 5'-chloro indole or 5'-
bromoindole with AlEtCl2 proceeded in lower yields of 3f and 3g, respectively (entries 3 and 4), while AlEt2Cl 
was almost ineffective. In a similar way, 2a reacted with 1-methylindole in the presence of AlEtCl2 affording 
3h (entry 5) with scarce selectivity. The reaction with 2-methylindole in the presence of AlEtCl2 (entry 6) or 
AlEt2Cl (entry 7) gave 3i in excellent yields. 7-Methylindole, 2'-methyl-7'-bromoindole, 2'-methyl-5'-
bromoindole and 2-aminophenylindole gave 3l, 3m, 3n and 3o, respectively (entries 8–11), in sufficient to 
good yields. Finally, 5-nitroindole scarcely reacted with 2a giving 3p (entry 12), while 2-benzylsulfonylindole 
gave only traces of the corresponding product (not shown). In addition, we confirmed that changing the 
methyl ester with a benzyl ester gave a moderate switch of stereoselectivity, from (S,R) to (S,S), also with 
some substituted indoles. Indeed, the reaction of 5'F-indole with 2c in the presence of AlEt2Cl, under the 
185 
 
same conditions reported for 2a, gave the 5'F-Trp containing dipeptide in 55% yield and 65/35 d.r., while 
2'Me-indole gave the corresponding product in 70% yield with the same d.r. In order to validate the 
procedure as a facile access to analogues containing modified Trp in either (S) or (R) configuration, we 
synthesized in a few steps the unprecedented analogues of endomorphin-1 6 and 7, containing (S)-2'-MeTrp 
and (R)-2'-MeTrp, respectively (Scheme 3). The endomorphin analogues 6 and 7 were obtained from the 
dipeptides (S,S)-3i and (S,R)-3i, obtained in turn by alkylation of 2-methylindole with 2a (Table 2, entry 6). 
The identities of all the intermediates were confirmed by ES-MS analyses. Purities were determined by RP-
HPLC and by normal phase HPLC. After separation by flash chromatography over silica gel, (S,S)-3i (41%) 
and (S,R)-3i (49%) were quantitatively deprotected by treatment with 2 M DMA in THF and reacted without 
prior purification with Boc-Tyr-OH in the presence of HOBt/EDC. The tripeptides Boc-Tyr- Pro-[(S)-2-MeTrp]-
OMe, or Boc-Tyr-Pro-[(R)-2-MeTrp]-OMe, were isolated in high yield by flash chromatography over silica gel. 
The tripeptides were treated with LiOH in H2O/THF and the resulting tripeptide acids were utilized without 
further purification. 
 
Table 2. Synthesis of dipeptides 3e-p by F.C. reaction of substituted indoles with 2a, promoted by 3.5 equiv. of Lewis acids, at 0°C for 
24h in DCM. 
 
Entry R2 Lewis acid 3 Yield (%)[a] S,S/S,R 
1 5’-F AlEtCl2 e 65 45/55 
2 5’-F  AlEt2Cl e 55 25/75 
3 5’-Cl AlEtCl2 f 30 45/55 
4 5’-Br AlEtCl2 g 20 - 
5 1’-Me  AlEtCl2 h 45 45/55 
6 2’-Me AlEtCl2 i 90 45/55 
7 2’-Me AlEt2Cl i 75 28/72 
8 7’-Me AlEtCl2 l 60 40/60 
9 2’-Me-7’-Br AlEtCl2 m 50 40/60 
10 2’-Me-5’-Br AlEtCl2 n 40 40/60 
11 2-amino Ph AlEtCl2 o 50 - 
12 5’-NO2 AlEtCl2 p 15 - 
                 [a] After isolation by flash chromatography over silica-gel. 
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Scheme 3. Synthesis of the endomorphin-1 analogues 6 and 7 starting from the dipeptides (S,S)-3i and (S,R)-3i. 
 
Activation of the tripeptide acids with HOBt/EDC and coupling with H-Phe-NH2 gave Boc-6 and Boc-7, 
isolated by flash chromatography. Final deprotection with TFA gave the endomorphin-1 analogues 6 and 7 in 
good yields, 95% pure after semi-preparative RP-HPLC. 
 
7.2. Conclusions 
In summary, we have proposed a practical route for the preparation of protected dipeptides containing 
substituted tryptophans in either (S) or (R) configuration. The F-C alkylation of dipeptides containing Dha 
allowed the direct asymmetric synthesis of the tryptophanes within the peptidic structure. The reaction gave 
(S,S)- or (S,R)-dipeptides, albeit with moderate stereoselectivity. After isolation by normal-phase 
chromatography, the diastereomeric dipeptides can be readily utilized for preparing peptides of 
pharmacological interest. As a preliminary demonstration, we synthesized analogues of endomorphin-1 with 
a 2-methyltryptophan in position 3. Work is in progress to expand the scope of the reaction, in particular to 
improve the stereoselectivity. Further, the procedure will be utilized to synthesize a mini-library of 
endomorphin analogues, aiming to obtain new opioid peptides with improved performances as in vivo 
analgesic[21], as well as new clues about the role of Trp in receptor recognition and activation. 
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7.3. Supporting Information 
Experimental Section 
General methods. Standard chemicals were obtained from commercial sources and used without further 
purification. Analytical RP-HPLC was performed with an ODS column (4.6 mm particle size, 100 Å pore 
diameter, 250 mm, DAD 210 nm) using a linear gradient of H2O/CH3CN, 9:1 to 2:8 over 20 min at a flow rate 
of 1.0 mL min-1, followed by 10 min isocratic H2O/CH3CN 2:8. Chiral HPLC analysis was performed on a 
CHIRALPAK IC column (0.46 cm x 25 cm), n-hexane/2-propanol 1:1, at 0.8 mL min-1. Semipreparative RP-
HPLC was performed on a C18 column (7 mm particle size, 21.2 x 150 mm) with H2O:CH3CN 7:3, at a flow 
rate of 10 mL min-1. 1H NMR spectra were recorded at 400 MHz at r.t. with 5 mm tubes, using 0.05 M 
compound. Chemical shifts (δ) are reported relative to the solvent peak. 
 
Fmoc-Pro-Dha-OMe (2a). DSC (0.39 g, 1.51 mmol) was added to a stirred solution di 1 (0.44 g, 1.0 mmol) in 
acetonitrile (10 mL) followed by a 5% solution of  DIEA (1.5 mmol) in anhydrous DCM solution (5.22 mL) at 
r.t., under inert atmosphere. After 4 h, the solvent was removed at reduced pressure, the residue is diluted 
with 1M HCl (5 mL), and the mixture was extracted three times with EtOAc (3 x 10 mL). The combined 
organic layers were dried over sodium sulfate, filtered, and concentrated at reduced pressure. The residue 
was purified by flash chromatography over silica-gel (9:l hexane:EtOAc, column size: 15×1.5 cm2) to give the 
product 2a as waxy solid (0.38 g, 90%). 1H-NMR (CDCl3) δ: 1.95-2.20 (m, 4H, ProHɣ+ ProHβ), 3.30-3.50 (m, 
2H, ProHδ), 3.80 (s, 3H, OMe), 4.30 (m, 1H, ProHα), 4.48 (m, 3H, Fmoc), 5.93 (s, 1H, =CH), 6.62 (s, 1H, 
=CH), 7.25-7.45 (m, 5H, ArH + NH), 7.50-7.70 (m, 2H, ArH), 7.70-7.82 (m, 2H, ArH). 13C-NMR (CDCl3) δ: 
27.1, 47.4, 53.1, 61.6, 68.1, 109.6, 120.2, 125.3, 125.5, 127.3, 127.9, 129.2, 141.5, 144.0. ES-MS m/z: 421.2 
[M+1]; calcd: 421.2. 
 
Fmoc-Pro-(S/R)-Trp-OMe (3a). A 1 M solution of AlEt2Cl in hexane (0.7 mmol, 0.7 mL) was added dropwise 
to a stirred mixture of 2a (0.084 g, 0.2 mmol), indole (0.094 g, 0.8 mmol), and molecular sieves (3Å, 0.2 g) in 
dry CH2Cl2 (4 mL) at 0°C, under a nitrogen atmosphere. The mixture was stirred for 24 h, then it was poured 
into saturated aqueous sodium hydrogen carbonate (5 mL). The resulting suspension of was filtered through 
Celite and the aqueous layer was extracted with dichloromethane (3 x 15 mL). The combined organic layers 
were dried over sodium sulphate, filtered, and concentrated at reduced pressure. The crude residue was 
purified by flash chromatography over silica-gel (DCM:EtOAC 85:15, column size: 15 × 1.5 cm2) to give 
(S,S)-3a (0.015 g, 14%) and (S,R)-3a (0.049 g,  46%). 
(S,S)-3a. 1H-NMR (CDCl3) δ: 1.78-1.95 (m, 2H, ProHɣ), 2.00-2.20 (m, 2H, ProHβ), 3.30 (d, J = 14.0 Hz, 2H, 
TrpHβ), 3.38-3.48 (m, 2H, ProHδ), 3.55 (minor conformer) + 3.65 (major conformer) (s, 3H, OMe), 4.20-4.35 
(m, 3H, Fmoc), 4.30-4.40 (m, 1H, ProHα), 4.87-5.00 (m, 1H, TrpHα), 6.50 (br.d, 1H, TrpNH minor conformer), 
6.87-7.70 (m, 12H, ArH + TrpNH major conformer), 7.75-7.85 (m, 2H, ArH), 8.30 (major conformer) + 8.40 
(minor conformer ) (s, 1H, TrpH1). 13C-NMR (CDCl3) major conformer  δ: 4.7, 27.8, 28.6, 47.2, 47.3, 52.6, 
52.9, 53.2, 60.6, 67.9, 77.5, 109.9, 111.4, 118.6, 119.6, 120.2, 122.2, 123.4, 125.4, 125.5, 127.4, 128.1, 
136.3, 141.5, 144.3, 156.0, 171.5, 172.5. [α]D = +26.0 (c 1, CHCl3). ES-MS m/z: 537.1 [M+1]; calcd: 537.2. 
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(S,R)-3a. 1H-NMR (CDCl3) δ: 1.60-2.00 (m, 4H, ProHɣ + Pro Hβ), 3.15-3.35 (m, 2H, TrpHβ), 3.35-3.58 (m, 
2H, ProHδ), 3.68 (s, 3H, OMe), 3.88-4.08 (m, 1H, ProHα), 4.20-4.55 (m, 3H, Fmoc), 4.80-4.95 (m, 1H, TrpH
α), 6.45 (br.d, 1H, TrpNH minor conformer), 6.80-7.70 (m, 13H, ArH + TrpNH major conformer + TrpH1 major 
conformer), 7.81 (d, J = 14.0 Hz, 2H, ArH), 7.95 (s, 1H, TrpH1 minor conformer). 13C-NMR (CDCl3) major 
conformer  δ: 23.6, 24.6, 27.6, 29.3, 31.4, 47.3, 47.6, 52.5, 52.8, 61.1, 67.9, 77.5, 111.5, 118.3, 118.6, 119.7, 
120.3, 122.3, 122.9, 123.3, 125.3, 127.3, 128.1, 136.3, 141.5, 144.6, 156.1, 172.2, 172.3. [α]D = -61.2. (c 1, 
CHCl3). ES-MS m/z: 537.2 [M+1]; calcd: 537.2. 
 
Fmoc-Pro-[(S/R)-2-MeTrp]-OMe (3i). 1 M AlEtCl2 in hexane (0.7 mmol, 0.7 mL) was added to a mixture of 2a 
(0.084 g, 0.2 mmol), 2-methylindole (0.105 g, 0.8 mmol), and molecular sieves (3Å, 0.2 g) in dry CH2Cl2 (4 
mL) at 0 °C, under a nitrogen atmosphere. The same work-up and isolation procedures reported for 3a 
afforded (S,S)-3i (0.045 g, 41%) and (S,R)-3i (0.054 g, 49%). 
(S,S)-3i. 1H-NMR (CDCl3) δ: 1.60-2.00 (m, 4H, ProHβ + ProHɣ), 2.32 (s, 3H, Me), 3.10-3.27 (m, 2H, TrpHβ), 
3.30-3.52 (m, 2H, ProHδ), 3.62 (s, 3H, OMe), 3.88-4.08 (m, 1H, ProHα), 4.20-4.37 (m, 3H, Fmoc), 4.65-4.90 
(m, 1H, TrpHα), 6.40 (br.d, 1H, TrpNH minor conformer), 6.80-7.70 (m, 13H, ArH + TrpNH major conformer + 
TrpH1), 7.80 (d, J = 14.5 Hz, 2H, ArH). ES-MS m/z: 551.2 [M+1]; calcd: 551.2. 
(S,R)-3i. 1H-NMR (CDCl3) δ: 1.60-1.90 (m, 4H, ProHβ + ProHɣ), 2.32 (s, 3H, Me), 3.18-3.28 (m, 2H, TrpHβ), 
3.30-3.52 (m, 2H, ProHδ), 3.65 (s, 3H, OMe), ), 3.90-4.09 (m, 1H, ProHα), 4.20-4.55 (m, 3H, Fmoc), 4.65-
4.85 (m, 1H, TrpHα), 6.45 (br.d, 1H, TrpNH minor conformer), 6.90-7.60 (m, 13H, ArH + TrpNH major 
conformer + TrpH1), 7.82 (d, J = 14.5 Hz, 2H, ArH). ES-MS m/z: 551.1 [M+1]; calcd: 551.2. 
 
Boc-Tyr-Pro-[(S)-2-MeTrp]-OMe (4). The dipeptide (S,S)-3i (0.045 g, 0.082 mmol) was dissolved in 2M DMA 
in THF (3 mL) at r.t. The mixture was stirred for 20 min, then the solution was concentrated at reduced 
pressure. The procedure was repeated, affording H-Pro-[(S)-2-MeTrp]-OMe, used for the next step without 
further purification. ES-MS m/z: 329.1 [M+1]; calcd: 329.2. The crude H-Pro-[(S)-2-MeTrp]-OMe was 
dissolved in DCM (3 mL), and the solution was added at r.t. to a stirred mixture of HOBt (0.014 mg, 0.10 
mmol), Boc-Tyr-OH (0.027 g, 0.10 mmol), in DCM (2 mL) and DMF (1 mL). After 10 min, EDCI-HCl (0.018 
mg, 1.0 mmol), and TEA (0.028 mL, 0.20 mmol), were added to the mixture at r.t. After 3 h the reaction 
mixture was diluted with AcOEt (20 mL), and the suspension was washed with HCl 1M (4 mL) and with 
saturated aqueous sodium carbonate (4 mL). The organic layers were dried over sodium sulfate, and solvent 
was removed at reduced pressure. The crude product was purified by flash chromatography over silica gel 
(cyclohexane:EtOAc 1:1, column size: 10 × 1.0 cm2) to give the product 4 (0.042 g, 88%) as a waxy solid. 
ES-MS m/z: 592.3 [M+1]; calcd: 592.3. 
 
Boc-Tyr-Pro-[(R)-2-MeTrp]-OMe (5). The dipeptide (S,R)-3i (0.054 g, 0.098 mmol) was dissolved with 2M 
DMA in THF (4 mL) as reported for (S,S)-3i, giving H-Pro-[(R)-2-MeTrp]-OMe. ES-MS m/z: 329.1 [M+1]; 
calcd: 329.2. Treatment of H-Pro-[(R)-2-MeTrp]-OMe with HOBt (0.016 mg, 0.12 mmol), Boc-Tyr-OH (0.034 
g, 0.12 mmol), EDCI-HCl (0.023 mg, 0.12 mmol), and TEA (0.033 mL, 0.24 mmol), in DCM (5 mL) and DMF 
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(1 mL), under the same conditions and work-up procedures reported for 4, gave 5 (0.050 g, 86%). ES-MS 
m/z: 592.2 [M+1]; calcd: 592.3. 
 
TFA.[(S)-2-Me-Trp]-endomorphin-1 (6). To a stirred solution of the protected tripeptide 4 (0.042 g, 0.071 
mmol) in THF (2 mL), 0.6N LiOH in H2O (1 mL) was added at r.t. After 36 h the reaction was concentrated at 
reduced pressure to give Boc-Tyr-Pro-[(S)-2-MeTrp]-OH, which was used without further purification. ES-MS 
m/z: 578.2 [M+1]; calcd: 578.3. The crude Boc-Tyr-Pro-[(S)-2-MeTrp]-OH was dissolved in DCM (4 mL) and 
DMF (1 mL), and treated while stirring with HOBt (0.012 g, 0.085 mmol) at r.t. After 10 min the mixture was 
treated at r.t. with EDC-HCl (0.016 g, 0.085 mmol), TEA (0.024 mL, 0.17 mmol), and H-Phe-NH2-HCl (0.017 
mg, 0.085 mmol). After 3 h, the reaction was quenched as reported for the synthesis of 4. Purification by 
flash chromatography over silica-gel (AcOEt, column size: 10 × 1.0 cm2) gave Boc-Tyr-Pro-[(S)-2-MeTrp]-
PheNH2 (0.039 g, 76%). ES-MS m/z: 725.4 [M+1]; calcd: 725.4. Boc-Tyr-Pro-[(S)-2-MeTrp]-PheNH2 (0.039 g, 
0.054 mmol) was dissolved in DCM (3 mL) and TFA (1 mL) at r.t. After 1h, the solvent was removed at 
reduce pressure, and the crude peptide was precipitated with cold ether (30 mL). The solid was colleted by 
centrifugation, and purified by semi-preparative RP-HPLC on a C18 column, as reported in General Methods, 
affording 6 as TFA salt (0.038 g, 96%, 95% pure by analytical RP-HPLC). 1H-NMR (8:2 DMSO-d6:H2O) 
major conformer δ: 1.49 (m, 1H), 1.72-1.84 (m, 2H), 1.95 (m, 1H), 2.10 (s, 3H), 2.62 (dd, J = 6.5, 14.5 Hz, 
1H), 2.78 (dd, J = 7.5, 15.0 Hz, 1H), 2.82 (dd, J = 8.0, 14.0 Hz, 1H), 2.90 (m, 1H), 2.95-3.10 (m, 2H), 3.08 
(dd, J = 7.0, 15.5 Hz, 1H), 3.55 (m, 1H), 4.35-4.47 (m, 3H), 4.55 (m, 1H), 6.68 (d, J = 7.8 Hz, 2H), 6.90 (dd, 
J= 4.8, 7.2 Hz, 1H), 6.98-7.05 (m, 2H), 7.10 (d, J = 7.8 Hz, 2H), 7.10-7.25 (m, 7 H), 7.50 (d, J = 7.2 Hz, 1H), 
7.81 (d, J = 7.8 Hz, 1H), 7.87 (br.s, 2H), 8.21 (d, J = 9.0 Hz, 1H), 9.33 (s, 1H ), 10.66 (s, 1H). ES-MS m/z: 
625.3 [M+1]; calcd: 625.3.  
 
TFA.[(R)-2-MeTrp]-endomorphin-1 (7). The protected tripeptide 5 (0.050 g, 0.085 mmol) dissolved in THF (2 
mL) was treated with 0.6N LiOH in H2O (1 mL), under the same conditions and work-up procedures 
described for 4, giving Boc-Tyr-Pro-[(R)-2-MeTrp]-OH. ES-MS m/z: 578.3 [M+1]; calcd: 578.3. The crude 
Boc-Tyr-Pro-[(R)-2-MeTrp]-OH was reacted with HOBt (0.014 g, 0.10 mmol), EDC-HCl (0.019 g, 0.10 mmol), 
TEA (0.028 mL, 0.2 mmol), and H-Phe-NH2-HCl (0.020 mg, 0.10 mmol), in DCM (5 mL) and DMF (1 mL), as 
above reported for the synthesis of 6. Purification by flash chromatography over silica-gel (AcOEt, column 
size: 12 × 1.0 cm2) gave Boc-Tyr-Pro-[(R)-2-MeTrp]-PheNH2 (0.049 g, 79%). ES-MS m/z: 725.4 [M+1]; calcd: 
725.4. Boc-Tyr-Pro-[(S)-2-MeTrp]-PheNH2 (0.049 g, 0.068 mmol) in DCM (2 mL) was reacted with TFA (1 
mL) as described for the synthesis of 6, giving TFA.7 (0.045 g, 90%, 94% pure by analytical RP-HPLC). 1H-
NMR (8:2 DMSO-d6:H2O) major conformer δ: 1.42-1.52 (m, 2H), 1.63 (m, 1H), 1.75 (m, 1H), 2.25 (s, 3H), 
2.55 (m, 1H), 2.70-2.80 (m, 2H), 2.88 (m, 1H), 2.97-3.05 (m, 2H), 3.07 (m, 1H), 3.60 (m, 1H), 4.32 (m, 1H), 
4.39 (m, 1H), 4.45 (m, 1H), 4.56 (m, 1H), 6.67 (d, J = 7.8 Hz, 2H), 6.85 (m, 1H), 6.90-7.00 (m, 2H), 7.10 (d, J 
= 13.8 Hz, 2H), 7.10-7.25 (m, 7 H), 7.51 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 8.06 (br.s, 2H), 8.09 (d, 
J = 9.0 Hz, 1H), 9.28 (s, 1H ), 10.63 (s, 1H). ES-MS m/z: 625.4 [M+1]; calcd: 625.3. 
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Chapter 8 
Synthesis of Constrained Peptidomimetics Containing 2-Oxo-1,3-oxazolidine-
4-carboxylic Acids 
 
8. Introduction 
 In principle, many naturally occurring, biologically active peptides can be regarded as potential 
pharmaceutical agents. However, there are intrinsic weaknesses that hinder their clinical use, in particular, 
their rapid metabolism in vivo, which can lead to short half-life stability, and their poor permeation across 
membrane barriers. These inherent limitations can be bypassed by adopting the peptidomimetic strategy, 
which involves altering the structure of a peptide. Peptidomimetics very often contain non-amino acidic 
elements, but still bear identifiable similarity to the parent peptides, and either imitate or inhibit their 
biochemical effects [1]. During the course of our studies on biologically active mimetics of naturally occurring 
opioid peptides[2], we became interested in the preparation of dehydroalanine (DHA) containing peptides[3] as 
intermediates for the synthesis of sequences including substituted (S)- or (R)-tryptophans[4]. We obtained the 
DHA residue (80–90%) by dehydration of Boc- or Fmoc-protected serine-containing peptides with 
bis(succinimidyl) carbonate (DSC), according to a procedure reported in the literature (Scheme 1)[5]. 
Interestingly, we observed that, on submitting the corresponding sulfonyl peptides to the same reaction 
conditions, the serine residue underwent cyclization to form the 2-oxo-1,3-oxazolidine-4-carboxylate (Oxd; 
Scheme 1). 
 
 
 
Scheme 1. Different reactivities of Fmoc-, Boc-, or sulfonylpeptidescontaining serine. 
 
Peptides containing an oxazolidinone constitute a relatively uncommon class of peptidomimetics[6]. In some 
cases, they have been utilized as prodrugs[7] or as intermediates for the preparation of other 
peptidomimetics[8]. In medicinal chemistry, the oxazolidinone ring is present in some bioactive peptides or 
mimetics, such as the GPIIb/IIIa integrin antagonists, which are based on the (oxo-oxazolidinyl)- methyl 
scaffold[9], or the HIV-1 protease inhibitors, which incorporate an oxo-N-phenyloxazolidine-5-carboxylic acid 
moiety, that are designed to improve the cellular antiviral potency[10]. Very recently, oxazolidin-2-one-
containing peptides have found applications in the field of foldamers, which are short synthetic oligomers that 
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tend to assume ordered conformations[11]. Short Oxd-peptides were shown to form well-defined 3D 
structures, such as the dimeric Boc-(Phe-D-Oxd)2-OBn, which forms nanofibers with an antiparallel β-sheet 
structure[12]. The synthesis of the oxazolidin-2-one ring from an amino alcohol and a carbonate or a 
dicarbonate (CDI, diethyl or diphenyl carbonate, Boc2O, etc.) is well documented[13]. However, this work 
describes a new, highly efficient synthesis of some representative examples of Oxd-peptides directly from a 
peptide sequence, either in solution or in the solid phase. 
Furthermore, to demonstrate the utility of the procedure in medicinal chemistry, a constrained analogue of 
the endogenous opioid peptide endomorphin-1 (EM1)[14], H-Tyr-Pro-Trp-PheNH2, with the 2-oxo-oxazolidine-
4-carboxylate in position 2 was prepared as a proline mimetic; the compound was characterized by a trans 
conformation of the preceding peptide bond. 
 
8.1. Results and Discussion 
Peptides with DHA were obtained by treating a mixture of the corresponding serine-containing N-Boc- or 
Fmoc protected peptides and DSC in acetonitrile with a solution of DIPEA in dichloromethane at room 
temperature (Scheme 1). However, when the same conditions were applied to N-sulfonyl di-, tri-, or 
tetrapeptides 1 having the serine (or threonine) residue in different positions, the reaction gave the N-sulfonyl 
peptides 2, containing a 2-oxo-oxazolidine- 4-carboxylate ring, without significant formation of either DHA or 
aziridine[15] (Scheme 2). Optimization of the reaction conditions led to the adoption of some minor changes 
with respect to the conditions described in the literature, such as the replacement of acetonitrile with N,N-
dimethylformamide (DMF); the modifications resulted in excellent yields (Table 1) and reduced reaction times. 
 
 
              Table 1. Yields (%) of the Oxd-peptides 2 prepared as described in Scheme 2. 
1 R Xaa Yaa R1 2 (%)[a] 3 (%)[a] 
a 4-MePh Pro OMe H [b] 82 
b 4-MePh - PheNH2 H 80 [b] 
c 4-MePh Pro PheNH2 H 85 [b] 
d 4-MePh Ala PheNH2 H 88 - 
e 4-MePh Ala PheNH2 Me 85 - 
f 4-NO2Ph Ala PheNH2 H 90 - 
g 4-MePh Ala-Ala PheNH2 H 95 - 
h[c] 4-MePh Ala Phe-OH[d] H 77[e] - 
i 4-MePh Tyr Trp-
PheNH2 
H 85 - 
[a] Determined after isolation by flash chromatography over silica-gel. [b] Traces. [c] Ts-Ala-Ser-Phe-Wang. [d] Reaction performed in          
solid-phase (Wang resin), followed by peptide cleavage. [e] Determined after isolation by semi-preparative RP-HPLC. 
Tosyl (Ts) protected amino acids were prepared by allowing the amino acids, TsCl, and NaHCO3 in 
H2O/dioxane to react according to the literature[16];  the synthesis of 4-O2NC6H4SO2-(Nosyl or Ns)-Ala-OH 
was performed with Ns-Cl in H2O at pH = 8[17]. The dipeptide ester Ts-Pro-Ser-OMe (1a) was obtained in 
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solution from Ts-Pro-OH and H-Ser-OMe·HCl under standard conditions by using 1-[3-
(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC·HCl) and 1-hydroxybenzotriazole hydrate 
(HOBt) as activating agents. The sulfonyl di-, tri-, and tetrapeptide-amides of general sequence RSO2-Xaa-
Ser/Thr-Yaa-NH2 (1b–g and 1i) were readily obtained by standard solid-phase peptide synthesis (SPPS) on 
a Rink amide resin with Fmoc-protected amino acids, with N,N''-dicyclohexyl carbodiimide (DCC) and HOBt 
as coupling agents. After cleavage with trifluoroacetic acid (TFA) in the presence of scavengers, the peptides 
were isolated by flash chromatography on silica gel and analyzed by RP-HPLC and ES-MS (see 
Experimental Section,Table 2). Alternatively, the Ts-peptide 1h was prepared on Wang resin by using Fmoc-
protected amino acids, DCC, and HOBt; Ts-Ala-Ser-Phe-Wang was then utilized for the following cyclization 
reaction on a solid phase prior to cleavage. The cyclization reaction of sulfonyl-peptides 1a–g and 1i was 
performed in solution (Scheme 2). The corresponding Oxd-peptide amides 2 were isolated by flash 
chromatography on silica gel (purity higher than 95% by RP-HPLC analysis), whereas the Oxd-peptide acid 
2h was obtained after cleavage from the resin (see below). The Oxd-peptides were characterized by IR, 
NMR, RP-HPLC, ES-MS, and HRMS (FAB) analyses. 1H NMR resonances were assigned by using 2D 
gCOSY techniques. 
 
 
Scheme 2. Synthesis of Oxd-containing peptides 2. 
 
Only the reaction of dipeptide Ts-Pro-Ser-OMe (1a), containing a serine methyl ester, gave the dehydration 
product Ts-Pro-DHA-OMe (3a) as the major product (82%,Table 1). Apparently, in this case, the 
comparatively high acidity of the α-H atom of the serine methyl ester with respect to that of the serine amides 
(1b–i)[18] promoted the elimination of the intermediate Ser-O-succinimidyl carbonate. In contrast, all of the 
other Ts or Ns oligopeptides containing Ser or Thr amides gave the corresponding Oxd-peptides, as 
reported in Table 1. This is a significant result, because, provided the sulfonyl group is present, these 
conditions allow the introduction of the Oxd group directly into oligopeptides. Indeed, when the protecting 
group is a carbamate, such as Boc, Fmoc, or Cbz, the reaction of peptides containing a Ser amide gives rise 
to the formation of DHA, as previously reported[5a,5e]. For confirmation, we submitted the corresponding 
Fmoc- or Boc-protected versions of 1d (and 1f), 1g, and 1h to the same conditions described above; as 
expected, in all cases, the reactions gave dehydration products in variable yields, without any trace of Oxd 
(data not shown). The reaction of the dipeptide Ts-Ser-Phe-NH2 (1b) gave Ts-Oxd-Phe-NH2 (2b) in good 
yield and only traces of the dehydration product (3b). The tripeptides Ts-Pro-Ser-Phe-NH2 (1c) and Ts-Ala-
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Ser-Phe-NH2 (1d), containing a tosyl group that was not directly appended to the Ser residue, gave the 
corresponding Oxd-peptides 2c and 2d, respectively, in high yields. In a similar way, Ts-Ala-Thr-Phe-NH2 
(1e), which contains a Thr residue, gave the corresponding tripeptide with a trans-5-methyl-2-oxo-
oxazolidine-4-carboxylate (2e). In this case, the (2S,3R) stereochemistry of the threonine residue was 
retained, as determined from the 1H NMR coupling constant of the 4-H–5-H doublet (J = 4.8 Hz). The 
reaction could also be performed with a different sulfonyl group; thus, the Nosyl-peptide Ns-Ala-Ser-Phe- 
NH2 (1f), gave the expected product Ns-Ala-Oxd-Phe-NH2 (2f) with comparable yield. Furthermore, the 
tetrapeptide Ts-Ala-Ala-Ser-Phe-NH2 (1g), having the Ser residue in position 3 of the sequence, underwent 
cyclization to the corresponding Oxd-tetrapeptides Ts-Ala-Ala-Oxd-Phe-NH2 (2g) in almost quantitative yield. 
To expand the synthetic scope of the reaction, the Oxd tripeptide acid Ts-Ala-Oxd-Phe-OH (2h) was 
synthesized entirely on a solid phase (Table 1). The resin-bound precursor Ts-Ala-Ser-Phe-Wang (1h) was 
prepared under standard conditions, and then subjected to cyclization by treatment with a moderate excess 
of DSC and DIPEA in dichloromethane/DMF (4:1) for 2 h. The cleavage of the Oxd-peptide was performed 
by treatment with two consecutive portions of 10% TFA in dichloromethane and scavengers. Analysis of the 
crude reaction mixture by RP-HPLC and ES-MS analysis revealed the presence of the peptide Ts-Ala-Ser-
Phe-OH (ca. 5%). The peptide 2h was isolated by semipreparative RP-HPLC with satisfactory yield (77%, 
based on an average resin loading of 0.6 mmol/g). The feasibility of sulfonyl group removal under reasonably 
mild conditions was then investigated (Scheme 3). The tripeptide Ts-Ala-Oxd-PheNH2 (2d) was treated with 
iodotrimethylsilane [19] to give the deprotected product H-Ala-Oxd-PheNH2 (4) in moderate yield, together 
with a mixture of by-products. As an alternative, treatment of 2d with SmI2/pyrrolidine/water[20], was 
attempted, but this method gave 4 in only low yield. 
 
 
 
Scheme 3. Removal of Ts from 2d and Ns from 2f affording the deprotected Oxd-containing peptide 4. 
 
In contrast, cleavage of the Ns group was much easier (Scheme 3), and treatment of Ns-Ala-Oxd-PheNH2 
(2f) with K2CO3/PhSH [21] gave 4 in good yield. The superior performance of Ns compared with Ts is not 
unexpected[22]. Based on this result, the Ns group can be regarded as the best choice for the preparation of 
deprotected Oxd-peptides. 
Finally, to demonstrate the usefulness of Oxd-peptides as conformationally defined peptidomimetics 
containing a pseudo-proline[6], an analogue of the endogenous opioid peptide endomophin-1 (EM1), H-Tyr-
Pro-Trp-PheNH2 was prepared. Among the different natural or synthetic opioid peptides[23], EM1 is unique for 
high receptor affinity and selectivity towards the μ-opioid receptor (MOR). However, despite many structural 
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investigations performed on EM1 and its analogues, the identification of the bioactive conformation remains 
elusive[24]. Extensive NMR studies revealed that, in solution, EM1 exists as an approximate 1:3 cis /trans 
mixture of conformers with respect to the Tyr1–Pro2 peptide bond. The tetrapeptide Ts-Tyr-Ser-Trp-Phe-NH2 
(1i) gave Ts-Tyr-Oxd-Trp-Phe-NH2 (2i) in satisfactory yield. In solution, the Oxd-tetrapeptide 2i adopts an all-
trans conformation of the peptide bonds, as revealed by the NMR spectrum of the compound, which shows a 
single set of sharp resonances (Figure 1). 
 
Fig. (1). 1H NMR spectrum of 2i, showing the amide and aromatic region 
 
The trans conformation of 2i was confirmed by comparison of the NMR spectroscopic data with that of Oxd-
peptides described in the literature[11,12]. In Oxd-peptides, the carbonyl group of the cycle introduces a 
constraint that forces the pseudo-peptide bond to always have the trans conformation. This feature should 
be of help to investigate the bioactive conformation of EM1, which is an aspect that is under investigation. 
 
8.2. Conclusions 
In this paper we have illustrated the ready synthesis of some representative peptides incorporating a 2-oxo-
oxazolidine-4-carboxylate starting from sulfonyl peptides containing Ser or Thr. Interestingly, the outcome of 
the reaction was practically independent of the distance between the Ser or Thr residues and the sulfonyl 
group. Tosyl- or Nosyl-protected peptides gave equally excellent results; these sulfonyl groups can be 
removed under a variety of mild conditions, in particular, the removal of Nosyl gave the deprotected peptide 
in good yields. The cyclization reaction was performed either in solution or on a solid phase, making the 
entire process a promising approach to the preparation of this class of constrained peptidomimetics and 
foldamers. As a representative example, an all-trans Oxd analogue of EM1 was prepared. 
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8.3. Experimental Section 
8.3.1. General Methods: Unless stated otherwise, standard chemicals were obtained from commercial 
sources and used without further purification. Flash chromatography of 1 was performed on silica gel (230–
400 mesh) by using mixtures of distilled solvents. Compounds 1 were analyzed by RP-HPLC and ES-MS. 
RP-HPLC was performed on an ODS column [4.6 μm particle size, 100 Å pore diameter, 250 μm, DAD 210 
nm, from H2O/CH3CN (9:1) to H2O/ CH3CN (2:8) in 20 min] at a flow rate of 1.0 mL/min, followed by 10 min 
at the same composition. Semipreparative RP-HPLC purification of compounds 2 were performed on a C18 
column [7 μm particle size, 21.2 mm x 150 mm, from H2O/CH3CN (8:2) to 100% CH3CN in 10 min] at a flow 
rate of 10 mL/min. The purity of 2 (more than 95%) was assessed by analytical RP-HPLC under the above 
conditions. Semipreparative and analytical RP-HPLC of compound 4 were performed under the same 
conditions as reported for 2, but with the addition of 0.1% TFA in the mobile phase. Compounds 2 and 4 
were analyzed by RP-HPLC, ES-MS, and HRMS (FAB). 1H NMR spectra were recorded at 400 MHz at room 
temperature in CDCl3/[D6]DMSO (2:1) by using 5 mm tubes; 13C NMR spectra were recorded at 75 MHz. 
Chemical shifts are reported as δ values relative to the CDCl3 signal. 
 
Synthesis of 1: A measure of Fmoc-Rink amide resin (0.5 g, 1.1 mmol/g, resin particle size: 100–200 mesh) 
was introduced into a reactor of an automated synthesizer apparatus. Fmoc was removed with 
DMF/piperidine (4:1) (5 mL) under mechanical shaking. After 15 min, the suspension was filtered, the resin 
was washed with CH2Cl2 (5 mL) and treated, while shaking, with a second portion of DMF/piperidine (4:1). 
After 40 min, the suspension was filtered, and the resin was washed three times in sequence with CH2Cl2 (5 
mL) and CH3OH (5 mL). The resin was swollen in CH2Cl2 (5 mL), and a solution of the N-protected amino 
acid (1.1 mmol) and HOBt (1.1 mmol) in DMF (4 mL) was added, followed by DCC (1.1 mmol). The mixture 
was mechanically shaken, and, after 3 h, the resin was filtered and washed three times with the sequence 
CH2Cl2 (5 mL) and CH3OH (5 mL). Coupling efficacy was determined by means of the Kaiser test. The resin-
bound peptide was suspended in a solution of TFA (4.8 mL), H2O (0.20 mL), and PhOH (0.050 g), in CH2Cl2 
(5 mL), and mechanically shaken at room temp. After 2 h, the mixture was filtered, the resin was washed 
with 10% TFA in Et2O (2X5 mL) and Et2O (2X5 mL). Filtrate and washes were collected, and solvent and 
volatiles were removed under N2 flow at room temp. The resulting residue was suspended in Et2O, and the 
crude solid that precipitated was triturated and collected by using a centrifuge. The crude solid was purified 
by flash chromatography on silica gel (eluent: EtOAc; column size: 10 cm x 1.5 cm), giving 1 (70–80 %). The 
products were analyzed by RP-HPLC and by MS, and the results are summarized in Table 2. 
Table 2. RP-HPLC and ES-MS analyses of 1. 
1 ES-MS m/z  
[M+1] vs calcd 
Purity (%)[a] 1 ES-MS m/z 
[M+1] vs calcd 
Purity (%)[a] 
a 371.1/371.1 85 b 406.1/406.2 87 
c 503.2/503.1 91 d 477.2/477.1 89 
e 491.2/491.1 93 f 508.2/508.2 86 
g 548.2/548.1 84 i 755.3/755.2 90 
[a] Determined by analytical RP-HPLC, see General Methods 
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8.3.2. Solution-Phase Synthesis of Oxd-peptides 2b–g and 2i. DSC (0.45 mmol) was added to a stirred 
solution of 1 (0.3 mmol) in CH2Cl2/DMF (4:1) (3 mL) followed by DIPEA (0.45 mmol) at room temp., under an 
inert gas. After 1 h, the solvent was removed under reduced pressure, the residue was diluted with 0.1 m 
HCl (5 mL), and the mixture was extracted with CH2Cl2 (3x 5 mL). The combined organic layers were dried 
with Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (hexane/EtOAc, 1:1; column size: 15 cm x 1.0 cm) to give 2 (80–95%; purity 
higher than 95% as determined by analytical RP-HPLC). Under the same reaction conditions and workup 
protocol, Ts-Pro-Ser-OMe (1a) gave Ts- Pro-DHA-OMe (3a) (82%; 95% pure by analytical RP-HPLC). 
 
8.3.4. Solid-Phase Synthesis of 2h.  Wang resin pre-loaded with Fmoc-Phe (0.5 g, 0.4–0.8 mmol/g, resin 
particle size: 100–200 mesh) was introduced into a reactor of an automated synthesizer apparatus. Fmoc 
removal and couplings with the following N-protected amino acids were performed as described above; the 
quantities of the reagents were calculated based on an average resin loading of 0.6 mmol/g. The resin-
bound peptide was suspended in CH2Cl2/DMF (4:1) (5 mL), and DSC (0.75 mmol) and DIPEA (0.75 mmol) 
were added at room temp. under an inert gas. After 2 h, the mixture was filtered, and the resin-bound 
peptide was washed three times in sequence with CH2Cl2 (5 mL) and CH3OH (5 mL). The resin bound 
peptide was suspended in a mixture of TFA (1 mL), H2O (0.33 mL), ethane-dithiol (0.33 mL), and PhOH 
(0.33 mL), in CH2Cl2 (8 mL), and mechanically shaken at room temp. After 2 h, the mixture was filtered, the 
resin was washed with 5% TFA in Et2O (2x 5 mL) and Et2O (2x 5 mL). The cleavage procedure was 
repeated, and all of the filtrates and washes were collected; solvent and volatiles were removed under an N2 
flow at room temp. The resulting residue was suspended in Et2O, and the crude solid that precipitated was 
triturated and collected by using a centrifuge. The Oxd-peptide acid 2i was isolated by semipreparative RP-
HPLC (see General Methods) (77% based on the average resin loading of 0.6 mmol/g; 96% pure by 
analytical RP-HPLC). 
 
8.3.5. Removal of the Ts Group. To a suspension of sodium iodide (0.045 g, 0.3 mmol) in CH3CN (3 mL), 
TMSCl (0.038 mL, 0.3 mmol) was added, and the mixture was stirred at 0 °C under an inert gas for 10 min. 
To this stirred suspension, a solution of 2d (0.10 g, 0.2 mmol) in CH3CN (3 mL) was added, and the reaction 
mixture was heated to reflux for 3 h. The solvent was removed under reduced pressure, and the residue was 
diluted with satd. aqueous Na2CO3 (5 mL) and extracted with EtOAc (4x 5 mL). The collected organic layers 
were dried with anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by 
semipreparative RP-HPLC (see General Methods) to afford 4 (0.045 g, 65 %; 95% pure by analytical RP-
HPLC). 
 
8.3.6. Removal of the Ns Group. To a stirred solution of 2f (0.11 g, 0.2 mmol) in DMF (4 mL), PhSH (0.026 
mL, 0.24 mmol) and K2CO3 (0.83 g, 0.6 mmol) were added under an inert gas, and the mixture was stirred at 
room temp. for 1 h. The solvent was removed under reduced pressure, and compound 4 was isolated as 
described above (0.063 g, 90%; 96% pure by analytical RP-HPLC). 
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Ts-Pro-DHA-OMe (3a): IR (nujol): ν˜ = 3050, 1720, 1690 cm–1. 1H NMR: δ = 1.58–1.80 (m, 3 H, ProHβ, ProH
ɣ), 2.15 (m, 1 H, ProHβ), 2.42 (s, 3 H, TsCH3), 3.20 (m, 1 H, ProHδ), 3.46 (m, 1 H, ProHδ), 3.85 (s, 3 H, 
COOCH3), 4.15 (dd, J = 3.2, 8.6 Hz, 1 H,ProHα), 5.91 (s, 1 H, =CH), 6.57 (s, 1 H, =CH), 7.33 (d, J = 8.0 Hz, 
2 H, ArH), 7.74 (d, J = 8.0 Hz, 2 H, ArH), 9.15 (br. s, 1 H, NH)ppm. 13C NMR: δ = 19.1, 22.0, 22.4, 40.2, 50.5, 
56.8, 105, 125.3,129.5, 136.3, 138.4, 141.5, 165.3, 171.5 ppm. ES-MS: calcd. for C16H20N2O5S [M+ 1]+ 371.1; 
found 371.2. 
 
Ts-Oxd-PheNH2 (2b): IR (nujol): ν˜ = 1777, 1710, 1651 cm–1. 1H NMR: δ = 2.43 (s, 3 H, TsCH3), 3.15–3.28 
(m, 2 H, PheHβ), 4.16 (dd, J = 4.2, 8.6 Hz, 1 H, 4-H), 4.53 (t, J = 8.8 Hz, 1 H, 5-H), 4.65 (q, J = 6.8 Hz, 1 H, 
PheHα), 5.12 (dd, J = 4.2, 8.4 Hz, 1 H, 5-H), 6.82 (br. s, 1 H, CONH2), 7.23 (br. s, 1 H, CONH2), 7.23–7.42 
(m, 7 H, ArH), 7.76 (d, J = 8.0 Hz, 2 H, ArH), 8.60 (d, J = 8.0 Hz, 1 H, PheNH) ppm. 13C NMR: δ = 19.9, 36.0, 
52.7, 55.9, 65.2, 124.1, 125.7, 127.2, 127.9, 128.2, 128.3, 132.5, 133.0, 135.9, 150.2, 166.4, 171.8 ppm. 
HRMS (FAB): calcd. for C20H22N3O6S [M + H]+ 432.1229; found 432.1232. 
 
Ts-Pro-Oxd-PheNH2 (2c): IR (nujol): ν˜ = 1773, 1715, 1660 cm–1. 1H NMR: δ = 1.52 (m, 1 H, ProHɣ), 1.72 (m, 
1 H, ProHɣ), 1.82 (m, 1 H, ProHβ), 1.97 (m, 1 H, ProHβ), 2.35 (s, 3 H, TsCH3), 3.00– 3.09 (m, 3 H, ProHδ, 
PheHβ), 3.42 (m, 1 H, ProHδ), 4.22 (dd, J = 3.6, 9.4 Hz, 1 H, 4-H), 4.51 (t, J = 9.2 Hz, 1 H, 5-H), 4.62 (q, J = 
7.2 Hz, 1 H, PheHα), 5.02 (dd, J = 3.6, 9.2 Hz, 1 H, 5-H), 5.42 (dd, J = 3.8, 9.0 Hz, 1 H, ProHα), 6.50 (br. s, 1 
H, CONH2), 6.73 (br. s, 1 H, CONH2), 7.08–7.22 (m, 5 H, ArH), 7.24 (d, J = 8.4 Hz, 2 H, ArH), 7.62 (d, J = 8.4 
Hz, 2 H, ArH), 7.78 (d, J = 8.0 Hz, 1 H, PheNH) ppm. 13C NMR: δ = 17.9, 20.7, 23.1, 38.5, 40.7, 49.0, 51.1, 
54.8, 56.4, 126.1, 127.8, 128.5, 129.4, 136.9, 139.1, 143.5, 152.6, 170.2, 173.1, 175.0 ppm. HRMS (FAB): 
calcd. for C25H29N4O7S [M + H]+ 529.1757; found 529.1760. 
 
Ts-Ala-Oxd-PheNH2 (2d): IR (nujol): ν˜ = 1766, 1722, 1649, 1530 cm–1. 1H NMR: δ = 1.32 (d, J = 7.3 Hz, 3 H, 
AlaCH3), 2.40 (s, 3 H, TsCH3), 3.00–3.17 (m, 2 H, PheHβ), 4.27 (dd, J = 4.2, 9.3 Hz, 1 H, 4-H), 4.45 (t, J = 
9.3 Hz, 1 H, 5-H), 4.64 (q, J = 7.4 Hz, 1 H, PheHα), 4.91 (dd, J = 4.2, 8.6 Hz, 1 H, 5-H), 5.15 (dq, J = 7.4, 9.3 
Hz, 1 H, AlaHα), 6.07 (br. s, 1 H, CONH2), 6.39 (br. s, 1 H, CONH2), 6.41 (d, J = 9.3 Hz, 1 H, AlaNH), 7.10–
7.27 (m, 7 H, ArH), 7.75 (d, J = 8.4 Hz, 2 H, ArH), 7.98 (d, J = 8.0 Hz, 1 H, PheNH) ppm. 13C NMR: δ = 18.5, 
20.8, 39.1, 47.8, 50.7, 54.9, 56.0, 127.1, 127.3, 128.7, 129.4, 129.8, 136.4, 139.5, 143.9, 152.4, 167.9, 173.5, 
174.5 ppm. HRMS (FAB): calcd. for C23H27N4O7S [M + H]+ 503.1600; found 503.1598. 
 
Ts-Ala-(5-Me-Oxd)-PheNH2 (2e): IR (nujol): ν˜ = 1776, 1716, 1633 cm–1. 1H NMR: δ = 1.24 (d, J = 7.2 Hz, 3 
H, AlaCH3), 1.33 (d, J = 6.0 Hz, 3 H, 5-CH3), 2.36 (s, 3 H, TsCH3), 3.03 (d, J = 6.4 Hz, 2 H, PheHβ), 4.22 (d, 
J = 4.8 Hz, 1 H, 4-H), 4.42 (t, J = 5.2 Hz, 1 H, 5-H), 4.55 (q, J = 7.3 Hz, 1 H, PheHα), 4.98 (m, 1 H, AlaHα), 
5.70 (br. s, 1 H, CONH2), 5.81 (br. s, 1 H, CONH2), 6.17 (d, J = 7.9 Hz, 1 H, AlaNH), 7.09–7.20 (m, 5 H, ArH), 
7.22 (d, J = 7.2 Hz, 2 H, ArH), 7.38 (d, J = 8.0 Hz, 1 H, PheNH), 7.65 (d, J = 7.2 Hz, 2 H, ArH) ppm. 13C NMR: 
δ = 18.5, 20.3, 21.5, 37.8, 51.0, 54.9, 75.0, 75.9, 127.1, 127.3, 128.7, 129.2, 129.8, 136.3, 136.7, 147.5, 
151.8, 167.0, 173.0, 174.7 ppm. HRMS (FAB): calcd. for C24H29N4O7S [M + H]+ 517.1757; found 517.1761. 
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Ns-Ala-Oxd-PheNH2 (2f): IR (nujol): ν˜ = 1769, 1724, 1648, 1532 cm–1. 1H NMR: δ = 1.32 (d, J = 7.0 Hz, 3 H, 
AlaCH3), 3.00– 3.15 (m, 2 H, PheHβ), 4.20 (dd, J = 4.1, 9.1 Hz, 1 H, 4-H), 4.40 (t, J = 9.1 Hz, 1 H, 5-H), 4.59 
(q, J = 7.3 Hz, 1 H, PheHα), 4.81 (dd, J = 4.1, 8.5 Hz, 1 H, 5-H), 5.15 (dq, J = 7.0, 8.8 Hz, 1 H, AlaHα), 6.21 
(br. s, 1 H, CONH2), 6.80 (br. s, 1 H, CONH2), 7.10– 7.30 (m, 5 H, ArH), 7.37 (d, J = 8.8 Hz, 1 H, AlaNH), 
7.79 (d, J = 8.0 Hz, 1 H, PheNH), 7.96 (d, J = 9.0 Hz, 2 H, ArH), 8.22 (d, J = 9.0 Hz, 2 H, ArH) ppm. 13C NMR: 
δ = 19.6, 37.1, 50.2, 53.9, 65.8, 123.7, 126.3, 127.8, 127.9, 128.9, 136.2, 146.4, 149.3, 152.3, 167.1, 172.1, 
172.4 ppm. HRMS (FAB): calcd. for C22H24N5O9S [M + H]+ 534.1295; found 534.1300. 
 
Ts-Ala-Ala-Oxd-PheNH2 (2g): IR (nujol): ν˜ = 1783, 1710, 1705, 1653, 1525 cm–1. 1H NMR: δ = 1.20 (d, J = 
6.8 Hz, 3 H, AlaCH3), 1.35 (d, J = 7.2 Hz, 3 H, AlaCH3), 2.40 (s, 3 H, TsCH3), 3.03 (dd, J = 6.4, 13.8 Hz, 1 H, 
PheHβ), 3.08 (dd, J = 6.9, 13.8 Hz, 1 H, PheHβ), 3.78 (quint, J = 7.3 Hz, 1 H, AlaHα), 4.22 (dd, J = 4.3, 9.0 
Hz, 1 H, 4-H), 4.43 (t, J = 9.2 Hz, 1 H, 5-H), 4.63 (q, J = 7.1 Hz, 1 H, PheHα), 4.91 (dd, J = 4.3, 8.8 Hz, 1 H, 
5-H), 5.28 (quint, J = 6.8 Hz, 1 H, AlaHα), 5.80 (br. s, 1 H, CONH2), 6.50 (br. s, 1 H, CONH2), 6.60 (d, J = 8.4 
Hz, 1 H, AlaNH), 7.10–7.27 (m, 8 H, ArH, AlaNH), 7.72 (d, J = 8.0 Hz, 2 H, ArH), 7.81 (d, J = 7.2 Hz, 1 H, 
PheNH) ppm. 13C NMR: δ = 16.3, 18.0, 20.5, 36.7, 47.1, 51.3, 53.6, 55.2, 64.8, 125.9, 126.1, 127.4, 128.4, 
128.7, 135.6, 136.0, 142.6, 151.4, 166.8, 170.6, 171.7, 171.9 ppm. HRMS (FAB): calcd. for C26H32N5O8S [M 
+ H]+ 574.1972; found 574.1977. 
 
Ts-Ala-Oxd-Phe-OH (2h): IR (nujol): ν˜ = 2800–3450, 1766, 1722, 1716, 1649 cm–1. 1H NMR: δ = 1.20 (d, J = 
7.2 Hz, 3 H, AlaCH3), 2.41 (s, 3 H, TsCH3), 3.05–3.17 (m, 2 H, PheHβ), 4.27 (dd, J = 4.1, 8.5 Hz, 1 H, 4 H), 
4.36 (t, J = 9.2 Hz, 1 H, 5-H), 4.63 (q, J = 7.6 Hz, 1 H, PheHα), 4.92 (dd, J = 4.0, 9.2 Hz, 1 H, 5-H), 5.20 (m, 
1 H, AlaHα), 6.30 (d, J = 9.0 Hz, 1 H, AlaNH), 7.10–7.25 (m, 5 H, ArH), 7.30 (d, J = 8.0 Hz, 2 H, ArH), 7.52 (d, 
J = 7.6 Hz, 1 H, PheNH), 7.73 (d, J = 8.0 Hz, 2 H, ArH), 9.32 (br. s, 1 H, COOH) ppm. 13C NMR: δ = 17.9, 
20.5, 38.4, 47.9, 50.1, 54.2, 56.4, 126.8, 127.7, 128.2, 129.1, 130.2, 136.3, 139.2, 144.1, 152.4, 168.0, 173.2, 
176.0 ppm. HRMS (FAB): calcd. for C23H26N3O8S [M + H]+ 504.1441; found 504.1436. 
 
Ts-Tyr-Oxd-Trp-PheNH2 (2i): IR (nujol): ν˜ = 1776, 1718, 1675, 1526 cm–1. 1H NMR: δ = 2.38 (s, 3 H, TsCH3), 
2.42 (dd, J = 8.0, 14.0 Hz, 1 H, TyrHβ), 2.82 (dd, J = 7.6, 14.2 Hz, 1 H, TrpHβ), 2.99 (dd, J = 6.4, 14.2 Hz, 1 
H, TrpHβ), 3.15 (dd, J = 3.0, 14.0 Hz, 1 H, TyrHβ), 3.22 (d, J = 7.6 Hz, 2 H, PheHβ), 4.22 (dd, J = 4.1, 9.2 Hz, 
1 H, 4-H), 4.50 (t, J = 9.2 Hz, 1 H, 5-H), 4.57 (q, J = 6.8 Hz, 1 H, TrpHα), 4.92 (q, J = 7.0 Hz, 1 H, PheHα), 
5.02 (dd, J = 4.1, 8.8 Hz, 1 H, 5-H), 5.30 (quint, J = 6.8 Hz, 1 H, TyrHα), 5.72 (br. s, 1 H, CONH2), 6.05 (br. s, 
1 H, CONH2), 6.75 (d, J = 8.4 Hz, 2 H, TyrArH), 6.95 (d, J = 7.8 Hz, 1 H, TyrNH), 7.02–7.15 (m, 4 H, TrpNH, 
TrpH-5, TyrArH), 7.19 (t, J = 7.6 Hz, 1 H, TrpH- 6), 7.25 (s, 1 H, TrpH-2), 7.30 (d, J = 8.0 Hz, 2 H, ArH), 
7.32–7.45 (m, 5 H, PheArH), 7.50 (d, J = 8.0 Hz, 1 H, TrpH-7), 7.61 (s, 1 H, TyrOH), 7.66 (d, J = 7.9 Hz, 1 H, 
TrpH-4), 7.68 (d, J = 8.0 Hz, 2 H, ArH), 8.55 (d, J = 8.8 Hz, 1 H, PheNH), 9.81 (br. s, 1 H, TrpH1) ppm. 13C 
NMR: δ = 21.4, 31.9, 36.6, 37.3, 49.3, 52.7, 59.2, 60.1, 71.3, 111.8, 112.3, 116.6, 120.2, 121.0, 123.5, 125.0, 
126.2, 127.3, 129.5, 132.1, 132.3, 136.2, 137.6, 140.1, 141.3, 155.7, 156.2, 173.2, 174.0, 174.2, 176.0 ppm. 
HRMS (FAB): calcd. for C40H41N6O9S [M + H]+ 781.2656; found 781.2662. 
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H-Ala-Oxd-PheNH2 (4): IR (nujol): ν˜ = 3352, 3445, 1764, 1722, 1645 cm–1. 1H NMR: δ = 1.22 (d, J = 6.8 Hz, 
3 H, AlaCH3), 2.96 (dd, J = 9.8, 13.8 Hz, 1 H, PheHβ), 3.12 (dd, J = 4.6, 13.8 Hz, 1 H, PheHβ), 3.30 (q, J = 
6.8 Hz, 1 H, AlaHα), 4.08 (dd, J = 4.6, 8.4 Hz, 1 H, 4-H), 4.36 (dd, J = 4.6, 9.2 Hz, 1 H, 5-H), 4.43 (t, J = 8.4 
Hz, 1 H, 5-H), 4.50 (m, 1 H, PheHα), 7.10 (br. s, 1 H, CONH2), 7.15 (br. s, 1 H, CONH2), 7.16–7.30 (m, 5 H, 
ArH), 8.05– 8.25 (m, 3 H, PheNH, AlaNH) ppm. 13C NMR: δ = 17.3, 37.9, 47.7, 49.0, 56.1, 63.2, 126.0, 128.7, 
129.2, 137.1, 153.4, 172.4, 173.8, 174.0 ppm. HRMS (FAB): calcd. for C16H21N4O5 [M + H]+ 349.1512; found 
349.1509. 
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Chapter 9 
Expedient Synthesis of Pseudo-Pro-Containing Peptides: Towards 
Constrained Peptidomimetics and Foldamers 
9. Introduction 
Determining the receptor-bound structure of biologically active peptides is fundamental in drug design. 
However, the direct investigation of ligand-receptor complexes has met with considerable practical obstacles; 
in addition, many native peptides are highly flexible molecules, therefore their conformational analysis is a 
difficult task. As a consequence, many efforts have been dedicated to the design of conformationally defined 
peptidomimetics as tools for investigating the key structural and conformational features on which receptor 
recognition and binding are based[1]. 
 Generally, peptide backbones serve as 3D scaffolds for positioning the side chains involved in ligand-
receptor interactions. The presence of Pro residues strongly impacts the structural and conformational 
properties of the backbones. The cyclic structure of Pro forces the ϕ angle to -65°±15°, thus preventing the 
formation of a  α-helix, and promoting the formation of β-turns[2]. Turns and inverse turns play important roles 
in the architecture and bioactivity of native folded proteins[3]. Besides, while the barrier to secondary amide 
cis/trans isomerization is circa 10 kcal mol-1 (Fig. 1), the presence of Pro reduces the barrier to just 2 kcal 
mol-1, increasing the cis conformer[4]. 
Besides to Pro itself, numerous derivatives were found in proteins of microbial or marine origins, in antibiotics 
or cytotoxic peptides,[1] and many other (e.g. 2,4-MePro, Δ3Pro, Azi, Aze, Pip, Nip, etc., Fig. 1)[6]  were 
synthesized and utilized to design conformationally constrained peptidomimetics[Errore. Il segnalibro non è definito.,7]. 
For instance, pseudo-Pro such as thiazolidine- and oxazolidine-4-carboxylic acid (Tc, Oxi) dimethylated at 
the position 2, are known to be quantitative, or nearly quantitative, inducers of the cis conformation around 
the preceding peptide bond[8], while 1-aminocyclohexane-1-carboxylic acid (Chx) induces the trans 
conformation[9]. On the other hand, 5,5-dimethylthiazolidine-4-carboxylic acid (Dtc)[10] and azetine-2-
carboxylic acid (Aze)[11] (Fig. 1) favor angles in the ɣ -turn region, while 5-tert-butylproline (5-tBuPro) 
stabilizes type VI β-turn conformation[12]. 
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Fig. (1). Selected examples of pseudo-Pro structures. 
 
Finally, pseudo-Pro have found use in the preparation of foldamers[13], short synthetic oligomers which have 
a tendency to form well-defined secondary structures, stabilized by noncovalent interactions[14]. 
In the last years, we have been interested in the use of D-Pro, β-Pro, pseudo-Pro and pseudo-β-Pro for the 
preparation of constrained bioactive peptidomimetics[15]. In this contest, we recently proposed the 2-oxo-1,3-
oxazolidine-4-carboxylate (or oxazolidin-2-one, in short: Oxd) as a constrained pseudo-Pro residue. Indeed, 
the carbonyl group of the cycle introduces a constraint that enforces the pseudo-peptide bond to always 
have the trans conformation (Fig. 1). 
Apart from the different applications in medicinal chemistry[16], Oxd-peptides have been the subject of much 
interest as foldamers or as self-assembling scaffolds forming nanostructures. The oligomers of the Boc-(L-
Ala-D-Oxd)n-OBn series exhibit a strong tendency to form helices with 10-membered H-bonded rings in 
solution[17]. The α,β-hybrid oligomers of the Boc-(L-β3-hPhg-D-Oxd)n-OBn series, formed helices with 11-
membered H-bonded turns for n≥5. The Boc-(L-β3-hPhe-D-Oxd)n-OBn series displays chain length-
dependent behaviour. In the higher oligomers (n>2), there is a stronger tendency to form intramolecular H-
bonds, while the Boc-(L-β3-hPhe-D-Oxd)2-OBn motif forms an anti-parallel β-sheet-like structure, where only 
one intermolecular H-bond stabilizes the fibre-like material besides the hydrophobic forces between the 
aromatic side-chains[18]. 
In this work we considerably expand the scope of our preliminarily described preparation of peptides 
containing the Oxd ring[19]. The reaction proceeds by the direct cyclization of N-sulfonyl peptides containing a 
Ser residue (Scheme 1), by treatment with bis(succinimidyl) carbonate (DSC) and diisopropylethylamine 
(DIPEA).  
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Scheme 1. Different reactivity of N-carbamate and N-tosyl (Ts) or nosyl (Ns) oligopeptides. 
 
The distance between the sulfonyl and the Ser in the sequence is relatively unimportant. Indeed, the reaction 
of peptides having the sulfonyl group directly connected to the Ser, or separated by one or two amino acids 
(Scheme 1, Xaa = 0, 1, or 2 residues) proceeded with similar results. The reaction of the corresponding 
Fmoc- or Boc-peptides under the same conditions gave elimination to dehydroalanine (Dha), in agreement to 
the literature (Scheme 1)[20]. 
 
9.1. Results and discussion 
9.1.2.. Optimization of the reaction conditions 
The reaction depicted in Scheme 1 represents the first synthesis of a oxazolidin-2-one-4-carboxylate directly 
within a peptide sequence. Apparently, the reaction outcome depends on the presence of the sulfonyl group 
(see Introduction). Subsequently, in order to optimize the cyclization of these sulfonyl peptides, we 
investigated the role of the carbonate, solvent, base, and sulfonyl group, by reacting the model peptides 1a-d 
under different conditions (Scheme 2, Table 1).  
The preparation of 1a-d and of the other sulfonyl-protected peptides 4, 6, 8, 11, and 13, was conducted by 
coupling the amino acids under normal conditions, using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
hydrochloride (EDC-HCl) and 1-hydroxybenzotriazole hydrate (HOBt) as activating agents. N-Mesyl (Ms), 
tosyl (Ts), or nosyl (Ns) amino acids were prepared according to the literature[21]. 
The treatment of 1a (Table 1) with 1.5 equiv. of DSC and 1.5 equiv. of DIPEA in DCM/CH3CN[Errore. Il segnalibro 
non è definito.] gave the oxazolidinone-peptide 2a, Ts-Ala-Oxd-PheNH2 (Entry 1) in good yield, together with 
traces of the corresponding elimination product Ts-Ala-Dha-PheNH2 (3). The substitution of CH3CN with 
DMF allowed increasing the yield, while reducing the reaction time (Entry 2); the use of solely DMF or DMSO 
(Entry 3, and 4) was not beneficial. Different bases such as DBU (Entry 5) or DMAP (Entry 6) in DCM/DMF 
gave 2 with comparable yields. 
A second set of reactions was designed to test the role of the carbonate. The synthesis of a oxazolidin-2-one 
ring from an aminoalcohol and different kinds of carbonates or dicarbonates is well documented in the 
literature[22]. Nevertheless, none of the procedures attempted by us gave the oxazolidinone-peptide 2 in a 
significant yield. The reaction of 1a with 1,1’-carbonyldiimidazole (CDI) and DIPEA[23] gave Ts-Ala-Dha-
PheNH2 (3) as the major product, and only traces of 2a (Entry 7), the rest being the reagent. The treatment 
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of 1a with Boc2O and DIPEA (Entry 8) or DMAP[24] (Entry 9) gave a Boc-derivative of 1 (not isolated) and 
traces of 2, as determined by the HPLC-MS analysis of the reaction mixture. Triphosgene gave 2 and 3 only 
in traces (Entry 10), while ethylchloroformate was completely ineffective (entry 11)[Errore. Il segnalibro non è 
definito.,Errore. Il segnalibro non è definito.,25]. 
Furthermore, we observed that the reaction of 1a and DSC in the absence of a base did not furnish 2a (Entry 
12). However, the reaction was possible with a catalytic amount of DIPEA (Entry 13) or DMAP (Entry 14), 
giving 2a in excellent yield and in reasonable time in a DCM/DMF mixture, but not in DCM alone (Entry 15). 
By using DSC and a catalytic amount of DIPEA, Ts-Ala-D-Ser-PheNH2 (1b) was converted into Ts-Ala-D-
Oxd-PheNH2 (2b) with the same yield of 2a (Entry 16 compared to Entry 13). 
In order to gain more information about the role of the sulfonyl group in the cyclization, we compared the 
reaction of the Ts-peptide 1a to that of the peptides 1c and 1d carrying the nosyl and mesyl groups, 
respectively.  
Under the same conditions of Entry 13, Ns-Ala-Ser-PheNH2 (1c) gave the corresponding Oxd-peptide Ns-
AlaOxd-Phe-NH2 (2c) in very good yield (Entry 17). 
On the contrary, the mesyl group failed to promote the cyclization. The treatment of Ms-Ala-Ser-PheNH2 (1d) 
with DSC in the presence of a catalytic amount of DIPEA did not give rise to the formation of the Oxd-peptide 
(Entry 18); the use of 1.2 equiv. of DIPEA (Entry 19) or DMAP (Entry 20) afforded the product only in traces. 
 
 
Scheme 2. Reactions of the sulfonyl-peptides 2a, c, d, containing L-Ser, and of 2b, containing D-Ser, under the conditions reported in Table 1. 
Taken together, the results reported in Table 1 give several clues on the mechanism of the cyclization 
process. Albeit an accurate investigation of the reaction mechanism is beyond the scope of this work, we 
compared the elimination of Boc- or Fmoc-peptides containing a Ser vs a plausible mechanisms of 
cyclization of the corresponding tosyl peptides (Scheme 3). The two reactions proceed via a common Ser-O-
carbonate intermediate A. The elimination of the Boc- or Fmoc-intermediate A induced by the base (:B) gives 
Dha, as sketched in pathway a. 
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Table 1. Reagents and conditions tested for the synthesis of R-SO2-Ala-Oxd-PheNH2 (2) from R-SO2-Ala-Ser-PheNH2 (1 
entry Compd carbonate (equiv.) base (equiv.) solvent Time (h)a 2 (%)b 3 (%) 
1 a DSC (1.5) DIPEA (1.2) DCM/CH3CN 3:1 2 74 tracesc,d 
2 a DSC (1.5) DIPEA (1.2) DCM/DMF 3:1 1 88  - 
3 a DSC (1.5) DIPEA (1.2) DMF 1 80 - 
4 a DSC (1.5) DIPEA (1.2) DMSO 1 79 - 
5 a DSC (1.5) DBU (1.2) DCM/DMF 3:1 2 85 - 
6 a DSC (1.5) DMAP (1.2) DCM/DMF 3:1 3 87 - 
7 a CDI (1.2) DIPEA (1.2) DCM 24 tracesc,d 30d,e 
8 a BOC2O (2.1) DIPEA (1.2) CH3CN  24 -f,d,e - 
9 a BOC2O (2.1) DMAP (1.2) DCM/DMF 3.1 2 -f,d,e - 
10 a Cl3COCOOCCl3 (0.5) DIPEA (3.0) DCM/DMF 24 - tracesc,d 
11 a ClCOOMe DIPEA (1.2) DCM/DMF 3:1 24 -g,d,e - 
12 a DSC (1.2) - DCM/DMF 3:1 24 - - 
13 a DSC (1.2) DIPEA (0.1)h DCM/DMF 3:1 3 92 - 
14 a DSC (1.2) DMAP (0.3)h DCM/DMF 3:1 6 90 - 
15 a DSC (1.2) DIPEA (0.1)h DCM 24 tracesc,d,e - 
16 b DSC (1.2) DIPEA (0.1)h DCM/DMF 3:1 3 92 - 
17 c DSC (1.2) DIPEA (0.1)h DCM/DMF 3:1 3 90 - 
18 d DSC (1.2) DIPEA (0.1)h DCM/DMF 3:1 24 - - 
19 d DSC (1.5) DIPEA (1.2) DCM/DMF 3:1 24 tracesc,d,e tracesc,d,e 
20 d DSC (1.5) DMAP (1.2) DCM/DMF 3:1 24 tracesc,d,e tracesc,d,e 
a The reaction was stopped at the disappearance of the reagent, as determined by the t.l.c. analysis of the reaction, or after 24h. b After 
purification by flash chromatography. c <5%. d Not isolated, determined by the HPLC-MS analysis. e The rest being the reagent 1. f Boc-
1 was the mayor by-product. g MeOCO-1 was the mayor by-product. h The lower amount tested.  
 
The alternative cyclization to Oxd was investigated with the aid of theoretical computations performed 
employing ab initio molecular orbital (MO) theory at the HF/6-31G** level. These led to the proposal of the 
plausible reaction pathway b, which accounts for the experimental observations reported in Table 1. Upon 
treatment with :B, the Ts- or Ns-intermediate A would form the anionic intermediate B, which in turn gives 
rise to the five membered anionic intermediate C. The loss of 2,5- dioxopyrrolidin-1-olate from C leads to the 
Oxd-peptide D; the protonation of the anionic leaving group by HB+ would regenerate the free base, which 
can be utilized in catalytic amount. 
The optimized conformations of A-D and the estimated ΔE are shown in the Supporting Information section, 
Scheme S1. The most stable conformation of the anionic intermediate B shows the aromatic ring of the 
sulfonyl group stacked below the delocalized anion at a distance of 3.5 Å; this distance is perfectly 
compatible with the values reported in the literature for π -stacking interactions[26]. The ability of 
arylsulfonamido groups to form sandwich structures by π-stacking interactions is well described in the 
literature[27]. Besides, electron-poor aromatic rings effectively promote the reactivity of delocalized anions 
such as enolates, by means of a donor-acceptor π-stacking stabilization of the transition states[28]. In a 
208 
 
similar way, it is plausible that sulfonamido groups such as N-tosyl and N-nosyl, but not mesyl, might 
stabilize the intermediate anion B as well as the plausible transition state BC (Scheme 3). This effect would 
be impossible for Boc- or Fmoc-peptides; consequently, under the same conditions, these peptides undergo 
elimination to Dha. 
Interestingly, the calculated structures of C and D clearly revealed a AlaCHα···-1O-C interaction, and a non-
conventional AlaCHα···O=C(Oxd) hydrogen bond, respectively. The latter interaction was also confirmed by 
NMR analysis and modeling of the Oxd-peptides. (see next paragraph). 
Starting from the calculated structures A-D, the dioxopyrrolidin-1-olyl group was replaced by other leaving 
groups resulting from CDI, Boc2O, chloroformate, or triphosgene (see Table 1), and these new structures 
were optimized (not shown). The comparison revealed that the anionic intermediate C carrying the 
dioxopyrrolidin-1-olyl is significantly lower in energy with respect to these analogues. This comparatively 
higher stability might also reflect to the transition state BC, accounting for the efficacy of DSC in the 
cyclization, compared to the other carbonates or dicarbonates, etc., discussed in Table 1, Entries 8-11.  
Finally, it is plausible that the π-stacking is functional also at stabilizing the anionic intermediate of type B for 
peptides having the arylsulfonamido group and Ser separated by two amino acids[Errore. Il segnalibro non è definito.]. 
(not calculated).  
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Scheme 3. Plausible reaction pathways for the elimination of carbamate-peptides (pathway a) and alternatives for the cyclization of 
arylsulfonyl peptides (pathway b). 
Epimerization during the cyclization process was excluded on the basis of the comparison of the NMR and 
HPLC analyses of 2a vs 2b, including the HPLC analysis on a chiral stationary phase (see General Methods). 
The mild cleavage of the arylsulfonyl groups[29] was discussed previously[Errore. Il segnalibro non è definito.]. The 
tosyl group was removed in sufficient yield with iodotrimethylsilane[30], while the treatment with 
SmI2/pyrrolidine/water[31] was much less efficient. The cleavage of the Ns group was easily performed with 
K2CO3/PhSH[32], giving the deprotected peptide in good yield.  
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Scheme 4. Synthesis of 5 and Δδ/Δt VT-NMR values of the amide protons in 8:2 DMSO-d6/H2O. 
 
In summary, the comparison of the results enlisted in Table 1 led us to reckon the conditions of Entry 13 the 
best for the cyclization reaction. Consequently, the Oxd-tetrapeptide Ns-Ala-D-Oxd-Phe-GlyNH2 (5), useful 
for the investigation of the conformational features of the constrained peptides, was smoothly prepared from 
Ns-Ala-D-Ser-Phe-GlyNH2 (4) by treatment with DSC and 0.1 equiv. of DIPEA in 3:1 DCM/DMF (Scheme 4). 
 
2.2 Synthesis of di-Oxd-peptides 
Previous results[19] demonstrated that the position of a Ser or Thr residue in the sequence of the sulfonyl-
peptide is practically unimportant for the cyclization to Oxd-peptide (see above). As a consequence, we 
envisaged the opportunity to perform a single-step cyclization of sequences containing two Ser, or a Ser and 
a Thr, consecutive or alternating with other amino acids. 
The reaction of Ts-Ser-SerNH2 (6) with 2.5 equiv. of DSC in 3:1 DCM/DMF and in the presence of a catalytic 
amount of DIPEA (0.1 equiv.) gave the corresponding di-Oxd-amide 7 in excellent yield (Scheme 5) after 
isolation by flash chromatography.  
 
 
 
Scheme 5. Synthesis of the di-Oxd peptide amide 7.  
 
On the other hand, the reaction of the dipeptide ester Ts-Ser-SerOMe (8) under the same reaction conditions 
gave a circa 1:1 mixture of the expected di-Oxd peptide 9 and the dipeptide containing the Dha methyl ester 
10 (Scheme 6). 
Possibly, this result reflects the comparatively higher acidity of the Hα of serine methyl ester with respect to 
that of the serine amides[33], which promotes the elimination of the intermediate Ser-O-succinimidyl 
carbonate. 
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Scheme 6. Solvent effect in the alternative formation of the di-Oxd peptide 9 and Oxd-Dha peptide 10.  
 
Interestingly, the reaction outcome was dependent on the solvent utilized (Scheme 6). Indeed, on performing 
the reaction in DCM gave Ts-Oxd-OxdOMe (9) and Ts-Oxd-Dha-OMe (10, Dha = dehydroalanine) in 92:8 
ratio (88% overall yield), while in DMF the situation was completely reversed, giving a 95:5 ratio in favor of 
10 (86% overall yield). 
This dipeptide Ts-Oxd-Dha-OMe is of some interest, since it contains two distinct secondary structure-
inducer residues, the Oxd and a dehydroamino acid. Indeed, dehydroamino acids are well known inducer of 
β-turn structures; for instance, sequential placement of dehydroPhe (ΔPhe) in oligomers gives repeated β-
turns forming 310 helices[Errore. Il segnalibro non è definito.,34]. 
In a similar way as for the preparation of 9, the cyclization of the peptide esters 11a and b containing L-Ser, 
Thr, and D-Ser, Thr, respectively, gave in DCM the di-Oxd 12a, b in high yield (Scheme 7), with only traces 
of the elimination products.  
 
 
 
Scheme 7. Synthesis of the di-Oxd peptide esters 12a, b. 
 
The trans configuration of the 5-methyl-oxazolidin-2-one-4-carboxylate was deduced by the 1H-NMR 
coupling constant of the H4-H5 (J circa 5.0 Hz), thus retaining the (2S,3R) stereochemistry of Thr. The 
comparison of the NMR and HPLC analyses of 12a vs 12b, including the HPLC analysis on a chiral 
stationary phase (see General Methods) allowed considering epimerization negligible.  
Finally, the di-Oxd-tetrapeptide acid Ts-Oxd-Phe-Oxd-Phe-OH (14) was entirely synthesized on solid-phase 
(Scheme 8). The resin-bound precursor Ts-Ser-Phe-Ser-Phe-Wang (13) was prepared under standard 
conditions, and it was subjected to cyclization by treatment with a 5 equiv. excess of DSC and catalytic 
DIPEA (0.3 equiv) prior to the cleavage from the resin.  
212 
 
 
 
 
Scheme 8. Solid-phase synthesis of 14.  
 
The cleavage of the di-Oxd-peptide was performed by two consecutive treatments with 10% TFA in DCM in 
the presence of scavengers. The peptide 14 was isolated by semi-preparative RP-HPLC with a very 
satisfactory yield. 
 
2.3. Conformational aspects of the Oxd peptides 
In order to analyze the conformational bias exerted by the Oxd on the overall structure of the peptides, we 
performed the conformational analyses of the representative examples 2a, 2b, 5, 10, containing one Oxd, 
and of 12a, 12b, 14, which contain two consecutive or alternate Oxd rings.  
Electronic Circular Dichroism (ECD) is a widely used technique for studying protein and peptide 
conformations. This technique is intrinsically a low-resolution method; however it can furnish qualitative 
information on the presence of ordered secondary structures[35], although not too many examples on short 
peptides are reported[36]. ECD measurements of compounds 2a, 2b, 5, 10, 12a, 12b, 14, were performed at 
room temperature in TFE[37] and methanol; 10 and 12a also in chloroform (Supporting Information, Figure S2). 
These analyses gave a few information on the eventual occurrence of secondary structures. Spectra of 2b, 5, 
10, and 12b show a negative n* band at ca. 235 nm, compatible with β-turn structures[38]. Spectra of 
structurally correlated 2a 2b, and of 12a 12b show marked differences. CD intensity changes by moving from 
methanol (and chloroform for 10) to TFE, indicating that the nature of the solvent may influence the turn 
population. Different chiroptical properties are associated to the other compounds 2a, 12a, 14 in the same 
spectral region. For instance, by comparing ECD spectra of 12a with those of 12b, a specular relationship 
emerges in the n* region, possibly reflecting the inversion of configuration of Oxd1. CD spectra of 12a 
present a positive band centered at ca. 230 nm accompanied by a weak positive shoulder at lower energy, 
while a negative * band is observed at around 200 nm. In both cases magnitude of CD grows up by 
moving from TFE to methanol and chloroform. These spectral features suggest that for 12a, a different 
secondary structure becomes predominant with respect to the one characterizing 12b, and its stability is 
increased in chloroform.  
The Oxd-peptides were analyzed by NMR experiments using standard techniques at 400 MHz in CDCl3, 
CH3OH, and in the biomimetic medium 8:2 DMSO-d6/H2O[39]. For most compounds, the 1H-NMR resonances 
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of the compounds showed modest variations of the chemical shifts in the different solvents, suggesting 
conformational stability (exceptions are discussed throughout). 
It has been demonstrated that the Oxd confers the preceding amide bond a well defined trans 
conformation[Errore. Il segnalibro non è definito.,Errore. Il segnalibro non è definito.]. Accordingly, the 1H-NMR analyses of all 
of the Oxd-peptides showed a single set of sharp resonances in each solvent, indicating conformational 
homogeneity or a fast equilibrium between conformers; generally, linear peptides containing a Pro show two 
sets of resonances, for the cis and trans conformers (see Introduction). 
The 1H-NMR analyses of all of the compounds showed a significantly downfield position of the Hα proton of 
the residue preceding the Oxd. For instance, the AlaHα in Ts-Ala-Oxd-PheNH2 (2a) it is at circa 5.1 p.p.m., 
while in Ts-Ala-Ser-PheNH2 (1a) it is at circa 3.5 p.p.m.; in Ts-Oxd1-Oxd2-OMe (9), the Oxd1H4 is at circa 6.0 
p.p.m., while Oxd2H4 is at circa 5.0 p.p.m. This accounts for a strong deshielding effect exerted by 
Oxd(C=O)[Errore. Il segnalibro non è definito.,Errore. Il segnalibro non è definito.], compatible with a non-conventional, 
CH···O=C intramolecular hydrogen bond[40], and confirms the trans conformation of the amide bond between 
the Oxd and the preceding, deshielded residue. 
Variable temperature (VT)-1H-NMR experiments were utilized to deduce the presence of H-bonds (Tables 
S1-3, Supporting Information). The homochiral Oxd-peptide Ts-Ala-Oxd-PheNH2 (2a) did not manifest the 
presence of any H-bond: the Δδ/Δt values of AlaNH, PheNH in 8:2 DMSO/H2O were -6.8, and -4.3 p.p.b..⁄K, 
respectively. 
On the other hand, for Ts-Ala-D-Oxd-PheNH2 (2b) the  Δδ/Δt (p.p.b..⁄K, 8:2 DMSO/H2O) values of AlaNH, 
PheNH were -4.2, and -2.6, and for Ts-Ala-D-Oxd-Phe-GlyNH2 (5) the  Δδ/Δt (p.p.b..⁄K, 8:2 DMSO/H2O) 
values of AlaNH, PheNH, and GlyNH were -4.8, -2.7, and -7.4. The comparatively lower VT-1H-NMR  Δδ/Δt 
parameters of PheNH for 2b and 5 are suggestive of the occurrence of a significant amount of folded 
conformations having PheNH involved in a H-bond (| Δδ/Δt| < or close to 2.5 p.p.b..⁄K-1)[Errore. Il segnalibro non è 
definito.,41].  The same trends can be observed also in the other solvents (Table S1, Supporting Information). 
Molecular backbone conformations were investigated by 2D ROESY analysis in 8:2 DMSO/H2O at 400Mhz, 
and the intensities of the resulting cross-peak were ranked to infer plausible interproton distancies (Tables 
S4-10 Supporting Information). 2D gCOSY experiments were utilized for the unambiguous assignment of all 
of the resonances. 
Structures consistent with the spectroscopic analyses were obtained by restrained MD simulations, using the 
distances derived from ROESY as constraints, and minimized with the AMBER force field. The  ωbonds 
were set at 180°, as the absence of Hαi-Hαi+1) cross-peaks excluded cis peptide bonds. Simulations were 
conducted in a box of explicit, equilibrated TIP3P water molecules. Random structures were generated by 
unrestrained high-temperature MD; the structures were subjected to high-temperature restrained MD with a 
scaled force field, followed by a simulation with full restraints. Finally, the system was gradually cooled, and 
the structures were minimized. The results were clustered by the RMSD analysis of the backbone atoms.  
For Ts-Ala-Oxd-PheNH2 (2a) and Ts-Ala-D-Oxd-PheNH2 (2b), the procedure gave one mayor clusters each, 
comprising circa 80% of the structures. For each compound cluster, the representative geometries with the 
lowest internal energy were selected and analyzed (Figure 2). The comparison of the two structures show a 
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clear difference; while 2a adopts a extended conformation, the peptide containing the D-Oxd shows a 
preference for a folded conformation, compatible with a β-turn centered on D-Oxd. 
To investigate the dynamic behavior of 2a and 2b, the structures were analyzed by unrestrained MD for 10 
ns in a box of explicit water molecules. Besides to the different random conformations, the analysis of the 
trajectories of 2b, but not of 2a, revealed a well-defined β-turn secondary structure stabilized by a explicit H-
bond between PheNH and the Ala(C=O), in agreement with the VT-NMR parameters. 
For Ns-Ala-D-Oxd-PheGly-NH2 (5), the conformational analysis gave two clusters comprising alltogheter 
more than 85% of the structures. For each cluster, the representative geometries 5A and 5B with the lowest 
internal energy were selected and analyzed (Figure 2). They differ almost exclusively by the opposite 
orientation of the D-Oxd-Phe peptide bond. Possibly, the two structures represent conformers in fast 
equilibrium. The structure 5A shows a clear inverse β-turn centered on D-Oxd, and is circa 1.4 Kcal mol-1 
lower in energy than 5B; the latter shows some violations of the distance constraint involving PheNH.  
To investigate the dynamic behavior of 5, the two conformers A and B were analyzed by unrestrained MD for 
10 ns in a box of standard TIP3P water molecules. The simulation showed the conversion of one 
conformation into the other. The analysis of the trajectories of 5A revealed the occurrence of well-defined 
secondary structures stabilized by a explicit H-bond between Ala(C=O) and PheNH, in agreement to the VT-
NMR parameters. On the other hand, the analysis of the trajectories of 5b revealed that occasionally the 
structure adopts a inverse β-turn type I conformation, stabilized by a H-bond between GlyNH and the 
Ala(C=O), but this observation is not supported by the VT-NMR analysis. 
The preference for the folded structures shown by 2b and 5 makes sense. It is well known that linear 
oligopeptides including a heterochiral Pro show higher propensity to adopt stable inverse β- or ɣ-turns, the 
Pro occupying the position i+1, compared to the peptides composed of all L-amino acids[42]. Besides, 10- and 
7-membered H-bonded rings form competitively to each other, depending on the solvent[43], on the 
prevalence of a trans over cis conformation of the amide bond preceding Pro[44], and/or on the nature and 
steric hindrance of the amino acids preceding and following Pro[45]. 
 
2a     2b 
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5A    5B 
 
10 
 
12a   12b 
 
14 
 
Fig. (2). Representative low-energy structures of 2a, 2d, 5a, 5b, 10, 12a, 12b, 14 consistent with ROESY analysis, calculated by 
restrained MD in a 30x 30x30 box of standard TIP3P water molecules. Backbones and Oxd are rendered in balls-and cylinders, the rest 
in sticks. 
 
The conformational analysis of (10) gave one clusters comprising the large majority of the structures. The 
representative geometry with the lowest internal energy is shown in Figure 2. The calculated geometry of the 
Dha residue perfectly matches the structures reported in the literature[46]. 
The conformational preference of 10 showed some dependence on the solvent. The 1H-NMR resonances of 
the H4 and H5 protons of Oxd in CDCl3 showed significant differences with respect to 8:2 DMSO/H2O and 
CH3OH. 
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The VT-NMR analysis in CDCl3 gave DhaNH Δδ/Δt = -1.8 p.p.b..⁄K, and in 8:2 DMSO/H2O Δδ/Δt = -4.6 p.p.b. 
Apparently, in the less competitive CDCl3 the DhaNH is involved in a H-bond with one of the S=O, conferring 
10 a pseudo β-turn structure, which is not observed in 8:2 DMSO/H2O. Accordingly, the unrestrained 
molecular dynamics simulations for 10ns in explicit water did not show this pseudo β-turn conformation. 
The ROESY-restrained MD simulations of Ts-Oxd1-(5-Me-Oxd2)-OMe (12a) and Ts-D-Oxd1-(5-Me-Oxd2)-
OMe (12b) gave, after clustering, one clusters each, comprising almost the totality of the structures; the 
representative ones are shown in Figure 2. The two oxazolidin-2-ones are nearly orthogonal to each other. 
The unrestrained MD confirmed the rigidity of the conformations, since the rotation of the two Oxd rings one 
with respect to the other was not observed during the simulations. 
The calculated conformation of the Ts-Oxd1-Phe2-Oxd3-Phe4-OH (14), determined as above described, 
presents a extended conformation (Figure 2), confirming that homochiral peptides do not tend to fold.  
The 1H-NMR signals of the compound significantly vary in the different environments; for instance, the δ of 
Phe4Hα in CDCl3, 8:2 DMSO/H2O, and CH3OH is 4.83, 4.53, 4.22, respectively, and the δ of Phe2Hα is 5.78, 
5.57, 5.68. 
The VT-NMR analysis in 9:1 CDCl3/DMSO-d6 (this compound is not soluble in pure chloroform) indicated 
some preference for a pseudo β-turn on Oxd1 stabilized by a H-bond between Oxd1(S=O) and Phe2NH 
(Phe2NH Δδ/Δt = -2.9 p.p.b.). However, as observed for 10, this conformation is not stable in more polar 
environments (for instance, in 8:2 DMSO/H2O Phe2NH Δδ/Δt = -5.2 p.p.b.), and it is not observed during the 
unrestrained MD simulations in explicit water.  
 
3. Conclusions 
In this work we discuss our methodology for the straightforward preparation of Oxd-peptides starting from 
arylsulfonyl peptides containing L or D-configured Ser or Thr by treatmend with DSC and a base. 
The mechanism was investigated by varying the reaction conditions, and the results were rationalized with 
the aid of theoretical computations. The experiments highlighted the role of the arylsulfonylamido group and 
DSC. Indeed, while tosyl and nosyl gave the ring closure, the mesyl group was ineffective; further, CDI, 
Boc2O, triphosgene, and ClCOOMe, failed to afford the Oxd-peptides in significant yield. The reaction was 
performed by using catalytic amounts of DIPEA, DBU, or DMAP.  
Essentially, computations suggested that the electron-poor arylsulfonylamido group might effectively stabilize 
the anionic intermediate which leads to the Oxd ring by a π-stacking interaction. Computations also allowed 
to rationalize the effectiveness of DSC compared to other carbonates or dicarbonates.  
We expanded the scope of the methodology by preparing in a single step di-Oxd-peptides from peptides 
containing two consecutive Ser, or Ser and Thr, or two Ser separated by other amino acids. The peptides 
amide gave the corresponding di-Oxd-amides, as expected, while peptide methyl ester gave the di-Oxd-
ester or the peptide containing Oxd and Dha-ester, depending on the solvent selected for the reaction. The 
synthesis of the linear precursors and the cyclization reaction was performed either in solution or in the solid 
phase, making the entire process a convenient method for the preparation of constrained peptides or 
foldamers. 
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These Oxd residues can be regarded to as suitable constrained pseudo-Pro. The peptides containing the 
Oxd in place of Pro show an all-trans conformation instead of mixtures of cis and trans conformers. 
Homochiral sequences tend to adopt extended conformations, while the presence of a D-Oxd ring induces 
folded conformations, with a inverse ɣ-turn centered on D-Oxd, stabilized by a explicit H-bond. 
 
 
 
 
 
 
4. Experimental 
4.1 General Methods 
Unless stated otherwise, standard chemicals were obtained from commercial sources and used without 
further purification. Flash chromatography was performed on silica gel (230-400 mesh), using mixtures of 
distilled solvents. Analytical RP-HPLC was performed on an ODS column (4.6 μm particle size, 100 Å pore 
diameter, 250 m, DAD 210 nm, from a 9:1 H2O/CH3CN to a 2:8 H2O/CH3CN in 20 min) at a flow rate of 1.0 
mL/min, followed by 10 min at the same composition. Semi-preparative RP-HPLC was performed on a C18 
column (7 μm particle size, 21.2mm x 150 mm, from 8:2 H2O/CH3CN to 100% CH3CN in 10 min) at a flow 
rate of 12 mL/min. Purities were assessed by analytical RP-HPLC under the above reported conditions and 
elemental analysis. Chiral HPLC analysis was performed on a CHIRALPAK IC column (0.46 cm x 25 cm), n-
hexane/2-propanol 1:1, at 0.8 mL min-1. Semi-preparative and analytical RP-HPLC of the peptide acid 14 
were performed as reported above, with the addition of 0.1% TFA in the mobile phase. Elemental analyses 
have been performer using a Thermo Flash 2000 CHNS/O analyzer. NMR spectra were recorded on a 
Varian instrument. Circular Dichroism (CD) spectra were recorded on a Jasco J-710 spectropolarimeter. 
 
4.1.1. Peptide synthesis 
A stirred solution of the N-protected amino acid in 4:1 DCM/DMF (5 mL) was treated with HOBt (1.2 equiv.), 
at r.t and under inert atmosphere. After 10 min, the C-protected amino acid (1.1 equiv.), EDCI-HCl (1.2 
equiv.) and TEA (3 equiv.) were added while stirring at r.t. under inert atmosphere. After 3h, the mixture was 
concentrated at reduced pressure, and the residue was diluted with EtOAc (25 mL). The solution was 
washed with 0.1 M HCl (5 mL), and a saturated solution of NaHCO3 (5 mL). The organic layer was dried over 
Na2SO4 and the solvent was evaporated at reduced pressure. The crude peptides were analyzed by HPLC-
MS analysis, and were used without further purifications.  
The intermediate N-Boc peptides were deprotected by treatment with 1:2 TFA/DCM (5 mL), while stirring, at 
r.t. After 15 min, the solution was evaporated at reduced pressure, and the treatment was repeated. The 
residue was suspended in Et2O (20 mL). The peptide-TFA salts which precipitated were used for the next 
couplings without further purifications. 
 
Table 1. RP-HPLC and ES-MS analyses of the linear peptides. 
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compd ES-MS m/z [M+1] vs calcd Purity (%)[a] compd ES-MS m/z [M+1] vs calcd Purity (%)[a] 
1a 477.2/477.1 89 1b 477.1/477.1 86 
1c 508.2/508.2 86 1d 401.1/401.1 87 
4 565.1/565.2 85 6 346.0/346.1 88 
8 361.1/361.1 87 11a 374.1/374.1 90 
11b 374.1/374.1 88 13b -c -c 
a Determined by analytical RP-HPLC, see General Methods; b Ts-Ser-Phe-Ser-Phe-Wang; the following cyclization was performed in 
solid phase. c Not determined. 
 
 
 
4.1.2. Mono-Oxd-peptide synthesis 
Ts-Ala-Oxd-Phe-NH2 (2a). DSC (0.13 g, 0.50 mmol) was added to a stirred solution of the linear peptide Ts-
Ala-Ser-Phe-NH2 (1a, 0.20 g, 0.42 mmol), in 3:1 DCM/DMF (4 mL) followed by DIPEA (7.4 L, 0.04 mmol) at 
r.t. and under inert atmosphere. After 3h, the solvent was removed at reduced pressure, the residue was 
diluted with 0.1M HCl (5 mL), and the mixture was extracted three times with DCM (5 mL). The combined 
organic layers were dried over sodium sulphate, filtered, and concentrated at reduced pressure. The residue 
was purified by flash chromatography over silica-gel (eluant 1:1 hexane/EtOAc, column size: 15×1.0 cm2) to 
give 2a (0.194 g, 92%, 95% pure by analytical RP-HPLC). IR (nujol)  :1766, 1722, 1649, 1530 cm-1; 1H-
NMR (CDCl3) δ 1.31 (d, J=7.3 Hz, 3H, AlaMe), 2.39 (s, 3H, TsMe), 3.01-3.16 (m, 2H, PheHβ), 4.26 (dd, 
J=4.2, 9.3 Hz, 1H, OxdH5), 4.44 (t, J=9.3 Hz, 1H, OxdH5), 4.63 (q, J=7.4 Hz, 1H, PheHα), 4.90 (dd, J=4.2, 
8.6 Hz, 1H, OxdH4), 5.12 (dq, J=7.4, 9.3 Hz, 1H, AlaHα), 6.03 (br.s, 1H, CONH2), 6.35 (br.s, 1H, CONH2), 
6.40 (d, J=9.3 Hz, 1H, AlaNH), 7.09-7.26 (m, 7H, ArH), 7.75 (d, J=8.4 Hz, 2H, ArH), 7.96 (d, J=8.0 Hz, 1H, 
PheNH); 13C-NMR (2:1 CDCl3/DMSO-d6) δ: 18.5, 20.8, 39.1, 47.8, 50.7, 54.9, 56.0, 127.1, 127.3, 128.7, 
129.4, 129.8, 136.4, 139.5, 143.9, 152.4, 167.9, 173.5, 174.5; RP-HPLC (see general methods) 7.01 min; 
ES-MS m/z 503.2 [M+1], calcd 503.2; Elem. Anal. for C23H26N4O7S, calcd: C 54.97, H 5.21, N 11.15, S 6.38; 
found: C 54.92, H 5.19, N 11.10, S 6.36. 
 
Ts-Ala-D-Oxd-Phe-NH2 (2b). The reaction of Ts-Ala-D-Ser-Phe-NH2 (1b, 0.20 g, 0.42 mmol) under the same 
conditions described for 1a gave 2b (0.190 g, 90%, 96% pure by analytical RP-HPLC). IR (nujol) : 1770, 
1717, 1651, 1528 cm-1; 1H-NMR (CDCl3) δ: 1.25 (d, J=7.2 Hz, 3H, AlaMe), 2.38 (s, 3H, TsMe), 2.85 (dd, J= 
9.2, 14.0 Hz, 1H, PheHβ), 3.25 (dd, J= 4.8, 14.0 Hz, 1H, PheHβ), 3.75 (dd, J=3.0, 8.4 Hz, 1H, OxdH5), 4.28 
(t, J=9.2 Hz, 1H, OxdH5), 4.66 (q, J=7.4 Hz, 1H, PheHα), 4.72 (dd, J=3.6, 9.2 Hz, 1H, OxdH4), 5.09 (quint, 
J=7.8 Hz, 1H, AlaHα), 6.00 (br.s, 1H, CONH2), 6.62 (d, J=9.2 Hz, 1H, AlaNH), 6.70 (br.s, 1H, CONH2), 7.02-
7.29 (m, 7H, ArH), 7.65 (d, J=8.4 Hz, 2H, ArH), 8.23 (d, J=8.4 Hz, 1H, PheNH); 13C-NMR (2:1 CDCl3/DMSO-
d6) δ 19.0, 21.1, 40.1, 47.0, 50.2, 55.6, 55.8, 127.3, 127.5, 129.1, 129.5, 130.1, 136.7, 139.9, 143.1, 153.4, 
168.1, 173.2, 173.5; RP-HPLC (see general methods) 7.01 min; ES-MS m/z 503.2 [M+1], calcd 503.2; Elem. 
Anal. for C23H26N4O7S, calcd: C 54.97, H 5.21, N 11.15, S 6.38; found: C 54.94, H 5.24, N 11.09, S 6.34. 
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Ns-Ala-Oxd-Phe-NH2 (2c). The reaction of Ns-Ala-Ser-Phe-NH2 (1c, 0.20 g, 0.39 mmol) under the same 
conditions described for 1a gave 2c (0.189 g, 90%, 96% pure by analytical RP-HPLC). IR (nujol) : 1783, 
1710, 1705, 1653, 1525 cm-1; 1H-NMR (CDCl3) δ: 1.21 (d, J=6.8 Hz, 3H, AlaMe), 1.33 (d, J=7.2 Hz, 3H, 
AlaMe), 2.43 (s, 3H, TsMe), 3.02 (dd, J=6.4, 13.8 Hz, 1H, PheHβ), 3.06 (dd, J=6.9, 13.8 Hz, 1H, PheHβ), 
4.22 (dd, J=4.3, 9.0 Hz, 1H, OxdH5), 4.44 (t, J=9.2 Hz, 1H, OxdH5), 4.62 (q, J=7.1 Hz, 1H, PheHα), 4.92 (dd, 
J=4.3, 8.8 Hz, 1H, OxdH4), 5.27 (quint, J=6.8 Hz, 1H, AlaHα), 5.79 (br.s, 1H, CONH2), 6.51 (br.s, 1H, 
CONH2), 6.61 (d, J=8.4 Hz, 1H, AlaNH), 7.10-7.28 (m, 8H, ArH+AlaNH), 7.72 (d, J=8.0 Hz, 2H, ArH), 7.80 (d, 
J=7.2 Hz, 1H, PheNH); 13C-NMR (2:1 CDCl3/DMSO-d6) δ 16.3, 18.0, 20.5, 36.7, 47.1, 51.3, 53.6, 55.2, 64.8, 
125.9, 126.1, 127.4, 128.4, 128.7, 135.6, 136.0, 142.6, 151.4, 166.8, 170.6, 171.7, 171.9; Elem. Anal. for 
C22H23N5O9S, calcd: C 49.53, H 4.35, N 13.13, S 6.01; found: C 49.49, H 4.33, N 13.13, S 5.98. 
 
Ns-Ala-D-Oxd-Phe-Gly-NH2 (5). The reaction of Ns-Ala-D-Oxd-Phe-Gly-NH2 (4, 0.20 g, 0.35 mmol) under 
the same conditions described for 1a gave 5 (0.178 g, 85%, 96% pure by analytical RP-HPLC). IR (nujol) : 
1768, 1719, 1655, 1534 cm-1; 1H-NMR (9:1 CDCl3/DMSO-d6) δ 1.13 (d, J=7.0 Hz, 3H, Me), 3.01 (dd, J=6.2, 
13.8 Hz, 1H, PheHβ), 3.23 (dd, J=6.8, 13.8 Hz, 1H, PheHβ), 3.64 (dd, J=3.1, 8.9 Hz, 1H, D-OxdH5), 3.70-
3.79 (m, 2H, GlyHα), 4.30 (t, J=8.6 Hz, 1H, D-OxdH5), 4.64 (q, J=7.1 Hz, 1H, PheHα), 4.72 (dd, J=2.9, 9.0 
Hz, 1H, D-OxdH4), 5.13 (quint, 7.1 Hz, 1H, AlaHα), 6.62 (br.s, 1H, CONH2), 7.05 (br.s, 1H, CONH2), 7.11-
7.25 (m, 5H, ArH), 7.90 (d, J=8.4 Hz, 2H, ArH), 8.02 (t, J=7.9 Hz, 1H, GlyNH), 8.29 (d, J=8.0 Hz, 1H, 
PheNH), 8.35 (d, J=8.4 Hz, 2H, ArH), 8.40 (d, J=9.3 Hz, 1H, AlaNH); 13C-NMR (DMSO-d6) δ: 18.0, 37.6, 42.2, 
51.6, 56.0, 58.2, 62.4, 125.2, 125.9, 127.8, 128.8, 128.6, 136.7, 150.4, 151.3, 153.9, 169.9, 171.7, 172.3, 
173.2; RP-HPLC (see general methods) 7.85 min; ES-MS m/z 591.2 [M+1], calcd 591.1; Elem. Anal. for 
C24H26N6O10S, calcd: C 48.81, H 4.44, N 14.23, S, 5.43; found: C 48.77, H 4.47, N 14.19, S, 5.47. 
 
4.1.3. Di-Oxd-peptide synthesis 
Ts-Oxd1-Oxd2-NH2 (7). To a stirred solution of Ts-Ser-Ser-NH2 (6, 0.2 g, 0.58 mmol) in 3:1 DCM/DMF (4 mL), 
DSC (0.37 g, 1.45 mmol) and DIPEA (10 L, 0.06 mmol.) were added at r.t. under inert atmosphere. After 4h, 
work up was performed as described above for 2a, giving 7 (0.189 g, 82%, 95% pure by analytical RP-
HPLC). IR (nujol) : 1776, 1770, 1725, 1711; 1H-NMR (CDCl3) δ: 2.43 (s, 3H, Me), 4.37 (dd, J=2.8, 9.2 Hz, 
1H, Oxd1H5), 4.48 (dd, J=3.6, 9.6 Hz, 1H, Oxd2H5), 4.62-4.71 (m, 2H, Oxd1H5+Oxd2H5), 5.00 (dd, J=2.8, 
8.8 Hz, 1H, Oxd2H4), 5.99 (dd, J=3.6, 9.6 Hz, 1H, Oxd1H4), 7.07 (s, 1H, CONH2), 7.35 (d, J=8.1 Hz, 2H, 
ArH), 7.76 (s, 1H, CONH2), 7.93 (d, J=8.1 Hz, 2H, ArH); 13C-NMR (9:1 CDCl3/DMSO-d6) δ:  21.1, 50.6, 57.4, 
62.9, 63.2, 128.2, 129.7, 132.7, 137.9, 151.4, 154.1, 167.9, 170.6; RP-HPLC (see general methods) 5.7 min; 
ES-MS m/z 398.0 [M+1], calcd 398.1; Elem. Anal. for C15H15N3O8S, calcd: C 45.34, H 3.80, N 10.57, S 8.07; 
found: C 45.28, H 3.82, N 10.60, S 8.10. 
 
Ts-Oxd1-Oxd2-OMe (9). A stirred solution of Ts-Ser-Ser-OMe (8, 0.2 g, 0.56 mmol) in DCM (4 mL), was 
treated as described above for the synthesis of 7. The same work up gave 9 (0.187 g, 81%, 94% pure by 
analytical RP-HPLC) and 10 (0.016 g, 8%), separated by flash chromatography. 
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(9). IR (nujol) : 1779, 1769, 1721; 1H-NMR (CDCl3) δ 2.45 (s, 3H, Me), 3.82 (s, 3H, COOMe), 4.39 (dd, 
J=3.6, 9.6 Hz, 1H, Oxd1H5), 4.50 (dd, J=2.2, 9.1 Hz, 1H, Oxd2H5), 4.74 (t, J=9.4 Hz, 1H, Oxd1H5), 4.76 (t, 
J=9.3 Hz, 1H, Oxd2H5), 5.08 (dd, J=1.8, 9.1 Hz, 1H, Oxd2H4), 6.00 (dd, J=3.4, 9.6 Hz, 1H, Oxd1H4), 7.36 (d, 
J=8.0 Hz, 2H, ArH), 7.98 (d, J=8.0 Hz, 2H, ArH); 13C-NMR (2:1 CDCl3/DMSO-d6) δ: 21.0, 51.5, 52.1, 55.7, 
62.1, 62.5, 128.9, 129.3, 133.0, 137.4, 151.3, 153.3, 165.1, 166.6; RP-HPLC (see general methods) 7.81 
min; ES-MS m/z 413.0 [M+1], calcd 413.1; Elem. Anal. for C16H16N2O9S, calcd: C 46.60, H 3.91, N 6.79, S 
7.78; found: C 46.55, H 3.88, N 6.76, S 7.75. 
 
Ts-Oxd-Dha-OMe (10). A stirred solution of 8 (0.20 g, 0.56 mmol) in DMF (3.0 mL) was treated as described 
above for the synthesis of 7. The work up gave 10 (0.169 g, 82%, 94% pure by analytical RP-HPLC) and 9 
(9.2 mg, 4%), isolated by flash chromatography. 
(10). IR (nujol) : 1768, 1721, 1715; 1H-NMR (CDCl3) δ:  2.42 (s, 3H, Me), 3.88 (s, 3H, COOMe), 4.45 (dd, 
J=4.6, 9.0 Hz, 1H, OxdH5), 4.52 (t, J=9.2 Hz, 1H, OxdH5), 4.99 (dd, J=4.4, 9.2 Hz, 1H, OxdH4), 6.05 (s, 1H, 
=CH), 6.65 (s, 1H, =CH), 7.34 (d, J=8.4 Hz, 2H, ArH), 7.93 (d, J=8.4 Hz, 2H, ArH), 8.54 (s, 1H, DhaNH); 13C-
NMR (2:1 CDCl3/DMSO-d6) δ : 21.4, 52.6, 57.9, 66.0, 111.0, 128.7, 128.9, 129.1, 129.1, 131.0, 133.8, 145.4, 
151.5, 163.6, 166.8; RP-HPLC (see general methods) 7.47 min; ES-MS m/z 369.1 [M+1], calcd 369.1; Elem. 
Anal. for C15H16N2O7S, calcd: C 48.91, H 4.38, N 7.60, S 8.70; found: C 48.88, H 4.35, N 7.57, S 8.68. 
 
Ts-Oxd1-(5-Me-Oxd2)-OMe (12a). A stirred solution of Ts-Ser-ThrOMe (11a, 0.20 g. 0.53 mmol) in DCM (4 
mL), was treated as described above for the synthesis of 9, giving 12a (0.20 g 88%, 94% pure by analytical 
RP-HPLC). IR (nujol) : 1788, 1768, 1719; 1H-NMR (CDCl3) δ: 1.63 (d, J=6.0 Hz, 3H, 5-Me), 2.46 (s, 3H, 
TsMe), 3.82 (s, 3H, COOMe), 4.39 (dd, J=3.2, 9.2 Hz, 1H, Oxd1H5), 4.64 (d, J=5.0 Hz, 1H, Oxd2H4), 4.73 
(br.t, 2H, Oxd1H5+Oxd2H5), 6.04 (dd, J=4.0, 10.0 Hz, 1H, Oxd1H4), 7.36 (d, J=8.0 Hz, 2H, ArH), 7.99 (d, 
J=8.0 Hz, 2H, ArH); 13C-NMR (9:1 CDCl3/DMSO-d6) δ: 20.6, 21.3, 53.5, 57.6, 60.6, 65.0, 75.1, 128.9, 129.0, 
133.7, 145.6, 151.2, 152.0, 167.1, 167.7; RP-HPLC (see general methods) 8.33 min; ES-MS m/z 427.3 
[M+1], calcd 427.1; Elem. Anal. for C17H18N2O9S, calcd: C 47.89, H 4.25, N 6.57, S 7.52; found: C 47.93, H 
4.2 N 6.60, S 7.49. 
 
Ts-D-Oxd1-(5-Me-Oxd2)-OMe (12b). The reaction of Ts-D-Ser-ThrOMe (11b, 0.20 g. 0.53 mmol) under the 
same conditions described for 9 gave 12b (0.196 g, 86%, 94% pure by analytical RP-HPLC). IR (nujol) : 
1786, 1760, 1724; 1H-NMR (CDCl3) δ: 1.53 (d, J=6.0 Hz, 3H, 5-Me), 2.45 (s, 3H, TsMe), 3.90 (s, 3H, 
COOMe), 4.27 (dd, J=3.2, 10.0 Hz, 1H, Oxd1H5), 4.53 (d, J=5.3 Hz, 1H, Oxd2H4), 4.72 (t, J=9.2 Hz, 1H, 
Oxd1H4), 4.74 (t, J=6.0 Hz, 1H, Oxd2H5), 5.98 (dd, J=3.2, 9.6 Hz, 1H, Oxd1H4), 7.33 (d, J=8.0 Hz, 2H, ArH), 
7.96 (d, J=8.0 Hz, 2H, ArH); 13C-NMR (2:1 CDCl3/DMSO-d6) δ: 20.9, 21.7, 53.5, 58.2, 61.7, 65.2, 75.3, 129.3, 
129.4, 134.2, 145.7, 151.3, 152.2, 167.0, 167.6; RP-HPLC (see general methods) 8.33 min; ES-MS m/z 
427.3 [M+1], calcd 427.1; Elem. Anal. for C17H18N2O9S, calcd: C 47.89, H 4.25, N 6.57, S 7.52; found: C 
47.93, H 4.2 N 6.60, S 7.49. 
 
4.1.4. Di-Oxd-peptide solid-phase synthesis 
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Ts-Oxd1-Phe2-Oxd3-Phe4-OH (14). Wang resin pre-loaded with Fmoc-Phe (0.5 g, 0.4-0.8 mmol/g, resin 
particle size: 100-200 mesh) was introduced in one reactor of an automated synthesizer apparatus. 
Fmoc was removed with 4:1 DMF/piperidine (5 mL) under mechanical shaking. After 15 min, the suspension 
was filtered, the resin was washed with DCM (5 mL) and treated while shaking with a second portion of 4:1 
DMF/piperidine. After 40 min, the suspension was filtered, and the resin was washed three times in 
sequence with DCM (5 mL) and CH3OH (5 mL). 
The resin was swollen in DCM (5 mL), and a solution of the N-protected amino acid (1.2 equiv.) and HOBt 
(1.2 equiv.) in DMF (4 mL) was added, followed by DCC (1.2 equiv.). The mixture was mechanically shaken, 
and after 3h the resin was filtered and washed three times with the sequence DCM (5 mL), CH3OH (5 mL). 
Coupling efficacy was determined by means of the Kaiser test.  
The resin-bound peptide was suspended in 5:1 DCM/DMF (5 mL), and DSC (5 equiv.) and DIPEA (0.3 equiv.) 
were added at r.t. under inert atmosphere. After 3h the mixture was filtered, and the resin-bound peptide was 
washed three times in sequence with DCM (5 mL) and CH3OH (5 mL). 
The resin-bound peptide was suspended in a mixture of TFA (1 mL), H2O (0.33 mL), ethanedithiol (0.33 mL), 
and PhOH (0.33 mL), in DCM (8 mL), and mechanically shaken at r.t. After 2 h the mixture was filtered, the 
resin was washed twice with 5% TFA in Et2O (5 mL), twice with Et2O (5 mL). The cleavage procedure was 
repeated, and all of the filtrates and washes were collected; solvent and volatiles were removed under N2 
flow at r.t. The resulting residue was suspended in Et2O, and the crude solid which precipitated was triturated 
and collected by centrifuge. The Oxd-peptide acid 14 was isolated by semipreparative RP-HPLC (General 
Methods) (80%, 96% pure by analytical RP-HPLC). IR (nujol) : 3300-2900, 1784, 1776, 1727, 1719; 1715; 
1H-NMR (9:1 CDCl3/DMSO-d6) δ: 2.37 (s, 3H, Me), 2.70 (dd, J=3.0, 14.0 Hz, 1H, Phe2Hβ), 3.17 (dd, J=6.0, 
13.7 Hz, 1H, Phe4Hβ), 3.27 (dd, J=3.8, 14.0 Hz, 1H, Phe2Hβ), 3.41 (dd, J=5.8, 13.7 Hz, 1H, Phe4Hβ), 3.98 
(dd, J=4.0, 8.4 Hz, 1H, Oxd3H5), 4.25 (t, J=9.0 Hz, 1H, Oxd3H5), 4.45 (t, J=8.9 Hz, 1H, Oxd1H5), 4.52 (dd, 
J=4.1, 8.3 Hz, 1H, Oxd1H5), 4.64 (dd, J=4.1, 7.9 Hz, 1H, Oxd3H4), 4.79 (dd, J=3.8, 8.4 Hz, 1H, Oxd1H4), 
4.83 (q, J= 6.6 Hz, 1H, Phe4Hα), 5.78 (q, J= 6.8 Hz, 1H, Phe2Hα), 6.54 (d, J=7.6 Hz, 1H, Phe4NH), 6.67 (d, 
J=7.2 Hz, 1H, Phe2NH), 7.15-7.30 (m, 12H, Phe2ArH+Phe4ArH+TsArH), 7.76 (d, J=8.4 Hz, 2H, ArH); 13C-
NMR (2:1 CDCl3/DMSO-d6) δ 23.9, 36.1, 37.8, 53.4, 54.1, 56.2, 59.2, 61.9, 62.8, 125.9, 127.7, 127.7, 128.3, 
128.6, 128.8,, 128.9, 129.3, 129.5, 133.7, 136.6, 136.6, 137.6, 151.9, 153.1, 171.7, 171.7, 174.7, 175.2; RP-
HPLC (see general methods) 10.39 min; ES-MS m/z 693.2 [M+1], calcd 693.2; Elem. Anal. for C33H32N4O11S, 
calcd: C 57.22, H 4.66, N 8.09, S, 4.63; found: C 57.18, H 4.69, N 8.12, S, 4.64. 
 
5. Theoretical computations. 
All theoretical calculations were performed employing the HyperChem package[47]. The structures of the 
product D, and of the plausible reaction intermediates A, C, and D, were calculated employing ab initio 
molecular orbital (MO) theory. A systematic conformational analysis for the structures was done at the HF/6-
31G* level. The conformers were re-optimized at the HF/6-31G** level. Optimization was performed by 
conjugate gradient algorithm, convergence at 0.001; energies are expressed in Kcal mol-1. The following 
structures were included in the computations of A-D: A, DIPEA; B, DIPEAH+; C, DIPEAH+; D, 1-
hydroxypyrrolidine-2,5-dione, and DIPEA.  
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6. Conformational analysis  
 
6.1. Circular Dichroism.  
ECD spectra were recorded from 200 to 300 nm at 25 °C. Solutions were made up in spectral grade solvents 
and run in a 0.01 cm quartz cell. For each sample the absorbance value was set to 1.0 at max (225260 nm); 
concentrations used were in the range 511 mM. Data are reported in ellipticity (millidegree). 
 
 
 
6.2. NMR analyses. 
1H-NMR spectra were recorded at 400 MHz in 5 mm tubes, using 0.01 M peptide at room temperature. 
Solvent suppression was performed by the solvent presaturation procedure implemented in Varian 
(PRESAT). 13C-NMR spectra were recorded at 75 MHz. 
Chemical shifts are reported as δ values. The unambiguous assignment of 1H-NMR resonances was 
performed by 2D gCOSY, HMBC, and HSQC. gCOSY experiments were conducted with a proton spectral 
width of 3103 Hz. VT-1H-NMR experiments were performed over the range of 298-348 °K. 2D spectra were 
recorded in the phase sensitive mode and processed using a 90°-shifted, squared sine-bell apodization. 2D 
ROESY experiments were recorded in the biomimetic medium 8:2 DMSO-d6/H2O, with a 250 ms mixing time 
with a proton spectral width of 3088 Hz. Peaks were calibrated on DMSO. 
 
6.3. ROESY and molecular dynamics. 
Only ROESY-derived constraints were included in the restrained molecular dynamics. Cross-peak intensities 
were classified very strong, strong, medium, and weak, and were associated with distances of 2.2, 2.6, 3.0, 
and 4.5 Å, respectively. Geminal couplings and other obvious correlations were discarded. For the absence 
of Hα(i, i+1) ROESY cross peaks, all of the ω bonds were set at 180° (force constant: 16 kcal mol-1Å-2). The 
restrained MD simulations were conducted using the AMBER force field[48] in a 30×30×30 Å box of standard 
TIP3P models of equilibrated water[49]. All water molecules with atoms that come closer than 2.3 Å to a 
solute atom were eliminated. A 100 ps simulation at 1200 °K was used for generating 50 random structures 
that were subsequently subjected to a 50 ps restrained MD with a 50 % scaled force field at the same 
temperature, followed by 50 ps with full restraints (distance force constant of 7 kcal mol-1 Å-2), after which the 
system was cooled in 20 ps to 50 °K. H-bond interactions were not included, nor were torsion angle 
restraints. The resulting structures were minimized with 3000 cycles of steepest descent and 3000 cycles of 
conjugated gradient (convergence of 0.01 kcal Å-1 mol-1). The backbones of the structures were clustered by 
the rmsd analysis module of HyperChem[Errore. Il segnalibro non è definito.
 ]. 
Unrestrained MD simulation was performed in a 30×30×30 Å box of standard TIP3P water for 10 ns at 298 
°K, at constant temperature and pressure (Berendsen scheme [50], bath relaxation constant of 0.2). For 1-4 
scale factors, van der Waals and electrostatic interactions are scaled in AMBER to half their nominal value. 
The integration time step was set to 0.1 fs. 
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7. Supporting Information 
 
1H-NMR analyses of 2a, 2b, 5, 10, 12a, 12b, 14, in different solvents. 
 
Ts-Ala-Oxd-Phe-NH2 (2a).  
1H-NMR (8:2 DMSO/H2O) δ 1.11 (d, J=7.4 Hz, 3H, AlaMe), 2.39 (s, 3H, TsMe), 2.79 (dd, J=8.4, 13.6 Hz, 1H, 
PheHβ), 2.97 (dd, J=4.8, 13.6 Hz, 1H, PheHβ), 4.20 (dd, J=2.6, 9.2 Hz, 1H, OxdH5), 4.38 (q, J=8.0 Hz, 1H, 
PheHα), 4.52 (t, J=8.8 Hz, 1H, OxdH5), 4.69 (dd, J=2.6, 8.8 Hz, 1H, OxdH4), 5.06 (dq, J=6.8, 8.8 Hz, 1H, 
AlaHα), 7.09 (br.s, 1H, CONH2), 7.15-7.30 (m, 5H, ArH), 7.36 (d, J=8.4 Hz, 2H, ArH), 7.51 (br.s, 1H, CONH2), 
7.65 (d, J=8.4 Hz, 2H, ArH), 8.25 (d, J=9.2 Hz, 1H, AlaNH), 8.42 (d, J=8.0 Hz, 1H, PheNH). 
1H-NMR (CH3OH) δ 1.22 (d, J=7.1 Hz, 3H, AlaMe), 2.41 (s, 3H, TsMe), 2.80 (dd, J=8.0, 13.8 Hz, 1H, PheHβ), 
3.03 (dd, J=4.6, 13.8 Hz, 1H, PheHβ), 4.22 (dd, J=3.0, 9.0 Hz, 1H, OxdH5), 4.43 (q, J=7.8 Hz, 1H, PheHα), 
4.49-4.70 (m, 2H, OxdH5+OxdH4), 5.19 (quint, J=8.2 Hz, 1H, AlaHα), 7.15-7.30 (m, 6H, ArH+CONH2), 7.36 
(m, 3H, ArH+CONH2), 7.67 (d, J=8.2 Hz, 2H, ArH), 8.36 (d, J=9.0 Hz, 1H, AlaNH), 8.67 (d, J=8.2 Hz, 1H, 
PheNH). 
 
Ts-Ala-D-Oxd-Phe-NH2 (2b). 
1H-NMR (8:2 DMSO/H2O) δ 1H-NMR (8:2 DMSO/H2O) δ 1.06 (d, J=7.2 Hz, 3H, AlaMe), 2.36 (s, 3H, TsMe), 
2.73 (dd, J=10.2, 13.0 Hz, 1H, PheHβ), 3.08 (dd, J=4.6, 13.0 Hz, 1H, PheHβ), 3.42 (d, J=8.6 Hz, 1H, D-
OxdH5), 4.34 (t, J=8.8 Hz, 1H, D-OxdH5), 4.64 (m, 1H, PheHα), 4.72 (d, J=8.6 Hz, 1H, D-OxdH4), 5.12 
(quint, J=7.6 Hz, 1H, AlaHα), 7.15 (br.s, 1H, CONH2), 7.16-7.25 (m, 5H, ArH), 7.32 (d, J=7.8 Hz, 2H, ArH), 
7.54 (br.s, 1H, CONH2), 7.60 (d, J=7.8 Hz, 2H, ArH), 8.07 (d, J=9.2 Hz, 1H, AlaNH), 8.49 (d, J=8.8 Hz, 1H, 
PheNH). 
1H-NMR (CH3OH) δ 1H-NMR (8:2 DMSO-d6/H2O) δ 1H-NMR (8:2 DMSO/H2O) δ 1.30 (d, J=6.8 Hz, 3H, 
AlaMe), 2.19 (s, 3H, TsMe), 2.84 (dd, J=10.4, 14.0 Hz, 1H, PheHβ), 3.05 (dd, J=4.6, 14.0 Hz, 1H, PheHβ), 
3.63 (dd, J=3.5, 8.8 Hz, 1H, D-OxdH5), 4.36 (t, J=9.2 Hz, 1H, D-OxdH5), 4.60 (m, 1H, PheHα), 4.64 (dd, 
J=4.4, 8.6 Hz, 1H, D-OxdH4), 5.26 (quint, J=6.8 Hz, 1H, AlaHα), 7.15-7.30 (m, 8H, ArH+CONH2), 7.44 (br.s, 
1H, CONH2), 7.67 (d, J=7.8 Hz, 2H, ArH), 8.11 (d, J=9.0 Hz, 1H, AlaNH), 8.54 (d, J=8.2 Hz, 1H, PheNH). 
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Ns-Ala-D-Oxd-Phe-Gly-NH2 (5). 
1H-NMR (8:2 DMSO-d6/H2O) δ 1.35 (d, J=7.3 Hz, 3H, Me), 2.70 (dd, J=6.4, 13.9 Hz, 1H, PheHβ), 3.12 (dd, 
J=6.8, 13.9 Hz, 1H, PheHβ), 3.40 (dd, J=4.0, 8.4 Hz, 1H, D-OxdH5), 3.69-3.76 (m, 2H, GlyHα), 4.34 (t, J=9.2 
Hz, 1H, D-OxdH5), 4.65-4.74 (m, 2H, D-OxdH4+PheHα), 5.22 (quint, 7.1 Hz, 1H, AlaHα), 7.06 (br.s, 1H, 
CONH2), 7.11-7.25 (m, 6H, ArH+CONH2), 7.94 (d, J=8.5 Hz, 2H, ArH), 8.23 (t, J=7.9 Hz, 1H, GlyNH), 8.33 (d, 
J=8.5 Hz, 2H, ArH), 8.55 (d, J=8.0 Hz, 1H, PheNH), 8.66 (d, J=9.3 Hz, 1H, AlaNH). 
1H-NMR (CH3OH) δ 1H-NMR (8:2 DMSO-d6/H2O) δ 1.25 (d, J=7.1 Hz, 3H, Me), 2.86 (dd, J=9.0, 13.9 Hz, 1H, 
PheHβ), 3.20(dd, J=6.4, 13.9 Hz, 1H, PheHβ), 3.55 (dd, J=3.9, 8.5 Hz, 1H, D-OxdH5), 3.80-3.90 (m, 2H, 
GlyHα), 4.33 (dd, J=5.0, 9.0 Hz, 1H, D-OxdH5), 4.64 (ddd, J=6.4, 8.0, 9.0 Hz, 1H, PheHα), 4.72 ((dd, J=2.6, 
8.8 Hz, 1H, D-OxdH4), 5.19 (quint, 7.0 Hz, 1H, AlaHα), 7.11 (br.s, 1H, CONH2), 7.15-7.25 (m, 6H, 
ArH+CONH2), 7.98 (d, J=8.5 Hz, 2H, ArH), 8.28 (t, J=8.0 Hz, 1H, GlyNH), 8.39 (d, J=8.5 Hz, 2H, ArH), 8.64 
(d, J=8.0 Hz, 1H, PheNH), 8.69 (d, J=8.2 Hz, 1H, AlaNH). 
 
Ts-Oxd-Dha-OMe (10). 
1H-NMR (8:2 DMSO-d6/H2O) δ 2.41 (s, 3H, Me), 3.89 (s, 3H, COOMe), 4.34 (dd, J=4.0, 9.2 Hz, 1H, OxdH5), 
4.62 (t, J=8.8 Hz, 1H, OxdH5), 5.25 (dd, J=3.8, 9.0 Hz, 1H, OxdH4), 6.03 (s, 1H, =CH), 6.47 (s, 1H, =CH), 
7.44 (d, J=8.4 Hz, 2H, ArH), 7.94 (d, J=8.4 Hz, 2H, ArH), 10.01 (s, 1H, DhaNH). 
1H-NMR (CH3OH) δ 2.49 (s, 3H, Me), 3.79 (s, 3H, COOMe), 4.28 (dd, J=4.4, 8.6 Hz, 1H, OxdH5), 4.64 (t, 
J=9.0 Hz, 1H, OxdH5), 5.34 (dd, J=3.4, 9.0 Hz, 1H, OxdH4), 5.86 (s, 1H, =CH), 6.32 (s, 1H, =CH), 7.45 (d, 
J=8.4 Hz, 2H, ArH), 7.84 (d, J=8.4 Hz, 2H, ArH), 10.12 (s, 1H, DhaNH). 
 
Ts-Oxd1-(5-Me-Oxd2)-OMe (12a). 
1H-NMR (8:2 DMSO-d6/H2O) δ 1.53 (d, J=5.6 Hz, 3H, 5-Me), 2.42 (s, 3H, TsMe), 3.73 (s, 3H, COOMe), 4.32 
(dd, J=2.6, 9.0 Hz, 1H, Oxd1H5), 4.82-4.93 (m, 2H, Oxd2H4+Oxd1H5), 4.94 (quint, J=5.8 Hz, 1H, Oxd2H5), 
6.05 (dd, J=2.4, 9.6 Hz, 1H, Oxd1H4), 7.47 (d, J=8.4 Hz, 2H, ArH), 7.93 (d, J=8.4 Hz, 2H, ArH). 
1H-NMR (CH3OH) δ 1.61 (d, J=6.4 Hz, 3H, 5-Me), 2.49 (s, 3H, TsMe), 3.82 (s, 3H, COOMe), 4.42 (dd, J=3.6, 
9.2 Hz, 1H, Oxd1H5), 4.79-4.83 (m, 2H, Oxd1H5+Oxd2H4), 4.90 (dq, J=4.0, 6.4 Hz, 1H, Oxd2H5), 6.13 (dd, 
J=3.4, 9.8Hz, 1H, Oxd1H4), 7.43 (d, J=8.2 Hz, 2H, ArH), 8.00 (d, J=8.2 Hz, 2H, ArH). 
 
Ts-D-Oxd1-(5-Me-Oxd2)-OMe (12b). 
1H-NMR (8:2 DMSO-d6/H2O) δ 1.52 (d, J=6.4 Hz, 3H, 5-Me), 2.43 (s, 3H, TsMe), 3.81 (s, 3H, COOMe), 4.57 
(d, J=6.0 Hz, 1H, Oxd2H4), 4.71 (dd, J=2.8, 8.8 Hz, 1H, D-Oxd1H5), 4.74 (t, J=9.2 Hz, 1H, D-Oxd1H5), 4.94 
(quint, J=6.0 Hz, 1H, Oxd2H5), 5.97 (dd, J=3.2, 8.8 Hz, 1H, D-Oxd1H4), 7.46 (d, J=8.0 Hz, 2H, ArH), 7.86 (d, 
J=8.0 Hz, 2H, ArH). 
1H-NMR (CH3OH) δ 1.61 (d, J=6.4 Hz, 3H, 5-Me), 2.49 (s, 3H, TsMe), 3.91 (s, 3H, COOMe), 4.58 (dd, J=3.2, 
9.2 Hz, 1H, Oxd1H5), 4.63 (d, J=5.6 Hz, 1H, Oxd2H4), 4.75 (t, J=9.6 Hz, 1H, Oxd1H5), 4.86 (quint, J=6.4 Hz, 
1H, Oxd2H5), 6.06 (dd, J=3.2, 9.2 Hz, 1H, Oxd1H4), 7.43 (d, J=8.0 Hz, 2H, ArH), 7.95 (d, J=8.0 Hz, 2H, ArH). 
 
Ts-Oxd1-Phe2-Oxd3-Phe4-OH (14).  
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1H-NMR (8:2 DMSO-d6/H2O) δ 2.38 (s, 3H, Me), 2.68 (dd, J=3.3, 13.8 Hz, 1H, Phe2Hβ),2.95-3.05 (m, 1H, 
Phe4Hβ), 3.22 (m, 2H, Phe2HβPhe4Hβ), 4.06 (dd, J=3.8, 8.4 Hz, 1H, Oxd1H5), 4.20 (dd, J=4.0, 8.4 Hz, 1H, 
Oxd3H5), 4.53 (q, J= 6.6 Hz, 1H, Phe4Hα), 4.67 (t, J=9.0 Hz, 2H, Oxd1H5+Oxd3H5), 4.98 (dd, J=3.6, 8.8 Hz, 
1H, Oxd3H4), 5.02 (dd, J=3.8, 9.2 Hz, 1H, Oxd1H4), 5.57 (q, J= 6.8 Hz, 1H, Phe2Hα), 7.12-7.28 (m, 12H, 
Phe2ArH+Phe4ArH+TsArH), 7.64 (d, J=8.4 Hz, 2H, ArH), 8.85 (d, J=6.8 Hz, 1H, Phe4NH), 8.93 (d, J=7.6 Hz, 
1H, Phe2NH). 
1H-NMR (CH3OH) δ 2.45 (s, 3H, Me), 2.70 (dd, J=3.8, 13.6 Hz, 1H, Phe2Hβ),3.00-3.12 (m, 2H, Phe4Hβ), 
3.18 (dd, J=5.6, 13.6 Hz, 1H, Phe2Hβ), 4.14 (dd, J=3.6, 8.6 Hz, 1H, Oxd1H5), 4.22 (q, J= 6.6 Hz, 1H, Phe4H
α), 4.35 (dd, J=4.1, 8.5 Hz, 1H, Oxd3H5), 4.59 (t, J=8.9 Hz, 2H, Oxd1H5), 4.64 (t, J=8.8 Hz, 2H, Oxd1H5), 
4.76 (dd, J=3.8, 8.6 Hz, 1H, Oxd3H4), 4.99 (dd, J=3.6, 9.0 Hz, 1H, Oxd1H4), 5.68 (q, J= 6.8 Hz, 1H, Phe2Hα), 
7.18-7.30 (m, 10H, Phe2ArH+Phe4ArH), 7.38(d, J=8.4 Hz, 2H, ArH), 7.59 (d, J=8.4 Hz, 2H, ArH), 8.90 (d, 
J=6.8 Hz, 1H, Phe4NH), 9.00 (d, J=7.4 Hz, 1H, Phe2NH). 
 
Table S1. VT-1H-NMR Δδ/Δt values (p.p.b..⁄K) of Ts-Ala-L/D-Oxd-Phe-NH2 (2a, 2b), and Ts-Ala-D-Oxd-Phe-GlyNH2 (5) in different 
solvents. 
compd solvent AlaNH PheNH GlyNH CONH2 
 CDCl3 -12.9 -9.6 - -11.2/-9.2 
2a 8:2 DMSO-d6/H2O -6.8 -4.3 - -5.9/-5.4 
 CH3OH -7.0 -4.6 - -6.1/-5.8 
 CDCl3 -6.7 -5.7 - -5.9/-5.4 
2b 8:2 DMSO-d6/H2O -4.2 -2.6 - -5.6/-6.8 
 CH3OH -4.4 -3.0 - -6.0/-6.9 
 9:1 CDCl3/DMSO-d6 -5.9 -4.2 -6.5 -6.1/-6.4 
5 8:2 DMSO-d6/H2O -4.8 -2.7 -7.4 -6.0/-6.4 
 CH3OH -5.1 -3.1 -6.2 -6.0/-6.4 
 
 
Table S2. VT-1H-NMR Δδ/Δt values (p.p.b..⁄K) of Ts-Oxd-DHA-OMe (10), in different solvents. 
compd solvent DHANH 
 CDCl3 -1.8 
10 8:2 DMSO-d6/H2O -4.6 
 CH3OH -4.9 
 
 
Table S3. VT-1H-NMR Δδ/Δt values (p.p.b..⁄K) of Ts-Oxd1-Phe2-Oxd3-Phe4-OH (14), in different solvents. 
compd solvent Phe2NH Phe4NH 
 9:1 CDCl3/DMSO-d6 -2.9 -4.2 
14 8:2 DMSO-d6/H2O -5.2 -3.8 
 CH3OH -5.6 -4.2 
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Table S4. Non-obvious ROESY cross-peaks observed for Ts-Ala-L-Oxd-Phe-NH2 (2a) in 8:2 DMSO-d6/H2O.  
Cross peaka Intensityb Cross peaka Intensityb 
PheNH-PheHβ2,8 vs PheNH-PheHβ3.0 s 
PheNH-OxdH54.2 s PheNH-PheHα m 
PheNH-OxdH4 vs PheNH-OxdH54.5 m 
PheNH-PheArH m PheNH-CONH7.3 m 
AlaNH-AlaMe vs AlaNH-AlaHα m 
AlaNH-TsArH7.8 m TsArH7.8-AlaHα s 
TsArH7.8-AlaMe m CONH7.3-PheHα vs 
CONH7.3-PheHβ3.0 s CONH7.3-PheHβ2.8 s 
PheArH-PheHβ3.0 s PheArH-PheHβ2.8 s 
PheArH-PheHα s CONH7.0-PheHα m 
PheHα-PheHβ3.0 s PheHα-PheHβ2.8 s 
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak.  
 
 
Table S5. Non-obvious ROESY cross-peaks observed for Ts-Ala-D-Oxd-Phe-NH2 (2b) in 8:2 DMSO-d6/H2O.  
Cross peaka Intensityb Cross peaka Intensityb 
PheNH-PheHβ2.7 s PheNH-PheHβ3.1 w 
PheNH-OxdH53.4 m PheNH-PheHα m 
PheNH-OxdH4 vs PheNH-PheArH m 
PheNH-CONH7.6 m AlaNH-AlaMe s 
AlaNH-AlaHα m TsArH7.6-AlaMe m 
TsArH7.6-AlaHα m TsArH7.6-AlaNH w 
CONH7.6-PheHβ3.1 m CONH7.6-PheHβ2.7 w 
CONH7.6-PheHα s CONH7.3-PheH53.4 w 
CONH7.3-PheHβ3.1 w CONH7.3-OxdH53.4 w 
CONH7.3-PheHα w PheArH-PheHβ2.7 s 
PheArH-PheHβ3.1 s PheArH-OxdH53.4 m 
PheArH-PheHα s OxdH4-AlaMe w 
PheHα-PheHβ2.7 s PheHα-PheHβ3.1 vs 
TsMe-AlaMe w   
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak.  
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Table S6. Non-obvious ROESY cross-peaks observed for Ns-Ala-D-Oxd-Phe-GlyNH2 (5) in 8:2 DMSO-d6/H2O.  
Cross peaka Intensityb Cross peaka Intensityb 
AlaMe-AlaNH s AlaMe-NsArH7.9 m 
AlaMe-OxdH4 w AlaNH-PheHα w 
AlaNH-AlaHα m PheNH-OxdH54.3 w 
PheNH-GlyNH w PheNH-PheArH w 
PheNH-OxdH4 vs PheNH-PheHα m 
PheNH-OxdH53.4 m PheNH-PheHα vs 
PheNH-PheHβ3.2 w PheNH-GlyHα w 
GlyNH-CONH7.1 w GlyNH-CONH7.3 m 
GlyNH-PheHα vs GlyNH-GlyHα vs 
GlyNH-PheHβ3.2 m GlyNH-PheHβ2.7 w 
GlyNH-AlaHα w NsArH7.9-AlaHα w 
NsArH8.2-AlaMe w NsArH8.2-AlaHα w 
NsArH8.2-GlyHα w PheArH-PheHβ2.7 s 
PheArH-PheHβ3.2 s PheArH-OxdH53.4 m 
PheArH-PheHα s GlyHα-CONH7.1 m 
GlyHα-CONH7.3 s PheHα-PheHβ2.7 m 
PheHα-PheHβ3.2 s NsArH7.9-PheHβ2.7 w 
NsArH7.9-PheHβ3.2 m NsArH7.9-GlyHα w 
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak.  
 
Table S7. Non-obvious ROESY cross-peaks observed for Ts-Oxd-Dha-OMe (10) in 8:2 DMSO-d6/H2O.  
Cross peaka Intensityb Cross peaka Intensityb 
DhaNH-OxdH54.3 s DhaNH-OxdH54.7 w 
DhaNH-OxdH4 vs DhaNH-C=CH5.9 w 
DhaNH-C=CH6.3 m DhaNH-COOMe w 
TsArH7.8-C=CH5.9 w TsArH7.8-C=CH6.3 w 
TsArH7.8-OxdH4 s TsArH7.8-COOMe w 
TsArH7.4-C=CH5.9 w TsArH7.4-C=CH6.3 w 
TsArH7.4-COOMe w COOMe-TsMe w 
C=CH5.9-COOMe m OxdH54.3-TsMe w 
OxdH54.7-TsMe w   
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak.  
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Table S8. Non-obvious ROESY cross-peaks observed for Ts-Oxd1-(5-Me-Oxd2)-OMe (12a) in 8:2 DMSO-d6/H2O.  
Cross peaka Intensityb Cross peaka Intensityb 
TsArH7.9-Oxd2H4 w TsArH7.9-Oxd1H4 m 
Oxd1H4-Oxd2H4 w Oxd2H5-COOMe m 
Oxd2H4-COOMe w COOMe-Oxd1H54.3 w 
COOMe-5’Me w   
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak.  
 
 
Table S9. Non-obvious ROESY cross-peaks observed for Ts-D-Oxd1-(5-Me-Oxd2)-OMe (12b) in 8:2 DMSO-d6/H2O.  
Cross peaka Intensityb Cross peaka Intensityb 
TsArH7.9-Oxd1H4 w TsArH7.9-COOMe w 
TsArH7.5-COOMe w Oxd1H4-Oxd2H4 w 
Oxd1H54.3-5’Me w Oxd2H5-COOMe m 
Oxd2H4-COOMe w   
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak.  
 
 
Table S10. Non-obvious ROESY cross-peaks observed for Ts-Oxd1-Phe2-Oxd3-Phe4-OH (14), in 8:2 DMSO-d6/H2O. 
Cross peaka Intensityb Cross peaka Intensityb 
Phe2NH-Phe2Hβ2.6 vs Phe2NH-Phe2Hβ3.2 w 
Phe2NH-Oxd1H4 vs Phe2NH-Phe2Hα m 
Phe2NH-TsArH7.5 w Phe2NH-Phe2ArH m 
Phe4NH-Phe4Hβ3.0 s Phe4NH-Phe4Hα m 
Phe4NH-Oxd3H4 vs TsArH7.3-Oxd1H54.7 w 
Phe4ArH-Phe4Hβ3.0 vs Phe4ArH-Phe4Hα m 
Phe2ArH-Phe2Hβ2.6 s Phe2ArH-Phe2Hβ3.2 m 
Phe2ArH-Phe2Hα m Phe4Hα-Phe4Hβ3.0 vs 
Phe4Hα-Phe4Hβ3.2 w Phe2Hα-Phe2Hβ3.2 s 
Phe2Hα-Phe2Hβ2.6 w   
a Stereochemistry has been omitted. b vs = very strong, s = strong, m = medium, w = weak.  
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Figure S1. Structures and ΔE of the intermediates calculated for the cyclization of the model peptide Ts-Ala-Ser-NH2 with DSC and 
DIPEA, employing ab initio molecular orbital (MO) theory. A systematic conformational analysis for the structures was done at the HF/6-
31G* level. The conformers were re-optimized at the HF/6-31G** level. Backbones are rendered in balls-and-cylinders, the rest in sticks. 
Optimization was performed by conjugate gradient algorithm, convergence at 0.001; energies are expressed in Kcal mol-1. The following 
structures were included in the computations of A-D, but are not visualized for clarity: A, DIPEA; B, DIPEAH+; C, DIPEAH+; D, 1-
hydroxypyrrolidine-2,5-dione and DIPEA.  
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Figure S2. ECD spectra were recorded from 200 to 300 nm at 25 °C. Solutions were made up in spectral grade solvents and run in a 
0.01 cm quartz cell. For each sample the absorbance value was set to 1.0 at max (225260 nm); concentrations used were in the range 
511 mM. Data are reported in ellipticity (millidegree). 
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CONCLUSIONS 
This manuscript describes the results obtained during my PhD work in the period 2009-2011. The main topic 
of my experiments has been the synthesis of modified amino acids, and their insertion in peptides and 
peptidomimetics. Further, I studied the effects exerted by the modifications on structures and biological 
activities of the compounds so obtained. The last section of the paper deals with the use of the 
peptidomimetic strategy for designing structurally defined compounds as integrin inhibitors and opioid 
receptor agonists. 
In this regard, I prepared peptide analogues containing unusual amino acids such as halogenated, alkylated 
(S)- or (R)-tryptophans, useful for the synthesis of mimetics of the endogenous opioid peptide endomorphin-
1, or 2-oxo-1,3-oxazolidine-4-carboxylic acids, utilized as pseudo-prolines having a clear all-trans 
configuration of the preceding peptide bond. The latter gave access to a series of constrained 
peptidomimetics with potential interest in medicinal chemistry and in the field of the foldamers. 
In particular, I have dedicated much efforts to the preparation of cyclopentapeptides containing D-configured, 
alfa-, or beta-aminoacids, and also of cyclotetrapeptides including the retro-inverso modification. The 
conformational analyses confirmed that these cyclic compounds can be utilized as rigid scaffolds mimicking 
gamma- or beta-turns, allowing to generate new molecular and 3D diversity.  
Much work has been dedicated to the structural analysis in solution and in the receptor-bound state, 
fundamental for giving a rationale to the experimentally determined bioactivity, as well as for predicting the 
activity of virtual compounds (in silico pre-screen). The conformational analyses in solution has been done 
mostly by NMR (2D gCosy, Roesy, VT, molecular dynamics, etc.). A special section is dedicated to the 
prediction of plausible poses of the ligands when bound to the receptors by Molecular Docking. This 
computational method proved to be a powerful tool for the investigation of ligand-receptor interactions, and 
for the design of selective agonists and antagonists. 
As a practical application, I synthesized scaffolds based on a partially modified retro-inverso 
cyclotetrapeptide structure carrying side chains designed to mimic the pharmacophores on the RGD integrin-
recognition motive. Indeed, I could demonstrate a antiangiogenic effect of dual and selective α5β1/αvβ3 
integrin antagonists. 
Another practical use of cyclic peptidomimetics was the synthesis and biological evaluation of cyclic 
analogues of endomorphin-1 lacking in a protonable amino group. The studies revealed that a inverse type II 
beta-turn on D-Trp-Phe constituted the bioactive conformation. To my knowledge, this can be regarded to as 
a unprecedented pharmacophoric motif for MOR agonists.  
In conclusion, the researched described herein demonstrate that the peptidomimetic approach to 3D definite 
structures allows unambiguous investigation of the structure-activity correlation, giving an access to a wide 
range bioactive compounds of pharmaceutical interest, as demonstrated by the examples in the integrin and 
opioid fields. 
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